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ABSTRACT	  
CHARLTON,	  Rebecca	  Louise.	  Repurposing	  as	  a	  strategy	  for	  the	  discovery	  of	  a	  new	  
antileishmanial.	  Thesis	  (PhD	  in	  Chemical	  Biology),	  Chemistry	  Department,	  Durham	  
University,	  UK;	  (PhD	  in	  Biological	  Sciences),	  Instituto	  de	  Biofísica	  Carlos	  Chagas	  Filho,	  
Universidade	  Federal	  do	  Rio	  de	  Janeiro,	  Brazil. 
Leishmaniasis	  is	  a	  vector-­‐borne	  Neglected	  Tropical	  Disease,	  caused	  by	  protozoan	  parasites	  
of	   the	  genus	  Leishmania	   for	  which	   there	   is	   a	   shortage	  of	  effective	  and	  viable	  non-­‐toxic	  
drugs.	   There	   are	   approximately	   1.3	   million	   new	   cases	   of	   leishmaniasis	   each	  
year	  with	  the	  greatest	   impact	   in	   the	  poorest	  communities.	  Therefore,	   repurposing	   is	  an	  
important	  strategy	  as	  established	  medicines	  have	  cheaper	  and	  faster	  development	  times.	  	  
Leishmania	   major	   inositol	   phosphorylceramide	   synthase	   (LmjIPCS)	   is	   involved	   in	   the	  
biosynthesis	   of	   sphingolipids	   and	   has	   been	   identified	   as	   a	   potential	   drug	   target	   by	   our	  
group.	  A	  set	  of	  screens	  against	  LmjIPCS	  and	  the	  parasite	  were	  performed	  on	  a	  library	  of	  
1040	  bioactive	  compounds.	  The	  over-­‐the-­‐counter	  antihistamine	  clemastine	  was	  selected	  
as	   the	   most	   promising	   compound	   to	   develop	   further.	   Clemastine	   has	   now	  
shown	   submicromolar	   activity	   against	   species	   that	   cause	   cutaneous	   (L.	   major	   and	   L.	  
amazonensis)	   and	   visceral	   leishmaniasis	   (L.	   donovani	   and	   L.	   infantum)	   as	  well	   as	   being	  
effective	   against	  L.	   amazonensis	   intramacrophage	  amastigotes	   (EC50	  =	   0.4	  µM,	  SI	   =	   50).	  	  
Progression	   of	   clemastine	   into	   a	   mouse	   model	   of	   L.	   amazonensis	   infection	   showed	  
significant	   reduction	   in	   parasite	   burden	   when	   given	   via	   the	   intralesional	   (IL)	   or	  
intraperitoneal	  (IP)	  route.	   In	  order	  to	  optimise	  the	  antileishmanial	  activity,	  two	  series	  of	  
clemastine	  analogues	  were	  synthesised.	  The	  first	  series,	  named	  nor-­‐clemastine	  analogues,	  
lack	  the	  clemastine	  quarternary	  methyl	  group.	  An	  enantioselective	  route	  was	  developed	  to	  
show	   the	   role	   stereochemistry	   plays	   on	   antileishmanial	   activity	   with	   greatest	  
activity	  residing	  in	  the	  (R,	  R)-­‐configuration	  of	  nor-­‐clemastine.	  The	  second	  series,	  named	  N-­‐
linked	   analogues,	   identified	   a	   more	   synthetically	   accessible	   and	   selective	   analogue	  
against	  L.	  amazonensis	  intramacrophage	  amastigotes	  (EC50	  value	  =	  0.5	  µM,	  SI	  =	  146).	  This	  
compound	   was	   progressed	   into	   a	   mouse	   model	   infected	   with	   L.	   amazonensis	   and	  
significantly	  reduced	  the	  parasite	  burden	  when	  given	  via	  the	  IL	  route.	  Overall,	  this	  thesis	  
demonstrates	   the	   potential	   of	   drug	   repurposing	   as	   well	   as	   the	   development	   of	   new	  
analogues	  in	  the	  search	  of	  a	  new	  antileishmanial	  therapy.	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RESUMO	  
CHARLTON,	  Rebecca	  Louise.	  Reposicionamento	  como	  estratégia	  para	  o	  descobrimento	  
de	  um	  novo	  antileishmanial.	  Tese	  (PhD	  em	  Química	  Biológica),	  Departamento	  de	  
Química,	  Durham	  Universidade,	  Reino	  Unido;	  (PhD	  em	  Ciências	  Biológicas)	  Instituto	  de	  
Biofísica	  Carlos	  Chagas	  Filho,	  Universidade	  Federal	  do	  Rio	  de	  Janeiro,	  Brasil.	  
As	  leishmanioses	  são	  doenças	  negligenciadas	  transmitidas	  por	  inseto	  vetor	  e	  causadas	  por	  
protozoários	  do	  gênero	  Leishmania,	  para	  os	  quais	  existe	  uma	  carência	  de	  medicamentos	  
eficazes	   e	   seguros.	   Aproximadamente	   1.3	  milhões	   de	   novos	   casos	   de	   leishmaniose	   são	  
registrados	   por	   ano,	   com	   grande	   impacto	   nas	   populações	   mais	   pobres.	   Portanto,	   o	  
reposicionamento	   de	   fármacos	   torna-­‐se	   uma	   estratégia	   importante,	   uma	   vez	   que	  
medicamentos	   já	   comercializados	   possuem	   tempo	   de	   desenvolvimento	   mais	   rápido	   e	  
barato.	  A	  enzima	  inositol	  fosforilceramida	  sintase	  de	  Leishmania	  major	  (LmjIPCS)	  envolvida	  
na	  biossíntese	  de	  esfingolipídeos	  e	   já	  foi	   identificada	  como	  um	  potencial	  alvo	  de	  drogas	  
pelo	  nosso	  grupo.	  Neste	  estudo,	  uma	  biblioteca	  de	  1040	  compostos	  bioativos	  foi	  avaliada	  
quanto	   à	   atividade	   cruzada	   entre	   a	   LmjIPCS	   e	   toxicidade	   contra	   o	   parasito.	   Dentre	   os	  
compostos,	  o	  anti-­‐histamínico	  clemastina	  foi	  selecionado	  como	  o	  mais	  promissor	  por	  seu	  
alto	  efeito	  inibitório	  contra	  a	  	  enzima,	  e	  contra	  promastigotas	  de	  espécies	  causadoras	  das	  
formas	   cutânea	   (L.	   major	   e	   L.	   amazonensis)	   e	   visceral	   (L.	   donovani	   e	   L.	   infantum)	   da	  
leishmaniose,	  e	  amastigotas	  intracelulares	  de	  L.	  amazonensis	  (EC50	  =	  0.4	  µM,	  SI	  =	  50).	   In	  
vivo,	   a	   clemastina	   reduziu	   significativamente	   a	   carga	   parasitária	   de	   camundongos	  
infectados	   com	   L.	   amazonensis	   quando	   administrada	   por	   via	   inralesional	   (IL)	   ou	  
intraperitoneal	  (IP).	  	  Buscando	  sua	  otimização,	  foram	  sintetizadas	  duas	  séries	  de	  análogos	  
da	  clemastina.	  Na	  primeira	  série	  de	  compostos	  denominados	  nor-­‐clemastina,	  os	  análogos	  
eram	   desprovidos	   do	   grupamento	   metila	   quaternário.	   Uma	   rota	   enantiosseletiva	  
evidenciou	   nos	   compostos	   nor-­‐clemastina	   o	   papel	   da	   estereoquímica	   na	   atividade	  
antileishmanial,	  sendo	  as	  moléculas	  na	  configuração	  (R,	  R)	  as	  mais	  ativas.	  Na	  segunda	  série	  
de	   compostos	   denominados	   N-­‐linked,	   foi	   identificado	   um	   análogo	   ainda	   mais	   seletivo	  
contra	  amastigotas	  intracelulares	  de	  L.	  amazonensis	  (EC50	  value	  =	  0.5	  µM,	  SI	  =	  146).	  Quando	  
testado	  pela	  via	  IL	  em	  camundongos	  infectados	  com	  L.	  amazonensis,	  este	  análogo	  N-­‐linked	  
também	   reduziu	   significativamente	   a	   carga	   parasitária.	   Em	   conclusão,	   esta	   tese	  
demonstrou	  o	  potencial	  do	  reposicionamento	  de	  fármacos	  bem	  como	  o	  desenvolvimento	  
de	  novos	  análogos	  na	  busca	  por	  uma	  nova	  terapia	  contra	  a	  leishmaniose.	  	  
Palavras-­‐chave:	   Leishmaniose,	   reposicionamento,	   clemastina,	   alvo	   terapêutico,	  
antileishmanial,	  terapia,	  síntese	  química.
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   1	  
1.	  Introduction	  
	  
	  1.1.	  Overview	  
	  
The	   work	   in	   this	   thesis	   is	   aimed	   at	   utilising	   the	   antileishmanial	   drug	   target	   inositol	  
phosporylceraminde	   synthase	   (IPCS),	   an	   essential	   enzyme	   involved	   in	   sphingolipid	  
biosynthesis.	  Previous	  work	  identified	  clemastine	  1,	  an	  over-­‐the-­‐counter	  antihistamine,	  as	  
an	   inhibitor	   of	   Leishmania	   major	   IPCS	   (LmjIPCS)	   and	   therefore	   later	   chapters	   will	  
investigate	   repurposing	   clemastine	   1	   as	   a	   potential	   therapy	   for	   the	   neglected	   tropical	  
disease	  leishmaniasis.	  
	  
This	  thesis	  is	  made	  up	  of	  8	  chapters.	  Chapter	  2	  will	  provide	  details	  on	  the	  drug	  target	  IPCS	  
and	  describe	  previous	  work	  carried	  out	  by	  the	  group	  including	  the	  identification	  of	  the	  drug	  
candidate	  clemastine	  1.	  Chapter	  3	  will	  discuss	  the	  activity	  of	  clemastine	  1	  in	  vitro	  and	  its	  
efficacy	  in	  a	  mouse	  model.	  Chapter	  4	  and	  5	  will	  present	  the	  work	  undertaken	  to	  develop	  
synthetic	  routes	  to	  clemastine	  analogues	  and	  obtain	  structure-­‐activity	  relationship	  (SAR)	  
data	  to	  probe	  LmjIPCS	  and	  identify	  a	  more	  potent	  and	  selective	  drug	  candidate.	  Chapter	  6	  
will	   discuss	   any	   additional	   work	   including	   the	   synthesis	   of	   fluorescent	   analogues	   and	  
imaging	  in	  vitro.	  Finally,	  Chapter	  7	  and	  8	  will	  detail	  the	  chemical	  and	  biological	  experimental	  
procedures	  developed	  in	  this	  project.	  	  
	  
The	  remaining	  section	  of	  this	  chapter	  reviews	  previous	  drug	  repurposing	  strategies	  in	  the	  
search	  for	  new	  treatments	  for	  leishmaniasis.1	  	  
 
	  1.2.	  Drug	  repositioning	  
	  



































	   2	  
The	  introduction	  of	  a	  new	  drug	  from	  initial	  concept	  to	  public	  release	  is	  a	  slow	  expensive	  
process.	  Developing	  a	  new	  chemical	  entity	  (NCE)	  drug	  and	  delivering	  it	  to	  market,	  de	  novo	  
drug	   discovery	   (Figure	   1),	   is	   estimated	   to	   take	   10-­‐17	   years	   and	   cost	   ∼$1.8	   billion.3	  
Moreover,	  the	  probability	  of	  success	  is	  lower	  than	  10%	  and	  the	  costs	  of	  late	  stage	  failures	  
in	   this	  process	  are	  significant	  and	  are	  accounted	  for	   in	   the	  high	  cost	  of	  patented	  drugs.	  
Consequently,	  the	  discovery	  of	  new	  drugs	  for	  leishmaniasis,	  and	  other	  neglected	  tropical	  
diseases,	  for	  which	  the	  average	  patient	  suffering	  from	  visceral	  leishmaniasis	  (VL)	  exists	  on	  
an	   income	   of	   less	   than	   $2	   per	   day,	   is	   simply	   not	   a	   commercially	   viable	   operation	   for	  
pharmaceutical	  companies	  without	  significant	  cross-­‐subsidy.	  	  
	  
Alternative	   strategies	   are	   therefore	   needed	   and	   the	   process	   of	   drug	   repositioning	   or	  
repurposing,	  where	  new	  applications	  for	  existing	  drugs	  or	  drug	  candidates	  are	  discovered	  
and	  refined,	  has	  become	  increasingly	  common.4,5,6,7,8,9,10	  When	  using	  a	  drug	  repositioning	  
strategy	  several	  development	  phases	  necessary	  to	  develop	  NCE	  drugs	  can	  be	  bypassed	  or	  
considerably	  shortened	  (Figure	  1)	  because	  candidates	  will	  have	  passed	  various	  checkpoints	  
and	   information	   is	   available	   about	   their	   pharmacokinetic	   and	   safety	  profiles.	   Reflecting	  
this,	  the	  process	  of	  finding	  new	  uses	  for	  drugs	  outside	  their	  original	  indication	  is	  becoming	  
increasingly	  successful	  as	  more	  companies	  are	  screening	  their	   libraries	   for	   repositioning	  
candidates.	   Figure	   2	   illustrates	   two	   examples	   of	   approved	   drugs	   possessing	   optimum	  
properties	   for	   their	   new	   indication.	   However,	   it	   should	   be	   noted	   that	   these	   cases	   are	  
relatively	  rare	  and	  some	  development	  work	  is	  still	  commonly	  required.	  Moreover,	  whilst	  
serendipity	  (phenotypic	  screening)	  can	  play	  a	  sizeable	  role	  in	  identifying	  repurposed	  drugs,	  
it	  is	  important	  to	  establish	  the	  molecular	  connection	  between	  old	  drugs	  and	  new	  targets	  
as	  this	  information	  aids	  the	  development	  of	  the	  new	  therapeutics.	  Despite	  these	  caveats	  
drug	  repositioning	  can	  reduce	  time,	  cost	  and	  risk,	  and	  is	  a	  particularly	  attractive	  approach	  
for	  neglected	  tropical	  diseases	  where	  new	  medications	  are	  needed	  urgently	  to	  treat	  the	  
poorest	  of	  people.	  This	  review,	  will	  focus	  on	  the	  neglected	  tropical	  disease,	  leishmaniasis,	  
and	  how	   repositioning	   strategies	   have	   shown	  potential	   to	   enable	   the	  discovery	  of	   new	  
medicines	  for	  this	  disease.	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Leishmaniasis	   is	   an	   important	   vector	   borne	   ´Neglected	   Tropical	   Disease’	   caused	   by	  
protozoan	   parasites	   of	   the	   genus	   Leishmania.11	   Leishmania	   spp.	   (causative	   agent	   of	  
Leishmaniasis),	  Trypanosoma	  brucei	  (causative	  agent	  of	  Human	  African	  Trypanosomiasis,	  
HAT),	   and	   Trypanosoma	   cruzi	   (causative	   agent	   of	   Chagas	   disease)	   belong	   to	   the	  
Trypanosomatidae	   family.	   Trypanosomatids	   are	   a	   subgroup	   of	   Kinetoplastids	   and	  
distinguished	  by	  having	  only	  a	  single	  flagellum	  (Figure	  3).	  
Over	   350	  million	   people	  world	  wide	   are	   considered	   at	   risk	   of	   leishmaniasis,	   12	  million	  
people	  currently	  infected12	  and	  one	  million	  new	  cases	  reported	  annually.	  This	  has	  resulted	  
in	  more	  than	  30,000	  deaths	  each	  year13	  and	  an	  economic	  cost	  that	  can	  be	  best	  estimated	  
in	  terms	  of	  2.4	  million	  disability	  adjusted	  life	  years,	  the	  health	  challenge	  is	  only	  surpassed	  
amongst	   parasitic	   diseases	   by	   malaria,	   schistosomiasis	   and	   lymphatic	   filariasis.14,15	  







Thalidomide first marketed as a mild 
sleeping pill caused birth defects around 















Sildenafil (Viagra) origionally discovered as a
 treatment for cardiovascular disorders. It is now
 used as a treatment for erectile dysfunction and
 pulmonary arterial hypertension.
Figure	  3:	  Taxonomy	  of	  Kinetoplastida	  (the	  Leishmania	  species	  shown	  are	  those	  of	  major	  medical	  importance	  to	  
humans)	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as	  Category	  I:	  emerging	  or	  uncontrolled	  diseases.	  In	  particular,	  the	  spread	  and	  severity	  of	  
infection	  is	  exacerbated	  by	  its	  status	  as	  an	  important	  co-­‐infection	  of	  AIDS	  patients	  and	  the	  
overlap	  in	  prevalence	  of	  HIV	  and	  Leishmania	  spp.16	  The	  disease	  is	  endemic	  in	  98	  countries	  
across	   5	   continents	   and	   has	   strong	   links	  with	   poverty,	   principally	   affecting	   low	   income	  
regions	  of	  Africa,	  Asia	  and	  Latin	  America.17	  However,	  the	  impact	  of	  the	  disease	  is	  spreading	  
and,	   reflecting	  population	  movements	   and	   climate	   change,	   leishmaniasis	   has	   also	  been	  
recorded	  with	  growing	  frequency	  in	  Southern	  Europe.18	  
	  
Leishmaniasis	  is	  transmitted	  through	  the	  bite	  of	  infected	  female	  phlebotomine	  sandflies.	  
Subsequently,	  in	  the	  mammalian	  host,	  flagellated	  promastigote	  Leishmania	  spp.	  are	  taken	  
up	   by	   macrophages	   where	   they	   transform	   into	   the	   non-­‐flagellated	   amastigote	   form,	  
proliferate	  and	  cause	  disease.	  Infected	  macrophages	  can	  then	  be	  taken	  up	  by	  the	  insect	  
vector	  during	  a	  second	  blood	  meal,	  the	  parasite	  then	  transforms	  back	  to	  the	  promastigote	  
form	  and	  the	  cycle	  is	  perpetuated	  (Figure	  4).	  	  Importantly,	  many	  Leishmania	  spp.	  can	  infect	  
multiple	   mammalian	   species	   leading	   to	   animal	   reservoirs	   for	   human	   infection,	   most	  
notably	  in	  canines.19	  
	  
Human	  disease	  is	  caused	  by	  20	  of	  the	  31	  parasite	  species	  that	  infect	  mammals	  with	  the	  
different	   species	   leading	   to	   different	   clinical	   manifestations.20	   Depending	   on	   parasite	  
tropism	   for	   skin	  or	   visceral	  macrophages,	   and	  host	   immune	   status,	   clinical	   forms	   range	  
from	   localised	   cutaneous	   leishmaniasis	   (CL),	   diffuse	   CL,	   disseminated	   CL,	   mucosal	  
leishmaniasis	  (ML),	  to	  visceral	  leishmaniasis	  (VL)	  (Table	  1).	  The	  most	  common	  form	  of	  the	  
Figure	  4:	  Life	  cycle	  of	  Leishmania	  spp.	  (reproduced	  from	  CDC19	  with	  permission)	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disease	   is	   CL	  which,	   although	   not	   fatal,	   leads	   to	   slow	   growing	   skin	   lesions	  which	   leave	  
permanent	  scars	  and	  in	  some	  cases	  cause	  serious	  disability.	  ML	  is	  the	  most	  disfiguring	  form	  
and	  causes	  destruction	  of	  soft	  tissue	  in	  the	  nose,	  mouth	  and	  throat.	  In	  contrast,	  VL	  is	  the	  
most	  severe	  form	  of	  the	  disease	  as	  it	  affects	  the	  vital	  organs	  of	  the	  body	  and	  is	  fatal	  if	  left	  
untreated.21	  
	  
Treatment	   of	   leishmaniasis	   is	   challenging	   and	   there	   are	   currently	   no	   vaccines	   or	  
prophylactic	   drugs	   to	   prevent	   human	   infection.	   For	   over	   70	   years,	   the	   mainstay	   of	  
antileishmanial	  therapy	  has	  been	  pentavalent	  antimonials	  (Pentostam	  2	  and	  Glucantime	  3)	  
which	  are	  administered	  by	   slow	   intravenous	  or	   intramuscular	   injections.22	  The	  mode	  of	  
action	  is	  not	  fully	  understood	  but	  one	  possibility	  involves	  the	  biological	  reduction	  of	  Sb(V)	  
to	   Sb(III)	   by	   the	   parasite	   or	   by	   infected	   host	   cells	   to	   create	   antileishmanial	   activity.23,24	  
Unfortunately,	   antimonials	   are	   also	   toxic25	   and	   reports	   of	   resistance	   are	   becoming	  
increasingly	  common.	  For	  example,	  a	  study	  of	  the	  efficacy	  of	  Pentostam	  2,	  in	  North	  Bihar,	  
India,	  revealed	  that	  only	  36%	  of	  patients	  could	  be	  cured	  when	  treated	  with	  a	  dose	  of	  20	  
mg	  kg-­‐1	  for	  30	  days.26	  
	  
For	  the	  past	  seven	  decades,	  amphotericin	  B	  4	  (AmpB)	  and	  pentamidine	  5	  have	  been	  used	  
in	   case	   of	   antimonial	   failure.22	   Pentamidine	   5	   is	   an	   antimicrobial	   medication	   that	   was	  
commonly	  used	  as	  a	   second	   line,	  parenteral,	   treatment	   for	   leishmaniasis	   in	   the	  case	  of	  
antimonial	  failure.	  The	  primary	  mode	  of	  action	  of	  pentamidine	  5	   in	  kinetoplastids	   is	  not	  
well	  understood	  but	  there	  is	  some	  evidence	  that	  it	  inhibits	  the	  active	  transport	  system	  and	  
disrupts	   the	   mitochondrial	   membrane	   potential.	   However,	   pentamidine	   5	   has	   lower	  
efficacy	  than	  AmpB	  427	  and	  this,	  coupled	  with	  severe	  toxicity,	  have	  resulted	  in	  a	  gradual	  
decline	  in	  its	  use.28	  
	  
The	  antifungal	  drug	  AmpB	  4,	  first	  isolated	  in	  1955,	  was	  reported	  to	  have	  antileishmanial	  
activity	   in	  the	  early	  1960s.	  AmpB	  4	  binds	  to	  ergosterol,	  forming	  pores	   in	  the	  membrane	  
which	   leads	   to	   the	   death	   of	   the	   parasite.29	   Whilst	   severe	   side	   effects	   limited	   its	   use,	  
liposomal	  formulations	  that	  circumvent	  these	  problems	  have	  been	  developed.	  However,	  a	  
course	  of	  L-­‐AmpB	  4	  still	  requires	  parenteral	  administration	  and,	  without	  extensive	  subsidy	  
is	  expensive	  (up	  to	  $3,000	  per	  course).	  This	  makes	  L-­‐AmpB	  4	  inaccessible	  to	  most	  patients	  
who	  live	  in	  the	  poorest,	  least	  developed	  regions.	  In	  comparison,	  an	  equivalent	  course	  of	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pentavalent	  antimonials	  costs	  between	  $150	  and	  $198.30	  Despite	  this,	  L-­‐AmpB	  4	   is	  now	  
often	  preferred	  over	  Pentostam	  2	  for	  VL	  because	  it	  is	  less	  toxic	  and	  there	  are	  fewer	  reports	  
of	  parasitic	  resistance.26,31	  	  	  
	  
Along	  with	  L-­‐AmpB	  4,	  paromomycin	  6	  and	  miltefosine	  7	  are	  now	  approved	  drugs	  for	  VL.32	  
Paromomycin	  6	  is	  an	  antibiotic	  and	  a	  relatively	  new	  therapy	  for	  the	  parenteral	  treatment	  
of	  VL	  in	  India.	  It	  has	  been	  shown	  to	  be	  effective	  and	  relatively	  cheap	  first-­‐line	  treatment	  
with	  low	  toxicity,	  requiring	  a	  course	  of	  15	  mg/kg	  for	  21	  days.28,33	  The	  mechanism	  of	  action	  
is	  not	   fully	  understood	  but	   it	   is	   thought	  to	   inhibit	  protein	  synthesis.34	  As	  with	  the	  other	  
treatments	  there	  are	  drawbacks,	  the	  drug	  is	  administered	  by	  injection35	  and	  shows	  poor	  
efficacy	  in	  some	  regions	  in	  Africa.36	  	  
	  
As	   discussed	   above,	   these	   current	   medications	   all	   involve	   prolonged	   parenteral	  
administration	   which	   leads	   to	   many	   complications,	   including	   poor	   patient	   compliance,	  
blood-­‐borne	   disease	   from	   unsanitary	   conditions	   and	   the	   need	   for	   medical	   facilities.	  
Therefore,	   in	   the	   past	   two	   decades	   there	   has	   been	   a	   focus	   on	   developing	   new	   oral	  
therapies.	   In	   2002	   miltefosine	   7,	   originally	   developed	   as	   an	   anticancer	   agent,	   was	  
introduced	  as	   the	   first	  oral	  antileishmanial	  agent.37	  The	  primary	  mechanism	  of	  action	   is	  
poorly	   understood,	   although	   the	   drug	   is	   thought	   to	   involve	   disruption	   of	   ether-­‐
phospholipid	   metabolism,	   glycosylphosphatidylinositol	   anchor	   biosynthesis	   and	   signal	  
transduction	  within	  the	  parasite.28	  Miltefosine	  7	  efficacy	  against	  both	  VL	  and	  CL	  has	  been	  
reported	  and,	   in	   2014,	   the	  US	   Food	  and	  Drug	  Administration	  approved	   the	  drug	   for	   all	  
forms	  of	  leishmaniasis.38	  However,	  this	  oral	  therapy	  does	  have	  limitations,	  including	  high	  
costs	  and	   teratogenic	  effects.	  Moreover,	   the	   long-­‐term	  effectiveness	  of	  miltefosine	  7	   is	  
questionable,	  with	  reports	  of	  VL	  relapses	   in	  Nepalese	  patients	  treated	  with	  this	  drug.	   In	  
addition,	  miltefosine	  7	  resistance	  is	  readily	  induced	  in	  L.	  donovani	  in	  vitro.39	  
	  
In	  conclusion,	  all	  current	  treatments	  (Figure	  5)	  have	  serious	  limitations	  such	  as	  high	  cost,	  
route	  of	  administration,	  severe	  toxic	  side	  effects	  and	  increasing	  drug	  resistance.	  Currently,	  
there	   are	   some	   new	   therapies	   under	   clinical	   investigation	   as	   monotherapies	   or	   in	  
combination	   with	   existing	   antileishmanials.40,40,41,42,43,44	   These	   include	   paromomycin	   6	  
topical	  cream,	  currently	  in	  phase	  3	  trials	  as	  a	  treatment	  for	  CL,	  and	  sitamaquine	  8	  in	  phase	  
2	  to	  treat	  VL.	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Figure	  5:	  Current	  antileishmanials	  
1.4.	  Repositioning	  of	  drugs	  targeting	  leishmaniasis	  
	  
Significantly,	   as	   noted	   above	   in	   the	   Introduction,	   many	   of	   the	   existing	   therapies	   for	  
leishmaniasis	  are	  licensed	  or	  were	  initially	  intended	  for	  other	  illnesses.	  For	  example,	  AmpB	  
4	   is	   an	   antifungal	   drug,	   paromomycin	   6	   is	   an	   aminoglycoside	   antibiotic	   used	   to	   treat	  
intestinal	   infections,	  and	  miltefosine	  7	  was	  originally	  developed	  as	  an	  anticancer	  agent.	  
This	   section	   will	   review	   drugs	   for	   different	   disease	   states;	   cancer,	   microbial	   infection,	  
depression,	   allergies	   and	   others;	   that	   have	   shown	   potential	   to	   be	   repurposed	   as	   new	  
antileishmanial	  therapies,	  and	  discuss	  their	  putative	  parasitic	  drug	  targets.	  	  
	  
It	  should	  be	  noted	  that	  many	  natural	  products	  often	  used	   in	  traditional	  medicines	  have	  
antileishmanial	  activity,	   including	  vast	  numbers	  of	  different	  alkaloids,45,46	   flavonoids,47,48	  
chalcones49,50,51,52	   and	   terpenoids.53,54,55,56	   These	   compounds	   have	   been	   discussed	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molecules,	  often	  affecting	  multiple	  targets	  and	  possess	  properties	  that	  make	  them	  unlikely	  
to	   be	   orally	   active	   drugs.	   As	   such	   the	   greatest	   potential	   of	   natural	   products	   is	   for	   the	  
identification	  of	  novel	  targets	  required	  to	  underpin	  target-­‐based	  drug	  discovery	  and	  not	  as	  
starting	  points	  for	  a	  repositioning	  strategy	  and	  therefore	  they	  will	  not	  be	  discussed	  further	  
in	  this	  review.	  
	  
1.4.1.	  Anticancer	  drugs	  	  
	  
Both	  cancerous	  cells	  and	  Leishmania	  spp.	  have	  the	  ability	  to	  proliferate	  in	  a	  host	  organism	  
for	  prolonged	  periods	  of	  time	  and	  some	  enzymes	  targeted	  by	  anticancer	  therapies	  can	  also	  
be	  used	  in	  the	  development	  of	  antileishmanials	  (Figure	  6,	  Appendix	  A).59,60	  	  
	  
Kinases	  have	  long	  been	  recognised	  as	  a	  major	  target	  in	  oncology	  and	  this	  has	  spawned	  a	  
number	  of	  efforts	  to	  repurpose	  a	  range	  of	  kinase	  inhibitors	  for	  leishmaniasis.	  For	  example,	  
miltefosine	  7	  is	  the	  first,	  and	  still	  the	  only,	  oral	  drug	  in	  the	  treatment	  of	  VL	  but	  was	  originally	  
developed	   as	   a	   treatment	   for	   breast	   cancer.	   Like	  many	   anticancer	   drugs,	  miltefosine	  7	  
induces	   apoptosis	   through	   kinase	   inhibition.	   In	   this	   case	   the	   PI3K/Akt/PkB	   pathway	   is	  
targeted	   and	   it	   has	   been	   reported	   that	   inhibition	   of	   this	   pathway	   may	   influence	   the	  
susceptibility	  of	  host	  cell	  to	  Leishmania	  infection.38	  	  
	  
The	  genomes	  of	  trypanosomatids	  encode	  at	  least	  12	  proteins	  belonging	  to	  the	  PI3K	  protein	  
superfamily,	  many	  of	  which	  are	  unique	  to	  the	  parasites.	  The	  Target	  of	  Rapamycin	  (TOR)	  
kinase	   is	  a	  member	  of	   the	  PI3K-­‐related	  kinase	   (PKK)	  subfamily	  and	  has	  a	  central	   role	   in	  
fundamental	   processes	   such	   as	   growth,	   cell	   shape	   and	   autophagy.	   Trypanosomatids	  
possess	  four	  distinct	  genes	  belonging	  to	  the	  TOR	  family	  whereas	  mammals	  only	  possess	  
one	  mTOR	  protein.	  On	  this	  basis,	  a	  targeted	  set	  of	  eight	  known	  mTOR	  inhibitors	  with	  varied	  
potencies	   and	   selectivity	   for	   mTOR/PI3K	   were	   screened	   against	   T.	   brucei,	   T.	   cruzi,	  
cutaneous	  L.	  major	  and	  visceral	  L.	  donovani.	   	  From	  these	  data,	   the	  mTor/PI3K	   inhibitor,	  
Dactolisib	  9,	  was	   identified	   as	   being	   the	  most	   active	   against	   all	   the	   species	   tested	   and	  
therefore	   was	   tested	   in	   animal	  models	   of	   T.	   brucei	   rhodesiense,	   T.	   cruzi	   and	   L.	   major.	  
Unfortunately,	  no	  efficacy	  was	  observed	  against	  either	  T.	  cruzi	  or	  L.	  major;	  this	  may	  reflect	  
the	  need	  for	  the	  drug	  to	  cross	  into	  the	  phagolysosomal	  compartment	  where	  the	  parasite	  
resides.	  In	  contrast,	  and	  consistent	  with	  this	  hypothesis,	  Dactolisib	  9	  significantly	  reduced	  
the	  parasite	  burden	  and	  extended	  the	  survival	  of	  mice	  infected	  with	  T.	  brucei	  rhodesiense,61	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a	  blood	  stream	  parasite.	  Although	  the	  exact	  mechanism	  of	  action	  has	  yet	  to	  be	  identified	  
this	  investigation	  has	  demonstrated	  a	  potential	  target	  in	  the	  search	  for	  antitrypanosomal	  
therapies.	  	  
	  
Similar	  small	  scale	  focused	  screens	  against	  specific	  kinase	  targets	  have	  been	  conducted.	  
For	   example,	   through	   exploring	   Aurora	   kinases,	   hesperidin	  10	   has	   been	   identified	   as	   a	  
putative	  antileishmanial	  lead	  but	  host	  cell	  toxicity	  was	  observed	  when	  the	  compound	  was	  
screened	   against	   the	   hepatic	   cancer	   cell	   line.62	   Although,	   further	   structure-­‐activity	  
relationship	  (SAR)	  studies	  demonstrated	  that	  these	   inhibitors	  are	  not	  general	  toxins	  but	  
can	  be	  modified	  to	  improve	  selectivity,	  useful	  antileishmanial	  selectivity	  was	  not	  obtained.	  
More	  significantly,	  and	  consistent	  with	  other	  reports,63	  there	  was	  no	  correlation	  between	  
activity	   against	   promastigotes	   and	   axenic	   amastigotes	   with	   the	   latter	   being	   the	   less	  
sensitive	  form.	  
	  
Although	   target-­‐based	   screening	   is	   an	   attractive	   strategy,	   the	   need	   for	   a	   specific	  
orthologous	  target	  protein	  may	  not	  be	  essential	  as	  many	  kinase	  inhibitors	  affect	  multiple	  
proteins	   and	   simply	   the	   proven	   cellular	   accessibility	   of	   these	   compounds	   is	   a	   sufficient	  
starting	  point.	   	  For	  example,	  tyrosine	  kinases	  are	  not	  expressed	  in	  trypanosomatids,	  but	  
protein	  phosphorylation	  occurs	   in	  parasites	  and	  therefore	  kinase	  inhibitors	  may	  interact	  
with	  other	  enzymes.64,65	  Reflecting	   this,	   in	  a	   screen	  of	  eleven	   tyrosine	  kinase	   inhibitors,	  
sunitib	   11,	   sorafenib	   12	   and	   lapatinib	   13	   showed	   antileishmanial	   activity	   against	  
intracellular	   L.	   donovani	   amastigotes.66	   Control	   experiments	   confirmed	   that	   the	  
leishmanial	  targets	  were	  unlikely	  to	  be	  the	  same	  as	  those	  found	  in	  mammalian	  cells	  and	  
these	  kinase	  inhibitors	  showed	  a	  degree	  of	  selectivity	  against	  amastigotes	  compared	  with	  
mammalian	   cells.	   In	   addition,	   an	   oral	   dose	   of	   sunitib	  11,	   sorafenib	  12	  and	   lapatinib	  13	  
reduced	   liver	   parasite	   burden	   in	   mice	   infected	   with	   L.	   donovani.	   Whilst	   these	   screens	  
identify	  new	  leads,	  the	  challenge	  for	  such	  studies	  is	  in	  the	  identification	  of	  the	  actual	  target	  
to	  guide	  further	  optimisation.	  	  
	  
Kinases	   also	   proved	   to	   be	   the	   most	   common	   predicted	   target	   from	   a	   set	   of	   192	  
antileishmanial	   compounds	   identified	   from	  a	  high	   throughput	  phenotypic	   screen	  of	   1.8	  
million	  compounds	  against	   representative	  kinetoplastid	  species,	   including	  L.	  donovani.65	  
However,	  since	  most	  of	  these	  compounds	  have	  no	  literature	  precedent	  this	  was	  not	  strictly	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a	  repurposing	  study,	  and	  further	  discussion	  is	  outside	  the	  scope	  of	  this	  review.	  Finally,	  an	  
interesting,	  and	  somewhat	  different,	  study	  involving	  the	  repurposing	  of	  kinase	  inhibitors,	  
was	  the	  use	  of	  imatinib	  14	  (Gleevec,	  another	  tyrosine	  kinase	  inhibitor	  used	  in	  the	  treatment	  
of	  multiple	   cancers)	   to	   target	   the	  host	  macrophage	  AbI	   and	  Arg	   kinases	  believed	   to	  be	  
involved	  in	  parasite	  entry	  to	  the	  cell.	  Mice	  infected	  with	  L.	  amazonensis	  were	  treated	  with	  
oral	  imatinib	  14	  which	  resulted	  in	  smaller	  lesions	  that	  developed	  later	  and	  a	  reduction	  in	  
parasite	   burden	   relative	   to	   controls.67	   Imatinib	   14	   is	   a	   clinically	   approved	   drug	   with	  
relatively	  benign	  side	  effects	  when	  compared	  to	  antileishmanials	  on	  the	  market.	  It	  would	  
be	  of	  great	  benefit	  to	  further	  understand	  the	  cell	  entry	  pathway	  to	  provide	  new	  lines	  of	  
therapy	  for	  leishmaniasis.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	  approach	  of	  starting	  with	  inhibitors	  with	  known	  modes	  of	  action,	  for	  example	  against	  
mammalian	  kinases,	  and	  screening	  for	  new	  antileishmanial	  activities	  for	  which	  orthologous	  
protozoal	  targets	  can	  then	  be	  identified	  is	  an	  attractive	  concept.	  However,	  good	  levels	  of	  
host	  parasite	  selectivity	  are	   required	  before	  any	  hits	  can	  be	  repurposed	  as	  antiparasitic	  
therapeutics.	  This	  was	  nicely	  illustrated	  in	  a	  study	  exploring	  Lysine	  Deacetylases	  (KDAC)	  as	  
putative	  antileishmanial	  drug	  targets.	  KDACs	  are	  one	  of	  the	  most	  studied	  epigenetic	  drug	  
targets	   of	   humans68	   and	   inhibition	   of	   their	   activity	   is	   a	   validated	   strategy	   for	   cancer	  
treatment.69	  As	  with	   the	  kinases	  discussed	  above,	  Leishmania	   spp.	  have	  multiple	  genes	  
encoding	  different	  KDACs	  isoenzymes	  some	  of	  which	  are	  essential	  to	  parasite	  survival.69	  
Whilst,	  the	  homology	  between	  kinetoplastid	  and	  mammalian	  KDACs	  is	  low	  (~40%)	  much	  
higher	   levels	   of	   similarity	   are	   found	   in	   active	   site	   residues.68	   Reflecting	   this	   only	   one	  
compound,	  Hydroxamate	  15,	   showed	  significant	   selectivity	   (~10	   fold)	  between	  host	  cell	  
and	  parasite	  and	  high	  (nanomolar)	  activity	  against	  axenic	  L.	  donovani	  amastigotes.68	  
	  
Paclitaxel	  16	  is	  sold	  under	  the	  brand	  name	  Taxol	  and	  is	  used	  to	  treat	  a	  number	  of	  cancers.	  
Drugs	  that	  target	  microtubule	  assembly	  may	  be	  a	  class	  of	  potential	  antileishmanials	  since	  
tubulin	  is	  one	  of	  the	  most	  abundant	  leishmanial	  proteins.70	  Unlike	  many	  drugs	  that	  target	  
tubulin,	  paclitaxel	  16	  does	  not	  inhibit	  microtubules	  but	  stabilises	  their	  assembly,	  which	  in	  
turn	   blocks	   mitosis.	   Taxol	   at	   nanomolar	   concentrations	   inhibits	   the	   growth	   of	   both	   L.	  
donovani	  promastigotes	  and	  intracellular	  amastigotes	  and	  was	  selective	  for	  the	  parasite	  
over	  the	  mammalian	  macrophage.71,70	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In	  the	  cell	  cycle,	  the	  interphase	  is	  before	  the	  mitotic	  (M)	  phase	  and	  is	  an	  important	  period	  
for	  antileishmanials	  to	  target.	  The	  interphase	  can	  be	  broken	  down	  into	  three	  steps:	  The	  G1	  
phase	  responsible	  for	  cell	  growth	  and	  increasing	  number	  of	  proteins	  and	  organelles;	  the	  S	  
phase	  involving	  DNA	  duplication	  and	  histone	  production	  and	  finally	  the	  G2	  phase	  which	  is	  
the	  last	  chance	  the	  cell	  has	  to	  prepare	  for	  mitosis	  and	  involves	  further	  duplication	  of	  DNA,	  
organelle	  replication	  and	  protein	  synthesis.72	  	  	  	  
	  
Hydroxyurea	  17	  is	  used	  to	  treat	  myelogenous	  leukemia	  and	  cervical	  cancer	  as	  well	  as	  sickle-­‐
cell	  disease.	  More	   recently,	  hydroxyurea	  17	  has	  been	  shown	   to	  possess	   in	  vitro	   activity	  
against	  L.	  mexicana	   causing	  cell	   cycle	  arrest	  at	   the	  G1/S	   transition	   in	  promastigotes.	  As	  
such,	  hydroxyurea	  17	  is	  a	  potential	  drug	  candidate	  to	  treat	  leishmaniasis	  with	  the	  added	  
advantage	  of	  conventionally	  being	  administered	  orally.73	  
	  
Cisplatin	  18	  is	  another	  anticancer	  drug,	  which	  has	  been	  shown	  to	  cause	  cell	  cycle	  arrest	  in	  
Leishmania,	  but	  this	  time	  at	  the	  S	  and	  G2	  phases	  in	  promastigotes	  and	  axenic	  amastigotes.	  
This	  platinum-­‐containing	  drug	  is	  used	  to	  treat	  various	  cancers	  and	  has	  shown	  in	  vitro	  and	  
in	   vivo	   activity	   against	   VL.74,75	  However,	   cisplatin	  18	   does	   not	   completely	   eliminate	   the	  
parasite	  at	  the	  low	  dosages	  of	  0.5	  and	  1	  mg	  kg-­‐1	  and	  higher	  doses	  (≥	  1	  mg	  kg-­‐1)	  can	  cause	  
nephrotoxicity.	  Therefore,	  a	  more	  recent	  study	  has	  used	  5	  and	  2.5	  mg	  kg-­‐1	  of	  cisplatin	  18	  in	  
combination	   with	   different	   antioxidants	   (e.g.	   vitamin	   C,	   vitamin	   E	   and	   silibinin)	   to	  
successfully	  reduce	  nephrotoxicity	  and	  parasite	  burden	  making	  the	  combination	  a	  potential	  
antileishmanial	   therapy.76	   In	  addition,	  nanocarriers	   (e.g.	  single-­‐	  and	  multi-­‐walled	  carbon	  
nanotubes)	  improve	  the	  intracellular	  uptake	  of	  the	  drug	  in	  infected	  cells,	  and	  effectively	  
reduce	  the	  dosage.	  For	  example,	  a	  recent	  study	  showed	  that	  cisplatin	  18	  bound	  to	  multi-­‐
walled	  carbon	  nanotubes	  had	  greater	  activity	  and	  selectivity	  against	  L.	  major	  amastigotes	  
compared	   to	   free	   cisplatin	   18;	   however,	   the	   efficacy	   of	   this	   therapy	   still	   needs	   to	   be	  
evaluated	  in	  an	  animal	  model.77	  
	  
Doxorubicin	  19	  is	  used	  to	  treat	  a	  range	  of	  cancers	  through	  inhibition	  of	  topoisomerase	  II	  
and	  shows	  in	  vitro	  activity	  against	  VL.	  Like	  cisplatin	  18,	  nanocapsules	  bearing	  doxorubicin	  
NCs-­‐19	  have	  been	  prepared	  and	  show	  greater	  activity	  than	  free	  doxorubicin	  19	  both	  in	  vitro	  
and	  in	  vivo.78	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A	   final	   class	   of	   anticancer	   agents	   that	   may	   have	   potential	   as	   antileishmanials	   are	   the	  
selective	  estrogen-­‐receptor	  modulators,	  tamoxifen	  20	  and	  raloxifene	  21.	  Tamoxifen	  20	  is	  
used	  to	  prevent	  and	  treat	  breast	  cancer	  and	  whilst	   raloxifene	  21	  can	  reduce	  the	  risk	  of	  
breast	  cancer	  in	  those	  at	  high	  risk,	  it	  is	  mostly	  used	  to	  prevent	  and	  treat	  osteoporosis	  in	  
post-­‐menopausal	   women.	   Both	   have	   been	   identified	   as	   potential	   candidates	   for	  
leishmaniasis	   treatment	   with	   micro-­‐molar	   potency	   against	   intracellular	   L.	   amazonensis	  
amastigotes.79,80,81	  The	  exact	  mechanism	  of	  action	  of	  tamoxifen	  20	  and	  raloxifene	  21	  is	  still	  
unclear	  as	  estrogen	  responses	  have	  not	  been	  described	  in	  Leishmania	  spp.82,83	  However,	  a	  
recent	   study	   showed	   one	   of	   the	   most	   likely	   targets	   of	   tamoxifen	   20	   is	   inositol	  
phosphorylceramide	  synthase	   (IPCS).	  As	   it	  will	  be	  discussed	   in	  chapter	  2,	   this	  enzyme	   is	  
involved	  in	  the	  biosyntheisis	  of	  sphingolipids,	  which	  are	  essential	  components	  of	  the	  cell	  
membrane	  in	  Leishmania.	  Sphingolipids	  are	   important	   in	  a	  range	  of	  biological	  processes	  
such	   as	   cell	   signalling,	   growth,	   differentiation	   and	   apoptosis.	   In	   addition,	   inositol	  
phosphorylceramide	  (IPC)	  is	  the	  most	  abundant	  sphingolipid	  in	  Leishmania	  and	  is	  absent	  in	  
mammalian	   cells.84	   Therefore,	   IPCS,	   which	   is	   the	   enzyme	   responsible	   for	   IPC,	   has	   the	  
potential	  to	  be	  a	  valuable	  target	  for	  new	  antileishmanials	  and	  will	  be	  discussed	  in	  more	  
detail	  in	  later	  chapters	  of	  this	  thesis.	  
	  
In	  contrast,	  raloxifene	  21	  is	  thought	  to	  damage	  the	  cell	  membrane	  and	  the	  mitochondrion	  
of	   the	   parasite.79	   Whilst	   the	   antileishmanial	   activity	   of	   these	   compounds	   has	   not	  
necessarily	  been	  optimised,	   the	  proven	   safety	  profile	  of	   these	   repurposed	  drugs	  allows	  
them	   to	   be	   considered	   as	   synergists	   in	   combination	   therapies	   to	   help	   combat	   growing	  
concerns	   about	   the	   emergence	   of	   parasitic	   resistance.	   For	   instance,	   combination	   of	  
tamoxifen	  20	  and	  miltefosine	  7	   in	  vitro	  and	   in	  vivo	  revealed	  no	  interaction	  between	  the	  
two	  drugs	  and	  suggested	   that	   tamoxifen	  20	   could	   slow	   the	  emergence	  of	  miltefosine	  7	  
resistance.80	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Figure	  6:	  Treatments	  for	  cancer	  that	  could	  be	  repurposed	  as	  antileishmanials	  
	  
1.4.2.	  Antimicrobial	  drugs	  	  
	  
An	  antimicrobial	  is	  any	  compound	  that	  kills	  or	  inhibits	  the	  growth	  of	  a	  microorganism;	  this	  
can	  include	  bacteria,	  fungi,	  viruses	  and	  protozoa.	  Antimicrobial	  drugs	  that	  were	  originally	  
licensed	  for	  other	  indications	  have	  already	  been	  repurposed	  as	  antileishmanial	  therapies.	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used	  to	  treat	  the	  parasitic	  diseases,	  cryptosporidiosis	  and	  amoebiasis.	  These	  examples	  of	  
successfully	  repurposed	  antimicrobials	  as	  treatments	   for	   leishmaniasis	  have	  encouraged	  
further	  investigation	  into	  the	  leishmanicidal	  activity	  of	  other	  antimicrobial	  drugs	  (Figures	  
7-­‐10,	  Appendix	  A).	  
1.4.3.	  Antifungals	  
	  
As	  discussed	  above,	  the	  main	  use	  of	  AmpB	  4	  is	  in	  the	  treatment	  of	  a	  wide	  range	  of	  fungal	  
infections	  but	  is	  now	  also	  used	  to	  treat	  VL.	  Liposomal	  AmpB	  4	  is	  the	  treatment	  of	  choice	  
for	   immunocompetent	  patients	   in	  the	  Mediterranean	  region	  and	  the	  preferred	  drug	  for	  
HIV/VL	   co-­‐infection.85	  AmpB	  4	   functions	  by	  binding	   to	  ergosterol	   disrupting	   the	  plasma	  
membrane.	  This	  is	  the	  major	  sterol	  of	  the	  fungal	  plasma	  membranes	  and	  there	  are	  other	  
antifungal	  azoles,	  which	  inhibit	  C14α-­‐demethylase,	  an	  essential	  enzyme	  in	  the	  biosynthesis	  
of	  ergosterol.	  As	  the	  sterol	  biosynthesis	  pathway	  is	  conserved	  in	  Leishmania	  spp.	  parasites	  
and	   is	   important	   for	   their	   survival,86	   these	   antifungal	   azoles	   have	   the	   potential	   to	   be	  
repurposed	  as	  antileishmanials.	  	  
	  
Fluconazole	   22	   and	   terbinafine	   23,	   two	   antifungal	   azoles	   which	   have	   similar	  modes	   of	  
actions,	  can	  be	  administered	  orally	  and	  possess	  low	  levels	  of	  toxicity;	  therefore,	  the	  use	  of	  
these	   drugs	   as	   putative	   antileishmanials	   in	   clinical	   trials	   can	   be	   approached	  with	   some	  
confidence.	  Oral	  fluconazole	  22	  was	  shown	  to	  be	  a	  safe	  and	  useful	  drug	  for	  the	  treatment	  
of	  CL	  caused	  by	  L.	  major	  41	  and	  was	  reported	  to	  be	  more	  efficacious	  in	  higher	  doses	  after	  a	  
phase	  2	  clinical	   study.87	  However,	  a	   recent	  phase	  3	  clinical	   trial	  of	   the	  use	  of	  high	  dose	  
fluconazole	   22	   in	   the	   treatment	   CL	   caused	   by	   L.	   braziliensis	   and	   L.	   guyanensis	   was	  
terminated	  due	  to	  a	  low	  cure	  rate,	  suggesting	  species	  dependent	  activity.88	  The	  potential	  
for	  terbinafine	  23	  as	  a	  new	  treatment	  for	  CL	  was	  first	  described	  in	  1997.	  Significantly,	  at	  
the	   dosage	   used,	   no	   patients	   reported	   any	   side	   effects.	   However,	   the	   efficacy	   appears	  
lower	   than	   other	   azole	   antifungals	   notably,	   ketoconazole	   24	   and	   itraconazole	   25,	   and	  
further	   investigation	   is	   required	   to	   optimise	   the	   efficacy	   of	   the	   drug	   before	   it	   can	   be	  
considered	  as	  an	  effective	  solution.40	  One	  method	  being	  investigated	  is	  using	  terbinafine	  
23	   in	   combination	   therapies.	   For	   example,	   oral	   terbinafine	   23	   and	   cryotherapy	   has	  
completed	  phase	  1	  of	  clinical	  trials	  for	  treatment	  of	  CL	  and	  results	  show	  a	  similar	  level	  of	  
efficacy	  to	  glucantime	  3.89	  In	  addition,	  the	  antileishmanial	  effect	  of	  terbinafine	  23	  has	  led	  
to	   the	   discovery	   of	   butenafine	   26	  which	   is	   another	   allylamine	   antifungal	   drug	   able	   to	  
eliminate	  promastigotes	  and	  amastigotes	  of	  L.	  amazonensis	  and	  L.	  braziliensis.90	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Positive	   results,	   coupled	  with	  attractive	  pharmacokinetic	  and	  safety	  profiles,	  with	   these	  
antifungal	  azoles	  have	  encouraged	  the	  investigation	  of	  similar	  compounds.	  For	  example,	  
itraconazole	   25	   and	   posaconazole	   27	   exhibit	   in	   vitro	   and	   in	   vivo	   activity	   against	   L.	  
amazonensis,	  L.	  donovani	  and	  L.	  infantum.	  	  
	  
In	  addition,	  in	  a	  separate	  study,	  econazole	  28,	  bifonazole	  29	  and	  chlotrimazole	  30	  showed	  
activity	   against	   L.	   infantum	   chagasi	   promastigotes	   and	   econazole	   28	   showed	   similar	  
intramacrophage	   effectiveness	   to	   miltefosine	   7.	   Unfortunately,	   bifonazole	   29	   and	  
chlotrimazole	   30	   showed	   no	   activity	   against	   intracellular	   amastigotes.91	   However,	  
chlotrimazole	   30	   complexed	   to	   ruthenium	   shows	   activity	   against	   L.	   major	   intracellular	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Figure	  7:	  Antifungal	  drugs	  that	  could	  be	  repurposed	  as	  antileishmanials	  
1.4.4.	  Antiparasitics	  
	  
A	  second	  source	  of	  antimicrobial	  compounds	  that	  have	  been	  exploited	  as	  antileishmanials	  
are,	  not	  surprisingly,	  other	  antiparasitics.	  In	  one	  approach,	  a	  collection	  of	  400	  compounds	  
obtained	   from	  Medicines	   for	  Malaria	   Venture	   (MMV)	  was	   screened	   for	   antileishmanial	  
activity.	  Significantly,	  in	  contrast	  to	  many	  other	  such	  approaches	  which	  use	  promastigote	  
or	  axenic	  amastigotes,	  this	  study	  developed	  an	  assay	  using	  intracellular	  amastigotes,	  thus	  
enabling	  screening	  against	  the	  most	  clinically	  relevant	  form	  of	  the	  parasite.94	  The	  results	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interest	  was	  the	  anticancer	  drug,	  MMV666080	  31,	  which,	  with	  an	  IC50	  of	  15	  nM,	  is	  more	  
potent	   and	   also	   less	   toxic	   than	   AmpB	   4.	   In	   addition,	   a	   series	   of	   substituted	  
aminobenzimidazoles	  (32-­‐34)	  were	   identified	  from	  this	  screen	  as	  active	  antileishmanials	  
with	  IC50	  values	  ranging	  from	  61	  nM	  to	  134	  nM.	  A	  current	  focus	  for	  these	  compounds	  is	  to	  
validate	  the	  results	  using	  in	  vivo	  models.95	  	  
	  
A	  second	  set	  of	  studies	  has	  focused	  on	  the	  use	  of	  nitazoxanide	  35,	  an	  oral	  drug	  used	  in	  the	  
treatment	   of	   infectious	   diarrhea	   caused	   by	   the	   protozoan	   parasites,	   Cryptosporidium	  
parvum	   and	   Giardia	   lamblia.	   The	   lethal	   action	   of	   nitazoxanide	   35	   against	   L.	   infantum	  
involves	  upregulation	  of	  reactive	  oxygen	  species	  resulting	  in	  oxidative	  stress	  and	  parasite	  
death.96	  Nitazoxanide	  35	  also	  displays	  activity	  against	  L.	  donovani	  and	  L.	  amazonensis,97,98	  
with	  spleen	  and	  liver	  parasite	  load	  being	  reduced	  by	  86%	  in	  L.	  donovani-­‐infected	  mice.97	  In	  
addition,	  nitazoxanide	  35	  demonstrates	  low	  cytotoxicity	  against	  mammalian	  VERO	  cell	  line	  
and	   exhibits	   activity	   against	   Giardia	   intestinalis	   and	   Trichomonas	   vaginalis;	   therefore	  
derivatives	   of	   nitazoxanide	   35	   would	   generally	   be	   attractive	   starting	   points	   for	   new	  
antiparasitic	  drugs	  98.	  
	  
Due	  to	  the	  closer	  taxonomy	  lineage,	   it	  would	  be	  expected	  that	  anti-­‐trypanosomal	  drugs	  
would	   be	  more	   likely	   repurposed	   to	   leishmaniasis	   than	   other	   antiparasitics.	   	   However,	  
apart	  from	  pentamidine	  5	  used	  to	  treat	  African	  trypanosomiasis	  caused	  by	  Trypanosoma	  
gambiense,	  no	  other	  anti-­‐trypanosomal	  drugs	  including	  those	  used	  to	  treat	  Chagas	  disease	  
are	  presently	  used	  against	  leishmaniasis.	  
	  
Whilst	  nitroaromatics,	  such	  as	  nitazoxanide	  35,	  are	  generally	  avoided	  in	  the	  pharmaceutical	  
industry	  due	  to	  the	  known	  potential	  mutagenicity	  and	  carcinogenicity	  of	  the	  nitro	  group,	  
recent	  research	  has	  revealed	  the	  potential	  of	  nitroaromatics	  to	  treat	  neglected	  parasitic	  
diseases.99	  Reflecting	  this,	  another	  antiparasitic	  nitroaromatic	  compound,	  fexinidazole	  36,	  
is	  being	  explored	  as	  a	  potential	  treatment	  for	  leishmaniasis.	  Fexinidazole	  36	   is	   in	  clinical	  
trials	  for	  treating	  African	  trypanosomiasis	  (T.	  brucei)	  and	  Chagas	  disease	  (T.	  cruzi)	  where	  
the	  mechanism	  of	  action	  is	  proposed	  to	  involve	  reductive	  activation	  of	  the	  nitro	  group	  by	  
NADH-­‐dependent	  bacterial-­‐like	  nitroreductase.	  A	  study	  involving	  the	  overexpression	  of	  the	  
leishmanial	   orthologue	   of	   the	   nitroreductase	   demonstrated	   that	   a	   similar	   mechanism	  
occurs	  in	  Leishmania	  spp.	  Building	  on	  this	  fexinidazole	  36	  and	  its	  two	  predominant	  in	  vivo	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metabolites	   (fexinidazole	   sulfoxide	   and	   sulfone)	   displayed	   excellent	   activity	   against	   L.	  
donovani	  promastigotes	  and	  axenic	   amastigotes.	  However,	   fexinidazole	  36	  was	   inactive	  
against	   intracellular	   amastigotes	   whereas	   fexinidazole	   sulfoxide	   and	   sulfone	   remained	  
potent	   against	   intracellular	   amastigotes	   (both	   EC50	   values	   equal	   to	   5.3	   µM).	   When	  
progressed	  into	  a	  murine	  model	  infected	  with	  L.	  donovani	  a	  98%	  suppression	  of	  infection	  
was	  observed	  with	  a	  single	  daily	  dose	  of	  fexinidazole	  36	  for	  5	  days.100	  With	  this	  positive	  
data,	  fexinidazole	  36	  was	  progressed	  into	  clinical	  trials	  as	  a	  treatment	  for	  VL.	   In	  2013,	  a	  
phase	  two	  study	  tested	  fexinidazole	  36	  on	  14	  patients	  suffering	  with	  VL	  and	  all	  patients	  
showed	  clinical	   improvement	  during	  treatment.	  Unfortunately,	  treatment	  relapses	  were	  
observed	  and	  thus	  the	  study	  was	  terminated	  in	  2014	  due	  to	  lack	  of	  efficacy.101	  However,	  
fexinidazole	  36	  is	  now	  being	  investigated	  as	  a	  combination	  therapy	  with	  miltefosine	  7	  in	  
Eastern	  Africa.102	  
	  
Artemisinin	   37	   was	   first	   isolated	   in	   1971	   from	   the	   plant,	   Artemisia	   annua,	   and	   today	  
artemisinin	  37	  and	  its	  derivatives	  are	  well	  established	  anitimalarials.103	  This	  sesquiterene	  
lactone	   contains	   an	   unusual	   endoperoxide	   bridge,	   which	   is	   essential	   for	   antimalarial	  
activity.	   One	   of	   the	   proposed	   mechanisms	   of	   actions	   is	   the	   cleavage	   of	   this	   bond	   to	  
generate	  free	  radicals	  that	  could	  act	  as	  alkylating	  agents	  and	  chemical	  modify	  a	  variety	  of	  
parasite	  molecules.104	  In	  1993	  artemisinin	  37	  was	  shown	  to	  have	  efficacy	  in	  vitro	  and	  in	  vivo	  
against	   CL	   but	   it	   was	   unknown	   whether	   the	   endoperoxide	   bridge	   was	   essential	   for	  
activity.105	  More	  recently,	  gelatin	  capsules	  containing	  dried	  Artemisia	  annua	  (A.	  annua)	  leaf	  
powder	   have	   been	   developed	   as	   an	   oral	   therapy	   for	   parasitic	   diseases.	   These	   capsules	  
proved	  to	  be	  an	  effective	  treatment	  in	  a	  hamster	  model	  infected	  with	  L.	  (V)	  panamensis	  
and	  2	  patients	  with	  CL	  were	  cured	  with	  30	  g	  of	  A.	  annua	  capsules,	  without	  any	  adverse	  
reactions.106	  A	  separate	  study	  investigating	  the	  effects	  of	  artemisinin	  37	  against	  VL	  revealed	  
that	   artemisinin	   37	   is	   7	   times	   more	   active	   against	   L.	   donovani	   amastigotes	   than	  
promastigotes.107	   Although	   IC50	   values	   are	   in	   the	   micromolar	   range,	   whereas	   only	  
nanomolar	  concentrations	  are	  required	  for	  antimalarial	  activity,	  artemisinin	  37	  has	  a	  good	  
selectivity	  index	  and	  should	  be	  progressed	  into	  an	  L	  donovani-­‐infected	  animal	  model	  where	  
micromolar	  concentrations	  can	  be	  achieved	  using	  oral,	  parenteral	  and	  rectal	  dosages.107	  
	  
Mefloquine	  38,	  chloroquine	  39	  and	  hydroxychloroquine	  40	  are	  antimalarials	  which	  have	  
been	   investigated	   for	   in	   vitro	   and	   in	   vivo	   activity	   against	   L.	   amazonensis.	   Their	   activity	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against	   the	   promastigote	   form	   was	   first	   evaluated	   and	   mefloquine	   38	   was	   the	   only	  
compound	  to	  show	  any	  significant	  activity.	  However,	  all	  three	  of	  these	  compounds	  showed	  
activity	   against	   intracellular	   amastigotes.	   It	   has	   been	   suggested	   that	   the	   drug	   action	   is	  
based	  on	   impairment	  of	  macromolecule	  absorption	  rather	   than	  an	  enhancement	  of	   the	  
immune	  response.108	  Mefloquine	  38	  and	  chloroquine	  39	  were	  tested	  in	  a	  mouse	  model	  and	  
results	  showed	  that	  treatment	  with	  chloroquine	  39	  by	  the	  oral	  route	  reduced	  lesion	  size	  
and	  parasite	  burden.	  In	  contrast,	  mefloquine	  38	  administered	  by	  oral	  and	  topical	  routes	  
reduced	  the	  lesion	  size	  but	  not	  the	  parasite	  burden.	  Further	  work	  is	  needed	  to	  understand	  
the	  mechanism	  of	  action	  of	  chloroquine	  39	  but	  these	  results	  reveal	  that	  this	  antimalarial	  
drug	  is	  also	  a	  potential	  drug	  candidate	  to	  treat	  CL.108	  	  
	  
Levamisole	   41	   is	   a	   heterocyclic	   compound	   that	   is	   immunoregulatory	   and	   an	   effective	  
antihelminthic	  agent.109	  Since	  the	  1970s	  it	  has	  been	  studied	  as	  a	  therapy	  for	  CL110	  and	  a	  
more	  recent	  study	  compared	  the	  effects	  of	  levamisole	  41	  and	  imidocarb	  42,	  a	  veterinary	  
medicine	  used	  to	  treat	  parasite	  infection,	  in	  murine	  models	  infected	  with	  L.	  amazonensis.	  
The	  results	  from	  a	  number	  of	  parameters	  (IgG	  levels,	  vacuolar	  area,	  megakaryocyte	  count	  
in	  spleen	  and	  parasite	  burden)	  demonstrate	  that	  imidocarb	  42	  has	  the	  most	  potential	  as	  a	  
therapy	  for	  CL.111	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Figure	  8:	  Antiparasitic	  drugs	  that	  could	  be	  repurposed	  as	  antileishmanials	  
	  
1.4.5.	  Antibacterials	  	  
	  
Metronidazole	   43	   is	   an	   antibiotic	   and	   antiprotozoal	   medication.	   It	   is	   not	   sold	   as	   an	  
antileishmanial	  but	  has	  been	  employed	  to	  treat	  leishmaniasis	  for	  a	  number	  of	  years.112,113	  
For	  instance,	  in	  1976	  21	  of	  30	  patients	  with	  South	  American	  leishmaniasis	  were	  reported	  
as	  cured	  when	  treated	  with	  metronidazole	  43.114	  However,	  the	  inefficacy	  of	  metronidazole	  
43	   in	  animal	  models	   infected	  with	  L.	  donovani	  and	  L.	  mexicana	  has	  been	  reported.115	   In	  
addition,	   two	   separate	   studies	   testing	   on	   patients	   suffering	   from	   cutaneous	   and	  
mucocutaneous	  in	  Iran	  and	  Ethopia	  showed	  that	  intralesional	  metronidazole	  43	  injections	  
were	   painful	   and	   had	   little	   effect	   on	   the	   treatment	   of	   leishmaniasis.116,117	   Therefore,	  
further	   study	   into	   the	   route	   of	   administration	   and	   efficacy	   of	   metronidazole	   43	   as	   a	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Azithromycin	  44	  is	  an	  antibiotic	  used	  to	  treat	  several	  bacterial	  infections	  and	  can	  also	  be	  
used	   in	   combination	   with	   other	   medications	   to	   treat	   malaria.	   This	   azalide,	   a	   type	   of	  
macrolide	   antibiotic,	   concentrates	   in	   the	   tissue	   and	   especially	   the	   macrophages.	  
Leishmania	  resides	  in	  these	  cells	  and	  therefore	  it	  is	  an	  attractive	  drug	  candidate	  for	  in	  vitro	  
and	   in	  vivo	  studies.	  One	  study	  showed	  promising	  activity	  against	  L.	  major	  promastigotes	  
and	   intramacrophage	   amastigotes	   as	   well	   as	   in	   vivo	   efficacy	   against	   L.	   major	   infected	  
mice.118	   This	   treatment	   was	   given	   via	   subcutaneous	   injection	   and	   more	   recent	  
investigations	   have	   shown	   the	   superior	   activity	   of	   oral	   azithromycin	   44	   over	   oral	  
miltefosine	  7	  in	  the	  treatment	  of	  L.	  major	  infected	  mice.	  However,	  a	  combination	  therapy	  
of	  miltefosine	  7	  and	  azithromycin	  44	  showed	  signs	  of	  relapse	  after	  the	  end	  of	  treatment.119	  
The	  effect	  of	  azithromycin	  44	  on	  other	  species	  of	  Leishmania	  was	  evaluated	  and	  revealed	  
in	  vitro	  activity	  against	  L.	  amazonensis,	  L.	  braziliensis	  and	  L.	  chagasi.120	  An	   in	  vivo	   study	  
showed	  activity	  against	  L.	  braziliensis	  and	  oral	  azithromycin	  has	  been	  used	  to	  treat	  patients	  
with	  CL	  caused	  by	  this	  species.121	  However,	  it	  should	  be	  noted	  that	  this	  in	  vivo	  study	  was	  
unsuccessful	  against	  L.	  amazonensis.	  Hence,	  azithromycin	  44	  could	  be	  used	  as	  a	  potential	  
therapy	  for	  CL	  but	  there	  should	  be	  studies	  into	  its	  limitations	  in	  certain	  Leishmania	  species	  
and	  in	  combination	  with	  other	  medications.	  
	  
Clofazimine	  45	   is	  used	   in	   combination	  with	   rifampicin	  46	   and	  dapsone	   to	   treat	   leprosy.	  
Clofazimine	  45	  has	  in	  vitro	  activity	  against	  L.	  amazonensis,	  L.	  donovani	  and	  L.	  major	  as	  well	  
as	  being	  effective	  both	  orally	  and	  topically	  in	  an	  animal	  model	  of	  CL.122	  In	  addition,	  it	  is	  a	  
highly	   lipophilic	   drug	   and	   therefore	   also	   concentrates	   in	   the	   macrophages	   where	  
Leishmania	   resides.	   Unfortunately,	   clofazimine	   45	   was	   ineffective	   when	   used	   to	   treat	  
cutaneous	  L.	  major	   infection	  in	  humans.	  Higher	  doses	  of	  the	  drug	  could	  be	  effective	  but	  
clofazimine	  45	  has	  shown	  undesirable	  dose-­‐related	  side	  effects.	  Therefore,	  further	  clinical	  
trials	  of	  this	  drug	  for	  CL	  have	  been	  discouraged.123	  	  	  In	  contrast,	  positive	  results	  have	  been	  
shown	   when	   rifampicin	   46	   is	   given	   as	   an	   oral	   therapy	   to	   treat	   humans	   with	   CL.	   In	  
comparison	  to	  other	  antileishmanials	  available,	  rifampicin	  46	  is	  simple	  to	  administer,	  cheap	  
and	  well	  tolerated	  by	  patients.121	  However,	  one	  study	  highlighted	  the	  failures	  of	  rifampicin	  
46	  to	  cure	  patients	  with	  CL	  from	  Israel.124	  Therefore,	  efficacy	  against	  CL	  is	  uncertain	  and	  
investigations	  are	  also	  focused	  on	  combination	  therapies.125,126	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The	   activity	   and	   safety	   profile	   of	   fexinidazole	   36	   sparked	   the	   search	   for	   other	  
nitroimidazoles	  which	  may	  have	  potential	   as	   oral	   treatments	   for	  VL.	   This	   identified	   the	  
antituberculosis	  drugs	  PA-­‐824	  47	  and	  delamanid	  48,	  which	  can	  also	  undergo	  bioactivation	  
by	  a	  nitroreductase,	  as	  potential	  leads.127,128,129,130	  As	  with	  fexinidazole	  36	  the	  presence	  of	  
the	  nitro	  group	  has	  been	  shown	  to	  be	  essential	  for	  antileishmanial	  activity.129,127	  However,	  
the	   nitroreductase	   found	   in	  Mycobacterium	   tuberculosis	   [deazaflavin	   (F420)-­‐dependent	  
nitroreductase	  (Ddn)],131	   is	  absent	   in	  Leishmania	  and	  over-­‐expression	  of	  the	   leishmanial	  
nitroreductase	  did	  not	  provide	  enhanced	  sensitivity	   to	   the	  drugs,	   suggesting	  a	  different	  
mode	   of	   action.	   This	   suggests	   the	   potential	   for	   future	   combination	   therapies	   involving	  
fexinidazole	  36	  and	  these	  antituberculosis	  drugs.	  These	  differences	  are	  reinforced	  by	  the	  
observation	   that	   whilst	   the	   (S)-­‐enantiomer	   of	   PA-­‐824	   (S)-­‐47	   is	   currently	   in	   phase	   two	  
clinical	  trials	  for	  tuberculosis	  it	  is	  the	  (R)-­‐enantiomer	  of	  PA-­‐824	  (R)-­‐47	  which	  shows	  superior	  
activity	  against	  L.	  donovani	  parasites,	  both	  in	  vitro	  and	  in	  vivo,	  with	  a	  twice	  daily	  dose	  of	  
PA-­‐824	  (R)-­‐47	  at	  100	  mg	  kg-­‐1	  effectively	  curing	  a	  murine	  model	  of	  infection,	  suppressing	  
infection	  by	  99.9%.129	  More	  recently,	  the	  structurally	  similar	  compound	  delamanid	  48,	  (R)-­‐
enantiomer,	   has	   demonstrated	   high	   activity	   in	   vitro	   against	   intracellular	   L.	   donovani	  
amastigotes.	  In	  addition,	  a	  twice-­‐daily	  oral	  dose	  of	  this	  nitroimidazole	  at	  30	  mg	  kg-­‐1	  for	  5	  
days	  cured	  the	  mice	  infected	  with	  L.	  donovani.127	  Whilst	  these	  compounds	  appear	  to	  show	  
considerable	   potential,	   a	   cautionary	   note	   arises	   from	   the	   history	   of	   the	   chimeric	  
nitroimidazole,	  DNDI-­‐VL-­‐2098.	  This	   compound,	   following	  promising	  early	   results,	  was	  at	  
the	  final	  stages	  of	  preclinical	  development	  for	  the	  treatment	  of	  VL.	  However,	  results	  from	  
animal	  models	   showed	  a	   link	  between	  dose,	   length	  of	   treatment	  and	   testicular	   toxicity	  
leading	  to	  a	  decision	  to	  halt	  progression.132	  Whether	  this	  is	  a	  compound	  specific	  effect	  or	  
a	  class	  problem	  remains	  to	  be	  established.	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Tucaresol	   49	   is	   an	   investigational	   drug	   that	   has	   completed	   phase	   2	   clinical	   trials	   as	   a	  
treatment	   for	   HIV133,134	   and,	   similar	   to	   the	   antiparasitic	   drug	   Levamisole	   40,	   is	   an	  
immunomodulator	   that	   demonstrates	   antileishmanial	   activity	   in	   vivo.	   This	   novel	  
immunomodulator	  was	  inactive	  in	  L.	  donovani	  intracellular	  amastigote	  assays	  but	  showed	  
a	  reduction	   in	  parasite	  burden	   in	  mice	   infected	  with	  L.	  donovani.	  Tucaresol	  49	  could	  be	  
delivered	  orally	  at	  an	  optimum	  dose	  of	  5	  mg	  kg-­‐1	  to	  produce	  a	  44	  to	  62%	  suppression	  of	  
liver	  amastigotes.135	  
	  
Another	  drug	  with	  immunomodulatory	  effects	  being	  studied	  as	  a	  therapy	  for	  leishmaniasis	  
is	  imiquimod	  50.	  This	  immune-­‐response	  modifier	  is	  a	  treatment	  for	  genital	  warts	  caused	  by	  
human	   papillomaviruses	   and	   works	   through	   activation	   of	   immune	   cells,	   including	  
macrophages.	  Macrophages	  are	  the	  host	  cells	  of	  Leishmania	  and	  therefore	  in	  1999	  a	  study	  
was	   conducted	   to	   determine	   if	   imiquimod	   50	   could	   be	   used	   as	   potential	   therapy	   for	  
leishmaniasis.	  In	  vitro	  results	  determined	  that	  imiquimod	  50	  could	  induce	  leishmanicidal	  
properties	  in	  infected	  macrophages	  and	  a	  possible	  mode	  of	  action	  is	  through	  stimulated	  
signal	  transduction	  increasing	  the	  synthesis	  of	  nitric	  oxide	  which	  is	  toxic	  to	  the	  intracellular	  
parasites.	  Progression	  of	  5%	  imiquimod	  50	  cream	  into	  a	  in	  vivo	  study	  showed	  a	  significant	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trials.136,137	  In	  2005,	  a	  study	  focused	  on	  new	  approaches	  such	  as	  combination	  therapies	  and	  
conducted	  a	  clinical	  trial	  of	  parental	  antimony	  plus	  topical	  imiquimod	  50	  to	  treat	  patients	  
with	  CL.	  Results	  from	  this	  study	  showed	  that	  72%	  of	  patients	  treated	  with	  imiquimod	  50	  
achieved	  a	  cure	  at	  3	  months	  vs	  35%	  treated	  with	  the	  vehicle	  cream.	  In	  addition,	  accelerated	  
healing	  and	  less	  prominent	  scarring	  was	  observed	  in	  the	  group	  treated	  with	  antimony	  and	  
imiquimod	   50	   compared	   to	   therapy	   with	   antimony	   alone	   demonstrating	   that	   the	   next	  




Figure	  10:	  Antiviral	  drugs	  that	  could	  be	  repurposed	  as	  antileishmanials	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1.4.7.	  Antihistamines	  
	  
Anti-­‐allergic	   compounds,	   such	   as	   quercetin	   found	   in	   Kalanchoe	   plant	   extracts,	   display	  
potent	  antileishmanial	  effects.	  This	  reflects	  a	  capacity	  to	  restore	  the	  Th1/Th2	  T-­‐cell	  balance	  
and	   also	   to	   inhibit	   mast	   cell	   histamine	   release.139,140,141,142,143	   Consistent	   with	   these	  
observations,	   a	   set	   of	   seven	  H1-­‐antagonists	  were	   reported	   to	  display	   activity	   against	  L.	  
infantum	  promastigotes	  with	  IC50	  values	  in	  the	  range	  of	  13	  –	  84	  μM.144	  The	  activity	  recorded	  
for	  cinnarizine	  51	  (Figure	  11,	  Appendix	  A)	  was	  particularly	  noteworthy	  as,	  unlike	  the	  other	  
six	  H1-­‐antagonists	  tested,	  it	  also	  demonstrated	  potency	  against	  intracellular	  amastigotes	  
(EC50	   =	   21	   μM	   and	   NCTC	   cells	   EC50	   =	   87	   μM).	  Whilst,	   initial	   in	   vivo	   experiments	   using	  
hamsters	   infected	  with	   L.	   infantum	   revealed	   a	   lack	   of	   efficacy,	   a	   liposomal	   formulation	  
circumvented	  this	  problem	  and	  enabled	  effective	  treatment	  of	  infection	  in	  the	  liver	  but	  not	  
the	  spleen,	  which	  could	  be	  ascribed	  to	  the	  higher	  parasite	  burden	  (amastigotes/gram	  of	  
organ)	   in	   this	   latter	  organ.	  Cinnarizine	  51	  has	  also	  been	  described	  as	  a	  calcium	  channel	  
blocker	  which	  is	  significant	  because	  Reimão	  et	  al.	  (2010)	  demonstrated	  the	  activity	  of	  eight	  
calcium	   channel	   blockers	   against	   intracellular	   L.	   infantum	   amastigotes	   (EC50	   =	   5	   –	   176	  
μM).145	  Further	  development	  of	   cinnarizine	  51	  will	   require	   the	  synthesis	  of	  more	  active	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This	  thesis	  will	  explore	  a	  separate	  study	  which	  has	  successfully	  used	  an	  enzyme	  assay	  to	  
explore	   the	  potential	  of	   IPCS	  as	  a	  new	  antileishmanial	  drug	   target.146,147	   This	  assay	  was	  
employed	  to	  screen	  a	  set	  of	  1040	  pharmacologically	  active	  compounds	  selected	  from	  the	  
National	  Institute	  of	  Neurological	  Disorders	  and	  Stroke	  (NINDS).	  Many	  of	  the	  most	  active	  
and	   selective	   hits	   have	   reported	   antihistamine	   activity.	   As	   these	  maintained	   activity	   in	  
infected	   cell	  models	   they	  have	   considerable	  potential	   for	   repurposing	  as	   target	   specific	  
antileishmanials.	  A	  compound	  of	  particular	  interest	  from	  this	  screen	  and	  one,	  which	  will	  be	  
discussed	  in	  depth	  in	  this	  thesis,	  is	  the	  orally	  available	  antihistamine,	  clemastine	  1	  (Figure	  
11).	  This	  compound	  showed	  good	  in	  vitro	  activity	  against	  a	  range	  of	  	  promastigote	  species	  
and	  maintained	   activity	   against	   intracellular	   amastigotes.	   In	   addition,	   clemastine	   1	   has	  
shown	   activity	   against	   T.	   cruzi148	   and	   Ebola	   virus149	   as	   such	   this	   compound	   could	   be	  
considered	  a	  broad	  spectrum	  antimicrobial.	  It	  should	  be	  noted	  that	  an	  in	  vivo	  study	  on	  mice	  
with	   T.	   cruzi	   infection	   showed	   clemastine	   1	  was	   ineffective	   as	   a	   monotherapy	   but	   in	  
combination	  with	  posaconazole	  27	  could	  suppress	  parasitemia.148	  
	  
Figure	  11:	  An	  antihistamine	  that	  could	  be	  repurposed	  as	  an	  antileishmanial	  
	  	  	  
1.4.8.	  Central	  nervous	  system	  (CNS)	  active	  drugs	  
	  
Tricyclic	  heterocycles	  are	  part	  of	  numerous	   therapeutic	  agents	  and	  therefore	   important	  
structures	  in	  medicinal	  chemistry.150	  Chlorpromazine	  52	  is	  perhaps	  the	  best	  known	  of	  the	  
phenothiazine	   drugs	   (tricyclic	   heterocycles)	   for	   treatment	   of	   neurological	   disorders.	   In	  
1984	  this	  compound	  was	   identified	  as	  having	  activity	  against	  L.	  donovani	   in	  vitro	  and	   in	  
vivo151	  and	  in	  a	  separate	  study	  also	  showed	  it	  could	  kill	  L.	  mexicana,	  L.	  aethiopica	  and	  L.	  
major	  	  promastigotes	  at	  a	  concentration	  of	  7.5	  µg	  mL-­‐1.152	  The	  same	  study	  determined	  the	  
in	   vivo	   effect	   for	   chlorpromazine	   52	   in	   a	   murine	   model	   infected	   with	   L.	   major	   and	   L.	  
mexicana	  and	  demonstrated	  leishmanicidal	  effect	  in	  the	  spleen	  but	  not	  in	  the	  skin	  lesion.	  
152	  Therefore,	  like	  pentamidine	  5,	  this	  compound	  has	  shown	  to	  be	  effective	  against	  VL	  but	  
with	  only	  partial	  effect	  against	  the	  cutaneous	  form.	  Chlorpromazine	  52	  will	  probably	  not	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52	  have	  been	  developed	  to	  explore	  SAR.	  For	  instance,	  analogues	  like	  compound	  53	  with	  a	  
quaternary	   nitrogen	   atom	   have	   demonstrated	   antileishmanial,	   antitrypanosomal	   and	  
antimalarial	  activity.153,154	  These	  analogues	  are	  trypanothione	  reductase	  inhibitors	  which	  
are	   likely	   to	   affect	   the	   redox	   defence	   of	   the	   parasite	   and	   hence	   increase	   the	   parasites	  
sensitivity	   to	   redox-­‐damaged-­‐based	   drugs.	   In	   addition,	   the	   enzyme,	   trypanothione	  
reductase,	   is	   present	   in	   Leishmanias	   and	   Trypanosomes	   but	   not	   the	  mammalian	   hosts	  
providing	  the	  opportunity	  to	  design	  a	  selective	  inhibitor.153,154	  	  
	  
It	   should	   be	   noted	   that	   other	   tricyclic	   heterocycles	   are	   being	   studied155	   including	  
cyclobenzaprine	   54	   which	   like	   chlorpromazine	   52	   analogues	   inhibits	   trypanothione	  
reductase.	  Oral	  cyclobenzaprine	  54	  has	  recently	  been	  tested	  in	  vivo	  on	  L.	  infantum-­‐infected	  
BALB/c	  mice	  and	  the	  results	  showed	  significant	  reduction	  in	  parasite	  load	  in	  both	  the	  spleen	  
and	  liver.	  In	  addition,	  cyclobenzaprine	  54	  induces	  oxidative	  stress	  in	  the	  parasite,	  which	  is	  
consistent	   with	   trypanothione	   reductase	   inhibition,	   and	   also	   modulates	   the	   immune	  
response	  of	  the	  host	  contributing	  to	  the	  in	  vivo	  efficacy.	  However,	  cyclobenzaprine	  54	  is	  
thought	  to	  have	  off-­‐targets	  effects	  and	  these	  should	  be	  further	  investigated	  when	  exploring	  
the	  potential	  of	  this	  drug	  against	  VL.156	  
	  
Imipramine	  55	   is	  an	  example	  of	  another	  tricyclic	  antidepressant	  that	  has	  antileishmanial	  
activity.	  One	  study	  showed	  that	  this	  drug	  administered	  orally	  can	  effectively	  treat	  mice	  and	  
hamsters	  infected	  with	  antimony	  sensitive	  and	  antimony	  resistant	  L.	  donovani.157	  A	  more	  
recent	  study	  showed	  the	  in	  vitro	  activity	  of	  imipramine	  55	  against	  L.	  amazonensis	  and	  an	  
effect	  on	  the	  biosynthesis	  of	  sterols.	  In	  addition,	  they	  concluded	  that	  it	  would	  be	  beneficial	  
to	  study	  imipramine	  55	  in	  combination	  with	  azoles,	  which	  inhibit	  other	  steps	  of	  the	  sterol	  
biosynthesis	  pathway,	  to	  treat	  leishmaniasis.158	  
	  
The	  opioid	  receptor	  antagonist	  naloxonazine	  56	  was	  identified	  in	  a	  high-­‐throughput	  screen	  
against	  L.	  donovani	  intramacrophage	  amastigotes.	  This	  was	  the	  only	  compound	  from	  the	  
screen	  to	  affect	   intracellular	  but	  not	  axenic	  parasites.	  Curiously,	   the	  structurally	   related	  
opioid	   naloxone	   (Narcan®)	   was	   completely	   inactive	   against	   both	   parasitic	   forms.	   Since	  
homologs	   of	   opioid	   receptors	   have	   not	   been	   identified	   in	   the	   Leishmania	   genome	   it	   is	  
possible	  that	  opioids	  are	  involved	  in	  modulation	  of	  host	  resistance	  to	  parasite	  infection.	  In	  
support	  of	  this,	  Loperamide	  57,	  a	  µ-­‐opioid	  receptor	  agonist,	  was	  also	  identified	  in	  this	  study	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as	   inhibiting	   parasite	   growth	  with	   greater	   activity	   against	   the	   intracellular	   stage	   of	   the	  
parasite.63	  
	  
Antileishmanial	   activity	   was	   observed	   when	   the	   broad	   spectrum	   antidepressants,	  
ketanserin	  58	  and	  mianserin	  59,	  were	   screened	   against	   L.	   donovani	  promastigotes	   and	  
intramacrophage	  amastigotes.	  Amongst	  other	  enzymes	   these	  compounds	  are	  known	   to	  
target	  3-­‐hydroxy-­‐3-­‐methylglutaryl	  coenzyme	  A	  reductase	  (HMGR).	  This	  is	  the	  rate-­‐limiting	  
enzyme	  of	  the	  sterol	  biosynthesis	  which	  is	  also	  the	  putative	  pathway	  targeted	  by	  AmpB	  4.	  
In	   support	   of	   this	   proposal	   both	   compounds	   inhibited	   recombinant	   L.	   donovani	  HMGR,	  
although	   given	   the	   diverse	   reported	   activities,	   other	   modes	   of	   action	   cannot	   be	  
discounted.159,160	  
	  
Finally,	   another	   antidepressant	   under	   investigation	   for	   its	   antileishmanial	   activity	   is	  
sertraline	   60.	   This	   oral	   antidepressant	   has	   shown	   activity	   against	   L.	   infantum	   and	   L.	  
donovani	   	  promastigotes	  and	   intracellular	  amastigotes	  and	  tested	  successfully	   in	  animal	  
models	   of	   VL.161,162	  Unlike	   the	   previous	   antidepressants	  mentioned,	   sertraline	  60	   has	   a	  
tetrahydronaphthalene	   core	   and	   is	   a	   selective	   inhibitor	   of	   serotonin	   reuptake.	  
Unfortunately,	   there	   has	   been	   no	   reported	   Leishmania	   orthologue	   to	   the	   serotonin	  
reuptake	  transporter	  and	  the	  target	  cannot	  be	  solely	  based	  on	  its	  inhibition	  of	  one	  efflux	  
pump	  because	  of	  its	  broad	  spectrum	  antimicrobial	  activity.149	  Instead	  sertraline	  60	  targets	  
different	  essential	  metabolic	  pathways	  of	  Leishmania	  and	  kills	  the	  parasite	  through	  a	  multi-­‐
target	  mechanism	  of	  action.	  Therefore,	  sertraline	  60	  could	  be	  a	  valuable	  drug	  candidate	  to	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Figure	  12:	  CNS	  drugs	  that	  could	  be	  repurposed	  as	  antileishmanials	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1.4.9.	  Cardiac	  medication	  
	  
Similar	  to	  ketanserin	  58	  and	  mianserin	  59	  discussed	  above,	  statins	  target	  HMGR.	  Statins	  
are	  currently	  on	  the	  market	  to	  reduce	  cardiovascular	  disease	  by	  lowering	  the	  level	  of	  low-­‐
density	   lipoprotein	  cholesterol	  (‘bad	  cholesterol’)	   in	  the	  blood.	  Studies	  have	  shown	  that	  
statins	  also	  have	   the	  potential	   to	  be	   repurposed	  as	  antileishmanials.163,164	   For	  example,	  
mevastatin	  61	  also	  inhibits	  recombinant	  L.	  donovani	  HMGR	  enzyme	  with	  an	  IC50	  value	  of	  
42 ± 3	   μM.	   It	   also	   shows	   correspondingly	   good	   activity	   against	   both	   L.	   donovani	  
promastigotes	  and	  intracellular	  amastigotes	  with	  no	  toxicity	  exhibited	  towards	  the	  host	  cell	  
line.165	  
	  
Amiodarone	  62	  and	  dronedarone	  63,	  (Figure	  13)	  used	  to	  treat	  cardiac	  arrhythmias,	  have	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amastigotes,	  and	   inhibit	  oxidosqualene	  cyclase,	  another	  enzyme	  essential	   for	  ergosterol	  
biosynthesis.	  However,	  as	  with	  the	  antihistamines	  discussed	  above,	  these	  drugs	  are	  also	  
known	  to	  disrupt	  Ca2+	  homeostasis	  in	  Saccharomyces	  cerevisiae	  and	  Trypanosoma	  cruzi,	  so	  
may	   have	  multiple	  modes	   of	   action.166	   A	  murine	  model	   infected	  with	   L.	  mexicana	   was	  
treated	  with	  oral	  amiodarone	  62	  and	  although	   it	  prevented	  the	  development	  of	   lesions	  
during	   the	   course	   of	   treatment,	   reoccurrences	   of	   the	   infection	   were	   observed	   once	  
treatment	  had	  ended.	  Amiodarone	  62	  was	  then	  tested	  in	  combination	  with	  miltefosine	  7	  
and	  showed	  permanent	  control	  of	  lesion	  size.	  Hence,	  using	  this	  drug	  in	  combination	  with	  
currently	  available	  antiparasitics	  could	  lower	  the	  dosage	  and	  reduce	  the	  known	  side	  effects	  
of	   amiodarone	   62	   (e.g.	   cardiotoxicity,	   thyroid	   dysfunction	   and	   pulmonary	   fibrosis).167	  
Alternatively,	  dronedarone	  63	  appears	  to	  have	  great	  potential	  to	  be	  repurposed	  as	  it	  has	  
greater	   antiparasitic	   activity	   coupled	   with	   lower	   mammalian	   toxicity	   than	   amiodarone	  
62.168	  
	  
Like	   the	   antihistamine	   cinnarizine	  51	  discussed	   above,	   bepridil	  64	   is	   a	   calcium	   channel	  
blocker	  and	  was	  originally	  developed	  as	  a	  treatment	  for	  angina.	  Bepridil	  64	  was	  shown	  to	  
be	  active	  against	  a	  range	  of	  promastigote	  species	  and	  L.	  chagasi	  intracellular	  amastigotes	  
but	  showed	  a	  lack	  of	  activity	  at	  12	  mg	  kg-­‐1	  in	  a	  hamster	  model	  infected	  with	  L.	  chagasi.169	  
The	  mechanism	  of	   action	   for	   in	   vitro	   activity	   is	   unknown	  but	   the	   chemical	   structure	   of	  
bepridil	  64	  shares	  similarities	  to	  clemastine	  1	  and	  tamoxifen	  20	  which	  are	  known	  inhibitors	  
of	  IPC	  synthase.	  	  
	  
Two	  other	  calcium	  channel	  blockers	  that	  have	  been	  studied	  for	  their	  antileishmanial	  effects	  
are	  amlodipine	  65	  and	  lacidipine	  66	  which	  are	  used	  to	  treat	  cardiovascular	  disease	  and	  high	  
blood	  pressure.	  They	  showed	  good	  in	  vitro	  activity	  and,	  unlike	  bepridil	  64,	  amlodipine	  65	  
and	   lacidipine	  66	  showed	   in	  vivo	  antileishmanial	  efficacy	   in	  L.	  donovani-­‐infected	  BALB/c	  
mice.170	   This	  demonstrates	   that	   structural	  modification	   to	  drugs	  belonging	   to	   the	   same	  
pharmacological	  class	  can	  strongly	  affect	  antileishmanial	  activity.169	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Figure	  13:	  Cardiac	  medication	  that	  could	  be	  repurposed	  as	  antileishmanials	  
	  
1.4.10	  Other	  drugs	  
	  
Calpains	   are	   a	   family	   of	   neutral	   calcium-­‐dependent	   cysteine	   peptidases	   which	   when	  
inhibited	   could	   treat	   a	   variety	   of	   diseases	   such	   as	   muscular	   dystrophy,	   neurological	  
disorders,	  and	  cataracts.	  Leishmania	  cells	  express	  calpain-­‐related	  proteins	  and	  the	  calpain	  
inhibitor,	  MDL28170	  67,	  showed	  activity	  against	  6	  different	  species	  of	  Leishmania	  in	  both	  
the	   promastigote	   and	   amastigote	   forms.	   In	   addition,	   MDL28170	   67	   was	   selective	   for	  
Leishmania	   amastigotes	   over	   mammalian	   macrophages.171	   The	   next	   stage	   for	   this	  
compound	   is	   to	   investigate	   if	   the	   lack	   of	   intrinsic	   variation	   in	   species	   sensitivity	   to	  
MDL28170	  67	  is	  reflected	  in	  vivo.	  Little	  intrinsic	  variation	  in	  drug	  sensitivity	  could	  lead	  to	  
the	  development	  of	  a	  single	  drug	  for	  all	  species	  of	  Leishmania.171	  However,	   it	  should	  be	  
noted	  that	  MDL28170	  67	  and	  other	  calpain	  inhibitors	  need	  micro-­‐molar	  concentrations	  for	  
activity	   which	   could	   reflect	   low	   affinity	   for	   the	   calpain	   target	   or	   potential	   off-­‐target	  
effects.172	  
	  
This	  review	  has	  focused	  on	  repurposing	  synthetic	  small	  molecules,	  though	  there	  are	  studies	  
that	   have	   investigated	   polymers	   and	   natural	   products.	   For	   instance,	   a	   recent	   study	  
confirmed	  that	  polyhexanide	  68,	  a	  wound	  antiseptic	  and	  disinfectant,	  has	  antileishmanial	  
activity	  with	  IC50	  values	  of	  0.41	  μM	  against	  L.	  major	  promastigotes,	  69-­‐fold	  more	  potent	  












































	   31	  
thought	  to	  kill	  the	  parasite	  by	  disruption	  to	  membrane	  structure	  and	  selective	  chromosome	  
condensation	  and	  damage.	  Interestingly,	  it	  was	  also	  discovered	  that	  this	  cationic	  polymer	  
can	  be	  used	  as	  a	  vehicle	  to	  transport	  cargoes	  to	  the	  macrophage	  and	  thus	  has	  the	  ability	  to	  
deliver	  immunomodulatory	  agents173.	  
	  
Whilst	  the	  focus	  of	  this	  review	  has	  been	  on	  repurposing	  human	  therapeutics,	  there	  is	  the	  
potential	   for	   investigating	   other	   groups	   of	   bioactive	   chemicals,	   including	   both	  
agrochemicals	   and	   veterinary	   medicines	   for	   human	   use	   as	   treatments	   for	   neglected	  
diseases.	  For	  example,	  more	  than	  600	  commercial	  agrochemicals	  were	  screened	  against	  
parasitic	   protozoans	   and	   zoxamide	   69	  was	   found	   to	   be	   the	   most	   effective	   against	   L.	  
donovani	   promastigotes.	   Zoxamide	   69	   is	   an	   oomyceticidal	   compound	   used	   in	   fruit	   and	  
vegetables,	  and	  acts	  through	  the	  inhibition	  of	  microtubule	  formation.	  Zoxamide	  69	  killed	  
the	  promastigotes	  with	  an	  IC50	  value	  of	  250	  nM.174	  Although	  explored	  in	  other	  contexts,7	  
there	  has	  been	  little	  reported	  effort	  to	  repurpose	  veterinary	  medicines	  for	  leishmanaisis,	  
possibly	   due	   to	   the	   potential	   human	   toxicity	   issues	   which	   could	   arise	   and	   negate	   the	  
benefits	  of	  the	  repurposing	  approach.	  
	  
	  
1.5.	  Concluding	  remarks	  
	  
The	   repositioning	   of	   old	   drugs	   for	   new	   uses	   is	   not	   a	   new	   concept	   and	   is	   a	   particularly	  
attractive	   approach	   for	   neglected	   tropical	   diseases.	   Here	   the	   use	   of	   approved	   drugs	   is	  
particularly	  beneficial	  as	  clinical	  trials	  have	  already	  successfully	  been	  conducted	  and	  often	  
their	  patents	  have	  expired	  leading	  to	  shorter,	  cheaper	  discovery	  pipelines.	  As	  discussed	  in	  
the	   various	   sections	   above,	   a	   wide	   range	   of	   structures	   have	   been	   explored	   for	  
antileishmanial	  activity.	  Significantly,	  most	  of	   the	  medicines	  used	  to	   treat	   leishmaniasis,	  
either	  on	  the	  market	  or	  under	  development	  in	  the	  drug	  discovery	  process,	  were	  initially	  
intended	   for	   other	   indications.	   Furthermore,	   more	   novel	   approaches	   show	   drug	  
repositioning	  is	  extending	  beyond	  the	  scope	  of	  human	  medication	  as	  investigation	  into	  the	  


























Figure	  14:	  Other	  drugs	  that	  could	  be	  repurposed	  as	  antileishmanials	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repurposing	  is	  limited	  by	  the	  number	  of	  approved	  drugs	  and	  compounds	  with	  established	  
pharmacokinetic	  data,	  in	  addition	  the	  repositioning	  discovery	  process	  tends	  to	  mean	  that	  
there	   is	   less	  chance	  of	   finding	  treatments	  that	  act	   through	  a	  new	  mechanism	  of	  action.	  
Overall,	  whilst	  not	   the	  sole	  solution,	  drug	  repositioning	  represents	  a	  valuable,	   relatively	  
fast	   and	   cost-­‐effective,	   strategy	   for	   developing	   essential	   new	   therapies,	   particularly	   for	  
neglected	  tropical	  diseases	  such	  as	  leishmaniasis.	  	  
	  
Table	  1:	  Clinical	  manifestations	  and	  the	  related	  species	  and	  geographical	  location175	  
Clinical	  manifestation	   Leishmania	  species	   Geographical	  area	  
Cutaneous	  Leishmaniasis	  
	  
L	  (L.)	  tropica	   Eastern	  hemisphere	  
L	  (L.)	  major	   Eastern	  hemisphere	  
L	  (L.)	  aethiopica	   Eastern	  hemisphere	  
L	  (L.)	  amazonensis	   Western	  hemisphere	  
L	  (V.)	  braziliensis	   Western	  hemisphere	  
L.	  (L.)	  mexicana	   Western	  hemisphere	  
L	  (V.)	  panamensis	   Western	  hemisphere	  
Mucosal	  Leishmaniasis	   L	  (V.)	  braziliensis	   Western	  hemisphere	  
L	  (V.)	  panamensis	   Western	  hemisphere	  
L	  (V.)	  guyanensis	   Western	  hemisphere	  
L	  (L.)	  amazonensis	   Western	  hemisphere	  
L	  (L.)	  major	   Eastern	  hemisphere	  
Visceral	  Leishmaniasis	   L	  (L.)	  donovani	   Eastern	  hemisphere,	  
except	  Europe	  











	  Project	  Background	  
	   33	  
2.	  Project	  Background	  
	  
As	  discussed	   in	  Chapter	  1,	  previous	  work	   in	   the	  group	  had	   identified	  Leishmania	  major	  
inositol	   phosphorylceramide	   synthase	   (LmjIPCS)	   as	   an	   attractive	   drug	   target.	   IPCS	   is	   an	  
essential	   enzyme	   in	   the	   biosynthesis	   of	   sphingolipids	   and	   this	   chapter	   will	   provide	   a	  




Sphingolipids,	   discovered	   more	   than	   a	   hundred	   years	   ago,	   are	   an	   essential	   structural	  
component	  of	  eukaryotic	  cells	  and	  play	  crucial	  roles	  in	  a	  range	  of	  biological	  processes	  such	  
as	  signal	  transduction,	  cell	  growth,	  differentiation	  and	  apoptosis.146	  They	  are	  amphipathic	  
lipids	  characterised	  by	  their	  backbone	  called	  long-­‐chain	  or	  sphingoid	  bases.	  Underivatised	  
free	   sphingoid	  bases	   consist	  of	  hydroxyl	   groups	   (at	  C1	  and	  C3)	  and	  an	  amino	  group	   (at	  
C2).176	  However,	  most	  simple	  sphingolipids	  are	  amide-­‐linked	  with	  a	  long-­‐chain	  fatty	  acid	  to	  
form	  ceramides	   that	  can	  be	   further	  derivatised	  by	   the	  addition	  of	  a	  head	  group	   (at	  C1)	  
(Figure	  15).177	  	  
	  
2.2.	  De	  novo	  biosynthesis	  
	  
The	  de	  novo	  biosynthesis	  of	  sphingolipids	  takes	  place	   in	  the	  endoplasmic	  reticulum	  (ER)	  
and	  Golgi	  apparatus	  and	  begins	  with	  the	  condensation	  of	  palmitoyl-­‐CoA	  70	  with	  L-­‐serine	  
71	   (Scheme	   1).	   This	   reaction	   is	   catalysed	   by	   serine	   palmitoyltransferase,	   a	   membrane	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bound	   enzyme,	   producing	   3-­‐ketosphinganine	   72	  which	   is	   then	   reduced	   by	   an	   NADPH-­‐
dependent	  reductase	  to	  form	  sphinganine	  73.176,147	  
	  
At	   this	   point	   there	   is	   an	   evolutionary	   divergence	   in	   the	   pathway.	   In	   animals	   and	  
trypanosomatids,	  sphinganine	  73	   is	  acylated	  to	  form	  dihydroceramide	  74,	  which	   is	   then	  
desaturated	  to	  produce	  ceramide	  75.	  In	  contrast,	  in	  fungi	  and	  plants	  sphinganine	  73	  is	  first	  
hydroxylated	  to	  phytosphingosine	  76	  and	  then	  acylated	  to	  form	  phytoceramide	  77.147	  
There	   is	   further	   variance	   in	   the	   biosynthetic	   pathway	   for	   animals	   and	   kinetoplastids	  
(including	  Leishmania	  spp.).	  In	  animal	  cells,	  ceramide	  75	  is	  transformed	  into	  sphingomyelin	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Scheme	  1:	  Divergence	  in	  pathway	  for	  ceramide	  75	  biosynthesis	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ceramide	  75	  to	  produce	  inositol	  phosphorylceramide	  79	  (IPC)	  catalysed	  by	  IPCS	  (Scheme	  
2).	   In	   fungi	  and	  plants	  a	  similar	  reaction	  occurs	  where	  phytoceramide	   is	   transformed	  to	  
IPC.147	  
	  
2.3.	  Serine	  palmitoyl	  transferase	  (SPT)	  
	  
Serine	   palmitoyltransferase	   (SPT)	   catalyses	   the	   first	   and	   rate	   limiting	   step	   of	   the	  
biosynthetic	   pathway	   as	   shown	   in	   Scheme	   1.	   Denny	   and	   Beverley	   have	   independently	  
deleted	   one	   SPT	   subunit,	   LmLCB2,	   to	   generate	   SPT	   knock-­‐out	   mutant	   L.	   major	  
promastigotes	  (Δ	  LCB2).	  As	  a	  result,	  these	  parasites	  can	  no	  longer	  synthesise	  ceramide	  75	  
and	  de	  novo	  sphingolipids.178,179,180	  The	  Δ	  LCB2	  promastigotes	  were	  viable	  in	  the	  procyclic	  
stage,	  but	  unable	  to	  generate	  metacyclic	  parasites,	  which	  are	  in	  the	  infective	  stage	  of	  their	  
life	  cycle.	  However,	  L.	  major	  Δ	  LCB2	  amastigotes	  were	  fully	  virulent	  to	  macrophages	  and	  
mice.	  These	  studies	  suggest	  that	  in	  the	  promastigote	  stage,	  de	  novo	  sphingolipids	  play	  an	  
essential	   role	   in	   metacyclogenesis	   whereas	   Δ	   LCB2	   amastigotes	   can	   salvage	   host	  




IPCS	  is	  another	  key	  de	  novo	  biosynthetic	  enzyme	  in	  kinetoplastids	  and	  fungi.	  This	  enzyme	  
is	   responsible	   for	   producing	   the	   major	   phosphosphingolipid,	   IPC	   79,	   by	   catalysing	   the	  
transfer	  of	  the	  phosphorylinositol	  group	  from	  phosphatidylinositol	  (PI)	  to	  ceramide	  75.	  This	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reaction	   controls	   the	   balance	   between	   pro-­‐apoptotic	   ceramide	   75	   and	   mitogenic	  
diacylglycerol	  (DAG)	  (Scheme	  2).	  If	  the	  activity	  of	  this	  enzyme	  was	  inhibited	  it	  could	  cause	  
destruction	  to	  the	  cell	  structure	  and	  function	  and	  is	  therefore	  an	  attractive	  drug	  target.147	  
In	  addition,	  the	  mammalian	  orthologue	  of	  IPCS	  (SMS)	  has	  a	  different	  function	  which	  can	  be	  
utilised	  to	  develop	  selective	  antifungal	  and	  antiprotozoal	  therapies.146	  	  
	  
2.4.1.	  Discovery	  of	  L.	  major	  IPCS	  
	  
In	  support	  of	  this	  hypothesis,	  IPCS,	  encoded	  by	  the	  AUR1	  gene,	  has	  been	  validated	  as	  an	  
antifungal	   drug	   target.	   It	   is	   located	   within	   the	   Golgi	   apparatus	   of	   Saccharomyces	  
cerevisiae181	  and	  a	  mutant	  defective	  in	  IPCS	  will	  accumulate	  ceramide	  75,	   leading	  to	  cell	  
death.	  In	  addition,	  mutations	  in	  AUR1	  have	  shown	  to	  give	  resistance	  to	  the	  antifungal	  drug	  
aureobasidin	  A	  enabling	  this	  depsipeptide	  to	  be	  identified	  as	  a	  potential	  inhibitor	  of	  IPCS	  
in	   fungi.182	  However,	   it	   should	  be	  noted	   that	  although	  aureobasidin	  A	   is	  active	  across	  a	  
range	  of	  Leishmania	   species183	   it	   does	  not	   act	   as	   an	   IPCS	   inhibitor	   in	   kinetoplastids	  but	  
functions	   through	   a	   different	   and	   as	   yet	   unknown	   mechanism.	   This	   highlights	   the	  
difference	  between	  IPCS	  in	  yeast	  (AUR1p)	  and	  in	  Leishmania	  (LmjIPCS).	  	  
Denny	  et	  al.	  identified	  and	  characterised	  the	  single	  gene	  from	  L.	  major,	  LmjIPCS	  (GeneDB,	  
LmjF35.4990),	   which	   is	   the	   functional	   AUR1	   orthologue	   through	   bioinformatics	   and	  
functional	   genetic	   approaches.184	   The	   gene	   codes	   for	   a	   membrane-­‐bound	   protein	  
consisting	  of	  338	  amino	  acids	  with	  a	  mass	  of	  approximately	  38	  kDa.	  	  
	  
The	  macromolecular	  structures	  of	  fungal	  AUR1p	  and	  LmjIPCS	  are	  similar	  but	  only	  share	  a	  
limited	  amino	  acid	  sequence	  identity.	  A	  greater	  similarity	  is	  observed	  with	  orthologues	  in	  
the	  related	  kinetoplastids	  L.	  major,	  L.	  donovani,	  T.	  cruzi	  and	  T.	  brucei.	  In	  fact,	  the	  sequence	  
identity	  of	  protozoan	  enzymes	  is	  more	  closely	  related	  with	  the	  animal	  SMS	  even	  though	  
the	  fungal	  AUR1p	  performs	  an	  equivalent	  function	  (Table	  2).	  This	  is	  demonstrated	  by	  the	  
100%	  sequence	  identity	   in	  domain	  D1	  for	  kinetoplastids	  and	  mammals	  (Figure	  16).	  Both	  
Leishmania	  and	  mammals	  utilise	  the	  substrate	  ceramide	  75	   therefore	  the	  conserved	  D1	  
domain	  may	  play	  an	  important	  role	  in	  the	  binding	  of	  this	  substrate.184	  
	  
LmjIPCS	   is	  predicted	  to	  contain	  six	  transmembrane	  helices	  (Figure	  17a)	  and	  two	  regions	  
located	  in	  the	  luminal	  domains	  of	  D3	  and	  D4	  are	  conserved	  relative	  to	  animal	  SMSs	  and	  are	  
also	   similar	   to	   fungal	   AUR1p.147	   These	   regions	   possess	   active	   histidine	   and	   aspartate	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residues	   that	   form	   the	   catalytic	   triad	   which	   participates	   in	   nucleophilic	   attack	   on	   lipid	  
phosphate	  ester	  bonds.147	  Sigal	  et	  al.	  have	  proposed	  a	  general	  mechanism	  for	  phosphoryl	  
transferases,	   which	   was	   adapted	   by	   Mina	   et	   al.	   for	   LmjIPCS	   (Figure	   17b).	   Sigal	  
demonstrated	  that	  one	  arginine	  residue	  close	  to	  the	  nucleophilic	  histidine	  of	  the	  active	  site	  
is	   conserved	   across	   different	   families	   of	   enzymes	   and	   organisms.	   Investigations	   of	   the	  
LmjIPCS	  sequence	  identified	  Arg262	  as	  a	  conserved	  residue	  and	  potentially	  involved	  in	  the	  


























Figure	  16:	  The	  sequence	  alignment	  of	  highly	  conserved	  regions	  from	  fungus	  AUR1	  protein,	  human	  SMS,	  T.	  brucei	  
brucei	  (TRYB2)	  SLS,	  T.	  cruzi	  (TRYCC)	  SLS,	  L.	  major	  (LEIMA)	  IPCS	  and	  L.	  donovani	  (LEIMAD)	  IPCS.	  *	  Indicates	  highly	  
conserved	  residues	  and	  the	  residues	  in	  the	  catalytic	  triad	  are	  highlighted	  in	  yellow.186	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Table	   2:	   Percentage	   sequence	   identity	   of	   orthologous	   sphingolipid	   synthases	   from	   yeast,	   human,	   T.	   brucei	   brucei	  













Figure	  17:	  a)	  Predicted	  topology	  model	  of	  IPCS	  from	  kinetoplastids	  (adapted	  from	  Goren	  et	  al.	  with	  permission).187	  
Four	  domains	  are	  highlighted	  in	  yellow.	  b)	  LmjIPCS	  catalytic	  triad	  showing	  phosphorylation	  of	  ceramide	  75	  (adapted	  
from	  Mina	  et	  al.	  with	  permission).147	  
	  
2.4.2.	  Characterisation	  of	  IPCS	  in	  Leishmania	  
	  
Unfortunately,	   the	   function	   and	   structure	   of	   Leishmania	   IPCS	   cannot	   be	   analysed	   by	  
conventional	   methods188,189	   as	   this	   enzyme	   is	   membrane-­‐bound	   with	   multiple	  
transmembrane	  domains	  making	  protein	  purification	  and	  crystallisation	  challenging.190	  To	  
circumvent	  this	  problem,	  Denny	  et	  al.	  developed	  an	  enzyme	  assay	  using	  S.	  cerevisiae	  as	  a	  
vehicle.	  The	  AUR1	  gene	  in	  S.	  cerevisiae	  was	  deleted	  to	  generate	  a	  yeast	  knock-­‐out	  mutant.	  
This	  was	  transformed	  with	  the	  exogenous	  LmjIPCS	  gene	  to	  generate	  a	  mutant	  yeast	  strain	  
which	  has	  only	  LmjIPCS	  as	  its	  functional	  sphingolipid	  synthase	  (SLS).191	  
	  
These	  cells	  were	  propagated	  and	  then	  used	  to	  isolate	  microsomal	  membranes	  enriched	  in	  
IPCS.	  The	  enzyme	  assay,	  which	  can	  be	  formatted	  into	  a	  96-­‐well	  plate	  format,	  uses	  these	  
microsomes	  to	  convert	   fluorescent	  NBD-­‐C6-­‐ceramide	  80	   into	  NBD-­‐C6-­‐IPC	  81	   (Scheme	  3).	  












AUR1	  YEAST	   100	   19	   17	   16	   16	   17	  
SMS2	  HUMAN	   19	   100	   24	   24	   24	   24	  
SLS1	  TRYB2	   17	   24	   100	   47	   41	   39	  
SLS11	  TRYCC	   16	   24	   47	   100	   49	   46	  
SLS	  LEIMA	   16	   24	   41	   49	   100	   93	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The	  substrate	  and	  product	  are	  then	  separated	  using	  anion	  exchange	  chromatography	  and	  
the	  fluorescence	  is	  measured	  to	  quantify	  NBD-­‐IPC	  81.146	  
	  
	  
The	  biochemical	  assay	  outlined	  above	  was	  used	  to	  characterise	  LmjIPCS	  and	  demonstrated	  
that	  this	  enzyme	  proceeds	  via	  a	  double-­‐displacement	  mechanism	  (Scheme	  4).	  Out	  of	  the	  
two	  substrates,	  ceramide	  75	  has	  a	  higher	  affinity	  for	  the	  enzyme	  compared	  to	  the	  more	  
abundant	  substrate,	  PI.	  This	  suggests	  that	  ceramide	  75	  is	  the	  rate-­‐limiting	  substrate	  in	  the	  
reaction146	  and	  therefore,	  analogues	  of	  ceramide	  75	  were	  synthesised	  to	  probe	  the	  active	  
site.	  The	  biochemical	  assay	  described	  above	  was	  used	  to	  identify	  a	  number	  of	  structure-­‐
activity	  relationships	  (SARs)	   (Figure	  18a).	   Interestingly,	   it	  was	  found	  that	  the	  free	  amino	  
analogue	  82	  (Figure	  18b)	  could	  function	  as	  an	  IPCS	  inhibitor	  rather	  than	  as	  an	  alternative	  
substrate.	  Analogue	   82	  was	   shown	   to	  be	  active	  against	  L.	  major	   promastigotes	  but	  on-­‐
target	  effects	  required	  validation.	  	  
	  
Knock-­‐out	  L.	  major	  promastigotes	  which	  lack	  IPCS	  could	  not	  be	  generated	  and	  Denny	  et	  al	  
proposed	  that	  this	  may	  be	  due	  to	  the	  build-­‐up	  of	  toxic	  metabolites	  (data	  unpublished).191	  
Fortunately,	  mutant	  L.	  major	  Δ	  LCB2	  can	  test	  the	  activity	  of	  potential	  LmjIPCS	  inhibitors	  as	  
this	  enzyme	  is	  redundant	  in	  these	  parasites.	  These	  mutants	  are	  3-­‐4	  fold	  less	  sensitive	  to	  
analogue	  82	  than	  wild	  type	  L.	  major	  promastigotes.	  This	  suggests	  mostly	  on-­‐target	  effects	  




























NBD-C6-Ceramide 80 NBD-C6-Inositol Phosphorylceramide 81 (IPC)
Phosphatidylinositol (PI)
Scheme	  3:	  LmjIPCS	  biochemical	  assay	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2.5.	  National	  Institute	  of	  Neurological	  Disorders	  and	  Stroke	  (NINDS)	  compound	  screen	  
	  
Utilitising	  the	  biochemical	  assay12	  described	  above	  (Scheme	  3)	  a	  screen	  was	  performed	  on	  
1040	   pharmacologically	   active	   compounds	   from	   the	   National	   Institute	   of	   Neurological	  
Disorders	  and	  Stroke	  (NINDS)	  (data	  unpublished).	  57	  compounds,	  at	  a	  concentration	  of	  20	  
µM,	  showed	  greater	  than	  70%	  inhibition	  of	  IPCS	  and	  these	  were	  tested	  at	  10	  µM	  for	  activity	  
against	   the	   parasite.	   The	   anti-­‐promastigote	   assay	   was	   carried	   out	   with	   L.	   major	  
promastigotes	   using	   a	   resazurin-­‐based	   cell-­‐viability	   assay	   and	   the	   results	   are	   shown	   in	  
Figure	   19.192	   The	   known	   cytotoxic	   compounds	   used	   as	   controls	   were	   removed	   and	   16	  













N-acyl group not essential 







Scheme	  4:	  Double-­‐displacement	  mechanism	  of	  LmjIPCS	  
Figure	  18:	  a)	  SAR	  data	  for	  ceramide	  analogues	  b)	  Free	  amino	  ceramide	  analogue	  with	  inhibitory	  effects	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Figure	  19:	  Cytotoxicity	  of	  NINDS	  library	  against	  L.	  major	  promastigotes.	  Green	  bars	  are	  potential	  lead	  compounds;	  
blue	  bars	  are	  compounds	  with	  poor	  activity;	  red	  bars	  are	  known	  cytotoxic	  and	  non-­‐selective	  compounds;	  lane	  1	  is	  no	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2.5.1.	  Confirmation	  of	  hit	  compound	  activity	  
	  
Pure	  material	  of	  the	  16	  chosen	  inhibitors	  was	  purchased	  from	  commercial	  sources	  and	  a	  
dose-­‐response	  study	  was	  performed	  to	  confirm	  activity	  (Figure	  21).	  	  	  
Figure	  21:	  Activity	  of	  hit	  compounds	  against	  LmjIPCS	  and	  promastigotes	  (adapted	  from	  Brown	  with	  permission)191 
The	  dose-­‐response	  studies	  highlight	  compounds	  that	  disagree	  with	  the	  initial	  enzyme	  and	  
parasite	   screens.	   For	   example,	   IC50	   values	   against	   LmjIPCS	   could	   not	   be	   obtained	   for	  
pararosaniline	   83	   or	   sulfamethizole	   84	   and	   both	   drugs	   displayed	   poor	   antileishmanial	  
activity	  (EC50	  =	  9.78	  µM	  and	  39.63	  µM	  respectively).	  In	  addition,	  doxepin	  and	  pimozide	  85	  
exhibit	  EC50	  values	  greater	  than	  10	  µM	  against	  L.	  major	  promastigotes	  (30.03	  µM	  and	  22.93	  
µM	  respectively).	  Subsequently,	  these	  compounds	  were	  not	  investigated	  further.	  	  
The	  known	  antileishmanial	  pentamidine	  5	  was	  confirmed	  as	  a	  LmjIPCS	  inhibitor	  with	  an	  IC50	  
value	  of	  3.10	  µM	  and	  an	  EC50	  against	  the	  parasite	  of	  2.05	  µM.	  Four	  compounds	  exhibited	  
antileishmanial	  activity	  greater	  than	  pentamidine	  5.	  These	  compounds	  were	  amlodipine	  86	  
(EC50	   =	   1.91	  µM),	   clemastine	   1	   (EC50	   =	   0.47	  µM),	   flunarizine	   87	   (EC50	   =	   1.73	  µM)	   and	  
suloctidil	  88	  (EC50	  =	  1.33	  µM).	  Interestingly,	  all	  these	  compounds	  showed	  higher	  activity	  
against	  the	  parasite	  than	  the	  enzyme.	  The	  cause	  of	  this	  difference	  in	  activity	  is	  unknown	  
but	  may	   be	   due	   to	   the	   drugs	   having	  multiple	   targets,	   undergoing	  metabolism	   to	  more	  
active	   compounds	   or	   the	  microsomes	   possessing	   higher	   concentrations	   of	   the	   enzyme	  






















Enzyme	  and	  parasite	  activity	  of	  hit	  compounds
LmjIPCS	  IC50 L.	  major	  promastigotes	  EC50
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2.5.2.	  Intramacrophage	  L.	  major	  anti-­‐amastigote	  assay	  	  
	  
Amlodipine	   86,	   clemastine	   1,	   flunarizine	   87	   and	   suloctidil	   88	  were	   then	   tested	   against	  
murine	  peritoneal	  macrophages	  infected	  with	  L.	  major	  amastigotes.	  Flunarizine	  87	  showed	  
poor	  antileishmanial	  activity	  against	  the	  clinically	  relevant	  amastigotes	  (EC50	  >	  30	  µM)	  but	  
amlodipine	  86,	   clemastine	  1	   and	  suloctidil	  88	  displayed	  single	  digit	  micromolar	  potency	  
(EC50	  =	  3.65	  µM,	  3.06	  µM	  and	  4.28	  µM	  respectively).	  The	  cytotoxicity	  against	  uninfected	  
macrophages	   of	   amlodipine	   and	   suloctidil	   88	   was	   greater	   than	   10	   µM	   whereas	   for	  
clemastine	  1	   it	  was	  greater	  than	  20	  µM.	  Hence,	  clemastine	  1	  was	  identified	  as	  the	  most	  
selective	  compound	  for	  Leishmania	  and	  was	  progressed	  as	  the	  lead	  compound.	  
Clemastine	  1	  is	  an	  orally	  available	  antihistamine	  sold	  under	  the	  brand	  name	  Tavegil®	  and	  
acts	  as	  an	  antagonist	  for	  the	  histamine	  H1-­‐receptor.193	  Also,	  clemastine	  1	   is	  currently	   in	  
phase	  2	  clinical	  trials	  as	  remyelinating	  therapy	  for	  treatment	  of	  multiple	  sclerosis.194	  This	  
over-­‐the-­‐counter	  drug	  has	  a	  well-­‐established	  safety	  profile195,196	  with	  the	  major	  side	  effects	  
being	  sedation,	  dizziness,	  disturbed	  coordination,	  epigastric	  distress	  and	  dry	  mouth.197	  In	  
addition,	   clemastine	   has	   good	   pharmacokinetic	   properties	   such	   as	   a	   high	   volume	  
distribution	  of	  9.5	  ±	  3.8	  L	  kg-­‐1	  which	  contributes	  to	  a	  terminal	  elimination	  half-­‐life	  (t1/2)	  of	  
21.3	  ±	   11.6	   h.198	   	   This	   positive	   drug	   profile	   highlights	   clemastine	   as	   an	   appealing	   drug	  
candidate	  for	  repurposing	  as	  an	  oral	  antileishmanial	  and	  this	  will	  be	  explored	  in	  Chapter	  3.	  
2.5.3.	  On-­‐target	  validation	  	  
	  
Work	  performed	  in	  collaboration	  with	  Mike	  Barrett	  (University	  of	  Glasgow)	  measured	  the	  
effect	  of	  clemastine	  1	  on	  the	  metabolome	  of	  L.	  major	  promastigotes.	  The	  promastigotes	  
were	   incubated	  with	   clemastine	  1	   for	   42	   h	   before	   the	  metabolites	  were	   extracted	   and	  
analysed	   by	   LC-­‐MS.	   Results	   found	   that	   parasites	   treated	  with	   clemastine	   1	   showed	   an	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Lipidomic	  analysis	  performed	  in	  collaboration	  with	  Terry	  Smith	  (University	  of	  St	  Andrews)	  
supports	   the	   findings	   from	   the	  metabolomic	   study.	   	   L.	  major	  promastigotes	  were	  again	  
incubated	  with	  clemastine	  1	  for	  42	  h	  before	  the	  lipids	  were	  extracted	  and	  analysed	  by	  ES-­‐
MS	  and	  GC-­‐MS.	  Focus	  was	  on	  the	  inositol	  lipids	  and	  the	  ratio	  of	  IPC	  79	  relative	  to	  PI	  was	  
quantified	  (Figure	  23).	  The	  results	  showed	  that	  promastigotes	  treated	  with	  clemastine	  1	  
demonstrate	   a	   reduction	   in	   the	   ratio	   of	   IPC	   79	   relative	   to	   PI.	   This	   is	   consistent	   with	  





















Figure	  22:	  Metabolomic	  analysis	  of	  L.	  major	  promastigotes	  which	  had	  
been	  treated	  with	  clemastine	  1	  for	  42	  h	  (data	  unpublished)	  
Figure	  23:	  Lipidomic	  analysis	  of	  L.	  major	  promastigotes	  with	  a)	  DMSO	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2.6.	  Synthesis	  of	  clemastine	  	  
In	  1976	  the	  synthesis	  of	  all	  four	  possible	  stereoisomers	  of	  clemastine	  1	  was	  reported	  by	  
Ebnöther	  and	  Weber.	  Clemastine	  1	  is	  sold	  as	  the	  most	  active	  diastereomer,	  (R,	  R)-­‐isomer	  
1,	  with	  the	  stereochemistry	  of	  the	  quaternary	  benzhydryl	  carbon	  determining	  activity	  to	  a	  
greater	   extent	   than	   the	   stereocentre	   in	   the	   pyrrolidine	   ring.199	   All	   published	   routes	   to	  
clemastine	  1	  employ	  the	  disconnection	  at	  the	  ether	  bond	  to	  give	  tertiary	  alcohol	  89	  (tail	  
group)	  and	  chloroethylpyrrolidine	  90	  (head	  group)	  shown	  in	  Scheme	  5.199,200,197,201	  It	  should	  
be	  noted	  that	  until	  recently	  resolution	  was	  employed	  to	  separate	  the	  diastereomers	  but	  in	  
2010	  Clayden	  et	  al.202	  and	  in	  2015	  Lee	  et	  al.200	  developed	  asymmetric	  synthetic	  routes	  to	  
clemastine,	  discussed	  further	  in	  	  2.6.1.	  and	  2.6.2.	   
 
2.6.1.	  Tertiary	  alcohol	  (tail	  group)	  
	  
A	  patent	  published	  in	  2009	  uses	  a	  simple	  Grignard	  reaction	  to	  form	  the	  tail	  group	  89	  but	  as	  
a	  racemic	  mixture	  in	  a	  low	  yield	  of	  25%	  (Scheme	  6a).197	  Both	  Lee	  and	  Clayden	  developed	  
enantioselective	  reactions	  to	  afford	  the	  tail	  group	  as	  one	  enantiomer.	   In	  Lee’s	  synthetic	  
route	  (Scheme	  6b),	  the	  chiral	  benzyl	  group,	  alcohol	  91,	  acts	  as	  a	  chiral	  auxiliary	  as	  well	  as	  a	  
protecting	   group.	   The	   key	   reaction	   is	   the	   chelation-­‐controlled	   asymmetric	   nucleophilic	  
addition	  of	  4-­‐chlorophenylmagnesium	  bromide	  to	  phenyl	  ketone	  92,	  pre-­‐complexed	  with	  
MgBr2.OEt	   in	  DCM	  (Scheme	  6b),	   to	  afford	  compound	  93	  with	  good	  diastereoselectivity,	  
97%	  diastereomeric	  excess	  (de).200	  Overall	  the	  route	  consists	  of	  6	  steps	  with	  variable	  yields	  
in	   comparison	  with	   Clayden’s	   route	  which	   is	   only	   4	   steps	   and	   benefits	   from	   an	   overall	  
higher	   yield.	   In	  Clayden’s	  procedure	   (Scheme	  6c)	   the	   (S)-­‐tertiary	   alcohol	   (S)-­‐89	   is	  made	  
from	  p-­‐chloroacetophenone	  94	  that	  is	  reduced	  to	  alcohol	  (S)-­‐95	  via	  a	  Noyori	  asymmetric	  
hydrogenation.	  Alcohol	  (S)-­‐95	  	  is	  converted	  into	  carbamate	  (S)-­‐96	  which	  is	  treated	  with	  LDA	  
to	  form	  a	   lithiated	  carbamate	  that	  undergoes	  aryl	  migration	  to	  compound	  (S)-­‐97	  with	  a	  
moderate	   enantiomeric	   excess	   of	   68%.	   Finally,	   tertiary	   alcohol	   (S)-­‐89	   was	   formed	   by	  
refluxing	  compound	  (S)-­‐97	  with	  NaOEt	  in	  ethanol.202	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2.6.2.	  Chloroethylpyrrolidine	  (head	  group)	  
	  
The	  patent	  involves	  the	  straightforward	  homologation	  of	  proline	  (R)-­‐98	  via	  nitrile	  (R)-­‐99	  to	  
form	  the	  head	  group	  (R)-­‐90	  and	  although	  the	  yields	  are	  good	  for	  each	  individual	  step	  it	  is	  a	  
long	  synthesis	  (seven	  steps)	  (Scheme	  7).197	  
	  
	  
Scheme	  6:	  Synthesis	  of	  tail	  group	  89	  reported	  a)	  in	  US	  patent;196	  asymmetric	  synthesis	  of	  tail	  group	  89	  b)	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The	  route	  described	  by	  Nikiforov	  (Scheme	  8)	  in	  1990	  comprises	  of	  six	  steps	  but	  yields	  from	  
the	   steps	   are	   not	   reported.	   It	   starts	   from	   1-­‐methyl-­‐2-­‐thiopyrrolininone	  100	   which	   is	   S-­‐
alkylated	  and	  then	  directly	  subjected	  to	  a	  sulfide	  contraction	  to	  form	  compound	  101.	  The	  
crucial	  step	  was	  to	  resolve	  benzyl	  ester	  102	  to	  yield	  the	  (R)-­‐	  enantiomer.	  This	  was	  achieved	  
using	  the	  R-­‐isomer	  of	  di-­‐p-­‐toluoyl-­‐tartaric	  acid	  and	  (R)-­‐102	  was	  subsequently	  reduced	  and	  
chlorinated	  to	  form	  head	  group	  90.203	  
 
Lee	  et	  al.	   starts	   from	  L-­‐homoserine	   lactone	   (S)-­‐103	   (Scheme	  9).	  Following	  racemisation-­‐
minimized	  N-­‐allylation	  three	  further	  steps	  afford	  the	  acyclic	  diene	  (S)-­‐104	  ready	  for	  ring-­‐
closing	   metathesis	   (RCM)204.	   After	   this	   RCM	   step,	   chloroethylpyrrolidine	   (R)-­‐90	   was	  













































 Scheme	  7:	  Formation	  of	  (R)-­‐head	  group	  90	  via	  straightforward	  homologation	  of	  (R)-­‐proline	  98196	  
 
Scheme	  8:	  (R)-­‐head	  group	  90	  formation	  involving	  the	  resolution	  of	  benzyl	  ester	  102202 
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Clayden’s	  synthesis	  of	  (S,	  S)-­‐	  clemastine	  (S,	  S)-­‐1	  (Scheme	  10),	  forms	  the	  head	  group	  (S)-­‐90	  
from	   N-­‐Cbz-­‐proline	   (S)-­‐105	   using	   an	   Arndt-­‐Eistert	   reaction.	   The	   first	   step	   involves	  
conversion	   of	   N-­‐Cbz-­‐proline	   (S)-­‐105	   into	   diazoketone	   (S)-­‐106	   and	   then	   a	   Wolff-­‐
rearrangement	   to	   form	   the	   chain-­‐extended	   methyl	   ester	   (S)-­‐107	   with	   retention	   of	  
stereochemistry.	  Both	  the	  ester	  and	  carbamate	  protecting	  group	  were	  reduced	  to	  afford	  
homoprolinol	   (S)-­‐108,	   which	   again	  was	   treated	  with	   thionyl	   chloride	   to	   form	   the	   head	  













2.6.3.	  Etherification	  to	  form	  clemastine	  
	  
The	  formation	  of	  the	  hindered	  ether	  is	  challenging	  and	  both	  reported	  procedures	  involve	  
free-­‐basing	  the	  head	  group	  and	  deprotonating	  the	  tertiary	  alcohol	  with	  either	  NaNH2	  or	  
NaH.	  This	  is	  followed	  by	  heating	  alkoxide	  89	  with	  alkyl	  chloride	  90	  under	  reflux	  for	  16h	  to	  
afford	  clemastine	  1	  in	  moderate	  to	  low	  yields	  and	  azepane	  109	  as	  a	  by-­‐product	  (Scheme	  
11).197,202	  Clayden	  assumed	  that	  the	  formation	  of	  isomer	  109	  arises	  through	  intramolecular	  
alkylation	  to	   form	  the	  reactive	  bicyclic	  cation	  110	   (Scheme	  12)	  which	  can	  then	  undergo	  
expansion	  with	  alkoxide	  89.	  Consistent	  with	  this,	  amine	  protection	  as	  a	  carbamate	  on	  the	  
head	  group	  showed	  no	  coupling	  and	  therefore	  participation	  of	  the	  amine	  N	  is	  involved	  in	  
the	  pathway	  of	  both	  products.202	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2.7.	  Clemastine	  analogues	  
	  
Inhibitors	  from	  the	  screen	  described	  in	  section	  2.5.	  exhibited	  narrow	  chemical	  diversity.	  
Therefore,	  previous	  work	   in	   the	  group	  developed	  a	  synthetic	   route	   to	  a	  small	   library	  of	  
clemastine	  analogues	  based	  on	  the	  literature	  routes	  to	  clemastine	  reported	  in	  section	  2.6.	  
The	  development	  of	  this	  synthetic	  route	  by	  Brown191	  will	  be	  discussed	  in	  this	  section,	  along	  
with	  the	  biological	  results	  which	  demonstrate	  the	  requirements	  for	  activity	  of	  clemastine	  
against	  LmjIPCS.	  	  
2.7.1	  Synthesis	  of	  head	  and	  tail	  groups	  
	  
An	   initial	   concern	   was	   the	   quaternary	   methyl	   group	   on	   the	   benzhydyl	   carbon	   of	   89.	  
Previous	   research	   in	   the	  group	  demonstrated	   that	   tertiary	  alcohol	  89	  was	  unstable	  and	  























Scheme	  12:	  Etherification	  via	  bicyclic	  cation	  110201	  
 


















































Scheme	  13:	  Instability	  of	  tertiary	  alcohol	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Therefore,	  the	  synthesis	  of	  a	  library	  of	  clemastine	  analogues	  lacking	  the	  quaternary	  methyl	  
group	  on	  the	  benzhydryl	  carbon	  (nor-­‐clemastine	  analogues)	  was	   investigated.	  Using	  the	  
literature	  procedures	  outlined	   above,	   nor-­‐clemastine	   analogue	   (R)-­‐112	  was	   synthesised	  
from	  benzhydrol	  tail	  group	  113	  and	  homoprolinol	  head	  group	  (R)-­‐108	   (Scheme	  14).	  The	  
synthesis	   of	   both	   moieties	   and	   their	   coupling	   to	   form	   nor-­‐clemastine	   analogues	   is	  
described	  below.	  	  
 
The	  synthesis	  of	  this	  tail	  group	  113	  was	  facile	  and	  used	  a	  Grignard	  reaction	  to	  furnish	  the	  
desired	  benzhydrol	  tail	  group	  113	  in	  a	  good	  yield	  (Scheme	  15).	  
 
Initially,	  Brown	  attempted	  to	  access	  the	  Boc-­‐protected	  homoprolinol	  head	  group	  (S)-­‐114	  
and	  this	  involved	  a	  straightforward	  homologation	  of	  proline	  as	  outlined	  in	  Scheme	  16.	  It	  
should	  be	  noted	   that	   tosylate	  115	  was	  very	  unstable	  and	   immediately	  displaced	  by	   the	  
cyanide	  anion	  to	  form	  the	  desired	  nitrile	  99.	  The	  literature	  procedure	  was	  then	  modified	  
and	   nitrile	   99	   was	   hydrolysed	   with	   the	   mild	   reagent	   Na2O2	   which	   did	   not	   cleave	   the	  
protecting	  group	  and	  afforded	  compound	  (S)-­‐116	   in	  a	  good	  yield.	  Subsequent	  reduction	  
using	  BH3	  then	  afforded	  the	  enantiomerically	  pure	  Boc-­‐protected	  (S)-­‐homoprolinol	  (S)-­‐114.	  
The	  overall	  yield	  was	  33%	  over	  5	  steps	  and	  the	  route	  involved	  an	  unstable	  intermediate,	  
therefore,	  other	  routes	  were	  explored.191	  
 
Another	  procedure	  described	  by	  Brown	  involved	  using	  a	  Wittig	  homologation	  followed	  by	  
a	   hydroboration	   as	   shown	   in	   Scheme	   17.	   The	   oxidation	   of	   prolinol	   (S)-­‐117	   to	   form	  
Scheme	  14:	  Disconnection	  of	  nor-­‐clemastine	  analogues	  
Scheme	  16:	  Formation	  of	  (S)-­‐homoprolinol	  from	  nitrile	  99	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compound	   (S)-­‐118	   was	   efficient	   on	   a	   gram-­‐scale	   using	   a	   Parikh-­‐Doeing	   oxidation,	   with	  
SO3.pyridine.	  However,	  the	  subsequent	  Wittig	  reaction	  formed	  (S)-­‐119	  in	  a	  low	  yield	  and	  
caused	   racemisation	   of	   the	   stereocentre.	   A	   hydroboration	   reaction	   followed	   by	   an	  
oxidation	  with	  hydrogen	  peroxide	  furnished	  Boc-­‐protected	  homoprolinol	  (S)-­‐114.191	  
Although	   this	   route	   was	   successful	   it	   had	   a	   poor	   overall	   yield	   of	   14%	   over	   4	   steps.	   In	  
addition,	  there	  was	  a	  loss	  of	  enantiopurity	  and	  therefore	  was	  unsuitable	  for	  the	  synthesis	  
of	  a	  nor-­‐clemastine	  analogues.191	  
Brown	   found	   that	   the	   most	   efficient	   route	   was	   to	   access	   homoprolinol	   108	   via	  
homologation	  of	  N-­‐Cbz-­‐proline	  using	  an	  Arndt-­‐Eistert	  reaction	  described	  by	  Clayden	  et	  al.	  
and	  outlined	  in	  Scheme	  10.202	  This	  route	  retained	  stereochemistry	  and	  proved	  to	  be	  the	  
most	  efficient,	  with	  overall	  yields	  of	  62%	  for	  (S)-­‐108	  and	  43%	  for	  (R)-­‐108	  over	  4	  steps.191	  
2.7.2.	  Etherification	  step	  to	  form	  nor-­‐clemastine	  analogues	  
	  
The	  final	  step	  of	  the	  synthetic	  route	  is	  a	  challenging	  etherification	  of	  a	  sterically	  hindered	  
benzhydrol	   113	   and	   results	   in	   low-­‐to-­‐moderate	   yields	   of	   the	   final	   compound	   112.	   As	  
described	   in	   section	   2.6.3.	   and	   shown	   in	   Scheme	   12,	   this	   reaction	   forms	   azepane	   by-­‐
product	  109	  via	   assistance	  of	   the	  amine	  group	  on	  chloroethylpyrolidine	  90	   to	   form	   the	  
reactive	   bicyclic	   cation	  110.	   To	   try	   and	   circumvent	   this	   problem,	   Brown	   decreased	   the	  
nucleophilicity	  of	   the	  nitrogen	  atom	  by	  using	   the	  Boc-­‐protected	  homoprolinol	  114.	   The	  
alcohol	   group	   of	   compound	   114	   was	   activated	   to	   a	   reaction	   with	   benzhydrol	   113	   via	  
tosylation.	  However,	  tosylate	  120	  was	  unstable	  and	  degraded	  before	  it	  could	  be	  reacted	  
with	  benzhydrol	  113.	  Brown	  suggests	  that	  the	  instability	  was	  due	  to	  an	  interaction	  between	  
the	  carbamate	  and	  tosyl	  group	  (Scheme	  18).	  Nevertheless,	  this	  route	  was	  abandoned	  and	  
another	  explored.	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Previous	  reports	  have	  demonstrated	  that	  benzhydrols	  can	  undergo	  acid-­‐catalysed	  ether	  
formation;205,	  206	  therefore,	  benzhydrol	  113	  and	  Boc-­‐protected	  alcohol	  114	  	  were	  refluxed	  
with	  p-­‐toluenesulfonic	  acid	  in	  the	  presence	  of	  4	  Å	  molecular	  sieves	  to	  afford	  the	  desired	  
nor-­‐clemastine	  analogue	  121.	  This	  general	  procedure	  was	  used	  to	  synthesise	  121,	  (S)-­‐112	  
and	  (R)-­‐112	  in	  moderate	  yields	  of	  66%,	  34%	  and	  57%	  respectively	  (Scheme	  19).191	  	  
 
2.7.3.	  SAR	  data	  for	  clemastine	  analogues	  
	  
Molecules	  with	  different	  linker	  moieties	  were	  also	  synthesised	  and	  tested	  in	  addition	  to	  
nor-­‐clemastine	  analogues	  and	  the	  SAR	  data	  obtained	  by	  Brown	  is	  summarised	  in	  Figure	  24.	  
The	  synthetic	   routes	   to	  many	  of	   the	  analogues	  have	  not	  been	   included	   in	   this	   thesis	  as	  
these	   changes	   had	   a	   detrimental	   effect	   on	   potency.	   Pleasingly,	   the	   quaternary	  methyl	  
group	  on	  the	  benzhydryl	  carbon	  was	  not	  essential	  to	  activity,	  however,	  the	  methyl	  group	  
on	   the	   amine	   improved	   potency.191	   The	   most	   active	   analogue	   of	   clemastine	   was	   nor-­‐
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clemastine	  (R)-­‐112	  which	  retained	  activity	  in	  both	  the	  enzyme	  and	  parasite	  assays	  (Figure	  
25).	  Therefore,	  an	  initial	  focus	  of	  this	  project	  was	  to	  optimise	  the	  route	  to	  nor-­‐clemastine	  
analogues	  developed	  by	  Brown	  and	  synthesise	  analogues	  that	  would	  further	  explore	  the	  

















2.8.	  Project	  objectives	  
	  
The	  previous	  work	  discussed	  in	  this	  chapter	  identifies	  the	  overall	  aims	  of	  this	  project,	  which	  
can	  be	  summarised	  as:	  	  
•   Investigate	  the	  effects	  of	  clemastine	  in	  an	  animal	  model	  of	  cutaneous	  leishmaniasis	  
and	  identify	  the	  most	  appropriate	  route	  of	  administration.	  
•   Improve	  accessibility	  to	  clemastine	  analogues	  through	  the	  development	  of	  robust	  
synthetic	  routes.	  	  
•   Enhance	   potency	   and	   selectivity	   of	   these	   clemastine	   analogues	   towards	  
Leishmania.	  	  	  
•   Validate	  the	  on-­‐target	  effects	  of	  clemastine	  and	  its	  analogues.	  
Figure	  25:	  Enzyme	  and	  anti-­‐promastigote	  activity	  of	  clemastine	  and	  analogue	  (R)-­‐112190	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3.	  Clemastine	  activity	  	  
	  
3.1.	  Anti-­‐promastigote	  assays	  
	  
Chapter	  2	  demonstrated	  the	  potential	  of	  clemastine	  1	  as	  a	  novel	  antileishmanial	  with	  its	  
high	  activity	  against	  LmjIPCS	  and	  L.	  major	  promastigotes	  and	  amastigotes.	  L.	  major	  is	  found	  
in	  the	  Eastern	  hemisphere	  and	  manifests	  as	  CL,	  the	  most	  common	  form	  of	  the	  disease.175	  
However,	  what	  is	  really	  essential	  is	  a	  drug	  that	  is	  active	  against	  all	  species	  of	  Leishmania	  
and	  therefore	  has	  the	  potential	  to	  treat	  all	  forms	  of	  the	  disease	  around	  the	  globe.	  Thus,	  in	  
addition	  to	  the	  L.	  major	  species	  clemastine	  1	  was	  tested	  against	  L.	  amazonensis;	  which	  also	  
leads	  to	  CL	  but	  is	  found	  in	  the	  Western	  hemisphere;207	  L.	  infantum	  and	  L.	  donovani,	  which	  
both	  manifest	  as	  the	  most	  fatal	  form	  of	  the	  disease,	  VL.175	  	  
	  
Dose-­‐response	  assays	  were	  performed	  for	  clemastine	  1	  against	  L.	  major,	  L.	  amazonensis,	  
L.	   donovani	   and	   L.	   infantum	  promastigotes.	   In	   brief,	   promastigote	   parasites,	   in	   the	   log	  
growth	  phase,	  were	  incubated	  with	  clemastine	  1	  for	  48	  h	  or	  72	  h	  prior	  to	  the	  addition	  of	  
resazurin	   solution,	   and	   after	   4	   h	   the	   fluorescence	   was	   quantified	   to	   measure	   cell-­‐
viability.192	  In	  all	  cases,	  for	  each	  species	  standard	  growth	  curves	  were	  constructed	  to	  ensure	  
that	  the	  parasite	  density	  and	  conditions	  were	  appropriate	  for	  the	  assay.	  Assays	  against	  L.	  
major	  promastigotes	  were	  performed	  at	  Durham	  University	  using	  a	  48	  h	  protocol	  whereas	  
assays	  using	  L.	  amazonensis,	  L.	  donovani	  and	  L.	  infantum	  promastigotes	  were	  carried	  out	  
at	   Universidade	   Federal	   do	   Rio	   de	   Janeiro	   (UFRJ)	   using	   a	   72	   h	   protocol	   and	   adjusted	  
materials	  (Chapter	  8).	  	  
	  
Figure	  26	  shows	  that	  L.	  major	  promastigotes	  incubated	  with	  10	  µM	  of	  clemastine	  1	  for	  24	  
h	  become	  more	  rounded	  and	  less	  elongated	  in	  shape.	  This	  rounded	  morphology	  indicates	  
that	  the	  parasites	  have	  started	  to	  die.	  The	  results	  from	  these	  assays	  show	  that	  clemastine	  
1	  is	  2-­‐3	  times	  more	  active	  against	  L.	  major	  (FV1)	  than	  previously	  reported,191	  presumably	  
due	  to	  a	  longer	  incubation	  time	  of	  48	  h	  rather	  than	  performing	  a	  24	  h	  assay.	  Figure	  27	  and	  
28	   clearly	  demonstrates	   that	   clemastine	  1	   has	   sub-­‐micromolar	   activity	   across	   all	   of	   the	  
Leishmania	  species	  tested.	  The	  differences	  in	  activity	  between	  the	  L.	  major	  and	  L.	  donovani	  
species	  are	  interesting	  (Figure	  28)	  as	  the	  sequence	  identity	  of	  IPCS	  is	  93%	  and	  domains,	  D3	  
and	  D4,	  that	  contain	  the	  active	  residues	  possess	  100%	  sequence	  identity.	  This	  suggests	  that	  
the	  other	  IPCS	  domains	  are	  influencing	  binding	  affinities	  to	  the	  protein	  or	  that	  clemastine	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a)	   b)	  
1	  has	  off-­‐target	  effects.	  In	  addition,	  the	  EC50	  value	  of	  clemastine	  1	  is	  particularly	  high	  against	  
L.	  infantum	  compared	  to	  other	  Leishmania	  species.	  A	  possible	  explanation	  is	  that	  more	  of	  
the	   target	   protein	   is	   being	   expressed	   in	   L.	   infantum	   compared	   to	   the	   other	   species;	  
therefore,	  a	  higher	  dose	  of	  clemastine	  is	  needed	  to	  inhibit	  IPCS	  and	  cause	  parasite	  death.	  	  
Clemastine	  1	  is	  most	  potent	  against	  L.	  amazonensis	  and	  L.	  donovani	  with	  an	  EC50	  value	  in	  
the	  nanomolar	  range	  (20	  nM).	  	  Consequently,	  this	  compound	  has	  the	  potential	  be	  used	  as	  
a	   therapy	   for	   both	   CL	   and	   VL.	   Having	   demonstrated	   broad	   spectrum	   activity,	   the	   next	  
requirement	   was	   to	   assess	   activity	   in	   the	   clinically	   relevant	   amastigote	   form.	   This	   is	  






	   	   	   	   	   	  












Clemastine activity against L. infantum promastigotes











Clemastine activity against L. donovani promastigotes











Clemastine activity against L. amazonensis promastigotes











Clemastine activity against L. major promastigotes











a)	   b)	  
c)	   d)	  
Figure	  27:	  Dose-­‐response	  curves	  of	  clemastine	  against	  L.	  major,	  L.	  amazonensis,	  L.	  donovani	  and	  L.	  infantum	  
promastigotes;	  assays	  were	  performed	  in	  triplicate	  and	  each	  curve	  shows	  a	  representative	  experiment.	  
Figure	  26:	  Images	  of	  L.	  major	  promastigotes	  a)	  untreated	  and	  b)	  
treated	  with	  10	  µM	  clemastine	  1	  for	  24	  h.	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3.2.	  Cytotoxicity	  to	  bone	  marrow	  derived	  macrophages	  (BMDM)	  
	  
The	  cytotoxicity	  of	  clemastine	  1	  against	  peritoneal	  mouse	  macrophages	  (CC50	  >	  20	  µM)	  was	  
investigated	   in	   Chapter	   2.	   Before	   an	   intramacrophage	   assay	   could	   be	   performed	   an	  
accurate	  assessment	  of	  macrophage	  cytotoxicity	  using	  bone	  marrow-­‐derived	  macrophages	  
(BMDM)	  was	  required,	  as	  BMDM	  would	  be	  used	   in	  the	  following	  anti-­‐amastigote	  assay.	  
The	   benefit	   of	   BMDM	   over	   peritoneal	  macrophages	   is	   that	  more	  macrophages	   can	   be	  
harvested	  per	  animal.208	  Briefly,	  1	  ×	  106	  mL−1	  BMDM	  were	  incubated	  with	  clemastine	  1	  for	  
48	  h	  and,	  similarly	  to	  the	  anti-­‐promastigote	  assay	  described	  above,	  resazurin	  solution	  was	  
added	  and	  fluorescence	  quantified	  to	  measure	  cell-­‐viability.192	  The	  result	  is	  shown	  in	  Figure	  
29	  and	  was	  used	  to	  calculate	  a	  CC50	  value	  of	  20	  ±	  1	  µM	  for	  uninfected	  BMDM.	  Therefore,	  
clemastine	  1	  is	  more	  selective	  towards	  the	  promastigotes	  than	  mammalian	  cells	  (selectivity	  
index,	  SI	  ≈	  117,	  1247,	  998	  and	  29	  for	  L.	  major,	  L.	  amazonensis,	  L.	  donovani	  and	  L.	  infantum,	  
respectively)	  and	  this	  compound	  was	  progressed	  into	  an	  intracellular	  amastigote	  assay.	  	  
	  





Figure	  28:	  EC50	  values	  of	  clemastine	  1	  against	  L.	  major,	  L.	  amazonensis,	  L.	  donovani	  and	  L.	  infantum	  promastigotes;	  
EC50	  values	  are	  mean	  ±	  95%	  CI	  from	  at	  least	  three	  experiments.	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3.3.	  Intramacrophage	  anti-­‐amastigote	  assay	  
	  
Clemastine	   1	   was	   tested	   against	   BMDM	   infected	   with	   L.	   amazonensis	   amastigotes,	   as	  
depicted	   in	  Figure	  30a	  L.	  amazonensis	  was	  chosen	  due	  to	   its	  sensitivity	  to	  clemastine	  1,	  
infectivity	  towards	  BMDM	  and	  because	  it	   is	  responsible	  for	  many	  cases	  of	  CL	  and	  ML	  in	  
South	  America.209,207	  Briefly,	  BMDM	  with	   cover	   slips	  were	   infected	  with	  L.	  amazonensis	  
promastigotes	  (10:1).	  After	  24	  h,	  serial	  dilutions	  of	  clemastine	  1	  were	  added	  and	  incubated	  
for	  48	  h.	  Cover	   slips	  were	   then	  stained	  with	  Giemsa	  modified	  solution	  and	  amastigotes	  
were	  counted	  within	  200	  macrophages	  using	  an	  optical	  Nikon®	  microscope	  to	  generate	  the	  
dose-­‐response	  curve	  displayed	  in	  Figure	  30b.	  This	  assay	  revealed	  that	  clemastine	  1	  exhibits	  
sub-­‐micromolar	  inhibition	  of	  L.	  amazonensis	  amastigote	  growth	  with	  an	  EC50	  value	  of	  0.40	  
±	  0.06	  µM.	  In	  comparison	  with	  the	  CC50	  value	  observed	  in	  the	  macrophage	  assay	  (20	  ±	  1	  
µM),	   clemastine	   1	   is	   50	   times	   more	   selective	   towards	   the	   parasite	   over	   the	   host	  
macrophage	  (SI	  =	  50).	  	  
	  
In	  parallel	  with	  the	  results	  obtained	  in	  the	  anti-­‐promastigote	  assay,	  the	  activity	  against	  L.	  
amazonensis	  amastigotes	  was	  7-­‐8	  times	  more	  effective	  than	  that	  observed	  against	  L.	  major	  
amastigotes	   (Chapter	   2),191	   EC50	   =	   	   0.40	   ±	   0.06	   µM	   and	   EC50	   =	   3.06	   µM	   respectively.	  
However,	  no	  definite	  conclusions	  can	  be	  made	  due	  to	  the	  differences	  in	  the	  methods	  used	  
for	  the	  anti-­‐amastigote	  assays	  (such	  as	  different	  types	  of	  macrophages,	  incubation	  times	  
and	  analysis	  technique).	  
	  
Figure	  29:	  An	  example	  of	  dose-­‐response	  curves	  of	  clemastine	  against	  macrophages	  
(BMDM)	  and	  L.	  amazonensis	  promastigotes;	  assays	  were	  performed	  in	  triplicate	  
and	  each	  curve	  shows	  a	  representative	  experiment.	  
The  activity  of  clemastine  towards  promastigotes  and  BMDM
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Overall,	  these	  results,	  summarised	  in	  Table	  3,	  show	  that	  clemastine	  1	  could	  be	  effective	  at	  
a	  dose	   that	  does	  not	  cause	  any	  adverse	  side	  effects	   to	   the	  host.	  Before	   this	  hypothesis	  
could	  be	  tested	  further	  with	  an	  in	  vivo	  infection	  study,	  additional	  tests	  were	  carried	  out	  to	  
validate	  on-­‐target	  effects	  and	  explore	  if	  clemastine	  1	  has	  macrophage	  modulatory	  activity,	  
which	  could	  contribute	  to	  its	  intracellular	  activity.	  	  	  
	  
Table	  3:	  EC50	  values	  of	  clemastine	  1	  against	  L.	  amazonensis	  promastigotes	  and	  amastigotes	  and	  CC50	  value	  of	  clemastine	  
1	  towards	  BMDM;	  values	  are	  mean	  ±	  95%	  CI	  from	  at	  least	  three	  experiments.	  
Promastigote	  EC50	  (µM)	   Macrophages	  CC50	  (µM)	   Amastigotes	  EC50	  (µM)	  
0.020	  ±	  0.003	  
	  
20	  ±	  2	   0.40	  ±	  0.06	  µM	  
	  
3.4.	  Macrophage	  modulation	  	  
	  
Macrophages	   are	   important	   immune	   cells	   involved	   in	   the	   detection,	   phagocytosis	   and	  
destruction	  of	  pathogens.	  Macrophages	  can	  destroy	  pathogens	  via	  two	  mechanisms	  and	  
the	   first	   involves	   the	  generation	  of	   reactive	  oxygen	  species	   (ROS)	  and	   reactive	  nitrogen	  
species	  (RNS).	  Upon	  microorganism	  invasion,	  the	  macrophages	  rely	  on	  the	  NADPH	  oxidase	  
complex	  activity	  to	  generate	  superoxide	  radicals	  inside	  the	  phagosome.	  At	  the	  same	  time,	  
the	   stimulation	   of	   nitric	   oxide	   synthase	   catalyses	   the	   production	   of	   nitric	   oxide	   in	   the	  
cytosol	  which	  readily	  diffuses	  to	  the	  phagocytic	  vacuole.	  Inside	  the	  phagosome	  superoxide	  
radicals	   and	  nitric	   oxides	   react	   to	   generate	  peroxynitrites,	  which	   are	  powerful	   oxidants	  
capable	  of	  killing	  microorganisms.210	  The	  second	  mechanism	  occurs	  when	  the	  phagosome	  
fuses	   with	   lysosome	   to	   become	   a	   phagolysosome.	   Formation	   of	   the	   acidified	  
phagolysosome	  rapidly	  kills	  and	  degrades	  the	  pathogen.211	  
	  
a)	  
Figure	  30:	  a)	  BMDM	  infected	  with	  L.	  amazonensis	  amastigotes	  stained	  with	  Giemsa	  modified	  solution	  and	  b)	  dose-­‐
response	  curves	  of	  clemastine	  1	  plotting	  the	  percentage	  of	  macrophage,	  promastigote	  and	  amastigote	  growth	  
inhibition;	  assays	  were	  performed	  in	  triplicate	  and	  each	  curve	  shows	  a	  representative	  experiment.	  
b)	   The activity of clemastine towards promastigotes, amastigotes and BMDM  
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In	  the	  case	  of	  Leishmania	  parasites,	  amastigotes	  have	  adapted	  to	  survive	  in	  macrophage	  
phagolysosomes	  by	  disrupting	  the	  generation	  of	  ROS.212	  However,	  in	  order	  to	  differentiate	  
into	   amastigotes,	   the	   promastigotes	   must	   first	   survive	   antimicrobial	   activities	   of	  
macrophages.	  A	  mechanism	  used	  to	  achieve	  this	  involves	  the	  inhibition	  of	  phagolysosome	  
biogenesis.	  This	   leads	  to	  a	  decrease	  in	  the	  NADPH	  oxidase	  complex	  activity	  and	  reduces	  
exposure	  to	  ROS.	  In	  addition,	  inhibition	  of	  phagosome	  maturation	  excludes	  the	  vesicular	  
proton-­‐ATPase	   (V-­‐ATPase)	   from	   the	   phagosomes.	   The	   V-­‐ATPase	   mediate	   phagosomal	  
acidification	   which	   is	   essential	   for	   microbicidal	   properties	   and	   for	   optimal	   pathogen	  
processing,	  as	  most	  lysosomal	  hydrolases	  are	  optimally	  active	  at	  acidic	  pH.212	  In	  summary,	  
Leishmania	   parasites	   reduce	   the	   antimicrobial	   activities	   of	   macrophages	   enabling	   the	  
parasite	  to	  proliferate	  inside	  these	  cells	  and	  cause	  the	  clinical	  manifestations.	  Therefore,	  a	  
promising	  therapeutic	  approach	  for	  many	  diseases	  involves	  the	  modulation	  of	  macrophage	  
activities.213	  
	  
It	  was	  hypothesised	  that	  clemastine	  1	  was	  affecting	  the	  activity	  of	  the	  macrophage	  which	  
was	  contributing	  to	  the	  observed	  antileishmanial	  activity.	  As	  described	  above	  nitric	  oxide	  
(NO)	   is	   important	   as	   a	   toxic	   defence	   molecule	   against	   infectious	   organisms	   and	   is	  
synthesised	  by	  many	  cell	  types	  involved	  in	  immunity	  and	  inflammation.214	  It	  was	  postulated	  
that	  clemastine	  1	  could	  increase	  the	  synthesis	  of	  NO	  in	  host	  macrophages,	  which	  would	  be	  
toxic	   to	   the	   intracellular	   parasites.	   In	   brief,	   uninfected	  macrophages	  were	   treated	  with	  
serial	  dilutions	  of	  clemastine	  1	  and	  incubated	  for	  48	  h.	  Subsequently,	  supernatants	  were	  
treated	  with	   the	  Griess	   reagent3	   and	  absorbance	  at	  570	  nm	  was	  quantified.	   The	  Griess	  
Reagent	  System	  measures	  nitrite,	  a	  stable	  and	  non-­‐volatile	  breakdown	  product	  of	  NO,	  and	  
in	   our	   case	   a	   negative	   result	   was	   obtained.	   Therefore,	   NO	   cannot	   contribute	   to	   the	  
observed	  antiparasitic	  activity.	  	  
	  
Another	   mechanism	   of	   action	   by	   which	   immune	   response	   can	   contribute	   the	  
antileishmanial	  activity	  is	  through	  the	  activation	  of	  the	  P2X7	  receptor	  (P2X7R).	  The	  P2X7R	  
is	  a	  membrane-­‐bound	  protein	  with	  a	  ubiquitous	  distribution	  and	  is	  mostly	  highly	  expressed	  
in	  immune	  cells.	  Activation	  of	  P2X7	  by	  extracellular	  ATP	  opens	  a	  cation-­‐specific	  ion	  channel	  
which	  results	  in	  an	  influx	  of	  Na+	  and	  Ca2+	  and	  efflux	  of	  K+.215	  This	  leads	  to	  the	  secretion	  of	  
pro-­‐inflammatory	  cytokines,	  such	  as	  IL-­‐1β	  and	  IL-­‐18,	  and	  the	  production	  of	  reactive	  oxygen	  
and	  nitrogen	  species.216	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Significantly,	   it	  has	  been	   reported	  by	  Nörenberg	  et	  al.	   that	   clemastine	  1	   is	   an	  allosteric	  
modulator	  of	  P2X7R,	  resulting	  in	  sensitisation	  of	  the	  receptor	  to	  lower	  ATP	  concentrations	  
and	  facilitation	  of	  its	  pore	  dilation.	  	  The	  activity	  of	  clemastine	  1	  on	  P2X7R	  was	  confirmed	  in	  
HEK293	   cells	   stably	   transfected	   with	   human	   P2X7R, human	   monocyte-­‐derived	  
macrophages	  and	  murine	  bone	  marrow-­‐derived	  macrophages.	  These	  assays	  measured	  the	  
intracellular	  concentration	  of	  calcium	  using	  fluorescence	  as	  the	  cells	  were	  loaded	  with	  a	  
calcium	  indicator.217	  Upon	  treatment	  with	  clemastine	  1,	  the	  human	  P2X7R	  is	  sensitised	  to	  
extracellular	   ATP.	   This	   could	   stimulate	   an	   immune	   response	   and	   contribute	   to	   the	  
antileishmanial	   activity.	   In	   support	   of	   this	   hypothesis,	   it	   has	   been	   reported	   by	   Rossi-­‐
Bergmann	   et	   al.218	   that	   macrophages	   infected	   with	   L.	   amazonensis	   display	   enhanced	  
expression	  of	  P2X7R	  and	  are	  significantly	  more	  responsive	  to	  extracellular	  ATP.	  In	  fact,	  as	  
low	  as	  100	  µM	  extracellular	  ATP	  diminishes	  the	  percentage	  of	  infected	  cells	  from	  BALB/c	  
mice.	  It	  is	  unlikely	  that	  extracellular	  ATP	  is	  having	  a	  direct	  drug	  effect	  as	  it	  enhances	  axenic	  
parasite	   growth.218	   Consistent	   with	   the	   results	   from	   the	   Griess	   Reagent	   assay,	   Rossi-­‐
Bergmann	  discovered	  that	  parasite	  death	  was	  unlikely	  due	  to	  NO	  production	  as	  this	  was	  
unaltered	   with	   extracellular	   ATP	   concentrations.	   Hence,	   the	   mechanism	   of	   action	   is	  
unknown	  but	  it	  was	  postulated	  that	  it	  involves	  host	  cell	  apoptosis.218	  
	  
Collectively,	  this	  suggested	  that	  enhancement	  of	  the	  P2X7R,	  resulting	  from	  treatment	  with	  
clemastine	  1,	  could	  contribute	  to	  the	  elimination	  of	  the	  parasites.	  To	  explore	  this	  idea,	  anti-­‐
amastigote	  assays	  were	  performed	  with	  macrophages	  from	  C57BL/6	  WT	  mice	  and	  from	  
C57BL/6	  mice	   deficient	   in	   the	   P2X7	   receptor	   (P2X7R-­‐).	   Analysis	   of	   the	   results	   obtained	  	  
(Figure	  31)	  revealed	  that	  clemastine	  1	   is	  5-­‐6	  times	  more	  active	  against	  infected	  WT	  cells	  
when	  a	   low	  concentration	  of	  extracellular	  ATP	   (100	  µM)	   is	  added.	   In	  contrast,	  a	   similar	  
experiment	   with	   P2X7R-­‐	   macrophages	   did	   not	   show	   any	   effect	   with	   the	   addition	  
extracellular	  ATP.	  This	  suggests	  that	  WT	  infected	  cells	  treated	  with	  clemastine	  1	  have	  an	  
enhanced	  P2X7	  receptor	  activity	  which	  is	  responsive	  to	  low	  concentrations	  of	  extracellular	  
ATP	  with	  a	  downstream	  impact	  on	  intracellular	  parasite	  viability.	  	  
	  
Overall,	  treatment	  of	  infected	  BMDM	  with	  clemastine	  1,	  results	  in	  sensitisation	  of	  the	  P2X7	  
receptor	   to	   extracellular	   ATP,	   which	   contributes	   to	   intracellular	   clearance	   (Figure	   31).	  
Therefore,	  the	  mechanism	  of	  action	  for	  antileishmanial	  activity	  of	  clemastine	  1	  may	  involve	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modulation	  of	  macrophage	  activities	  as	  well	  as	  directly	  acting	  on	  the	  parasite	  by	  inhibition	  
of	  IPCS.	  Whether	  or	  not	  IPCS	  inhibition	  and	  P2X7R	  expression	  are	  related	  events	  remains	  












3.5.	  On-­‐target	  validation	  
	  
Clemastine	  1	  was	  identified	  as	  an	  inhibitor	  of	  LmjIPCS	  from	  the	  biochemical	  assay	  described	  
in	   Chapter	   2.	   Further	   validation	   of	   this	   target	   came	   from	   metabolomic	   and	   lipidomic	  
analyses,	  which	  showed	  a	  relative	  increase	  in	  LmjIPCS	  substrate	  concentrations	  (ceramide	  
and	  PI)	  after	  incubation	  with	  clemastine	  1.	  Collectively,	  this	  suggested	  that	  clemastine	  1	  
functions	  as	  a	  LmjIPCS	  inhibitor.	  
	  
To	  confirm	  that	  the	  antileishmanial	  action	  of	  clemastine	  1	  occurred	  due	  to	  its	  activity	  as	  an	  
LmjIPCS	   inhibitor,	  assays	  were	  conducted	  with	   the	   sphingolipid-­‐free	  L.	  major	  mutant	   (Δ	  
LCB2).	   	   These	   parasites	   were	   created	   through	   targeted	   deletion	   of	   one	   SPT	   subunit,	  
LmLCB2.179,178	  Therefore,	  although	  these	  promastigotes	  have	  a	  functional	  IPCS	  they	  do	  not	  
possess	  de	  novo	  synthesised	  ceramide	  which	  means	  IPCS	  is	  redundant.	  As	  a	  control,	  the	  Δ	  
LCB2	  cells	  were	  complemented	  by	  transfection	  with	  a	  plasmid	  encoding	  LmLCB2	  [pX	  NEO	  
LmLCB2]	  to	  generate	  an	  ‘add-­‐back’	  cell	  line	  termed	  PX.	  Ceramide	  and	  IPC	  synthesis	  were	  
restored	  in	  these	  PX	  parasites.178	  Dose-­‐response	  assays	  for	  clemastine	  1	  against	  L.	  major	  
WT	  promastigotes,	  Δ	  LCB2	  and	  PX	  cell	   lines	  were	  performed	  and	  EC50	  values	  calculated.	  
Results	  showed	  that	  the	  EC50	  value	  of	  clemastine	  1	  against	  Δ	  LCB2	  promastigotes	  was	  0.45	  
Figure	  31:	  EC50	  values	  of	  clemastine	  against	  L.	  amazonensis	  amastigotes	  in	  BMDM	  from	  WT	  and	  P2X7R
-­‐	  C57BL/6	  
(KO)	  mice;	  results	  are	  from	  one	  experiment.	  Asterisks	  indicate	  that	  the	  difference	  between	  WT	  and	  WT	  +	  ATP	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  EC50:  0.554 ±  0.126
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±	   0.07	   µM,	   which	   is	   about	   3	   times	   less	   active	   compared	   to	   that	   observed	   for	   WT	  
promastigotes.	  In	  addition,	  clemastine	  1	  shows	  similarly	  good	  levels	  of	  activity	  against	  the	  
PX	  cell	  line	  as	  against	  the	  WT	  parasites	  (EC50	  value	  of	  0.08	  ±	  0.01	  µM,	  Figure	  32).	  By	  contrast	  
the	  positive	  control,	  cycloheximide,	  maintained	  an	  EC50	  value	  of	  0.02	  µM	  against	  mutant	  
promastigotes	  and	  therefore	  acts	  via	  a	  separate	  mode	  of	  action.	  	  
	  
	  Overall,	  the	  activity	  of	  clemastine	  1	  against	  Δ	  LCB2	  parasites	  is	  lower	  than	  that	  observed	  
against	  WT	  and	  PX	  parasites,	  which	  suggests	  that	  clemastine	  1	  is	  having	  an	  effect	  on	  the	  
sphingolipid	  pathway.	  This	   result	   together	  with	   the	  positive	   IPCS	  biochemical	  assay	  and	  
metabolomic	  and	  lipidomic	  results	  (Chapter	  2)	  supports	  the	  hypothesis	  that	  clemastine	  1	  




3.6.	  In	  vivo	  infection	  studies	  
	  
It	  has	  been	  established	  that	  clemastine	  1	  is	  effective	  against	  Leishmania	  promastigotes	  and	  
amastigotes,	   and	   that	   this	   antileishmanial	   action	   is	   due	   to	   its	   activity	   as	   an	   LmjIPCS	  
inhibitor,	  as	  well	  as	  potentially	  stimulating	  the	  immune	  system	  of	  the	  host.	  Therefore,	  the	  
next	   step	  was	   to	   analyse	   the	   in	   vivo	   efficacy	   of	   clemastine	  1	   in	   the	   treatment	   of	  mice	  
infected	  with	  L.	  amazonensis.	  Drugs	  can	  be	  administered	  to	  laboratory	  animals	  by	  a	  wide	  
variety	  of	  routes219	  but	  initial	  investigations	  focused	  on	  the	  intralesional	  (IL)	  and	  oral	  routes	  
of	  administration.	  The	  intralesional	  route	  was	  chosen	  as	  it	  is	  immediately	  absorbed	  at	  the	  
site	  action	  and	  therefore	  the	  most	  effective	  means	  of	  delivering	  the	  drug.	  The	  oral	  route	  
Figure	  32:	  EC50	  values	  of	  clemastine	  1	  against	  WT,	  Δ	  LCB2	  and	  PX	  L.	  major	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was	  studied	  as	  an	  oral	  drug	  would	  be	  most	  accessible	  to	  those	  infected	  with	  leishmaniasis	  
living	  in	  deprived	  communities,	  and	  also	  because	  clemastine	  is	  already	  orally	  available	  for	  
humans	   as	   an	   antihistamine.	  A	   gavage	  was	  used	   for	   the	  oral	   administration	  of	  mice	   to	  
ensure	  precise	  and	  accurate	  dosing.219	  
	  
The	   first	   in	  vivo	   study	  used	  BALB/c	  mice	   infected	  with	  L.	  amazonensis	  expressing	  green	  
fluorescent	   protein	   (GFP).220	   Treatment	   of	   the	   five	   groups	  was	   initiated	   one-­‐week	   post	  
infection:	  clemastine	  1	  (oral),	  miltefosine	  (oral),	  clemastine	  1	  (intralesional,	  IL),	  pentostam	  
2	  (intralesional,	  IL)	  and	  untreated.	  Clemastine	  1	  was	  given	  to	  the	  mice	  at	  an	  oral	  dose	  of	  30	  
mg	  kg-­‐1	  five	  times	  a	  week,	  which	  was	  calculated	  from	  the	  average	  human	  dose	  when	  used	  
as	  an	  antihistamine.221,222	  Miltefosine	  was	  used	  as	  the	  positive	  control	  with	  an	  oral	  dose	  of	  
2.5	  mg	  kg-­‐1	  five	  times	  a	  week.	  The	  intralesional	  dose	  of	  clemastine	  1	  was	  217	  µg	  kg-­‐1,	  1.09	  
mM,	  over	  100-­‐fold	  higher	  than	  the	  in	  vitro	  anti-­‐amastigote	  EC100	  of	  8	  µM,	  and	  administered	  
twice	  a	  week.	  The	  same	  intralesional	  dose	  of	  Pentostam	  2	  (217	  µg	  kg-­‐1	  twice	  a	  week)	  was	  
used	   for	  direct	   comparison	  and	   the	  untreated	   infected	  mice	  were	  used	  as	   the	  negative	  
control	  group.	  Mice	  were	  treated	  for	  28	  days	  and	  weight	  variation	  and	   lesion	  size	  were	  
measured	   at	   least	   once	   a	  week	   to	  monitor	   toxicity	   and	   the	   progression	   of	   the	   disease	  
(Figure	  33a	  and	  33b).	  On	  day	  45	  the	  animals	  were	  sacrificed	  and	  the	  fluorescence	  measured	  
(Figure	  33c)	  and	  parasite	  load	  quantified	  using	  limiting	  dilution	  assay	  (LDA)	  (Figure	  33d).223	  
Lesion	   progression	   was	   analysed	   for	   statistical	   significance	   by	   using	   the	   Dunnett	   test	  
(comparing	  every	  mean	  to	  a	  control	  mean)	  as	  part	  of	  the	  one-­‐way	  ANOVA	  (GraphPad	  Prism	  
8	  software).224	  A	  result	  was	  considered	  significant	  at	  P	  ≤	  0.05.225,	  226	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It	  should	  be	  noted	  that	  there	  were	  slight	  sedative	  effects	  for	  the	  oral	  clemastine	  1	  group	  
directly	  after	  treatment	  but	  no	   long-­‐lasting	  effects	  were	  observed	  and	  weight	  remained	  
constant	   during	   treatment.	   The	   data	   from	   lesion	   size	   measurements	   and	   fluorescence	  
readings	   were	   inconclusive.	   The	   LDA	   showed	   a	   reduction	   in	   parasite	   burden	   when	  
clemastine	  1	  was	  given	  as	  an	  intralesional	  treatment;	  however,	  the	  reduction	  was	  not	  great	  
Figure	  33:	  In	  vivo	  study	  1	  from	  BALB/c	  mice	  infected	  with	  2x106	  L.	  amazonensis	  GFP	  promastigotes	  in	  the	  right	  ear.	  Mice	  
were	  divided	  into	  the	  following	  groups:	  oral	  clemastine	  (n=3),	  miltefosine	  (n=4),	  IL	  clemastine	  fumarate	  (n=5),	  IL	  pentostam	  
(n=5)	  and	  untreated	  (n=4).	  n	  denotes	  the	  number	  of	  mice	  used	  in	  each	  group.	  During	  28	  days	  of	  treatment	  a)	  weight	  
variation	  of	  mice	  and	  b)	  progression	  of	  lesion	  thickness	  were	  measured.	  After	  completion	  of	  treatment	  the	  parasite	  burden	  
of	  the	  infected	  ear	  was	  evaluated	  by	  c)	  fluorescence	  measurements	  and	  d)	  LDA;	  asterisks	  indicate	  that	  the	  difference	  
between	  control	  and	  drug-­‐treated	  groups	  are	  statistically	  significant.	  *	  P	  ≤	  0.05,	  ***	  P	  ≤	  0.001.	  














































c)	   LDA from infected ear


















d)	  In vivo fluorescence readings
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enough	   to	   show	   statistical	   significance	   between	   the	   clemastine	  1	   IL	   and	   the	   untreated	  
groups	  (P=	  0.08).	  In	  addition,	  the	  oral	  dose	  of	  clemastine	  1	  used	  in	  this	  in	  vivo	  assay	  was	  
not	   effective.	   The	   lack	   of	   oral	   activity	   may	   be	   due	   to	   the	   poor	   aqueous	   solubility	   of	  
clemastine	  1	  which	  makes	  dosing	  with	  the	  gavage	  difficult	  and	  results	  in	  insufficient	  drug	  
absorption.	  Thus,	  despite	  a	  tendency	  of	   intralesional	  (and	  oral)	  clemastine	  in	  controlling	  
parasite	  burden,	  the	  results	  were	  not	  statistically	  conclusive.	  Therefore,	  in	  the	  second	   in	  
vivo	  study	   there	  was	  a	  4-­‐5	   times	   increase	   in	   the	  dosage	  of	  oral	   clemastine	  1	   to	   try	  and	  
increase	   drug	   absorption.	   Furthermore,	   the	   drug	   formulation	   consisted	   of	   a	   higher	  
percentage	  of	  tween-­‐80	  to	  increase	  viscosity	  and	  therefore	  improve	  the	  drug	  suspension	  
(Chapter	  8).	  	  
	  
The	  second	  in	  vivo	  study*	  involved	  treatment	  of	  BALB/c	  mice	  infected	  with	  L.	  amazonensis	  
GFP	  which	  again	  was	  initiated	  one-­‐week	  post	  infection.	  Animals	  were	  divided	  into	  the	  five	  
groups	  plus	  a	  sixth	  group	  treated	  with	  a	  clemastine	  analogue	  which	  will	  be	  discussed	   in	  
Chapter	   5.	   The	   five	   groups	   discussed	   in	   this	   chapter:	   clemastine	   1	   (oral),	   clemastine	   1	  
(intraperitoneal,	  IP),	  clemastine	  1	  (intralesional,	  IL),	  glucantime	  3	  solution	  (intraperitoneal,	  
IP)	  and	  untreated.	  As	  mentioned	  previously,	  oral	  clemastine	  1	  was	  administered	  at	  a	  much	  
higher	  dose	  of	  134	  mg	  kg-­‐1	   five	  times	  a	  week	  and	  the	  drug	  formulation	  was	  changed	  to	  
produce	  a	  more	  evenly	  distributed	  suspension.	  Clemastine	  1	  was	  given	  as	  an	  IP	  injection	  at	  
a	   dose	   of	   11.65	  mg	   kg-­‐1	   twice	   a	   week	   to	   give	   an	   insight	   into	   the	   pharmacokinetics	   of	  
clemastine	  1	   as	   they	  should	  be	  similar	   to	   those	  observed	  by	  oral	  administration.219	  The	  
previous	  in	  vivo	  study	  showed	  clemastine	  1	  had	  the	  potential	  to	  reduce	  the	  parasite	  burden	  
as	  an	  IL	  therapy.	  With	  the	  aim	  of	  showing	  statistical	  significance,	  the	  IL	  dose	  was	  increased	  
to	  1.17	  mg	  kg-­‐1	  twice	  a	  week.	  It	  should	  be	  noted	  that	  the	  IL	  dose	  is	  10-­‐fold	  less	  than	  the	  IP	  
dose	  as	  the	  absorption	  of	  material	  delivered	  via	  IP	  is	  typically	  much	  smaller	  and	  slower	  than	  
for	  IL.	   Finally,	  glucantime	  3	  solution	  was	  used	  as	  the	  positive	  control	  at	  an	  IP	  dose	  of	  1.30	  
g	  kg-­‐1	  twice	  a	  week.	  Mice	  were	  treated	  for	  28	  days	  and	  weight	  variation	  and	   lesion	  size	  
were	  measured	  at	  least	  once	  a	  week	  to	  monitor	  the	  progression	  of	  the	  disease.	  On	  day	  41	  
the	  animals	  were	  sacrificed	  and	  the	  fluorescence	  measured	  and	  parasite	  load	  quantified	  
using	  limiting	  dilution	  assay	  (LDA).
*Collaboration	  with	  Douglas	  Escrivani	  at	  UFRJ	  




As	  before,	  there	  was	  little	  variation	  in	  weight	  of	  treated	  mice	  (Figure	  34a)	  and	  the	  assay	  
showed	  positive	  results.	  Figure	  34b	  and	  34c	  illustrate	  a	  significant	  reduction	  in	  lesion	  size	  
between	  the	  untreated	  group	  and	  all	  clemastine-­‐treated	  mice	  at	  day	  35	  post-­‐infection.	  It	  
should	   be	   noted	   that	   lesion	   sizes	   are	   typically	   larger	   for	   IL	   therapies	   as	   they	   cause	  
inflammation	  to	  the	  ear.	  The	  animals	  were	  sacrificed	  on	  day	  41	  and	  the	  in	  vivo	  fluorescence	  
measurements	   from	   the	   infected	   ear	   are	   shown	   in	   Figure	   34d.	   There	   is	   a	   statistical	  
significance	  between	  the	  untreated	  group	  and	  clemastine	  1	  	  administered	  via	  IP	  or	  IL	  (P	  ≤	  
0.001).	  However,	  fluorescence	  readings	  from	  the	  infected	  ear	  show	  no	  decrease	  in	  parasite	  
burden	  when	  the	  untreated	  mice	  are	  compared	  with	  the	  oral	  clemastine	  group.	  Finally,	  
results	  from	  the	  LDA	  show	  a	  statistical	  significance	  between	  the	  average	  parasite	  burden	  
of	  the	  untreated	  group	  and	  the	  group	  treated	  with	  oral	  clemastine	  1	  (P	  ≤	  0.001,	  Figure	  34e).	  
The	  LDA	  is	  a	  more	  sensitive	  and	  reliable	  technique	  than	  fluorescent	  measurements	  from	  L.	  
amazonensis	  GFP	  which	  may	  account	   for	   the	  contrasting	   results	   for	   the	  oral	   clemastine	  
group.	  In	  the	  LDA	  the	  greatest	  statistical	  significance	  was	  between	  the	  untreated	  group	  and	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The	   effectiveness	   of	   the	   IL	   therapy	   was	   not	   surprising	   given	   the	   in	   vitro	   efficacy	   of	  
clemastine	  1	  as	  through	  this	  method	  the	  drug	  is	  immediately	  absorbed	  at	  the	  site	  of	  action.	  
In	  addition,	  it	  was	  observed	  that	  IL	  treatment	  of	  clemastine	  1	  is	  more	  effective	  at	  the	  higher	  
dose	  1.17	  mg	  kg-­‐1	  twice	  a	  week	  compared	  to	  the	  dose	  of	  217	  µg	  kg-­‐1	  used	  in	  the	  first	  in	  vivo	  
study.	   By	   contrast,	   clemastine	   1	   administered	   via	   oral	   gavage	   was	   not	   as	   effective	   at	  
reducing	  parasite	  burden	  even	  at	   the	  high	  dose	  administered.	  Achieving	  oral	  efficacy	   is	  

















































LDA from infected eard)	   e)	  
Figure	  34:	  In	  vivo	  study	  2	  from	  BALB/c	  mice	  infected	  with	  2x106	  L.	  amazonensis	  GFP	  promastigotes	  in	  the	  right	  ear.	  Mice	  
were	  divided	  into	  the	  following	  groups:	  oral	  clemastine	  (n=5),	  IP	  clemastine	  (n=5),	  IL	  clemastine	  (n=5),	  IP	  glucantime	  
solution	  (n=5)	  and	  untreated	  (n=6).	  n	  denotes	  the	  number	  of	  mice	  used	  in	  each	  group.	  During	  28	  days	  of	  treatment	  a)	  
weight	  variation	  of	  mice	  and	  b)	  progression	  of	  lesion	  thickness	  were	  measured.	  After	  completion	  of	  treatment,	  c)	  
representative	  photographs	  of	  the	  infected	  ear	  for	  each	  group	  were	  taken	  and	  the	  parasite	  burden	  was	  evaluated	  by	  d)	  
fluorescence	  measurements	  and	  e)	  LDA;	  Asterisks	  indicate	  that	  the	  difference	  between	  control	  and	  drug-­‐treated	  groups	  
are	  statistically	  significant.	  *	  P	  ≤	  0.05,	  **	  P	  ≤	  0.01,	  ***	  P	  ≤	  0.001,	  ****	  P	  ≤	  0.0001.	  
	  




limitations;	   such	   as	   slower	   onset	   of	   action	   compared	   with	   parental	   delivery,	   reduced	  
efficacy	   through	   hepatic	   first-­‐pass	   elimination,	   lack	   of	   absorption	   and	   degradation	   by	  
digestive	  enzymes	  and	  acids.219	  	  
	  
Pleasingly,	   clemastine	  1	  administered	  via	   IP	  decreased	   the	  parasite	  burden	  to	  a	  greater	  
extent	  than	  the	  antileishmanial	  drug,	  glucantime	  3.	  It	  should	  be	  noted	  that	  parasite	  burden	  
was	  reduced	  by	  a	  much	  smaller	  concentration	  of	  5.83	  mM	  of	  clemastine	  1	  via	  IP	  compared	  
with	   819	  mM,	   glucantime	  which	   corresponds	   to	   221	  mM	  of	   pentavalent	   antimonial.	   In	  
addition,	  clemastine	  1	  administered	  via	   IP	  was	  more	  effective	  than	  the	  IL	  route	  which	  is	  
surprising	  because	   the	   IP	   route	  delivers	   the	  drug	   slower	   than	   the	   IL	   route.	  Although	   IP	  
delivery	   is	   considered	   a	   parental	   route	   of	   administration,	   the	   pharmacokinetics	   of	  
substances	   administered	   intraperitoneally	   are	   more	   similar	   to	   those	   seen	   after	   oral	  
administration	  as	  compounds	  are	  subjected	  to	  hepatic	  first-­‐pass	  elimination.227	  Therefore,	  
there	  is	  still	  potential	  for	  oral	  clemastine	  1	  to	  be	  used	  as	  a	  therapy	  for	  leishmaniasis	  but	  
this	  may	  require	  investigation	  into	  other	  formulations	  and	  drug	  delivery	  vehicles	  such	  as	  




The	  work	  described	  in	  this	  chapter	  involved	  assessing	  the	  activity	  of	  clemastine	  1	  against	  a	  
range	   of	   Leishmania	   species.	   Clemastine	   1	   showed	   sub-­‐micromolar	   activity	   against	   all	  
species	  of	  promastigotes	  and	  was	  selective	  for	  the	  parasite	  over	  mammalian	  macrophages.	  
This	   compound	   was	   progressed	   into	   an	   intramacrophage	   anti-­‐amastigote	   study	   where	  
clemastine	  1	  retained	  its	  activity.	  Clemastine	  1	  causes	  sensitisation	  of	  the	  P2X7	  receptors	  
expressed	  in	  host	  macrophages	  which	  in	  turn	  trigger	  cellular	  responses	  and	  may	  contribute	  
to	  the	  observed	  antileishmanial	  activity.	  The	  drug	  target	  of	  clemastine	  1	  was	  validated	  as	  
LmjIPCS	  through	  analyses	  of	  dose-­‐response	  assays	  using	  L.	  major	  WT,	  Δ	  LCB2	  and	  PX	  cell	  
lines.	   Finally,	   in	   vivo	   studies	   showed	   that	   clemastine	   1	   can	   significantly	   decrease	   the	  
parasite	  burden	  when	  administered	  intraperitoneally	  or	  intralesionally	  and	  future	  work	  will	  
focus	  on	  achieving	  efficacy	  for	  the	  oral	  administration	  of	  clemastine	  1.	  	  
	  
	  




4.	  Nor-­‐clemastine	  analogues	  
	  
As	  discussed	   in	  Chapters	   2,	   nor-­‐clemastine	   analogues	   (lacking	   the	  methyl	   group	  on	   the	  
benzhydryl	  carbon)	  were	  found	  to	  be	  more	  synthetically	  accessible	  than	  clemastine	  whilst	  
still	  possessing	  activity	  and	  selectivity	  in	  both	  the	  enzyme	  and	  parasite	  assays.	  The	  initial	  
goal	  was	  to	  develop	  a	  robust	  synthetic	  route	  to	  nor-­‐clemastine	  analogues	  (Scheme	  20a)	  




4.1.1.	  Homoprolinol	  head	  group	  
	  
The	  initial	  focus	  of	  this	  project	  was	  to	  use	  Clayden’s	  protocol,202,191	  described	  in	  Chapter	  2,	  
to	  homologate	  N-­‐carboxybenzyl	  (Cbz)	  proline	  105	  using	  an	  Arndt-­‐Eistert	  reaction	  (Scheme	  
20b).	   Cbz-­‐proline	   (R)-­‐105	   was	   converted	   to	   the	   acid	   chloride	   with	   oxalyl	   chloride	   and	  
without	  isolation,	  acid	  chloride	  was	  treated	  with	  trimethylsilyldiazomethane	  (TMSCHN2)	  to	  
produce	  diazoketone	  (R)-­‐106	  as	  a	  yellow	  oil	  in	  a	  yield	  of	  56%.	  Formation	  of	  the	  diazoketone	  
(R)-­‐106	  was	  confirmed	  by	  the	  appearance	  of	  the	  characteristic	  CHN2	  peaks	  at	  δH	  5.48	  and	  
5.25	  ppm	  in	  the	  1H	  NMR	  spectrum	  which	  correspond	  to	  the	  two	  rotamers	  of	  diazoketone	  
(R)-­‐106	  and	  the	  presence	  of	  a	  C=N	  stretch	  at	  2102	  cm-­‐1	  in	  the	  IR	  spectrum.	  Subsequently,	  
treatment	   of	   diazoketone	   (R)-­‐106	   with	   silver	   benzoate	   in	   MeOH	   initiated	   the	   Wolff	  
rearrangement	  to	  afford	  methyl	  ester	  (R)-­‐107	  in	  a	  yield	  of	  80%.	  The	  formation	  of	  the	  methyl	  
ester	  (R)-­‐107	  was	  verified	  by	  the	  presence	  of	  a	  methyl	  signal	  at	  δH	  3.64	  ppm	  in	  the	  1H	  NMR	  
spectrum,	  and	  retention	  of	  stereochemistry	  in	  the	  majority	  of	  product,	  was	  confirmed	  via	  
comparison	   of	   the	  optical	   rotation	  measurements	  with	   literature	   values	   ([α]D	   (c	   =	   1.00	  
g/100	  mL,	  CHCl3)	  +23.4°	  (lit.:
191	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +27.2°)	  for	  (R)-­‐107	  and	  [α]D	  
(c	   =	   1.00	   g/100	  mL,	   CHCl3)	   -­‐53.2°	   (lit.:
202	   [α]D	   (c	   =	   1.02	   g/100	  mL,	   CHCl3)	   -­‐42.7°)	   for	   (S)-­‐
107.
202,191	   Reduction	  of	   both	   the	   ester	   and	   the	  protecting	   group	  were	  performed	  using	  
lithium	  aluminum	  hydride	  (LiAlH4)	  in	  THF	  at	  room	  temperature	  (rt)	  to	  afford	  homoprolinol	  
(R)-­‐108	   in	   a	   52%	   yield.	   This	   was	   confirmed	   by	   the	   loss	   of	   carbonyl	   signals	   at	   δC	   171.9	  
(CO2CH3)	  and	  154.8	  (NCO2)	  ppm	  in	  the	  13C	  NMR	  spectrum	  and	  the	  presence	  of	  a	  broad	  OH	  
stretch	  at	  3314	  cm-­‐1	   in	   the	   IR	  spectrum.	  However,	   there	  were	   initial	  problems	  purifying	  
homoprolinol	   (R)-­‐108	   from	   the	   benzylalcohol	   by-­‐product.	   In	   order	   to	   circumvent	   this	  




problem,	  an	  analogous	  procedure	  was	  followed	  using	  methyl	  carbonate	  protected	  proline.	  
The	   overall	   yields	   starting	   from	   Cbz-­‐proline	   (R)-­‐105	   and	   methyl	   carbamate	   protected	  
proline	  was	  23%	  and	  13%	  respectively.	  Therefore,	  the	  higher	  yields	  coupled	  with	  greater	  
ease	  of	  analysis	  using	  the	  Cbz	  group	  did	  not	  warrant	  a	  change	  of	  protecting	  groups.	  
	  
4.1.2.	  Benzhydrol	  tail	  group	  
	  
The	   second	   fragment	   required	   for	   the	   synthesis	   of	   nor-­‐clemastine	   analogues	   is	   a	  
benzhydrol	  group,	  and	  the	  synthesis	  of	  4-­‐bromobenzhydrol	  122	  was	  initially	  investigated	  
(Scheme	   20c).	   Benzhydrol	   122	   was	   chosen	   as	   an	   analogue	   to	   test	   the	   synthetic	   route	  
because	  the	  starting	  material,	  bromobenzaldehyde	  123,	  was	  already	  purchased	  and	  the	  
bromo-­‐substituent	   could	   act	   as	   handle	   providing	   access	   to	   further	   analogues	   via	   cross	  
coupling	   reactions	   (e.g.	  Suzuki	   reaction,	  Heck	   reaction	  or	  Buchwald-­‐Hartwig	  amination).	  
Synthesis	   of	   substituted	   benzhydrol	   122	   was	   achieved	   using	   a	   Grignard	   reaction	   as	  
illustrated	  in	  Scheme	  20c.	  Treatment	  of	  bromobenzaldehyde	  123	  with	  phenylmagnesium	  
bromide	   generated	   the	   desired	   alcohol	   122	   in	   a	  moderate	   yield	   of	   66%.	   Formation	   of	  
benzhydrol	  122	  was	  evident	  by	  the	  presence	  of	  the	  Ar2CH	  peak	  at	  δH	  5.76	  ppm	  in	  the	  1H	  
NMR	   spectrum.	   Complete	   formation	   of	   the	   Grignard	   reagent	   before	   addition	   of	   4-­‐























































4.1.3.	  Etherification	  step	  
	  
As	   described	   in	   Chapter	   2,	   substituted	   benzhydrols	   could	   form	   ethers	   under	   acidic	  
conditions	  via	  an	  SN1	  reaction.	  However,	  yields	  varied	  and	  were	  generally	  low	  (∼30%).	  	  It	  
was	   initially	  decided	   to	   re-­‐examine	   this	   reaction	  and	   ideally	  optimise	   the	  yields,	  but	   an	  
attempt	   at	   the	   acid-­‐catalysed	   condensation	   to	   produce	   ether	   124	   was	   unsuccessful	  
(Scheme	  21a).	  However,	  etherification	  was	  successful	  using	  a	  model	  substrate;	  benzhydrol	  
125	   and	  3-­‐phenyl-­‐1-­‐propanol	  126	  were	   coupled	   to	   form	  diphenylmethyl	   ether	  127	   in	   a	  
moderate	   yield	   of	   48%	   (Scheme	   21b).	   Formation	   of	   ether	   127	   was	   confirmed	   by	   the	  





Further	   work	   was	   needed	   to	   find	   conditions	   for	   an	   etherification	   reaction	   that	   would	  
produce	  good	  yields	  of	  clemastine	  analogues.	  Initial	  efforts	  focused	  on	  transforming	  the	  
alcohol	  group	  of	  diphenylmethanol	  125	  into	  a	  better	  leaving	  group.	  In	  order	  to	  investigate	  
this,	  mesylation	  of	  125	  was	  attempted	  using	  methanesulfonyl	  chloride	  in	  the	  presence	  of	  
NEt3	  and	  DCM	  (Scheme	  22a).	  Interestingly,	  this	  reaction	  formed	  chloride	  128	  instead	  of	  the	  
mesylate	  as	  verified	  by	  the	  observation	  of	  the	  characteristic	  isotope	  pattern	  for	  bromine	  
and	  chlorine	  via	  GC-­‐MS	  m/z	  =	  280	  (M(79Br)(35Cl)+),	  282	  (M(79Br)(37Cl)+)	  and	  (M	  (81Br)(35Cl)+),	  
284	  (M(81Br)(37Cl)+)	  with	  a	  peak	  intensity	  ratio	  of	  3:4:1	  respectively.	  This	  chloride	  128	  was	  















































reacted	   with	   3-­‐pheny-­‐1-­‐propanol	   126	   using	   two	   different	   conditions	   (Scheme	   22b),	  
involving	  deprotonation	  of	  the	  primary	  alcohol	  using	  either	  NaH	  or	  Ag2CO3.	  Unfortunately,	  
neither	  of	  these	  reactions	  generated	  the	  desired	  ether	  linkage	  as	  crude	  1H	  NMR	  and	  LC-­‐MS	  





Analysis	   of	   the	   literature	   showed	   that	   0.1	   equiv.	   of	   PdCl2	   catalysed	   the	   formation	   of	  
benzhydryl	   ethers.230	   The	   conditions	   were	   used	   on	   the	   test	   reaction	   and	   produced	  
benzhydryl	  ether	  127	  via	  a	  SN1	  reaction	  in	  a	  very	  high	  yield	  of	  95%	  (Scheme	  23).	  
	  
In	  a	  second	  reaction,	  2-­‐dimethylaminoethanol	  129	  was	  coupled	  with	  benzhydrol	  125	  under	  
Pd-­‐catalysed	   conditions	   to	   discover	   whether	   the	   reaction	   would	   be	   successful	   in	   the	  
presence	  of	  an	  amine.	  Unfortunately,	  LC-­‐MS	  analysis	  showed	  no	  sign	  of	  product	  130	  after	  
48h,	  only	  starting	  material	  and	  some	  debrominated	  reagent	  could	  be	  detected	  (Scheme	  
24a).	  It	  is	  likely	  that	  the	  PdCl2	  does	  not	  activate	  the	  alcohol	  group	  of	  benzhydrol	  125	  but	  























Scheme	  23:	  PdCl2-­‐catalysed	  formation	  of	  benzhydryl	  ethers	  





































To	  try	  and	  avoid	  co-­‐ordination	  of	  Pd(II)	  to	  the	  amino	  alcohol,	  the	  amine	  was	  protected	  as	  a	  
carbamate	  131.	  Although	  the	  etherification	  to	  form	  compound	  132	  was	  possible	  (Scheme	  




Based	  on	  this	  observation,	  it	  was	  speculated	  that	  palladium	  catalysed	  conditions	  should	  be	  
tried	  with	  N-­‐Cbz	  homoprolinol	  (R)-­‐108	  as	  a	  more	  hindered	  tertiary	  amine	  may	  be	  less	  likely	  
to	  bind	  to	  the	  palladium.	  To	  test	  this,	  a	  selective	  reduction	  of	  methyl	  ester	  (R)-­‐107	  was	  first	  
required	   to	   synthesise	   the	   carbamate	   protected	   homoprolinol	   (R)-­‐133.	   Initial	   efforts	  
employed	  Clayden’s	  conditions	  of	  3.5	  equiv.	  of	  LiBH4	  at	  rt	  for	  70	  h	  to	  afford	  product	  (R)-­‐
133	  	  in	  a	  low	  yield	  of	  35%.202	  Attempts	  to	  optimise	  this	  using	  either	  5.5	  equiv.	  of	  LiBH4	  or	  
3.5	  equiv.	  of	  DIBAL	  were	  not	  productive.	  However,	  an	  improvement	  in	  yield	  was	  observed	  
when	  the	  temperature	  was	  increased	  to	  60	  °C	  in	  the	  presence	  of	  3.5	  equiv.	  of	  LiBH4,	  this	  
led	  to	  the	  selective	  reduction	  of	  methyl	  ester	  (R)-­‐107	  to	  N-­‐Cbz	  homoprolinol	  (R)-­‐133	  in	  a	  
moderate	  yield	  of	  58%	  (Scheme	  26).	  Confirmation	  of	  the	  N-­‐protected	  alcohol	  was	  obtained	  
by	  the	  appearance	  of	  a	  characteristic	  OH	  stretch	  at	  3440	  cm-­‐1	  in	  the	  IR	  spectrum	  and	  the	  
presence	  of	  only	  one	  carbonyl	  peak	  at	  156.9	  ppm	  in	  the	  13C	  NMR	  spectrum.	  
Scheme	  24:	  a)	  PdCl2-­‐catalysed	  etherification	  in	  the	  presence	  of	  amine	  129	  b)	  generation	  of	  Pd(0)	  from	  Pd(II)	  
































































N-­‐Cbz	   homoprolinol	   (R)-­‐133	   was	   then	   used	   in	   the	   PdCl2-­‐catalysed	   etherification	   and	  
produced	  the	  desired	  compound	   (R)-­‐134,	  but	   in	  a	   low	  yield	  of	  26	  %	  (Scheme	  27a).	  One	  
hypothesis	   was	   that	   the	   PdCl2	   could	   be	   cleaving	   the	   carbamate	   protecting	   group.	   This	  
theory	  was	  tested	  by	  heating	  N-­‐Cbz	  homoprolinol	  (R)-­‐133	  to	  80	  °C	  with	  PdCl2;	  however,	  






	   	  
	  
Another	   hypothesis	   was	   that	   a	   stable	   6-­‐membered	   ring	  was	   being	   formed	   with	   Pd(II),	  
complex	  136,	   through	  chelation	  to	  the	  alcohol	  and	  amine	   (Scheme	  28).	  This	  means	   less	  
Pd(II)	  is	  available	  to	  activate	  benzhydrol	  125	  and	  the	  nucleophilicity	  of	  amino	  alcohol	  131	  
is	  reduced.	  Both	  these	  factors	  would	  result	  in	  a	  decrease	  in	  ether	  formation.	  	  
Scheme	  26:	  Selective	  reduction	  of	  N-­‐Cbz	  methyl	  ester	  (R)-­‐107	  to	  








3.5 equiv.  LiBH4















































To	  test	  this	  hypothesis	  a	  longer	  chain	  protected	  amino	  alcohol	  was	  reacted	  with	  benzhydrol	  
125	  (Scheme	  29).	  This	  reaction	  with	  N-­‐Cbz	  aminohexanol	  137	  afforded	  the	  desired	  ether	  
138	  in	  a	  yield	  of	  46%,	  as	  chelation	  is	  less	  favourable,	  and	  therefore	  supports	  the	  hypothesis.	  	  
Other	  Lewis	  acids	  were	  explored	  with	  the	  aim	  of	  finding	  a	  catalyst	  which	  does	  not	  hinder	  
the	   reaction	  via	   unfavourable	   co-­‐ordination	   to	   the	   substrate.	   Eight	   condition	   sets	  using	  
benzhydrol	  125	  and	  3-­‐phenyl-­‐1-­‐propanol	  126	  (Scheme	  30)	  were	  screened	  in	  parallel	  with	  
varying	  Lewis	  acids.	  The	  yields	  were	  estimated	  using	  integrals	  from	  GC-­‐MS	  analysis	  with	  
dodecane	  as	  the	  standard.	  The	  data	  showed	  that	  the	  etherification	  catalysed	  by	  AuCl	  led	  


































Scheme	  28:	  Hypothesis	  for	  the	  co-­‐ordination	  of	  Pd(II)	  to	  




















The	  next	  step	  was	   to	   test	   the	  effect	  of	  a	  chelating	  group	  on	   the	  efficacy	  of	  Au(I)	   in	   the	  
presence	  of	  an	  amine.	  Benzhydrol	  125	  with	  N-­‐Cbz	  aminopropanol	  139	  were	  reacted	  in	  the	  
presence	  of	  0.1	  equiv.	  of	  AuCl	  and	  DCE	  and	  produced	  the	  desired	  ether	  140	  in	  a	  good	  yield	  
of	  70%	   (Scheme	  31).	  Au(I)	   is	  a	   softer	   transition	  metal	   ion	   than	  Pd(II)	  and	   therefore	   it	   is	  




The	  AuCl-­‐catalysed	  reaction	  was	  then	  attempted	  using	  N-­‐methyl	  homoprolinol	  (R)-­‐108	  to	  
form	   the	  clemastine	  analogue	   (R)-­‐124.	  Unfortunately,	  no	  product	  was	   formed	  and	  only	  
starting	  material	  could	  be	  recovered	  (Scheme	  32).	  This	  suggests	  that	  the	  more	  electron	  rich	  






















A	  Screen	  of	  Lewis	  acids
CuCl2 BF3 AlCl3 PdCl2p-­‐TSA FeCl3 Sc(OTf)3 AuCl











































To	  verify	  this,	  the	  reaction	  was	  then	  performed	  using	  the	  N-­‐Cbz	  homoprolinol	  (R)-­‐134	  and	  
benzhydrol	  125	  (Scheme	  33).	  Gratifyingly,	  ether	  (R)-­‐134	  was	  formed	  in	  a	  moderate	  yield	  of	  
63%	  which	  is	  consistent	  with	  the	  N-­‐Cbz	  protected	  homoprolinol	  (R)-­‐134	  exhibiting	  a	  weaker	  
coordination	  to	  the	  Au(I)	  species.	  
 
Having	  developed	  an	  efficient	  method	  to	  generate	  the	  key	  ether	  linkage	  the	  final	  step	  was	  
to	  reduce	  the	  N-­‐Cbz	  group	  to	  access	  the	  desired	  clemastine	  analogue	  (R)-­‐124.	  Attempts	  to	  
reduce	  compound	  (R)-­‐135	  using	  LiAlH4	  in	  THF	  both	  at	  rt	  and	  reflux	  resulted	  in	  the	  formation	  
of	  an	   intractable	  mixture	  containing	  the	  debrominated	  product	   (R)-­‐141	   (Scheme	  34),	  as	  
identified	  by	  LC-­‐MS	  analysis	  which	  contained	  a	  peak	  with	  (m/z	  296	  (MH+))	  lacking	  bromine	  
isotope	  pattern.	  	  
	  
	  
However,	  this	  synthetic	  route	  did	  successfully	  access	  other	  desired	  clemastine	  analogues	  
with	  substituents	  that	  were	  not	  prone	  to	  reduction	  with	  LiAlH4	  (Figure	  36).	  The	  chlorine	  
substituted	  analogue	  (R)-­‐112	  was	  chosen	  because	  it	  closely	  resembles	  clemastine	  and	  was	  
the	   most	   active	   analogue	   synthesised	   in	   previous	   work	   by	   Brown	   (Chapter	   2).191	   The	  
fluorine	  analogue	  (R)-­‐142	  was	  investigated	  in	  order	  to	  understand	  the	  role	  of	  the	  halogen	  
on	  antileishmanial	   activity	   and	  methoxy	  analogues,	   (R)-­‐143	  and	   (R)-­‐144,	  were	  explored	  
with	   the	  aim	  of	  attaching	  a	   linker	   in	   the	  4	  or	  3	  position	  on	   the	   ring.	  Finally,	   clemastine	  
analogue	  (R)-­‐145	  was	  designed	  from	  two	  hit	  compounds	  in	  the	  NINDS	  screen	  (Chapter	  2),	  
Scheme	  33:	  AuCl-­‐catalysed	  etherification	  with	  N-­‐Cbz	  protected	  homoprolinol	  (R)-­‐134	  and	  benzhydrol	  125	  

































flunarizine	   87	   and	   pimozide	   85,	   which	   possess	   a	   4,4’-­‐difluorobenzhydyl	   tail	   fragment	  













4.2.	  In-­‐vitro	  activity	  of	  nor-­‐clemastine	  analogue	  
	  
With	   the	   nor-­‐clemastine	   analogues	   in	   hand	   (Figure	   36),	   attention	   turned	   towards	  
measuring	  their	  activity	  against	  Leishmania	  promastigotes.	  Dose	  response	  studies	  for	  nor-­‐
clemastine	  analogues	   investigated	  the	  growth	   inhibition	  of	  L.	  major	  and	  L.	  amazonensis	  
promastigotes.	  	  
	  
Brown	  previously	  showed	  that	  nor-­‐clemastine	  (R)-­‐112	  possesses	  a	  similar	  but	  slightly	  lower	  
level	  of	  activity	  to	  clemastine	  1	  against	  L.	  major	  promastigotes	  (Chapter	  2).	  Figure	  37	  and	  
38	   supports	   these	   findings	   as	   nor-­‐clemastine	   (R)-­‐112	   is	   marginally	   less	   active	   than	  
clemastine	  against	  both	  L.	  major	  and	  L.	  amazonensis	  promastigotes.	  As	  noted	  in	  Chapter	  3,	  
results	   from	   this	   assay	   are	   2-­‐3	   times	  more	   active	   against	   L.	  major	   promastigotes	   than	  
previously	  reported	  by	  Brown,191	  presumably	  due	  to	  the	   longer	   incubation	  time	  of	  48	  h	  
rather	  than	  performing	  a	  24	  h	  assay.	  Overall,	  the	  absence	  of	  a	  quaternary	  methyl	  group	  on	  
the	  benzhydryl	  carbon	  or	  the	  mixed	  stereochemistry	  at	  this	  position	  could	  be	  responsible	  
for	  this	  lower	  activity	  and	  will	  be	  discussed	  further	  in	  section	  4.3.	  	  





















































The	   unsubstituted	   and	  methoxy	   substituted	   nor-­‐clemastine	   analogues,	   (R)-­‐141,	   (R)-­‐143	  
and	  (R)-­‐144,	  were	  more	  potent	  against	  L.	  amazonensis	  than	  L.	  major	  promastigotes	  (Figure	  




Figure	  37:	  An	  example	  of	  dose	  response	  curves	  for	  clemastine	  and	  RC1248	  against	  a)	  
L.	  major	  b)	  L.	  amazonensis;	  assays	  were	  performed	  in	  triplicate	  and	  each	  curve	  
shows	  a	  representative	  experiment.	  
Figure	  38:	  EC50	  values	  for	  clemastine	  1	  and	  analogue	  (R)-­‐112	  against	  L.	  amazonensis	  and	  L.	  major;	  













Activity	  of	  clemastine	  and	  nor-­‐clemastine	  (R)-­‐112	  against	  L.	  
amazonensis	  and	  L.	  major
L.	  amazonensis L.	  major
Clemastine  and  (R)-­112  activity  against L.  amazonensis  promastigotes













Clemastine  and  (R)-­112  activity  against L.  major  promastigotes


















Figure	  39:	  EC50	  values	  of	  (R)-­‐112,	  (R)-­‐141,	  (R)-­‐143	  and	  (R)-­‐144	  against	  L.	  amazonensis	  and	  L.	  major;	  values	  are	  mean	  ±	  
95%	  CI	  from	  at	  least	  three	  experiments.	  
 
Nor-­‐clemastine	  analogue	   (R)-­‐145	  with	  a	  4,4’-­‐difluorobenzhydyl	   tail	  unit	  demonstrated	  a	  
drop	   in	   potency	  when	   compared	   to	   analogue	   (R)-­‐112	  which	   possessed	   sub-­‐micromolar	  
levels	  of	  activity.	  Although	  the	  mono-­‐fluorinated	  analogue	  (R)-­‐142	  regained	  some	  activity,	  




















EC50 values	  of	  clemastine	  analogues	  against	  Leishmania
L.	  amazonensis L.	  major
Figure	  40:	  EC50	  values	  for	  nor-­‐clemastine	  analogues	  (R)-­‐112,	  (R)-­‐145	  and	  (R)-­‐142	  against	  L.	  












EC50 values	  showing	  the	  effect	  of	  fluorine	  substituents
L.	  amazonensis L.	  major




4.3.	  Role	  of	  stereochemistry	  	  
	  
Analogue	  (R)-­‐112	  is	  the	  most	  active	  nor-­‐clemastine	  analogue	  and,	  like	  clemastine,	  analogue	  
(R)-­‐112	  possesses	  2	  stereocentres,	  therefore,	  the	  effect	  of	  stereochemistry	  was	  explored.	  
Previous	   work	   in	   the	   group	   demonstrates	   the	   limited	   effect	   of	   varying	   pyrrolidinyl	  
stereochemistry,	   with	   the	   (R)-­‐configuration	   possessing	   slightly	   higher	   activity.	   This	  
observation	  was	  confirmed	  by	  the	  preparation	  and	  testing	  of	  analogues	  (R)-­‐112	  and	  (S)-­‐
112	   derived	   from	   (R)-­‐	   and	   (S)-­‐proline	   respectively.	   Having	   established	   the	   optimum	  
pyrrolidinyl	  stereochemistry	  attention	  turned	  to	  the	  benzhydryl	  centre	  (Figure	  41).	  	  
	  
	  
Compound	  (R)-­‐112	  is	  made	  up	  of	  two	  diastereomers	  due	  to	  mixed	  stereochemistry	  at	  the	  
benzhydryl	   carbon.	  Attempts	   to	   separate	   these	  using	   chiral	  HPLC	   (ChiralPak	   IA	   column)	  
were	   undertaken.	   However,	   although	   there	   is	   literature	   precedent	   for	   using	   chiral	  
preparatory	  HPLC	  to	  separate	  diastereomers	  of	  clemastine197	  these	  were	  not	  successful.	  As	  
a	  result,	  an	  enantioselective	  synthetic	  route	  was	  developed.	  
	  
4.3.1.	  Asymmetric	  synthesis	  of	  the	  benzhydrol	  tail	  group	  
	  
A	  search	  of	  literature	  on	  how	  to	  form	  enantiopure	  benzhydrols,	  identified	  an	  asymmetric	  
aryl	   transfer	   reaction.231	   Chiral	   pyrrolidindylmethanols	   were	   used	   as	   ligands	   in	   a	   zinc-­‐
catalysed	  addition	  of	  boronic	  acids	  to	  aldehydes	  (Scheme	  35).	  The	  arylzinc	  species	  were	  
generated	  in	  situ	  from	  boron-­‐zinc	  exchange	  and	  the	  stereochemical	  course	  of	  the	  addition	  
reaction	  to	  aldehydes	  was	  tentatively	  proposed	  by	  Soai	  et	  al.232	  Following	  this	  precedent,	  
Figure	  41:	  EC50	  values	  for	  clemastine	  1	  and	  nor-­‐clemastine	  analogues	  (R)-­‐112	  and	  (S)-­‐112	  


















Effect	  of	  the	  pyrrolidine	  ring	  stereocenter




the	   (R)-­‐amino	  alcohol	   (R)-­‐146	   and	   (S)-­‐amino	  alcohol	   (S)-­‐146	  were	  used	   to	  generate	   the	  
respective	   enantiopure	   benzhydrols	   (R)-­‐125	   and	   (S)-­‐125.	   Overall,	   these	   reactions	  
proceeded	  in	  good	  yields	  with	  high	  enantioselectivities	  as	  revealed	  by	  chiral	  HPLC	  analysis	  
using	  a	  ChiralPak	  IA	  column	  as	  shown	  in	  Figure	  42	  and	  43.	  Optical	  rotation	  measurements	  
were	  compared	  with	  literature	  values	  to	  confirm	  the	  configuration	  of	  the	  benzhydrols	  ([α]D	  
(c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐27.0	  °	  (lit.:	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐16	  °)	  for	  (R)-­‐125,	  [α]D	  
(c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +17.9	  °	  (lit.:






Scheme	  35:	  Asymmetric	  arylation	  of	  aldehydes	  with	  arylboronic	  acids	  	  
Figure	  42:	  	  HPLC	  spectrum	  for	  a)	  Racemic	  mixture	  of	  benzhydrol	  113	  b)	  (S)-­‐benzhydrol	  (S)-­‐113	  




















































With	  the	  enantiopure	  benzhydrol	  tail	  units,	  (R)-­‐113	  and	  (S)-­‐113,	  and	  head	  group	  (R)-­‐90	  in	  
hand	  attention	  was	  drawn	  to	  the	  etherification	  step.	  The	  previously	  developed	  SN1	  reaction	  
could	  not	   be	  performed	  as	   it	  would	   generate	  mixed	   stereochemistry	   at	   the	  benzhydryl	  
carbon.	   Therefore,	   the	   SN2	   reaction	   developed	   by	   Clayden	   et	   al.202	   was	   carried	   out	   to	  
produce	   the	   enantiomerically	   pure	   diastereomers,	   using	   the	   slightly	   more	   active	   (R)-­‐
configuration	  on	  the	  pyrrolidine	  ring.	  This	  reaction	  involved	  harsh	  conditions	  as	  the	  free-­‐
based	  head	  group	   (R)-­‐90	   and	  deprotonated	   tertiary	  alcohol	   (R)-­‐113	  were	  heated	  under	  
reflux	  overnight	   to	  produce	   the	  desired	  product	   (R,	  R)-­‐112	   albeit	   in	   a	   low	  yield	  of	  38%	  
(Scheme	   36).	   The	   yields	   are	   low	   due	   to	   the	   formation	   of	   the	   azepane	   by-­‐product	   and	  
unidentified	  side	  reactions	  caused	  by	  the	  harsh	  conditions.	  The	  formation	  of	  the	  azepane	  
by-­‐product	  results	  in	  inversion	  of	  the	  azepane	  stereocentre	  to	  give	  the	  (S)-­‐configuration,	  
and	  this	  is	  likely	  due	  to	  attack	  at	  the	  less	  hindered	  face	  of	  the	  bicyclic	  cationic	  intermediate	  
110.	   Analysis	   of	   the	   13C	   NMR	   spectrum	   confirms	   a	   single	   configuration	   at	   the	   azepane	  
Scheme	  36:	  Accessing	  enantiomerically	  pure	  diastereomers	  



























stereocentre	  due	  to	  the	  presence	  of	  only	  one	  signal	  at	  75.6	  ppm.	  In	  addition,	  analysis	  of	  
the	  13C	  NMR	  spectrum	  for	  compound	  112	  did	  not	  show	  any	  duplication	  of	  carbon	  peaks	  in	  
the	  spectrum	  (Figure	  44)	  confirming	  that	  the	  majority	  of	  the	  product	  was	  the	  desired	  (R,	  






















4.4.	  Activity	  of	  diastereomers	  	  
	  
With	  the	  single	  diastereomers	  in	  hand,	  the	  biological	  effect	  of	  the	  stereochemistry	  could	  
be	  explored.	  Figure	  45	  shows	  the	  dose	  response	  curves	  for	  the	  nor-­‐clemastine	  analogues	  
(R)-­‐112,	  (R,	  S)-­‐112	  and	  (R,	  R)-­‐112	  with	  R-­‐configuration	  at	  the	  pyrrolidine	  ring.	  The	  most	  
active	  stereochemistry	  at	   the	  benzhydryl	   carbon	   is	   the	  R-­‐configuration,	   followed	  by	   the	  
racemate	  and	  then	  the	  (S)-­‐configuration.	  Figure	  45	  shows	  that	  nor-­‐clemastine	  analogue	  (R,	  
R)-­‐112	  is	  equipotent	  to	  clemastine	  1	  with	  EC50	  values	  of	  0.026	  ±	  0.003	  µM	  and	  0.020	  ±	  0.003	  
µM	  against	  L.	  amazonensis	  and	  0.13	  ±	  0.01 µM	  and	  0.172	  ±	  0.003	  µM	  against	  L.	  major	  for	  
nor-­‐clemastine	  (R,	  R)-­‐112	  and	  clemastine	  1	  respectively.	  This	  suggests	  that	  the	  quaternary	  
methyl	   group	   on	   the	   benzhydryl	   carbon	   is	   not	   essential	   for	   activity	   but	   rather	   the	  
stereochemistry	  at	  this	  position	  is	  important.	  Therefore,	  the	  most	  active	  isomer	  identified	  
was	  (R,	  R)-­‐112	  with	  the	  stereochemistry	  of	  the	  quaternary	  benzhydryl	  carbon	  determining	  
activity	  to	  a	  greater	  extent	  than	  the	  stereocenter	  in	  the	  pyrrolidine	  ring.	  This	  indicates	  that	  
the	   commercially	   available	   (R,	   R)-­‐isomer	   of	   clemastine	   1	   would	   be	   the	   most	   active	  
Figure	  44:	  Section	  of	  13C	  NMR	  spectrum	  of	  the	  a)	  racemate	  compound	  (R)-­‐112	  and	  b)	  the	  single	  
diastereomer	  (R,	  R)-­‐112	  
a)	  
b)	  




antileishmanial.	   Interestingly,	  as	  described	   in	  Chapter	  2	  a	   similar	   trend	   in	  antihistamine	  
activity	  is	  observed	  for	  the	  four	  diastereomers	  of	  clemastine	  where	  the	  (R,	  R)-­‐isomer	  is	  also	  





4.5.	  Cytotoxicity	  of	  nor-­‐clemastine	  analogues	  
 
Having	  established	  the	  optimum	  stereochemistry	  for	  the	  nor-­‐clemastine	  series	   it	  was	  of	  
interest	  to	  investigate	  the	  macrophage	  cytotoxicity	  of	  these	  compounds.	  Consequently,	  the	  
nor-­‐clemastine	  analogues	  were	  tested	  against	  BMDM	  as	  previously	  described	  in	  Chapter	  3.	  
The	  CC50	  values	  in	  Figure	  46	  shows	  that	  the	  quaternary	  methyl	  group	  on	  the	  benzhydryl	  
carbon	   has	   a	   great	   influence	   on	   macrophage	   cytotoxicity,	   with	   the	   nor-­‐clemastine	  



























EC50 values	  for	  clemastine	  and	  nor-­‐clemastine	  
diastereomers
L.	  amazonensis L.	  major
Figure	  45:	  EC50	  values	  of	  clemastine	  1	  and	  analogues	  (R)-­‐112,	  (R,	  S)-­‐112	  and	  (R,	  R)-­‐112	  against	  L.	  













CC50 value	  of	  clemastine	  and	  analogue	  (R,	  R)-­‐112
Figure	  46:	  CC50	  values	  of	  clemastine	  1	  and	  analogue	  (R,	  R)-­‐112	  against	  BMDM;	  values	  are	  mean	  ±	  95%	  
CI	  from	  at	  least	  three	  experiments.	  






The	  work	  described	  in	  this	  chapter	  involved	  developing	  a	  synthetic	  route	  to	  nor-­‐clemastine	  
analogues	   and	   in	   particular	   focused	   on	   forming	   the	   ether	   linkage.	   In	   addition,	   an	  
enantioselective	   route	   to	   access	   two	   enantiopure	   diastereomers	   of	   nor-­‐clemastine	  was	  
developed	   and	   revealed	   the	   role	   of	   stereochemistry	   on	   antileishmanial	   activity.	   The	  
analogue	  (R,	  R)-­‐112	  was	  identified	  as	  the	  most	  active	  diastereomer	  and	  possessed	  greater	  
selectivity	  towards	  the	  parasites	  over	  the	  murine	  macrophages	  (SI	  ≈	  2863	  and	  573	  for	  L.	  
amazonensis	  and	  L.	  major	  promastigotes	  respectively)	  than	  clemastine	  1	  (SI	  ≈	  1247	  and	  117	  
for	   L.	   amazonensis	   and	   L.	   major	   promastigotes	   respectively).	   Future	   work	   will	   aim	   to	  
understand	  if	  the	  quaternary	  methyl	  group	  on	  the	  benzhydryl	  carbon	  in	  clemastine	  plays	  
an	   important	   pharmacokinetic	   role.	   If	   analogue	   (R,	   R)-­‐112	   possesses	   a	   good	  





















5.	  N-­‐linked	  clemastine	  analogues	  
	  
As	  discussed	  in	  the	  previous	  chapter,	  some	  SAR	  data	  was	  obtained	  from	  the	  development	  
of	   the	   nor-­‐clemastine	   analogues	   that	   showed	   the	   quaternary	   methyl	   group	   on	   the	  
benzhydryl	  carbon	  was	  not	  essential	  for	  activity	  but	  the	  stereochemistry	  at	  this	  position	  
was	  important.	  However,	   in	  order	  to	  further	  develop	  this	  understanding	  of	  the	  SAR	  one	  
remaining	  challenge	  was	  to	  efficiently	  synthesise	  a	  library	  of	  these	  compounds.	  A	  specific	  
challenge	  arose	   in	   the	   synthesis	  of	   the	  head	  group	   (R)-­‐90.	   This	   required	   four	   steps	  and	  
produced	  (R)-­‐90	  in	  a	  moderate	  overall	  yield.	  In	  addition,	  the	  final	  SN2	  reaction	  generated	  
the	  desired	  analogue	  (R)-­‐112	  but	  suffered	  from	  low	  yields.	  Therefore,	  an	  alternative	  more	  
accessible	   series	  was	  explored	   in	  which	   the	  pyrrolidine	  nitrogen	  was	  moved	   round	  one	  
position	  to	  form	  novel	  N-­‐linked	  analogues	  such	  as	  analogue	  (R)-­‐147	  (Figure	  47).	  
	  
	  
5.1.	  Synthesis	  of	  N-­‐linked	  analogues	  
	  
The	  N-­‐linked	  analogues	  were	   initially	  prepared,	   in	  2	  steps,	  using	  the	  Au(I)	  catalysed	  SN1	  
reaction	   developed	   earlier	   (Chapter	   4).	   For	   example,	   coupling	   of	   benzhydrol	   113	   with	  
bromoethanol,	   followed	   by	   an	   alkylation	   with	   2-­‐methylpyrrolidine	   (R)-­‐148	   at	   elevated	  
temperature	  or	  at	  rt	  with	  KI	  as	  a	  catalyst	  gave	  N-­‐linked	  analogue	  (R)-­‐147.	  The	  higher	  overall	  
yield	  for	  (R)-­‐147	  of	  57%	  compared	  favourably	  to	  the	  15%	  yield	  for	  the	  synthesis	  of	  nor-­‐
clemastine	  (R)-­‐112.	  Ether	  formation	  and	  N-­‐alkylation	  was	  confirmed	  by	  analysis	  of	  the	  2D	  
HMBC	  correlations	  as	  illustrated	  in	  Scheme	  37.	  	  
	  
Pyrrolidinyl	  methanol	  149	   was	   synthesised	   to	   investigate	   the	   antileishmanial	   effects	   of	  
expansion	  into	  the	  2-­‐position	  on	  the	  pyrrolidine	  ring	  and	  the	  potential	  to	  hydrogen	  bond	  
in	  this	  position.	  Reduction	  of	  ester	  150	  using	  LiAlH4	  formed	  compound	  149	  in	  a	  moderate	  
yield	   (Scheme	   38).	   Confirmation	   of	   the	   pyrrolidinyl	   methanol	   149	  was	   obtained	   by	   a	  
Figure	  47:	  a)	  Compound	  (R)-­‐112	  from	  nor-­‐clemastine	  library	  














characteristic	  OH	  stretch	  at	  3408	  cm-­‐1	  in	  the	  IR	  spectrum	  and	  the	  presence	  of	  CH2OH	  peaks	  
in	  the	  13C	  NMR	  spectrum	  at	  62.4(1)	  and	  62.3(8)	  corresponding	  to	  the	  two	  diastereomers.	  
	  
As	  discussed	  in	  Chapter	  1,	  tamoxifen	  20	  has	  antileishmanial	  activity82	  and	  is	  likely	  to	  target	  
LmjIPCS.84	  Tamoxifen	  20	  possesses	  structural	  similarities	  to	  clemastine	  1	  and	  therefore	  the	  
dimethylamine	   head	   group	   of	   tamoxifen	   was	   used	   to	   design	   clemastine	   analogue	   151	  
(Scheme	  37,	   Figure	   48).	   The	   hypothesis	  was	   that	   this	   compound	  would	   have	   improved	  
activity	   and	   be	   less	   expensive	   to	   synthesise	   and	   scale	   up	   as	   it	   benefits	   from	   only	   one	  
stereocentre.	  
	  
Overall,	   the	   desired	   N-­‐linked	   analogues	   were	   attained	   quickly	   as	   head	   groups	   were	  
commercially	   available.	   In	   addition,	   this	   synthetic	   route	   could	   be	   adapted	   for	   high	  
throughput	  synthesis234	  to	  access	  a	  series	  of	  compounds	  in	  a	  short	  time;	  enhancing	  efforts	  





































R = H                    152  54%
       CO2CH3   (S)-150 54%
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       CH2OCH3 (S)-153 39%
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5.2.	  Activity	  of	  N-­‐linked	  analogues	  
 
With	  this	  initial	  set	  of	  analogues,	  the	  approach	  was	  validated	  by	  assaying	  the	  compounds	  
against	  L.	  major	  promastigotes.	  Unfortunately,	  these	  more	  accessible	  analogues	  were	  not	  
as	   active	   as	  nor-­‐clemastine	   (R)-­‐112	   showing	  micromolar	   as	  opposed	   to	   sub-­‐micromolar	  
potency	  (Appendix	  B).	  Hydrogen	  152,	  Ether	  (R)-­‐	  and	  (S)-­‐153,	  alcohol	  (R)-­‐	  and	  (S)-­‐149	  and	  
methyl	  (R)-­‐	  and	  (S)-­‐147	  substituents	  on	  the	  head	  group	  have	  moderate	  levels	  of	  activity	  
with	  EC50	  values	  ranging	  from	  2	  –	  15	  µM	  against	  L.	  major	  promastigotes.	  Ester	  analogues	  
(R)-­‐	  and	  (S)-­‐150	  had	  poor	  antileishmanial	  activity	  with	  EC50	  values	  greater	  than	  20	  µM	  and	  
analogue	   151	   was	   inactive	   against	   L.	   major	   promastigotes	   (EC50	   ≥	   50,	   Figure	   49).	   The	  
relationship	  between	  clemastine	  1	  and	  tamoxifen	  20	  and	   its	  effect	  on	  LmjIPCS	  could	  be	  
investigated	   further	  but	   it	   is	  outside	   the	  scope	  of	   this	   thesis.	  Overall,	   these	  compounds	  
were	  not	  sufficiently	  active	  to	  be	  progressed	  into	  an	  anti-­‐amastigote	  assay	  and	  therefore	  








5.3.	  Role	  of	  stereochemistry	  	  
	  
The	  previous	  chapter	  showed	  that	  one	  method	  to	  improve	  activity	  of	  clemastine	  analogues	  
was	  to	  investigate	  the	  stereochemistry.	  N-­‐linked	  compound	  147,	  R	  =	  Me,	  is	  structurally	  the	  
closest	   related	   analogue	   to	   clemastine	  with	  moderate	   levels	   of	   activity.	   Therefore,	   the	  
hypothesis	  was	  that	  the	  antileishmanial	  activity	  could	  be	  improved	  through	  synthesis	  of	  a	  

















L. major EC50 = 0.172 ± 0.003 μM
Analogue 151


















Figure	  48:	  Related	  structures	  	  




single	  diastereomer	  of	  compound	  147.	  	  It	  was	  discovered	  that	  	  similar	  to	  the	  nor-­‐clemastine	  
analogues,	   the	   stereocentre	   on	   the	   pyrrolidine	   ring	   has	   little	   effect	   on	   antileishmanial	  
activity	  as	  both	  (R)-­‐147	  and	  (S)-­‐147	  have	  an	  activity	  of	  approximately	  2	  µM	  against	  L.	  major	  
promastigotes	  (Appendix	  B).	  	  
	  
The	  enantioselective	  synthesis	  illustrated	  in	  Scheme	  39	  was	  performed	  to	  access	  analogues	  
which	  explore	  stereochemistry	  on	  the	  benzhydryl	  carbon.	  The	  enantiopure	  benzhydrol,	  (R)-­‐
113	  or	  (S)-­‐113,	  was	  synthesised	  using	  the	  same	  procedure	  described	  in	  Chapter	  2.	  The	  head	  
group	  was	  prepared,	   in	   two	  steps,	  by	  carrying	  out	  an	  N-­‐alkylation	  with	  2-­‐bromoethanol	  
under	  reflux	  to	  afford	  compound	  (R)-­‐154	  in	  a	  moderate	  yield	  of	  48	  %.	  The	  IR	  spectrum	  was	  
used	  to	  confirm	  the	  formation	  of	  (R)-­‐155	  with	  an	  OH	  signal	  at	  3385	  cm-­‐1.	  A	  subsequent	  
chlorination	  with	  thionyl	  chloride	  formed	  head	  group	  (R)-­‐154	  in	  a	  yield	  of	  37	  %.	  Formation	  
of	  (R)-­‐154	  was	  confirmed	  by	  the	  mass	  spectrum	  which	  showed	  a	  chlorine	  isotope	  pattern	  
with	  an	  intensity	  ratio	  of	  3:1	  (m/z	  =	  148	  (M(35Cl)H+),	  150	  (M(37Cl)H+)).	  The	  final	  step	  was	  the	  
SN2	  etherification,	  described	  in	  Chapter	  4,	  to	  form	  analogue	  (R,	  R)-­‐147	  or	  (R,	  S)-­‐147	   in	  a	  
moderate	   yield	   (Scheme	   39).	   This	   provides	   access	   to	   N-­‐linked	   clemastine	   analogues	   in	  
higher	  yields	  as	  no	  by-­‐product	  was	  formed,	  unlike	  the	  SN2	  reaction	  to	  form	  nor-­‐clemastine	  
(R,	  R)-­‐112	  (Scheme	  40a).	  This	  is	  because	  from	  bicyclic	  cation	  intermediate	  156	  the	  desired	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These	   single	   diastereomer	   N-­‐linked	   analogues	   were	   then	   tested	   against	   L.	   major	  
promastigotes	  and	  demonstrate	  that	  the	  (S)-­‐configuration	  on	  the	  benzhydryl	  carbon,	  (R,	  
S)-­‐147,	  is	  about	  4	  times	  less	  active	  than	  analogue	  (R)-­‐147	  with	  mixed	  stereochemistry	  at	  
this	   position	   (Figure	   50).	   Hence,	   the	   benzhydryl	   stereocentre	   contributes	   to	   the	  
antileishmanial	  activity	  to	  a	  greater	  extent	  than	  the	  chiral	  centre	  on	  the	  pyrrolidine	  ring.	  
Similar	  to	  the	  nor-­‐clemastine	  analogues,	  the	  (R)-­‐configuration	  at	  the	  benzhydryl	  carbon	  in	  
isomer	   (R,	   R)-­‐147	   provided	   the	   highest	   activity	   (EC50	   =	   1.7	   ±	   0.3	  µM)	   against	   L.	   major	  
promastigotes.	  The	  EC50	  value	  of	  racemate	  (R)-­‐147	  is	  twice	  that	  of	  (R,	  R)-­‐147	  whereas	  (R,	  
S)-­‐147	  is	  essentially	  inactive,	  which	  suggests	  that	  (R,	  R)-­‐147	  is	  the	  only	  active	  compound.	  It	  
can	  be	  summarised	  that	  the	  role	  stereochemistry	  plays	  in	  antileishmanial	  activity	  is	  similar	  
for	  nor-­‐clemastine	  and	  N-­‐linked	  analogues,	  which	  indicates	  that	  they	  may	  have	  the	  same	  





Scheme	  40:	  Formation	  of	  ether	  linkage	  via	  bicyclic	  cation	  intermediate	  to	  afford	  a)	  nor-­‐clemastine	  and	  by-­‐product	  







































Overall,	   section	  5.2.	   shows	   that	   the	  most	  active	  N-­‐linked	  analogue	   is	   (R,	  R)-­‐147,	  R=Me,	  
which	   is	   structurally	   the	   closest	   related	   analogue	   to	   clemastine	   1	   and	   possesses	   (R)-­‐
configuration	  at	  the	  benzhydryl	  carbon.	  However,	  unlike	  clemastine	  1	  and	  nor-­‐clemastine	  
(R,	  R)-­‐112,	  this	  compound	  still	  does	  not	  show	  sub-­‐micromolar	  potency.	  A	  potential	  reason	  
for	  this	  lack	  of	  activity	  involves	  the	  positing	  of	  the	  nitrogen	  atom	  in	  space	  and	  this	  will	  be	  
explored	  further	  in	  the	  following	  section.	  	  	  	  
	  
	  
5.4.	  Extending	  carbon	  linker	  
	  
The	   more	   accessible	   N-­‐linked	   analogues	   require	   optimisation	   to	   improve	   the	  
antileishmanial	   activity.	   As	   mentioned	   above,	   the	   key	   difference	   between	   the	   nor-­‐
clemastine	  analogues	  and	  the	  N-­‐linked	  compounds	  is	  that	  the	  nitrogen	  atom	  has	  moved	  
position	   in	   space,	   which	   could	   affect	   the	   drugs	   interaction	   with	   the	   enzyme.	   It	   was	  
hypothesised,	  that	  by	  extending	  the	  linker	  to	  3	  carbon	  units,	  to	  form	  analogue	  (S,	  R)-­‐157,	  
the	  nitrogen	  would	  be	   in	  a	  similar	  position	  as	   in	  clemastine	  1/nor-­‐clemastine	   (S,	  R)-­‐112	  
improving	   the	  antileishmanial	   activity.	   In	  addition,	   it	  was	  postulated	   that	   if	   the	   chain	   is	  
further	  extended	  to	  4	  carbon	  units,	  to	  form	  analogue	  (S,	  R)-­‐158,	  the	  nitrogen	  would	  fall	  out	  
of	  alignment	  and	  a	  drop	  in	  activity	  would	  be	  observed.	  	  
	  
Results	  for	  analogues	  (R)-­‐147	  and	  (S)-­‐147	  (section	  5.3.)	  show	  that	  the	  stereocentre	  on	  the	  
pyrrolidine	   ring	   has	   little	   effect	   on	   antileishmanial	   activity.	   The	   (S)-­‐configuration	   in	   the	  
Figure	  50:	  EC50	  values	  of	  (R)-­‐147,	  (R,	  S)-­‐147	  and	  (R,	  R)-­‐147	  against	  L.	  major	  promastigotes;	  















Stereochemistry	  of	  N-­‐linked	  analogues




pyrrolidine	   ring	   of	   analogues	   157	   and	   158,	   with	   3	   and	   4	   carbon	   unit	   linker	   chains	  
respectively,	  were	  synthesised	  with	  a	  racemic	  benzhydryl	  centre.	  Hence,	  (S)-­‐157	  and	  (S)-­‐
158	   were	   synthesised	   by	   performing	   an	   SN1	   reaction	   on	   benzhydrol	   113	   with	  
bromopropanol	   and	   bromobutanol	   respectively,	   followed	   by	   an	   alkylation	   with	   2-­‐
methylpyrrolidine	  148	  (Scheme	  41).	  This	  route	  is	  slightly	  shorter	  and	  benefits	  from	  higher	  





Gratifyingly,	  assaying	   these	  compounds	  against	  promastigotes	  generated	  dose	  response	  
curves	   for	  N-­‐linked	   analogues	   (S)-­‐147,	   (S)-­‐157	   and	   (S)-­‐158	   (Figure	   51)	   that	   support	   the	  
above	  hypothesis	  showing	  that	  the	  optimum	  chain	  length	  was	  3	  carbons.	  For	  analogue	  (S)-­‐
157	  the	  antileishmanial	  activity	  drops	  to	  sub-­‐micromolar	  (EC50	  =	  0.09	  ±	  0.02	  µM),	  which	  is	  
now	  equipotent	   to	  clemastine	   (EC50	  =	  0.172	  ±	  0.003	  µM)	  and	  nor-­‐clemastine	   (R,	  R)-­‐112	  
(EC50	   =	   0.13	   ±	   0.01	   µM).	   To	   further	   build	   on	   this	   success,	   analogue	   (S)-­‐157	   was	   then	  












Scheme	  41:	  Synthetic	  route	  to	  N-­‐linked	  analogues	  (S)-­‐147,	  (S)-­‐157	  and	  (S)-­‐158	  
Figure	  51:	  An	  example	  of	  dose	  response	  curves	  of	  (S)-­‐147,	  (S)-­‐157	  and	  (S)-­‐158	  
against	  L.	  major	  promastigotes;	  assays	  were	  performed	  in	  triplicate	  and	  each	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5.5.	  Activity	  of	  lead	  analogue	  
 
Based	  on	  the	  results	  in	  section	  5.3.	  for	  analogue	  147,	  the	  stereocentre	  on	  the	  pyrrolidine	  
ring	  has	  little	  effect	  on	  antileishmanial	  activity.	  However,	  (S)-­‐147	  is	  marginally	  more	  active	  
than	  (R)-­‐147	  against	  L.	  major	  promastigotes,	  therefore	  (S)-­‐157	  was	  prepared.	  In	  addition,	  
it	  was	  proposed	  that	  the	  (R)-­‐configuration	  on	  the	  benzhydryl	  carbon	  would	  result	   in	  the	  
isomer	  with	  the	  highest	  activity.	  Therefore,	  the	  single	  diastereomer,	  analogue	  (S,	  R)-­‐157,	  
was	  synthesised	  following	  the	  same	  procedure	  as	  employed	  for	  the	  earlier	  enantiomeric	  
compounds	  (Scheme	  39).	  It	  should	  be	  noted,	  that	  in	  the	  interest	  of	  time	  the	  other	  three	  
single	  diastereomers	  of	  compound	  157	  were	  not	  tested.	  
	  
5.5.1.	  Anti-­‐promastigote	  assays	  
	  
Analogue	   (S)-­‐157	   and	   (S,	  R)-­‐157	  were	   then	   tested	   against	   L.	  major	   and	   L.	   amazonensis	  
promastigotes.	  The	  EC50	  values	  shown	  in	  Figure	  52	  demonstrate	  that	  analogue	  (S,	  R)-­‐157	  is	  
about	  three	  times	  more	  active	  against	  L.	  major	  promastigotes	  (EC50	  =	  0.058	  ± 0.007	  µM)	  
than	   clemastine	   and	   equipotent	   to	   clemastine	   when	   tested	   against	   L.	   amazonensis	  
promastigotes	  (EC50=	  0.02	  ± 0.01	  µM).	  In	  addition,	  the	  EC50	  value	  for	  (S)-­‐157,	  the	  racemic	  
mixture	  of	  diastereomers,	  is	  approximately	  twice	  that	  of	  the	  value	  obtained	  for	  the	  single	  
diastereomer	   (S,	   R)-­‐157	   which	   is	   expected	   if	   (S,	   R)-­‐157	   is	   the	   only	   active	   compound.	  	  
Overall,	   the	   antileishmanial	   activity	   of	   N-­‐linked	   analogue	   (S,	   R)-­‐157	   was	   investigated	  

















Activity	  of	  clemastine	  and	  N-­‐linked	  compound	  (S)-­‐157	  
and	  (S,	  R)-­‐157
L.	  amazonensis L.	  major
Figure	  52:	  EC50	  values	  of	  clemastine	  1,	  and	  analogues	  (S)-­‐157	  and	  (S,	  R)-­‐157	  against	  L.	  amazonensis	  
and	  L.	  major	  promastigotes;	  values	  are	  mean	  ±	  95%	  CI	  from	  at	  least	  three	  experiments.	  




5.5.2.	  Cytotoxicity	  to	  BMDM	  
	  
Before	  the	  anti-­‐amastigote	  assay	  could	  be	  conducted	  the	  cytotoxicity	  of	  compound	  (S,	  R)-­‐
157	  against	  BMDM	  needed	  to	  be	  investigated	  using	  the	  resazurin-­‐based	  cell-­‐viability	  assay	  
described	  earlier.192	  Pleasingly,	  analogue	  (S,	  R)-­‐157	  proved	  to	  be	  3-­‐4	  times	  less	  cytotoxic	  to	  
host	  macrophages	  than	  clemastine	  (Figure	  53).	  The	  low	  levels	  of	  cytotoxicity	  of	  analogue	  
(S,	  R)-­‐157	  to	  BMDM	  (CC50	  =	  73	  ±	  14	  µM)	  suggest	  that	  this	  compound	  has	  the	  potential	  to	  
be	  a	  more	  selective	  antileishmanial	  drug	  than	  clemastine.	  Interestingly,	  N-­‐linked	  analogue	  
(S,	  R)-­‐157	  and	  nor-­‐clemastine	  (R,	  R)-­‐112	  are	  both	  less	  cytotoxic	  to	  host	  macrophages	  than	  
clemastine	  and	  both	  lack	  a	  quaternary	  methyl	  group	  on	  the	  benzhydryl	  carbon.	  Therefore,	  
the	   quaternary	   methyl	   group	   may	   be	   responsible	   for	   the	   higher	   levels	   of	   host	   cell	  
cytotoxicity.	  One	  reason	  for	  this	  may	   involve	  the	  benzylic	  methyl	  group	  being	  subjected	  
less	   to	   P450	   mediated	   metabolism	   than	   the	   benzylic	   C-­‐H	   bond.	   Therefore,	   clemastine	  
would	   have	   a	   lower	   intrinsic	   clearance	   than	   nor-­‐clemastine	   which	  may	   account	   for	   its	  
higher	  host	  cell	  cytotoxicity.235	  
5.5.3.	  Intramacrophage	  anti-­‐amastigote	  assay	  
	  
As	  analogue	   (S,	  R)-­‐157	  had	  a	   low	   level	  of	  host	  cell	  cytotoxicity	   it	  could	  be	  used	  to	  treat	  
BMDM	  infected	  with	  L.	  amazonensis,	  this	  species	  was	  chosen	  as	  it	  is	  sensitive	  to	  analogue	  
(S,	  R)-­‐157	  and	  infective	  towards	  BMDM.	  As	  described	  in	  Chapter	  3,	  the	  infected	  cells	  were	  
adhered	  to	  cover	  slips	  and	  treated	  with	  analogue	  (S,	  R)-­‐157	  for	  48h.	  The	  cover	  slips	  were	  
Figure	  53:	  CC50	  values	  of	  clemastine	  1	  and	  analogues	  (R,	  R)-­‐112	  and	  (S,	  R)-­‐157	  against	  BMDM;	  values	  are	  mean	  



















CC50 value	  of	  clemastine	  and	  analogues	  (R,	  R)-­‐112	  and	  
(S,	  R)-­‐157




then	   stained	  with	  Giemsa	  modified	   solution	   and	   amastigotes	  were	   counted	  within	   200	  
macrophages.	   This	   assay	   generated	   the	   dose-­‐response	   curve	   for	   analogue	   (S,	   R)-­‐157	  
(Figure	  54)	  and	  showed	  that	  clemastine	  1	  and	  analogue	  (S,	  R)-­‐157	  have	  similar	   levels	  of	  
activity	   against	   intramacrophage	   amastigotes	   (EC50	   =	   0.40	   ±	   0.05	   µM	   and	   0.51	   µM	  
respectively).	  Overall,	  (S,	  R)-­‐157	   is	  a	  more	  accessible	  and	  selective	  compound	  (SI	  =	  146)	  
than	  clemastine	  (SI	  =	  50)	  and	  Table	  4	  summarises	  the	  data	  for	  this	  analogue.	  However,	  on-­‐
target	  effects	  of	  analogue	  (S,	  R)-­‐157	  still	  required	  validation	  before	  it	  could	  be	  progressed	  











Table	  4:	  EC50	  values	  of	  analogue	  (S,	  R)-­‐157	  against	  L.	  amazonensis	  promastigotes	  and	  amastigotes	  and	  CC50	  value	  of	  
analogue	  (S,	  R)-­‐157	  towards	  BMDM;	  values	  are	  mean	  ±	  95%	  CI	  from	  at	  least	  three	  experiments;	  no	  error	  for	  amastigote	  
EC50	  as	  only	  one	  assay	  was	  performed.	  
Promastigote	  EC50	  (µM)	   Macrophages	  CC50	  (µM)	   Amastigotes	  EC50	  (µM)	  
0.02	  ±	  0.01	   73	  ±	  14	   0.51	  
	  
5.6.	  On-­‐target	  effects	  
	  
As	  described	   in	  Chapter	  3	   for	   clemastine	  1,	   the	  dose-­‐dependent	  growth	   inhibition	  of	  L.	  
major	  WT,	  Δ	  LCB2	  and	  PX	  cell	  line	  were	  assessed	  and	  compared	  to	  validate	  on	  target	  effects	  
of	  N-­‐linked	  analogue	  (S,	  R)-­‐157	  (Figure	  55).	  Using	  cycloheximide	  as	  a	  control	  these	  assays	  
showed	  that,	  similar	  to	  clemastine	  1,	  analogue	  (S,	  R)-­‐157	   is	  approximately	  3	  times	  more	  
active	  against	  WT	  and	  PX	  cell	  lines	  than	  the	  mutant	  Δ	  LCB2	  promastigotes.	  This	  suggested	  
that	  both	  clemastine	  1	  and	  N-­‐linked	  analogue	   (S,	  R)-­‐157	  are	  disrupting	   the	  sphingolipid	  
pathway.	  	  
Figure	  54:	  An	  example	  of	  dose	  response	  curves	  of	  clemastine	  1	  and	  analogue	  (S,	  R)-­‐157	  against	  intramacrophage	  
amastigotes;	  each	  curve	  shows	  a	  representative	  experiment.	  	  
L.  amazonensis  antiamastigote  assay


















The	  mutant	  assay	  discussed	  above	  indicates	  that	  analogue	  (S,	  R)-­‐157	  is	  having	  an	  effect	  on	  
sphingolipid	  biosynthesis,	  however,	  IPCS	  still	  needs	  to	  be	  validated	  as	  the	  target.	  To	  achieve	  
this,	   the	   biochemical	   assay146	   described	   in	   Chapter	   2	   was	   employed,	   in	   which	   NBD-­‐C6-­‐
ceramide	   80	   and	   NBD-­‐C6-­‐IPC	   81	   were	   separated	   via	   HPTLC	   and	   analysed	   through	  
fluorescence	  spectroscopy.	  This	  experiment	  demonstrated	  that	  (S,	  R)-­‐157	  was	  a	  functional	  
analogue	   of	   clemastine	   1,	   acting	   as	   an	   inhibitor	   of	   IPCS,	   because	   product	   IPC	  was	   not	  



























EC50 values	  for	  clemastine,	  analogue	  (S, R)-­‐157	  and	  
cycloheximide	  against	  L.	  major	  WT,	  Δ LCB2	  and	  PX
WT Δ	  LCB2 PX
Figure	  55:	  EC50	  values	  of	  clemastine	  and	  analogue	  (S,	  R)-­‐157	  against	  WT,	  Δ	  LCB2	  and	  PX	  L.	  major	  promastigotes;	  
cycloheximide	  is	  used	  as	  a	  positive	  control;	  values	  are	  mean	  ±	  95%	  CI	  from	  at	  least	  three	  experiments.	  
Figure	  56:	  Separation	  of	  NBD-­‐C6-­‐IPC	  81	  product	  from	  NBD-­‐C6-­‐
ceramide	  80	  substrate	  by	  HPTLC;	  Microsomes	  were	  treated	  with	  
5mM	  of	  analogue	  (S,	  R)-­‐157	  and	  negative	  and	  positive	  controls	  
were	  DMSO	  and	  5mM	  of	  clemastine	  1.	  




5.7.	  In	  vivo	  infection	  study	  
	  
As	  sub-­‐micromolar	  activity	  has	  been	  observed	  for	  analogue	  (S,	  R)-­‐157	  against	  Leishmania	  
in	  vitro,	   it	  was	  hypothesised	  that	  this	  compound	  would	  be	  effective	   in	  an	  animal	  model	  
infected	  with	  L.	  amazonensis	  parasites.	  Hence,	  analogue	  (S,	  R)-­‐157	  was	  the	  sixth	  group	  in	  
the	  second	  in	  vivo	  study*	  discussed	  in	  Chapter	  3.	  Analogue	  (S,	  R)-­‐157	  was	  administered	  at	  
a	  dose	  of	  1.17	  mg	  kg-­‐1	  via	  IL	  injection	  twice	  a	  week.	  	  This	  was	  the	  same	  treatment	  regime	  
as	  used	  in	  the	  clemastine	  IL	  group	  enabling	  the	  two	  therapies	  to	  be	  directly	  compared.	  	  
	  
Similar	  to	  the	  other	  groups,	  there	  was	  little	  variation	  in	  the	  weight	  of	  mice	  treated	  with	  
analogue	  (S,	  R)-­‐157	  (Figure	  57a).	  On	  day	  35	  post-­‐infection,	  mice	  treated	  with	  analogue	  (S,	  
R)-­‐157	   IL	  showed	  a	  significant	  reduction	   in	   lesion	  size	  when	  compared	  to	  the	  untreated	  
group.	  The	  lesion	  growth	  trend	  is	  similar	  for	  the	  groups	  treated	  with	  analogue	  (S,	  R)-­‐157	  
and	  clemastine	  1	  IL	  (Figure	  57b).	  It	  should	  be	  noted	  that	  mice	  treated	  with	  glucantime	  3	  
solution,	  positive	  control	  group,	  showed	  the	  greatest	  reduction	  in	  lesion	  size.	  This	  is	  partly	  
due	  to	  glucantime	  3	  solution	  being	  administered	  as	  an	  IP	  therapy,	  whereas	  IL	  treatments	  
can	  cause	  inflammation	  to	  the	  ear	  increasing	  lesion	  measurements.	  Images	  in	  Figure	  57c	  
show	   similar	   improvements	   in	   the	   appearance	   of	   the	   lesion	   for	   analogue	   (S,	  R)-­‐157	   IL,	  
clemastine	   1	   IL	   and	   glucantime	   3	   solution	   IP	   groups	  when	   compared	   to	   the	   untreated	  
group.	  	  
	  
The	  in	  vivo	  fluorescence	  measurements	  from	  the	  infected	  ear	  show	  a	  significant	  reduction	  
in	  parasite	  burden	  for	  analogue	  (S,	  R)-­‐157	  IL	  and	  clemastine	  1	  IL	  (P	  ≤	  0.001)	  when	  compared	  
to	  the	  untreated	  group	  (Figure	  57d).	  Again,	  similar	  to	  clemastine	  1	  IL,	  results	  from	  the	  LDA	  
showed	  statistical	   significance	  between	   the	  untreated	  group	  and	  analogue	   (S,	  R)-­‐157	   IL	  
group	  (P	  ≤	  0.0001)	  (Figure	  57e).	  This	  positive	   in	  vivo	  result	  supports	  the	  hypothesis	  that	  
analogue	  (S,	  R)-­‐157	  could	  be	  an	  effective	  treatment	  for	  CL	  in	  an	  animal	  model.	  	  
	  
*Collaboration	  with	  Douglas	  Escrivani	  at	  UFRJ	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The	  work	  described	  in	  this	  chapter	  involved	  developing	  simple	  synthetic	  routes	  to	  easily	  
and	  quickly	  access	  N-­‐linked	  analogues	  of	  clemastine.	  With	  a	  3-­‐carbon	  chain	  linker	  and	  the	  
appropriate	  (S,	  R)	  stereochemistry,	  analogue	  (S,	  R)-­‐157,	  was	  equipotent	  to	  clemastine	  1	  
against	  L.	  amazonensis	  promastigotes	  and	  more	  active	  than	  clemastine	  1	  against	  L.	  major	  
promastigotes.	   This	   compound	   was	   less	   toxic	   to	   macrophages	   than	   clemastine	   1	   and	  
showed	   similar	   activity	   to	   clemastine	   1	   against	   L.	   amazoneneisis	   intramacrophage	  
amastigotes.	   Therefore,	   analogue	   (S,	   R)-­‐157	   was	   a	   more	   accessible	   and	   selective	  
compound.	  The	  target	  of	  analogue	  (S,	  R)-­‐157	  was	  validated	  as	  IPCS	  using	  mutant	  Δ	  LCB2	  
promastigotes	   and	   an	   LmjIPCS	   biochemical	   HPTLC	   assay.146	   Analogue	   (S,	   R)-­‐157	   was	  
progressed	  into	  an	  in	  vivo	  infection	  study	  and	  showed	  efficacy	  as	  an	  IL	  therapy	  against	  CL.	  
It	   could	   be	   hypothesised	   that	   the	   structural	   similarities	   of	   analogue	   (S,	   R)-­‐157	   and	  
clemastine	  1	  would	  result	  in	  similar	  immunological,	  antihistamine	  and	  CNS	  effects.	  Hence,	  
future	   work	   would	   involve	   investigating	   these	   properties	   along	   with	   obtaining	   a	  
pharmacokinetic	  profile	  of	  analogue	  (S,	  R)-­‐157.	  	  Positive	  pharmacokinetic	  data	  could	  result	  





Figure	  57:	  In	  vivo	  study	  2	  from	  BALB/c	  mice	  infected	  with	  2x106	  L.	  amazonensis	  GFP	  promastigotes	  in	  the	  right	  ear,	  mice	  
were	  randomized	  into	  drug-­‐treated	  and	  control	  groups	  of	  5/6	  mice	  each.	  During	  28	  days	  of	  treatment	  a)	  weight	  variation	  of	  
mice	  and	  b)	  progression	  of	  lesion	  thickness	  were	  measured.	  After	  completion	  of	  treatment,	  c)	  representative	  photographs	  
of	  the	  infected	  ear	  for	  each	  group	  were	  taken	  and	  the	  parasite	  burden	  was	  evaluated	  by	  d)	  fluorescence	  measurements	  
and	  e)	  LDA;	  asterisks	  indicate	  that	  the	  difference	  between	  control	  and	  drug-­‐treated	  groups	  are	  statistically	  significant.	  *	  P	  ≤	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6.	  Additional	  work	  	  
	  
6.1.	  Fluorescent	  nor-­‐clemastine	  analogue	  
	  
As	  described	  previously,	  the	  antileishmanial	  target	  of	  clemastine	  1	  has	  been	  identified	  as	  
IPCS.	  This	  target	  enzyme	  could	  be	  validated	  using	  chemical	  probes,236	  which	  may	  provide	  
insight	  into	  the	  binding	  site	  and	  hence	  lead	  to	  the	  development	  of	  an	  efficacious	  drug	  with	  
minimal	   side	  effects.	   Chemical	   probes	  based	  on	   clemastine	   analogues	   could	  be	   formed	  
using	   the	   synthetic	   pathways	   discussed	   in	   Chapter	   4	   and	   5.	   A	   starting	   point	   to	   probe	  
development	  and	  the	  aim	  of	  this	  work	  was	  to	  design	  a	  fluorescent	  analogue	  of	  clemastine	  




Nitrobenzoxadiazole	   (NBD)	   has	   been	   used	   as	   fluorescent	   label	   for	   the	   lipids	   in	   the	  
biochemical	  assay	  described	  in	  Chapter	  2.	  There	  are	  literature	  reports	  using	  NBD	  labels	  to	  
develop	  small	  molecule	  chemical	  probes.237,238,239	  Hence,	  the	  aim	  was	  to	  synthesise	  4-­‐	  and	  
3-­‐	   benzoxadiazole	   analogues	   (R)-­‐159	   and	   (R)-­‐160	   using	   the	   same	   synthetic	   strategy	  





Pleasingly,	   the	   tail	   groups	   161	   and	   162	   were	   formed	   in	   good	   yields	   via	   the	   Grignard	  
procedure	  described	  in	  Chapter	  4	  for	  the	  synthesis	  of	  benzhydrols	  (Scheme	  43).	  














































Clayden’s	  procedure	  (Scheme	  20b,	  Chapter	  4)	  was	  performed	  to	  access	  head	  group	  (R)-­‐
108.	  The	  challenging	  step	  with	  tail	  groups	  161	  and	  162	  was	  the	  etherification	  step.	  This	  
reaction	  was	  unsuccessful	  with	  an	  acid	  catalyst	   (Scheme	  44)	  which	  could	  be	  due	   to	   the	  
instability	  of	  cation	  163	  caused	  by	  the	  electron	  withdrawing	  benzoxadiazole.	  	  	  
	  
	  
As	  a	  result,	  head	  group	  (R)-­‐90,	  formed	  via	  chlorination	  of	  compound	  (R)-­‐108,	  and	  tail	  group	  
161	  were	  coupled	  together	  using	  NaH	  and	  high	  temperatures	  (Scheme	  45).	  This	  afforded	  
the	  desired	  analogue	  (R)-­‐159	  and	  azepane	  by-­‐product	  (S)-­‐164	  in	  low	  yields	  of	  16%	  and	  9%	  
respectively.	   However,	   sufficient	   material	   of	   both	   analogues,	   (R)-­‐159	   and	   (S)-­‐164,	  was	  















































































Scheme	  45:	  Synthetic	  route	  to	  4-­‐	  benzoxadiazole	  nor-­‐clemastine	  analogue	  (R)-­‐159	  and	  by-­‐product	  (S)-­‐164	  




Similar	   to	   alcohol	   161	   the	   3-­‐	   benzoxadiazole	   162	   could	   not	   undergo	   an	   acid	   catalysed	  
etherification.	   In	   addition,	   the	   etherification	   with	   NaH	   to	   form	   analogue	   (R)-­‐160	   was	  
unsuccessful	  and	  this	  possibly	  could	  be	  due	  to	  the	  more	  sterically	  hindered	  nature	  of	  tail	  
group	  162	  (Scheme	  46).	  The	  synthesis	  of	  this	  compound	  was	  not	  investigated	  further	  due	  










6.1.2.	  Anti-­‐promastigote	  activity	  
	  
With	  nor-­‐clemastine	  analogue	  (R)-­‐159	  and	  azepane	  by-­‐product	  (S)-­‐164	  in	  hand,	  the	  activity	  
of	  these	  compounds	  against	  Leishmania	  promastigotes	  was	  assessed.	  Azepane	  by-­‐product	  
(S)-­‐164	  showed	  poor	  activity	  against	  both	  L.	  major	  and	  L.	  amazonensis	  promastigotes	  (EC50	  
=	  17	  ±	  1	  µM	  and	  6.0	  ±	  0.5	  µM	  respectively).	  On	  the	  other	  hand,	  nor-­‐clemastine	  analogue	  
(R)-­‐159	  showed	  sufficiently	  high	  levels	  of	  activity	  (EC50	  =	  2.80	  ±	  0.02	  µM	  and	  0.56	  ±	  0.03	  
µM	  against	  L.	  major	  and	  L.	  amazonensis	  promastigotes	  respectively)	  to	  be	  employed	  as	  a	  




Fluorescence	  for	  nor-­‐clemastine	  analogue	   (R)-­‐159	  was	  quantified	  (Figure	  58)	  and	  shows	  
low	   fluorescence	   intensity	   with	   an	   excitation	   wavelength	   at	   445	   nm	   and	   emission	  
wavelength	  at	  560	  nm.	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Figure	  58:	  Excitation	  and	  Emission	  scan	  of	  5	  mM	  analogue	  (R)-­‐159	  in	  DMSO	  
 
The	  excitation	  and	  emission	  wavelengths	  observed	  for	  analogue	  (R)-­‐159	  could	  theoretically	  
be	  used	  for	  imaging.	  In	  this	  case,	  the	  aim	  was	  to	  use	  a	  microscope	  fitted	  with	  a	  filter	  cube	  
(filter	  B-­‐2A,	  Ex470/Em515)	  to	  image	  the	  localisation	  of	  analogue	  (R)-­‐159	  in	  L.	  amazonensis	  
promastigotes.	  The	  excitation	  and	  emission	  wavelengths	  of	  filter	  block	  B-­‐2A	  did	  not	  directly	  
correspond	   to	   the	   excitation	   and	   emission	   wavelengths	   of	   analogue	   (R)-­‐159	   but	   the	  
fluorescence	  signal	  was	  still	  strong	  enough	  to	  obtain	  images	  of	  this	  compound	  within	  the	  








































Fluorescence	  profile	  of	  analogue	  (R)-­‐159
Excitation	  scan
Emission	  scan
Figure	  59:	  Schematic	  representation	  of	  the	  main	  intracellular	  organelles	  from	  Leishmania	  
promastigotes	  (left)	  and	  amastigotes	  (right).	  Reprinted	  with	  permission.6	  
	  















































Figure	  60:	  L.	  amazonensis	  WT	  promastigotes	  incubated	  with	  100	  µM	  of	  analogue	  (R)-­‐159	  in	  PBS	  for	  a)	  30	  min	  b)	  1	  h.	  
Left	  column	  white	  light	  image,	  right	  column	  fluorescence	  image	  showing	  localisation	  of	  analogue	  159	  at	  the	  flagella	  
pocket	  and	  possibly	  at	  the	  acidocalcisomes/glycosomes.	  
Figure	  61:	  L.	  amazonensis	  GFP	  promastigote	  a)	  untreated	  b)	  incubated	  with	  100	  µM	  of	  analogue	  (R)-­‐159	  in	  PBS	  for	  30	  










































Figure	   59	   shows	   the	   main	   intracellular	   organelles	   in	   Leishmania	   promastigotes	   and	  
amastigotes,	  the	  aim	  was	  to	  use	  this	  schematic	  to	  identify	  the	  possible	  targets	  of	  analogue	  
(R)-­‐159	  in	  the	  parasite.	  It	  was	  postulated	  that	  compound	  (R)-­‐159	  would	  target	  Leishmania	  
IPCS	  as	  it	  is	  an	  analogue	  of	  clemastine.	  However,	  IPCS	  is	  localised	  within	  the	  Golgi	  and	  the	  
fluorescent	  images	  do	  not	  show	  localisation	  in	  this	  organelle.	  
	  
Instead,	   the	   promastigotes	   incubated	  with	   analogue	   (R)-­‐159	   for	   30	  min	   localise	   at	   the	  
flagellar	  pocket,	  which	  is	  where	  the	  drug	  can	  enter	  the	  parasite	  (Figure	  60a).	  After,	  1	  h	  the	  
drug	  has	  moved	  to	  the	  posterior	  region.	  This	  assay	  was	  repeated	  with	  L.	  amazonensis	  GFP	  
promastigotes	  to	  validate	  the	  internalisation	  of	  analogue	  (R)-­‐159.	  Figure	  61a	  is	  an	  image	  of	  
the	   untreated	   parasite	   with	   no	   red	   fluorescence,	   this	   indicates	   that	   the	   observed	  
fluorescence	   in	   the	   treated	   parasites	   is	   from	   the	   probe	   and	   not	   an	   artefact	   of	  
Figure	  62:	  L.	  amazonensis	  GFP	  intramacrophage	  amastigotes	  incubated	  with	  100	  µM	  of	  analogue	  
(R)-­‐159	  in	  PBS	  for	  a)	  5	  min	  b)	  15	  min	  c)	  30	  min.	  Left	  column	  white	  light	  image,	  right	  column	  
fluorescence	  image	  showing	  internalisation	  of	  analogue	  (R)-­‐159	  into	  the	  macrophage.	  Arrows	  











autofluorescence.	  After	  treatment	  of	  the	  parasite	  with	  100	  µM	  of	  analogue	  (R)-­‐159	  for	  30	  
min,	  there	  is	  again	  localisation	  of	  analogue	  (R)-­‐159	  at	  the	  posterior	  region	  of	  the	  parasite.	  	  
	  
Figure	  62	  shows	  BMDM	  infected	  with	  L.	  amazonensis	  GFP;	  after	  5	  min	  analogue	  (R)-­‐159	  
has	  started	  to	  enter	  the	  macrophage	  but	  not	  the	  amastigotes.	  At	  15	  and	  30	  min	  analogue	  
(R)-­‐159	  has	   fully	  accessed	   the	  macrophage	  but	   it	   is	  unclear	  as	   to	  whether	  or	  not	   it	  has	  
penetrated	  the	  amastigotes.	  
	  
The	  fluorescent	  images	  of	  treated	  promastigotes	  (Figure	  60	  and	  61)	  show	  localisation	  of	  
analogue	   (R)-­‐159	   at	   the	   posterior	   of	   the	   parasite	   where	   organelle	   such	   as	   the	  
acidocalcisomes	   and	   glycosomes	   reside.	   Acidocalcisomes	   are	   acidic	   organelle	   rich	   in	  
calcium	  and	  polyphosphate	  and	  therefore	  involved	  in	  Ca2+	  homeostasis.	  Chapter	  1	  shows	  
examples	   of	   drugs	   with	   antileishmanial	   activity	   through	   disruption	   of	   intracellular	   Ca2+	  
homeostasis	  (e.g.	  amiodarone	  48	  and	  dronedarone	  49).	  In	  addition,	  glycosomes	  are	  a	  good	  
drug	   target	   in	   kinetoplastids	   as	   glycolysis	   is	   the	   only	   source	   of	   energy	   for	   these	  
parasites.240,241	  Hence,	  both	  of	  these	  organelles	  house	  viable	  antileishmanial	  drug	  targets.	  
	  
Although	  this	  was	  an	  interesting	  study,	  it	  requires	  further	  investigation.	  	  For	  example,	  to	  
improve	  the	  resolution	  of	  the	  image	  a	  molecule	  with	  an	  increased	  quantity	  of	  fluorescence,	  
such	  as	  a	  nitro	  substituted	  analogue	  of	  (R)-­‐159,	  could	  be	  synthesised.	  However,	  structural	  
alterations	  to	  the	  probe	  could	  cause	  loss	  in	  activity	  against	  the	  parasite	  or	  off-­‐target	  effects.	  	  
	  
An	   alternative	   approach	   to	   improve	   the	   quality	   of	   the	   image	   is	   to	   use	   confocal	   laser	  
scanning	  microscopy.	   This	   technique	  would	  enhance	   the	   resolution	  and	   contrast	  of	   the	  
image	   through	   reduction	   of	   background	   signal.242	   Confocal	   microscopy	   could	   image	  
analogue	   (R)-­‐159	   in	   combination	   with	   a	   Golgi	   tracker	   to	   study	   colocalisation	   and	  may	  
validate	  IPCS	  as	  the	  biological	  target.	  	  
	  
Furthermore,	  knowing	  the	  localisation	  of	  the	  probe	  is	  only	  useful	  if	  it	  shares	  the	  same	  target	  
as	   clemastine.	   This	   assumption	   can	   be	   validated	   via	   a	   competition	   assay,	   where	  
promastigotes	  are	  pre-­‐treated	  with	  clemastine,	  followed	  by	  the	  addition	  of	  the	  probe.	  If	  
the	  image	  shows	  clemastine	  blocking	  the	  localisation	  of	  the	  probe,	  then	  this	  indicates	  that	  
they	  target	  the	  same	  protein.	  	  






The	  work	  described	  in	  this	  chapter	  involved	  a	  preliminary	  study	  of	  a	  fluorescent	  analogue	  
of	   nor-­‐clemastine	   (R)-­‐159	   which	   demonstrated	  micro-­‐molar	   activity	   against	   Leishmania	  
promastigotes.	  The	  fluorescent	   images	  from	  the	  microscope	  fitted	  with	  a	  filter	  cube	  are	  
mostly	   inconclusive	  as	  to	  the	   localisation	  of	  analogue	  (R)-­‐159.	  However,	  this	  study	  does	  
provide	  a	  point	  for	  further	  investigation.	  
	  
In	  addition,	  there	  are	  reports	  in	  literature	  of	  using	  photoaffinity	  probes,	  coupled	  with	  mass	  
spectrometry	  analyses	  to	  identify	  and	  characterise	  biological	  targets.236	  Hence,	  future	  work	  
could	  investigate	  the	  design	  and	  synthesis	  of	  a	  photoaffinity	  probe	  based	  on	  clemastine	  to	  
validate	  the	  drug	  target.	  The	  general	  design	  of	  a	  photoaffinity	  probe	  is	  outlined	  in	  Figure	  
63	  and	  involves	  the	  small	  molecule	  of	  interest,	  a	  photoreactivity	  moiety	  (e.g.	  phenylazides,	  
phenyldiazirines	   and	   benzophenones)	   and	   a	   reporter	   tag	   (e.g.	   biotin).	   In	   response	   to	  
activation	  by	  light	  this	  chemical	  probe	  will	  covalently	  bind	  to	  its	  target.	  The	  aim	  would	  be	  




















Figure	  63:	  General	  designs	  for	  photoaffinity	  probes	  (adapted	  from	  Collins	  et	  al)2	  
	  
Photoaffinity	  group	  








7.	  Chemical	  experimental	  
	  
7.1.	  General	  experimental	  details	  
	  
SOLVENTS	  AND	  REAGENTS:	  All	  analytical	  grade	  solvents	  and	  commercially	  available	  regents	  
were	  used	  as	  received	  from	  their	  respective	  suppliers	  or	  dried	  as	  required,	  using	  standard	  
procedures.	   All	   reactions	   were	   performed	   under	   an	   inert	   atmosphere	   of	   argon	   unless	  
otherwise	  stated.	  	  
	  
CHARACTERISATION:	   Reactions	   were	   monitored	   by	   LC-­‐MS,	   GC-­‐MS	   or	   by	   TLC	   using	  
aluminium	  backed	  plates.	  Methods	  to	  visualise	   the	  spots	   included	  ultra-­‐violet	   light	   (254	  
nm)	   and	   colour	   reagents.	   The	   visualising	   stains	   used	   were	   potassium	   permanganate,	  
phosphomolybdic	   acid	   or	   ninhydrin.	   Column	   chromatography	   was	   performed	   using	   a	  
Teledyne	   Isco	   CombiFlash®	   System	  with	   RediSep®	   Rf	   normal-­‐phase	   and	   C-­‐18	   reversed-­‐
phase	  columns.	  Both	  carbon	  and	  hydrogen	  NMR	  spectra	  were	  acquired	  at	  295	  K	  on	  Varian	  
VNMRS	  700	  (1H	  at	  700	  MHz,	  13C	  at	  176	  MHz),	  Varian	  VNMRS	  600	  (1H	  at	  600	  MHz,	  13C	  at	  151	  
MHz),	  with	  sample	  dissolved	   in	  the	  analytical	  solvent	  CDCl3.	  2D	  COSY,	  HSQC,	  HMBC	  and	  
NOESY	  were	   run	   to	   aid	   assignment	   of	   peaks.	   Chemical	   shifts	   are	   reported	   in	   parts	   per	  
million,	  ppm,	  to	  2	  decimal	  places;	  with	  the	  multiplicity	  of	  the	  signal	  reported	  as	  s,	  singlet;	  
d,	  doublet;	  t,	  triplet;	  coupling	  constants,	  J,	  are	  quoted	  to	  the	  nearest	  ±	  0.5	  Hz.	  Ar	  refers	  to	  
aryl	  resonances	  which	  could	  not	  be	  accurately	  assigned.	  Infrared	  (IR)	  spectra	  were	  acquired	  
using	   a	   Perkin-­‐Elmer	   Paragon	  1000	   FT-­‐IR	   and	   absorption	  maxima	   (νmax)	   are	   reported	   in	  
wavenumbers	  (cm-­‐1)	  and	  assigned	  as	  strong	  (s),	  medium	  (m),	  weak	  (w)	  or	  broad	  (br).	  Mass	  
spectra	  were	  recorded	  using	  Shimadzu	  gas	  chromatography	  via	  electron	  ionization	  (EI)	  or	  
on	  a	  Waters	  TQD	  spectrometer	  coupled	  to	  an	  Acquity	  UPLC.	  Melting	  points	  are	  measured	  
using	  Fisher	  ScientificTM	  IA9000	  melting	  point	  apparatus.	  
	  
7.2.	  Experimental	  procedures	  
	  
General	  procedure	  A:	  Grignard	  reaction	  
Magnesium	  turnings	  (1.7	  equiv.)	  were	  added	  to	  a	  2-­‐necked	  flask	  equipped	  with	  a	  reflux	  
condenser	   and	   a	   dropping	   funnel	   containing	   dry	   THF	   (1	   mL/	   mmol)	   and	   a	   solution	   of	  
bromobenzene	  (1.3	  equiv.).	  About	  one	  quarter	  of	  the	  bromobenzene	  solution	  was	  added	  
to	  the	  magnesium	  turnings	  and	  heated	  to	  60	  °C	  until	  the	  turbidity	  of	  the	  reaction	  increased.	  




Once	  the	  reaction	  started	  the	  remaining	  bromobenzene	  solution	  was	  added	  dropwise	  and	  
the	  reaction	  was	  heated	  under	  reflux	  for	  1	  h.	  The	  solution	  was	  cooled	  to	  rt	  and	  a	  substituted	  
benzaldehyde	  (1	  equiv.)	  in	  THF	  (1	  mL/	  mmol)	  was	  added	  dropwise.	  The	  reaction	  was	  stirred	  
overnight	  at	  rt	  and	  then	  quenched	  with	  saturated	  NH4Cl(aq.).	  The	  mixture	  was	  washed	  with	  
EtOAc	   (3	  x	  20	  mL),	  dried	  over	  MgSO4	  and	   filtered.	  Solvent	  was	   removed	  under	   reduced	  
pressure.	  243	  
	  
General	  procedure	  B:	  Fieser’s	  method	  for	  the	  workup	  of	  LiAlH4	  reactions	  	  
A	  reaction	  mixture	  of	  lithium	  aluminium	  hydride	  (X	  g)	  was	  cooled	  to	  0	  °C	  and	  diluted	  with	  
ether.	  It	  was	  then	  carefully	  quenched	  with	  H2O	  (X	  mL),	  followed	  by	  3	  M	  NaOH(aq)	  (3X	  mL)	  
and	  finally	  H2O	  (3X	  mL).	  This	  was	  warmed	  to	  rt	  and	  stirred	  for	  15	  min	  before	  the	  addition	  
of	  anhydrous	  MgSO4	  and	  then	  stirring	  for	  another	  5	  min.	  The	  salts	  were	  then	  removed	  by	  
filtration	  and	  solvent	  was	  removed	  in	  vacuo	  to	  afford	  the	  crude	  product.244	  	  	  
 
General	  procedure	  C:	  Pd-­‐catalysed	  etherification	  	  
To	  a	  solution	  of	  alcohol	  (1	  equiv.)	  and	  diphenylmethanol	  (1	  equiv.)	  in	  DCE	  (5	  mL	  mmol-­‐1)	  
was	  added	  PdCl2	  (0.1	  equiv.).	  The	  reaction	  mixture	  was	  heated	  at	  80	  °C	  for	  48	  h.	  The	  solvent	  
was	  then	  removed	  under	  reduced	  pressure	  to	  afford	  the	  crude	  product.230	  
	  
General	  procedure	  D:	  SN2	  reaction	  of	  4-­‐chlorobenzhydrol	  and	  alkyl	  chloride202	  
The	  4-­‐chlorobenzhydrol	   (1	  equiv.)	  and	  NaH	  (60%,	  3	  equiv.)	  were	  dissolved	   in	  anhydrous	  
toluene	  (5	  mL	  mmol-­‐1)	  and	  heated	  under	  reflux	  for	  3	  h	  under	  nitrogen.	  The	  solution	  was	  
cooled	  to	  rt	  and	  chloroethylpyrrolidine	  (1	  equiv.)	  in	  toluene	  (2.5	  mL	  mmol-­‐1)	  was	  added.	  
The	  reaction	  mixture	  was	  then	  reacted	  under	  reflux	  overnight.	  The	  reaction	  mixture	  was	  
cooled,	  quenched	  with	  H2O	  and	  diluted	  with	  EtOAc.	  The	  aqueous	  layer	  was	  separated	  and	  
extracted	  twice	  with	  EtOAc.	  The	  combined	  organic	   layers	  were	   then	  dried	  over	  Na2SO4,	  











7.3.	  Compound	  characterisation	  	  
	  
4-­‐Bromophenyl(phenyl)methanol245	  122	  	  
	  
General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.60	   mL,	   24.84	   mmol)	   and	   4-­‐
bromobenzaldehyde	   (3.50	   g,	   18.92	   mmol).	   The	   product	   was	   purified	   by	   column	  
chromatography	  (0%	  →	  20%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (2.99	  g,	  66%)	  
as	  an	  off-­‐white	  solid.	  
	  
M.p.	  64	  –	  65	  °C	  (lit.:245	  65	  –	  66	  °C);	  νmax	  (ATR)	  3352	  (br),	  3063	  (w),	  2904	  (w),	  1906	  (w),	  1600	  
(w),	  1481	  (s),	  1397	  (m),	  1190	  (m),	  1008	  (s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.47	  –	  7.43	  (2H,	  m,	  
ArH),	  7.36	  –	  7.31	  (4H,	  m,	  ArH),	  7.30	  –	  7.27	  (1H,	  m,	  ArH),	  7.26	  –	  7.21	  (2H,	  m,	  ArH),	  5.76	  (1H,	  
s,	  Ar2CH),	  2.39	  (1H,	  s,	  OH);	  δC	  (176	  MHz,	  CDCl3)	  143.5	  (C-­‐1’),	  142.8	  (C-­‐1),	  131.7	  (ArC),	  128.8	  
(ArC),	  128.3	  (ArC),	  128.0	  (ArC),	  126.6	  (ArC),	  121.5	  (C-­‐4),	  75.8	  (Ar2CHO);	  m/z	  (LC-­‐MS,	  ESI+)	  




To	  a	  solution	  of	  4-­‐bromophenyl(phenyl)methanol	  122	  (150	  mg,	  0.57	  mmol)	  and	  NEt3	  (0.16	  
mL,	  1.15	  mmol)	  in	  DCM	  (2.50	  mL)	  at	  0	  °C	  was	  added	  methanesulfonyl	  chloride	  (0.10	  mL,	  
1.29	  mmol)	  dropwise	  and	  the	  reaction	  mixture	  was	  stirred	  overnight	  at	  rt.	  The	  mixture	  was	  
then	  washed	  with	  H2O	  (10	  mL),	  2M	  HCl	  (10	  mL)	  and	  brine	  (10	  mL)	  and	  dried	  over	  Na2SO4.	  
The	  solvent	  was	  removed	  in	  vacuo	  to	  afford	  the	  title	  compound	  (142	  mg,	  88%)	  as	  a	  yellow	  
oil	  which	  was	  carried	  forward	  without	  purification.	  	  	  
	  
νmax	  (ATR)	  2982	  (w),	  1739	  (w),	  1590	  (w),	  1487	  (s),	  1453	  (m),	  1404	  (m),	  1316	  (w),	  1216	  (w),	  
1173	  (m),	  1071	  (s),	  1010	  (s);	  δH	  (700	  MHz,	  CDCl3)	  δ	  7.49	  –	  7.46	  (2H,	  m,	  ArH),	  7.40	  -­‐	  7.37	  (2H,	  
m	  ArH),	  7.37	  -­‐	  7.34	  (2H,	  m,	  ArH),	  7.33	  –	  7.31	  (1H,	  m,	  ArH),	  7.30	  –	  7.27	  (2H,	  m,	  ArH),	  6.08	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(ArC),	   128.4	   (ArC),	   127.8	   (ArC),	   122.3	   (C-­‐4),	   63.6	   (Ar2CH);	   m/z	   (GC-­‐MS,	   EI)	   280	  
(M(79Br)(35Cl)+),	  282	  (M(79Br)(35Cl)+)	  and	  (M	  (81Br)(37Cl)+),	  284	  (M(81Br)(37Cl)+).	  
	  
(2R)-­‐1-­‐[(benzyloxy)carbonyl]pyrrolidine-­‐2-­‐carboxylic	  acid247	  (R)-­‐105	  
	  
2M	  NaOH(aq)	  (65	  mL,	  130	  mmol)	  was	  added	  to	  a	  three-­‐neck	  round-­‐bottom	  flask	  and	  cooled	  
with	  an	  ice-­‐salt	  bath.	  (D)-­‐proline	  (15.0	  g,	  130	  mmol)	  was	  added,	  followed	  by	  CbzCl	  (22	  mL,	  
156	   mmol)	   dropwise	   and	   4M	   NaOH(aq)	   (46	   mL,	   182	   mmol)	   over	   20	   min	   with	   vigorous	  
stirring.	  The	  solution	  was	  slowly	  warmed	  to	  rt	  and	  left	  to	  stir	  overnight.	  The	  mixture	  was	  
then	  washed	  with	   Et2O	   and	   the	   aqueous	   solution	  was	   acidified	   to	   pH	   2	   by	   a	   dropwise	  
addition	  of	  3M	  HCl(aq).	  The	  resulting	  mixture	  was	  extracted	  with	  EtOAc	  (3	  x	  50	  mL)	  and	  the	  
extracts	  were	  combined	  and	  dried	  over	  MgSO4.	  The	  volatiles	  were	  removed	  under	  reduced	  
pressure	   to	  afford	   the	   title	   compound	  as	  a	   colourless	  oil	   (27.3	  g,	   84%)	  which	  was	  used	  
without	  further	  purification.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +84.3°	  (lit.:
248	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +69.7	  °).	  νmax	  
(ATR)	  2982	  (w),	  2884	  (w),	  1704	  (s),	  1662	  (s),	  1415	  (s),	  1357	  (s),	  1240	  (m),	  1168	  (s),	  1120	  (s),	  
1089	  (m)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  7.38	  –	  7.27	  (5H,	  m,	  ArH),	  5.22	  –	  
5.12	  (2H,	  m,	  ArCH2),	  4.45	  –	  4.40	  (0.6H,	  m,	  2-­‐H),	  4.39	  –	  4.36	  (0.4H,	  m,	  2-­‐H),	  3.66	  –	  3.56	  (1H,	  
m,	  5-­‐HH’),	  3.55	  –	  3.50	  (0.4H,	  m,	  5-­‐HH’),	  3.50	  –	  3.44	  (0.6H,	  m,	  5-­‐HH’),	  	  	  2.32	  –	  2.23	  (1H,	  m,	  
3-­‐HH’),	  2.22	  –	  2.14	  (1H,	  m,	  3-­‐HH’),	  2.13	  –	  2.06	  (1H,	  m,	  4-­‐HH’),	  2.03	  –	  1.86	  (1H,	  m,	  4-­‐HH’);	  
δC	  (176	  MHz,	  CDCl3,	  mixture	  of	   rotamers)	  178.1	   (C-­‐1’),	  176.3	   (C-­‐1’),	  156.0	   (NCO2),	  154.6	  
(NCO2),	  136.6	  (ArC),	  136.4	  (ArC),	  128.6	  (ArC),	  128.5	  (ArC),	  128.3	  (ArC),	  128.1	  (ArC),	  128.0	  
(ArC),	  127.8	  (ArC),	  67.7	  (ArCH2),	  67.3	  (ArCH2),	  	  59.4	  (C-­‐2),	  58.8	  (C-­‐2),	  47.1	  (C-­‐5),	  46.8	  (C-­‐5),	  


















(2S)-­‐1-­‐[(benzyloxy)carbonyl]pyrrolidine-­‐2-­‐carboxylic	  acid247	  (S)-­‐105	  
	  
(L)-­‐Proline	  (4.00g,	  34.7	  mmol)	  was	  reacted	  under	  the	  same	  conditions	  as	  the	  synthesis	  of	  
(R)-­‐105,	  furnishing	  the	  title	  compound	  as	  a	  colourless	  oil	  (8.46g,	  98%).	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐71.4°	  (lit.:
248	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐69.7°).	  	  IR,	  NMR	  
and	  mass	  spectra	  were	  consistent	  with	  the	  R	  enantiomer.	  
	  
(2R)-­‐1-­‐(methoxycarbonyl)pyrrolidine-­‐2-­‐carboxylic	  acid249	  (R)-­‐165	  
	  
To	  a	  solution	  of	  (D)-­‐proline	  (2.00	  g,	  17.36	  mmol)	  in	  THF	  (26	  mL)	  and	  saturated	  NaHCO3(aq)	  
(26	  mL),	  cooled	  to	  0	  °C,	  was	  added	  dropwise	  methyl	  chloroformate	  (2.6	  mL,	  34.72	  mmol).	  
The	  solution	  was	  allowed	  to	  warm	  to	  rt	  and	  then	  stirred	  overnight.	  The	  reaction	  mixture	  
was	  then	  acidified	  with	  2M	  HCl	  (20	  mL)	  and	  extracted	  with	  CH2Cl2	  (3	  x	  20	  mL).	  The	  combined	  
organic	   layers	   were	   dried	   over	  MgSO4	   and	   concentrated	   to	   afford	   the	   title	   compound	  
(2.79g,	  93%)	  as	  a	  colourless	  oil	  which	  was	  used	  without	  further	  purification.	  	  
	  
νmax	  (ATR)	  2960	  (w),	  2886	  (w),	  1702	  (s),	  1662	  (s),	  1451	  (s),	  1386	  (s),	  1170	  (s),	  1125	  (s),	  1091	  
(m)	  cm-­‐1;	  δH	  (600	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  9.15	  (1H,	  s,	  OH),	  4.41	  –	  4.37	  (0.6H,	  m,	  
2-­‐H),	  4.34	  –	  4.29	  (0.4H,	  m,	  2-­‐H),	  3.74	  (2H,	  s,	  CH3),	  3.69	  (1H,	  s,	  CH3),	  3.62	  –	  3.56	  (0.4H,	  m,	  5-­‐
HH’),	  3.55	  –	  3.47	  (1H,	  m,	  5-­‐HH’),	  3.45	  –	  3.38	  (0.6H,	  m,	  5-­‐HH’),	  2.32	  –	  2.22	  (1H,	  m,	  3-­‐HH’),	  
2.21	  –	  2.14	  (1H,	  m,	  4-­‐HH’),	  2.13	  –	  2.06	  (1H,	  m,	  3-­‐HH’),	  2.02	  –	  1.88	  (1H,	  m,	  4-­‐HH’);	  δC	  (151	  
MHz,	  CDCl3,	  mixture	  of	   rotamers)	  178.0	   (C-­‐1’),	  176.3	   (C-­‐1’),	  156.6	   (NCO2),	  155.3	   (NCO2),	  
59.4	  (C-­‐2),	  58.7	  (C-­‐2),	  53.2	  (CH3),	  52.9	  (CH3),	  47.0	  (C-­‐5),	  46.7	  (C-­‐5),	  31.0	  (C-­‐3),	  29.4	  (C-­‐3),	  




























Benzyl	  (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate191	  (R)-­‐106	  
	  
A	  solution	  of	  (2R)-­‐1-­‐[(benzyloxy)carbonyl]pyrrolidine-­‐2-­‐carboxylic	  acid	  (R)-­‐105	  (1.05g,	  4.01	  
mmol)	  in	  DCM	  (13	  mL)	  was	  cooled	  to	  0	  °C	  and	  oxalyl	  chloride	  (0.46	  mL,	  5.41	  mmol)	  was	  
added	  dropwise,	  followed	  by	  DMF	  (7	  drops).	  The	  mixture	  was	  stirred	  for	  2	  h	  at	  rt	  and	  then	  
concentrated	  under	  reduced	  pressure	  before	  the	  addition	  of	  THF	  (16	  mL)	  and	  MeCN	  (16	  
mL).	  After	  cooling	  the	  solution	  in	  an	  ice	  bath,	  NEt3	  (1.14	  mL,	  8.02	  mmol)	  and	  TMSCHN2	  (2M	  
solution	  in	  hexanes,	  4.40	  mL)	  were	  added	  and	  stirred	  for	  4	  h	  at	  rt.	  The	  reaction	  was	  then	  
quenched	  with	  AcOH	  (1	  mL),	  diluted	  with	  H2O	  (31	  mL)	  and	  concentrated	  under	  reduced	  
pressure	  followed	  by	  the	  addition	  of	  EtOAc	  (30	  mL)	  and	  washing	  with	  sat.	  NaHCO3(aq)	  (2	  x	  
15	  mL).	  The	  organic	  phase	  was	   then	  washed	  with	  brine	   (15	  mL),	  dried	  over	  MgSO4	  and	  
concentrated.	   Purification	   by	   column	   chromatography	   (0%	   →	   80%	   EtOAC	   in	   hexanes)	  
afforded	  the	  title	  compound	  (616	  mg,	  56%)	  as	  a	  yellow	  oil.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +86.0°	  (lit.:
191	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +118.6°).	  νmax	  
(ATR)	  3083	  (w),	  2955	  (w),	  2883	  (w),	  2102	  (s),	  1699	  (s),	  1645	  (s),	  1409	  (s),	  1351	  (s),	  1116	  (s)	  
cm-­‐1;	  δH	   (700	  MHz,	  CDCl3,	  mixture	  of	   rotamers)	  7.41	  –	  7.27	   (5H,	  m,	  ArH),	  5.48	   (0.5H,	   s,	  
CHN2),	  5.25	  (0.5H,	  s,	  CHN2),	  5.21	  -­‐	  5.04	  (2H,	  m,	  ArCH2),	  4.35	  (0.5H,	  s,	  2-­‐H),	  4.28	  (0.5H,	  s,	  2-­‐
H),	  3.60	  –	  3.45	  (2H,	  m,	  5-­‐H2),	  2.23	  –	  2.15	  (0.5H,	  m,	  3-­‐HH’),	  2.13	  –	  2.01	  (1.5H,	  m,	  3-­‐HH’,	  3-­‐
HH’,),	  1.99	  –	  1.84	  (2H,	  m,	  4-­‐CH2);	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  195.4	  (C-­‐1’),	  
194.5	  (C-­‐1’),	  155.4	  (NCO2),	  154.7	  (NCO2),	  136.7	  (ArC),	  136.5	  (ArC),	  128.6(3)	  (ArC),	  128.5(9)	  
(ArC),	  128.2(3)	  (ArC),	  128.1(7)	  (ArC),	  128.0(6)	  (ArC),	  67.4	  (ArCH2),	  64.2	  (C-­‐2),	  53.5	  (CHN2),	  
52.8	  (CHN2),	  47.5	  (C-­‐5),	  47.1	  (C-­‐5),	  31.4	  (C-­‐3),	  29.8	  (C-­‐3),	  24.5	  (C-­‐4),	  23.7	  (C-­‐4);	  m/z	  (LC-­‐MS,	  



















Benzyl	  (2S)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate202	  (S)-­‐106	  
	  
(2S)-­‐1-­‐[(benzyloxy)carbonyl]pyrrolidine-­‐2-­‐carboxylic	   acid	   (S)-­‐105	   was	   reacted	   under	   the	  
same	  conditions	  as	  the	  synthesis	  of	  benzyl	  (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐106.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐103.1	  °	  (lit.:
191	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  =	  -­‐135.8°).	  
NMR	  and	  mass	  spectra	  were	  consistent	  with	  the	  R	  enantiomer.	  
 
Methyl	  (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐166	  
	  
(2R)-­‐1-­‐(methoxycarbonyl)pyrrolidine-­‐2-­‐carboxylic	   acid	   (R)-­‐165	   (1.20	   g,	   6.93	   mmol)	   was	  
reacted	   under	   the	   same	   conditions	   as	   the	   synthesis	   of	   benzyl	   (2R)-­‐2-­‐(2-­‐
diazoacetyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐106,	  to	  afford	  the	  title	  compound	  (515	  mg,	  38%)	  
as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  3083	  (w),	  2957	  (w),	  2883	  (w),	  2101	  (s),	  1697	  (s),	  	  1640	  (s),	  1447	  (s),	  1373	  (s),	  1119	  
(s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  5.49	  (0.5H,	  s	  CHN2),	  5.38	  (0.5H,	  s,	  CHN2),	  
4.31	  (0.5H,	  s,	  2-­‐H),	  4.23	  (0.5H,	  s,	  2-­‐H),	  3.70	  (1.5H,	  s,	  CH3),	  3.67	  (1.5H,	  s,	  CH3),	  3.58	  –	  3.46	  
(1.5H,	  m,	  5-­‐HH’,	  5-­‐HH’),	  3.45	  –	  3.39	  (0.5H,	  m,	  5-­‐HH’),	  2.22	  -­‐	  2.10	  (2H,	  m,	  3-­‐H2),	  1.94	  –	  1.84	  
(2H,	  m,	  4-­‐CH2);	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  195.5	  (C-­‐1’),	  194.6	  (C-­‐1'),	  156.0	  
(NCO2Me),	  155.5	  (NCO2	  Me),	  64.3	  (C-­‐2),	  64.1	  (C-­‐2),	  53.4	  (CHN2),	  52.9	  (CH3),	  52.8	  (CH3),	  47.5	  
(C-­‐5),	  47.0	  (C-­‐5),	  31.4	  (C-­‐3),	  29.8	  (C-­‐3),	  24.5	  (C-­‐4),	  23.7	  (C-­‐4);	  m/z	  (LC-­‐MS,	  ESI+)	  170	  (M	  –	  N2	  


























Benzyl	  (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate191	  (R)-­‐107	  
	  
Benzyl	  (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐106	  (2.88	  g,	  10.50	  mmol)	  in	  dry	  
MeOH	  (34	  mL)	  was	  treated	  dropwise	  with	  a	  solution	  of	  silver	  benzoate	  (243	  mg,	  1.06	  mmol)	  
in	  NEt3	  (4.40	  mL,	  31.50	  mmol).	  The	  reaction	  mixture	  was	  stirred	  at	  rt	  for	  3	  h	  before	  being	  
cooled	  in	  an	  ice	  bath	  and	  quenched	  with	  Na2S2O5(aq.)	  (20%,	  33	  mL).	  The	  reaction	  mixture	  
was	   filtered	   through	  Celite	  and	  washed	  with	  EtOAc	   (3	  x	  30	  mL)	  and	   the	  organic	   filtrate	  
washed	  with	  brine	  (60	  mL)	  and	  dried	  over	  MgSO4.	  The	  solvent	  was	  removed	  under	  reduced	  
pressure	  and	  purified	  by	  flash	  column	  chromatography	  (0%	  →	  80%	  EtOAC	  in	  hexanes)	  to	  
afford	  the	  title	  compound	  (2.32	  g,	  80%)	  as	  a	  colourless	  oil.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +23.4°	  (lit.:
191	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +27.2°).	  νmax	  
(ATR)	  2953	  (w),	  2881	  (w),	  1734	  (m),	  1697	  (s),	  1409	  (s),	  1357	  (m),	  1167	  (m),	  1095	  (m)	  cm-­‐1.	  
δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  7.38	  –	  7.32	  (4H,	  m,	  ArH),	  7.31	  –	  7.27	  (1H,	  m,	  ArH),	  
5.16	  –	  5.09	  (2H,	  m,	  ArCH2),	  4.27	  –	  4.20	  (1H,	  m,	  2-­‐H),	  3.64	  (3H,	  s,	  CH3),	  3.48	  –	  3.38	  (2H,	  m,	  
5-­‐H2),	  3.05	  –	  2.90	  (0.6H,	  m,	  1’-­‐HH’	  rotamer	  A),	  2.86	  –	  2.73	  (0.4H,	  m,	  1’-­‐HH’	  rotamer	  B),	  2.38	  
–	  2.31	  (1H,	  m,	  1-­‐HH’),	  2.12	  –	  2.03	  (1H,	  m,	  3-­‐HH’),	  1.93	  –	  1.80	  (2H,	  m,	  4-­‐H2),	  1.80	  –	  1.72	  (1H,	  
m,	  3-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  171.9	  (CO2CH3),	  154.8	  (NCO2),	  137.0	  
(ArC),	   128.5	   (ArC),	   128.0	   (ArC),	   127.9	   (ArC),	   66.8	   (ArCH2),	   54.7	   (C-­‐2),	   54.1	   (C-­‐2),	   51.7	  
(CO2CH3),	  46.8	  (C-­‐5),	  46.6	  (C-­‐5),	  39.2	  (C-­‐1’),	  38.3	  (C-­‐1’),	  31.5	  (C-­‐3),	  30.7	  (C-­‐3),	  23.6	  (C-­‐4),	  22.9	  























Benzyl	  (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate202	  (S)-­‐107	  
	  
benzyl	  (2S)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐carboxylate	  (S)-­‐106	  	  was	  reacted	  under	  the	  same	  
conditions	   as	   the	   synthesis	   of	   benzyl	   (2S)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐
carboxylate	  (R)-­‐107.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐53.2°	  (lit.:
202	  [α]D	  (c	  =	  1.02	  g/100	  mL,	  CHCl3)	  -­‐42.7°).	  NMR	  
and	  mass	  spectra	  were	  consistent	  with	  the	  R	  enantiomer.	  
	  
Methyl	  (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate249	  (R)-­‐167	  
	  
The	   conditions	   for	   the	   rearrangement	   of	   benzyl	   (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐
carboxylate	   (R)-­‐106	   were	   applied	   to	   methyl	   (2R)-­‐2-­‐(2-­‐diazoacetyl)pyrrolidine-­‐1-­‐
carboxylate	  (R)-­‐166	  (515	  mg,	  2.61	  mmol)	  to	  afford	  the	  title	  compound	  (334	  mg,	  64%)	  as	  a	  
yellow	  oil.	  	  
	  
νmax	  (ATR)	  2956	  (w),	  2882	  (w),	  1734	  (m),	  1695	  (s),	  1449	  (s),	  1383	  (s),	  1194	  (m),	  1121	  (m)	  cm-­‐
1;	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  4.22	  –	  4.11	  (1H,	  m,	  2-­‐H),	  3.71	  –	  3.61	  (6H,	  m,	  2	  
x	  CO2CH3),	  3.44	  –	  3.32	  (2H,	  m,	  5-­‐H2),	  2.98	  –	  2.90	  (0.5H,	  m,	  1’-­‐HH’	  rotamer	  A),	  2.78	  –	  2.71	  
(0.5H,	  m,	  1’-­‐HH’	  rotamer	  B),	  2.35	  –	  2.26	  (1H,	  m,	  1’-­‐HH’),	  2.09	  –	  2.01	  (1H,	  m,	  3-­‐HH’),	  1.88	  –	  
1.78	  (2H,	  m,	  4-­‐H2),	  1.77	  –	  1.69	  (1H,	  m,	  3-­‐HH’);	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  
172.0	  (CO2CH3),	  171.9	  (CO2CH3),	  155.5	  (NCO2),	  54.6	  (C-­‐2),	  54.0	  (C-­‐2),	  52.5	  (CO2CH3),	  52.30	  
(CO2CH3),	  	  51.7	  (CO2CH3),	  46.8	  (C-­‐5),	  46.5	  (C-­‐5),	  39.2	  (C-­‐1’),	  38.3	  (C-­‐1'),	  31.5	  (C-­‐3),	  30.7	  (C-­‐






























Procedure	   1:	   To	   a	   solution	   of	   benzyl	   (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐
carboxylate	  (R)-­‐107	  (349	  mg,	  1.74	  mmol)	  in	  THF	  (6.0	  mL)	  at	  0	  °C	  was	  slowly	  added	  LiAlH4	  
(2.4M	  solution	  in	  THF,	  2.2	  mL,	  5.23	  mmol).	  	  This	  was	  allowed	  to	  warm	  to	  rt	  and	  left	  to	  stir	  
for	  3	  h.	  The	  reaction	  mixture	  was	  then	  cooled	  in	  an	  ice	  bath	  and	  any	  reactive	  salts	  were	  
quenched	  according	  to	  Fieser’s	  method	  (general	  procedure	  B).	  Crude	  product	  was	  purified	  
by	  column	  chromatography	  (0%	  →	  10	  %	  MeOH	  in	  CHCl3	  with	  1%	  NEt3)	  to	  afford	  the	  title	  
compound	  (118	  mg,	  52%)	  as	  a	  colourless	  oil.	  	  
	  
Procedure	   2:	   The	   reduction	   was	   carried	   out	   using	   methyl	   (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐
oxoethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐167	  (289	  mg,	  1.44	  mmol)	  following	  the	  conditions	  
for	   the	   reduction	   of	   Benzyl	   (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐
107	  to	  afford	  the	  title	  compound	  (97	  mg,	  52%)	  as	  a	  colourless	  oil	  which	  was	  used	  without	  
any	  further	  purification.	  	  
	  
νmax	  (ATR)	  3314	  (br),	  2942	  (w),	  2872	  (w),	  2787	  (w),	  1667	  (w),	  1455	  (m),	  1371	  (w),	  1215	  (w),	  
1057	  (m),	  1020	  (m)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  5.28	  (1H,	  s,	  OH),	  3.92	  (1H,	  td,	  J	  =	  10.5,	  3.0	  Hz,	  
2’-­‐HH’),	  3.68	  –	  3.56	  (1H,	  m,	  2’-­‐HH’),	  3.10	  –	  2.97	  (1H,	  m,	  5-­‐HH’),	  2.58	  –	  2.50	  (1H,	  m,	  2-­‐H),	  
2.33	  (3H,	  s,	  NCH3),	  2.19	  –	  2.09	  (1H,	  m,	  5’-­‐HH’),	  1.98	  –	  1.84	  (2H,	  m,	  3-­‐HH’,	  1’-­‐HH’),	  1.82	  –	  
1.67	  (3H,	  m,	  3’-­‐HH’,	  4-­‐H2),	  1.52	  –	  1.47	  (1H,	  m,	  1’-­‐HH’);	  δC	  (151	  MHz,	  CDCl3)	  65.2	  (C-­‐2),	  60.2	  





















Benzyl	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐133	  
	  
Benzyl	   (2R)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐107	   (100	   mg,	   0.36	  
mmol)	  was	  dissolved	  in	  anhydrous	  THF	  (1.80	  mL)	  and	  cooled	  to	  0	  °C.	  LiBH4	  (27	  mg)	  was	  
added	  and	  the	  reaction	  mixture	  was	  stirred	  for	  2	  h	  at	  60	  °C.	  It	  was	  then	  diluted	  with	  H2O	  (5	  
mL)	  and	  extracted	  with	  EtOAc	  (2	  x	  5	  mL).	  The	  combined	  organic	   layers	  were	  dried	  over	  
Na2SO4	  and	  the	  solvent	  was	  evaporated	  in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  flash	  
column	  chromatography	  (0%	  →	  80%	  EtOAC	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (52	  
mg,	  58%)	  as	  a	  colourless	  oil.	  	  
	  
	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +4.7°	  (lit.:
250	  [α]D	  (c	  =	  1.0	  g/100	  mL,	  CHCl3)	  +7.2°).	  νmax	  (ATR)	  
3440	  (br),	  2971	  (m),	  1700	  (s),	  1414	  (s),	  1359	  (s),	  1217	  (m),	  1103	  (m)	  cm-­‐1;	  δH	  (600	  MHz,	  
CDCl3)	  7.39	  -­‐	  7.35	  (4H,	  m,	  ArH),	  7.34	  –	  7.30	  (1H,	  m,	  ArH),	  5.16	  –	  5.13	  (2H,	  m,	  ArCH2),	  4.27	  –	  
4.18	  (1H,	  m,	  2-­‐H),	  3.66	  –	  3.53	  (2H,	  m,	  2’-­‐H2),	  3.48	  –	  3.36	  (2H,	  m,	  5-­‐H2),	  2.06	  –	  1.95	  (1H,	  m,	  
3-­‐HH’),	  1.94	  –	  1.85	  (2H,	  m,	  4-­‐H2),	  1.76	  –	  1.68	  (1H,	  m,	  1’-­‐HH’),	  1.67	  –	  1.62	  (1H,	  m,	  3-­‐HH’),	  
1.55	  –	  1.47	  (1H,	  m,	  1’-­‐HH’);	  δC	  (151	  MHz,	  CDCl3)	  156.9	  (CO),	  136.8	  (ArC),	  128.6	  (ArC),	  128.2	  
(ArC),	  127.9	  (ArC),	  67.2	  (ArCH2),	  59.2	  (C-­‐2’),	  54.5	  (C-­‐2),	  46.5	  (C-­‐5),	  38.4	  (C-­‐1’),	  31.3	  (C-­‐3),	  
23.7	  (C-­‐4);	  m/z	  (LC-­‐MS,	  ESI+)	  250	  (MH+).	  
	  
Benzyl	  (2S)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (S)-­‐133	  
	  
Benzyl	   (2S)-­‐2-­‐(2-­‐methoxy-­‐2-­‐oxoethyl)pyrrolidine-­‐1-­‐carboxylate	   (S)-­‐107	   	   (200	   mg,	   0.72	  





















hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐133	  to	  afford	  the	  title	  compound	  (110	  mg,	  61%)	  
as	  a	  colourless	  oil.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐2.3	  °	  (lit.:	  [α]D	  (c	  =	  1.10	  g/100	  mL,	  CHCl3)	  -­‐7.6°).	  NMR	  and	  
mass	  spectra	  were	  consistent	  with	  the	  R	  enantiomer.	  
1’-­‐Bromo-­‐4’-­‐[phenyl(3-­‐phenylpropoxy)methyl]benzene230	  127	  
	  
General	  procedure	  C	  was	  used	  in	  the	  reaction	  of	  3-­‐phenyl-­‐1-­‐propanol	  126	  (0.14	  mL,	  0.77	  
mmol)	   and	   (4-­‐bromophenyl)(phenyl)methanol	   122	   (200	   mg,	   0.77	   mmol).	   The	   crude	  
product	  was	  purified	  by	  column	  chromatography	  (0%	  →	  30%	  EtOAC	  in	  hexanes)	  to	  afford	  
the	  title	  compound	  (293	  mg,	  95%)	  as	  a	  colourless	  oil.	  	  
	   	  
νmax	  (ATR)	  3062	  (w),	  3026	  (w),	  2941	  (w),	  2859	  (w),	  1602	  (w),	  1495	  (w),	  1485	  (m),	  1453	  (w),	  
1396	  (w),	  1295	  (w),	  1183	  (w),	  1095	  (m),	  1070	  (m),	  1010	  (m)	  cm-­‐1;	  δH	  (600	  MHz,	  CDCl3)	  7.48	  
-­‐	  7.42	  (2H,	  m,	  ArH),	  7.40	  –	  7.30	  (4H,	  m,	  ArH),	  7.32	  –	  7.20	  (5H,	  m,	  ArH),	  7.22	  –	  7.15	  (3H,	  m,	  
ArH),	  5.28	  (1H,	  s,	  Ar2CH),	  3.52	  –	  3.42	  (2H,	  m,	  1-­‐H2),	  2.79	  –	  2.72	  (2H,	  m,	  2-­‐H2),	  2.02	  –	  1.93	  
(2H,	  m,	  3-­‐H2);	  δC	  (151	  MHz,	  CDCl3)	  142.1(0)	  (ArC),	  142.0(6)	  (ArC),	  141.8	  (ArC),	  131.6	  (ArC),	  
128.8	   (ArC),	   128.6	   (ArC),	   128.4	   (ArC),	   127.7	   (ArC),	   127.5	   (ArC),	   127.1	   (ArC),	   125.9	   (ArC),	  
121.3	   (ArC),	   83.0	   (Ar2CH),	   68.3	   (C-­‐1),	   32.5	   (C-­‐2),	   31.4	   (C-­‐3);	   m/z	   (LC-­‐MS,	   ESI+)	   383	  
(M(81Br)H+),	  381	  (M(79Br)H+).	  	  
	  
Benzyl	  N-­‐(3-­‐hydroxypropyl)carbamate251	  139	  	  
	  
3-­‐Aminopropanol	  (1.02	  mL,	  13.32	  mmol)	  was	  dissolved	  in	  DCM	  (10	  mL)	  and	  cooled	  to	  0	  °C.	  
NEt3	   (0.91	  mL,	  6.50	  mmol)	  and	  CbzCl	   (0.95	  mL,	  6.69	  mmol)	  were	  added	  slowly	  and	   the	  

















mL)	  and	  H2O	  (5	  mL)	  were	  added	  and	  the	  product	  extracted	  with	  diethyl	  ether	  (3	  x	  5	  mL).	  
The	  combined	  organic	  extracts	  were	  then	  dried	  over	  Na2SO4,	  concentrated	  and	  the	  crude	  
product	  purified	  by	  column	  chromatography	  (0%→	  80%	  EtOAC	  in	  hexanes)	  to	  afford	  the	  
title	  compound	  (1.63	  g,	  61%)	  as	  a	  white	  solid.	  
	  
M.p.	  52	  –	  53	  °C	  (lit.:251	  51-­‐52	  °C);	  	  νmax	  (ATR)	  3324	  (s),	  3062	  (w),	  3039	  (w),	  2956	  (w),	  2886	  
(w),	  1683	  (s),	  1530	  (s),	  1454	  (m),	  1326	  (m),	  1254	  (s),	  1243	  (s),	  1142	  (m),	  1061	  (s),	  1022	  (s)	  
cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.37-­‐7.29	  (5H,	  m,	  ArH),	  5.11	  (2H,	  s,	  ArCH2),	  5.03	  (1H,	  s,	  NH),	  3.71	  
-­‐	  3.65	  (2H,	  m,	  1-­‐H2),	  3.39	  –	  3.33	  (2H,	  m,	  3-­‐H2),	  2.53	  (1H,	  s,	  OH),	  1.73	  –	  1.67	  (2H,	  m,	  2-­‐H2);	  δC	  
(176	  MHz,	  CDCl3)	  157.5	  (CO),	  136.6	  (ArC),	  128.7	  (ArC),	  128.3(3)	  (ArC),	  128.2(7)	  (ArC),	  67.0	  
(ArCH2),	  59.7	  (C-­‐1),	  37.9	  (C-­‐3),	  32.8	  (C-­‐2);	  m/z	  (LC-­‐MS,	  ESI+)	  232	  (MNa+).	  
Methyl	  N-­‐(3-­‐hydroxypropyl)carbamate252	  131	  
	  
3-­‐Aminopropanol	  (600	  mg,	  7.99	  mmol)	  was	  dissolved	  in	  H2O	  (4	  mL)	  and	  a	  solution	  of	  K2CO3	  
(1.77	   g,	   12.78	   mmol)	   in	   H2O	   (4	   mL)	   was	   added,	   followed	   by	   slow	   addition	   of	   methyl	  
chloroformate	  (0.92	  mL,	  11.99	  mmol)	  at	  0	  °C.	  Stirring	  was	  continued	  at	  0	  °C	  	  for	  2	  h.	  Then	  
the	  reaction	  was	  extracted	  with	  CH2Cl2	  (3	  x	  10	  mL),	  the	  combined	  organic	  layers	  dried	  over	  
Na2SO4	   and	   concentrated	   in	   vacuo	   to	   afford	   the	   title	   compound	   (472	   mg,	   45%)	   as	   a	  
colourless	  oil	  which	  was	  carried	  forward	  without	  purification.	  
	  
νmax	  (ATR)	  3328	  (br),	  2948	  (w),	  1695	  (s),	  1533	  (s),	  1447	  (w),	  1261	  (s),	  1046	  (s)	  cm-­‐1	  δH	  (600	  
MHz,	  CDCl3)	  5.25	  (1H,	  s,	  NH),	  3.66	  -­‐	  3.61	  (5H,	  m,	  CH3,	  3-­‐H2),	  3.28	  (2H,	  t,	  J	  =	  6.0	  Hz,	  1-­‐H2),	  
3.11	  (1H,	  s,	  OH),	  1.67	  (2H,	  p,	  J	  =	  6.0	  Hz,	  2-­‐H2).	  δC	  (151	  MHz,	  CDCl3);	  158.0	  (CO),	  59.7	  (C-­‐3),	  


















Benzyl	  N-­‐(6-­‐hydroxyhexyl)carbamate253	  137	  
	  
6-­‐Aminopropanol	  (1.00	  g,	  8.53	  mmol)	  was	  Cbz-­‐protected	  under	  the	  same	  conditions	  as	  the	  
synthesis	  of	  benzyl	  N-­‐(3-­‐hydroxypropyl)carbamate	  139,	  to	  afford	  the	  title	  compound	  (900	  
mg,	  84%)	  as	  a	  white	  solid.	  
	  
M.p.	  82	  –	  83	  °C	  (lit.:253	  83	  °C);	  νmax	  (ATR)	  3333	  (m),	  2941	  (m),	  2859	  (w),	  1685	  (s),	  1526	  (s),	  
1453	  (m),	  1360	  (m),	  1288	  (s),	  1250	  (s),	  1218	  (m),	  1137	  (m),	  1110	  (m),	  1064	  (m),	  1036	  (m),	  
1004	  (s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.38	  –	  7.34	  (4H,	  m,	  ArH),	  7.34	  –	  7.30	  (1H,	  m,	  ArH),	  5.09	  
(2H,	  s,	  ArCH2),	  4.73	  (1H,	  s,	  NH),	  3.66	  –	  3.60	  (2H,	  m,	  1-­‐H),	  3.23	  –	  3.16	  (2H,	  m,	  6-­‐H),	  1.56	  –	  
1.48	  (4H,	  m,	  2-­‐H2,	  5-­‐H2),	  1.42	  –	  1.28	  (4H,	  m,	  4-­‐H2,	  3-­‐H2);	  δC	  (176	  MHz,	  CDCl3)	  156.5	  (CO),	  
136.8	  (ArC),	  128.7	  (ArC),	  128.2(8)	  (ArC),	  128.2(5)	  (ArC),	  66.8	  (ArCH2),	  62.9	  (C-­‐1),	  41.1	  (C-­‐6),	  
32.7	  (C-­‐2),	  30.1	  (C-­‐5),	  26.5	  (C-­‐4),	  25.4	  (C-­‐3);	  m/z	  (GC-­‐MS,	  EI)	  251	  (M+),	  108	  (C7H8O+).	  
	  
Methyl	  N-­‐{3-­‐[(4’-­‐bromophenyl)(phenyl)methoxy]propyl}carbamate	  132	  
	  
General	   procedure	   C	   was	   used	   in	   the	   reaction	   of	   protected	   methyl	   N-­‐(3-­‐
hydroxypropyl)carbamate	   131	   (0.14	   mL,	   0.77	   mmol)	   and	   (4-­‐
bromophenyl)(phenyl)methanol	  122	  (200	  mg,	  0.77	  mmol).	  The	  crude	  product	  was	  purified	  
by	   flash	   column	   chromatography	   (0%	   →	   80%	   EtOAC	   in	   hexanes)	   to	   afford	   the	   title	  
compound	  (65	  mg,	  24%)	  as	  a	  pale	  yellow	  oil.	  
	  
νmax	  (ATR)	  3333	  (w),	  2951	  (w),	  1699	  (s),	  1521	  (m),	  1485	  (m),	  1449	  (m),	  1395	  (w),	  1260	  (s),	  
1070	  (s),	  1010	  (s)	  cm-­‐1;	  δH	  (600	  MHz,	  CDCl3)	  7.45	  –	  7.41	  (2H,	  m,	  ArH),	  7.34	  –	  7.23	  (5H,	  m,	  
ArH),	  7.21	  –	  7.17	  (2H,	  m,	  ArH),	  5.26	  (1H,	  s,	  Ar2CH),	  4.94	  (1H,	  s,	  NH),	  3.63	  (3H,	  s,	  CH3),	  3.49	  
























(NCO2),	  141.7	  (ArC),	  141.4	  (ArC),	  131.7	  (ArC),	  128.7	  (ArC),	  128.6	  (ArC),	  127.9	  (ArC),	  127.0	  
(ArC),	  121.5	  (ArC),	  83.4	  (Ar2CH),	  67.3	  (C-­‐1),	  52.1	  (CH3),	  39.2	  (C-­‐3),	  29.9	  (C-­‐2);	  m/z	  (LC-­‐MS,	  
ESI+)	   402	   (M(81Br)Na+),	   400	   (M(79Br)Na+).	   Accurate	   mass:	   Found	   MNa+,	   400.0523:	  
C18H20NO379BrNa	  requires	  M,	  400.0524.	  
	  
Benzyl	  N-­‐{6-­‐[(4’-­‐bromophenyl)(phenyl)methoxy]hexyl}carbamate	  138	  
	  
General	   procedure	   C	   was	   followed	   in	   the	   reaction	   of	   protected	   Benzyl	   N-­‐(6-­‐
hydroxyhexyl)carbamate	  137	  (194	  mg,	  0.77	  mmol)	  and	  (4-­‐bromophenyl)(phenyl)methanol	  
122	   (200	   mg,	   0.77	   mmol).	   The	   crude	   product	   was	   purified	   by	   by	   flash	   column	  
chromatography	  (0%	  →	  50%	  EtOAC	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (175	  mg,	  46%)	  
as	  a	  colourless	  oil.	  
νmax	  (ATR)	  3338	  (w),	  2935	  (w),	  1699	  (s),	  1520	  (m),	  1485	  (m),	  1454	  (m),	  1249	  (s),	  1090	  (m),	  
1070	  (m),	  1027	  (m),	  1010	  (s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.45	  –	  7.41	  (2H,	  m,	  ArH),	  7.37	  –	  7.34	  
(4H,	  m,	  ArH),	  7.33	  –	  7.29	  (5H,	  m,	  ArH),	  7.27	  -­‐	  7.23	  (1H,	  m,	  ArH),	  7.23	  –	  7.20	  (2H,	  m,	  ArH),	  
5.27	  (1H,	  s,	  Ar2CH),	  5.10	  (2H,	  s,	  ArCH2),	  4.75	  (1H,	  s,	  NH),	  3.45	  –	  3.39	  (2H,	  m,	  1-­‐H2),	  3.20	  –	  
3.14	  (2H,	  m,	  6-­‐H2),	  1.66	  –	  1.58	  (2H,	  m,	  5-­‐H2),	  1.53	  –	  1.45	  (2H,	  m,	  2-­‐H2),	  1.44	  –	  1.36	  (2H,	  m,	  
4-­‐H2),	  1.34	  -­‐	  1.28	  (2H,	  m,	  3-­‐H2);	  δC	  (176	  MHz,	  CDCl3)	  156.5	  (CO),	  142.1	  (ArC),	  141.8	  (ArC),	  
136.8	  (ArC),	  131.5	  (ArC),	  128.7	  (ArC),	  	  128.6(1)	  (ArC),	  128.5(6)	  (ArC),	  128.2(2)	  (ArC),	  128.1(8)	  
(ArC),	  127.7	  (ArC),	  127.0	  (ArC),	  121.3	  (ArC),	  83.1	  (Ar2CH),	  69.2	  (C-­‐1),	  66.7	  (ArCH2),	  41.1	  (C-­‐
6),	  30.0	   (C-­‐2),	  29.8	   (C-­‐5),	  26.7	   (C-­‐3),	  26.0	   (C-­‐4);	  m/z	   (LC-­‐MS,	  ESI+)	  520	   (M(81Br)Na+),	  518	  






















Benzyl	  N-­‐{3-­‐[(4’-­‐bromophenyl)(phenyl)methoxy]propyl}carbamate	  140	  
	  
General	  procedure	  C	  was	  used	  with	  protected	  benzyl	  N-­‐(3-­‐hydroxypropyl)carbamate	  139	  
(159	  mg,	  0.76	  mmol)	  and	  (4-­‐bromophenyl)(phenyl)methanol	  122	  (200	  mg,	  0.77	  mmol)	  with	  
the	  modification	  of	  AuCl	  (18	  mg,	  0.08	  mmol)	  as	  the	  catalyst	   in	  the	  place	  of	  PdCl2	  with	  a	  
reaction	  time	  of	  20	  h.	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0%	  
→	  40%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (259	  mg,	  90%)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  3334	  (w),	  2950	  (w),	  1699	  (s),	  1516	  (m),	  1485	  (m),	  1453	  (m),	  1395	  (m),	  1244	  (s),	  
1070	  (s),	  1010	  (s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.41	  (2H,	  d,	  J	  =	  8.0	  Hz,	  ArH),	  7.38	  –	  7.27	  (8H,	  m,	  
ArH),	  7.26	  –	  7.23	  (2H,	  m,	  ArH),	  7.19	  (2H,	  d,	  J	  =	  8.0	  Hz,	  ArH),	  5.27	  (1H,	  s,	  Ar2CH),	  5.09	  (s,	  2H,	  
ArCH2),	  3.51	  (2H,	  t,	  J	  =	  6.0	  Hz,	  1-­‐H),	  3.39	  -­‐	  3.31	  (2H,	  m,	  3-­‐H),	  1.84	  (2H,	  p,	  J	  =	  6.0	  Hz,	  2-­‐H);	  δC	  
(176	  MHz,	  CDCl3)	  156.5	  (CO),	  141.7	  (ArC),	  141.4	  (ArC),	  136.8	  (ArC),	  131.7	  (ArC),	  128.7(2)	  
(ArC),	  128.6(5)	  (ArC),	  128.6(2)	  (ArC),	  128.2(1)	  (ArC),	  128.1(8)	  (ArC),	  127.9	  (ArC),	  127.0	  (ArC),	  
121.5	  (ArC),	  83.5	  (Ar2CH),	  67.5	  (C-­‐1),	  66.7	  (ArCH2),	  39.4	  (C-­‐3),	  29.8	  (C-­‐2);	  m/z	  (LC-­‐MS,	  ESI+)	  
478	   (M(81Br)Na+),	   476	   (M(79Br)Na+);	   Accurate	   mass:	   Found	   MNa+,	   476.0855:	  
























Benzyl	   (2R)-­‐2-­‐{2’-­‐[(4’’-­‐bromophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐135	  
	  
General	   procedure	   C	   was	   used	   with	   benzyl	   (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐
carboxylate	   (R)-­‐133	   (80	  mg,	  0.32	  mmol)	  and	   (4-­‐bromophenyl)(phenyl)methanol	  122	   (84	  
mg,	  0.32	  mmol)	  with	  the	  modification	  of	  AuCl	  (8	  mg,	  0.03	  mmol)	  as	  the	  catalyst	  in	  the	  place	  
of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  	  The	  crude	  product	  was	  then	  purified	  by	  flash	  column	  
chromatography	  (0%	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (99	  mg,	  63%)	  
as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2872	  (w),	  1694	  (s),	  1484	  (m),	  1452	  (w),	  1408	  (s),	  1356	  (m),	  1183	  (w),	  1091	  (s),	  
1070	  (s),	  1010	  (s)	  cm-­‐1;	  δH	  (700	  MHz,	  CDCl3)	  7.47	  –	  7.38	  (2H,	  m,	  ArH),	  7.38	  –7.13	  (12H,	  m,	  
ArH),	  5.36	  –	  5.18	  (1H,	  m,	  Ar2CH),	  5.17	  –	  5.05	  (2H,	  m,	  ArCH2),	  4.07	  –	  3.96	  (1H,	  m,	  2-­‐H),	  3.55	  
-­‐	  3.33	  (4H,	  m,	  2’-­‐H2,	  5-­‐H2),	  2.26	  -­‐	  2.06	  (1H,	  m,	  1’-­‐HH’),	  1.99	  –	  1.90	  (1H,	  m,	  3-­‐HH’),	  1.90-­‐1.80	  
(2H,	  m,	  4-­‐H2),	  1.79-­‐1.72	  (1H,	  m,	  3-­‐HH’),	  1.70	  -­‐	  1.56	  (1H,	  m,	  1’-­‐HH’);	  δC	  (151	  MHz,	  CDCl3,	  
mixture	  of	   diastereomers)	   155.1	   (CO),	   142.0	   (ArC),	   141.9	   (ArC),	   141.7(6)	   (ArC),	   141.6(7)	  
(ArC),	  137.2	  (ArC),	  131.6	  (ArC),	  131.5	  (ArC),	  128.7	  (ArC),	  128.5(9)	  (ArC),	  128.5(7)	  (ArC),	  128.0	  
(ArC),	  127.9	  (ArC),	  127.8	  (ArC),	  127.7	  (ArC),	  127.0(2)	  (ArC),	  126.9(8)	  (ArC),	  121.3(4)	  (ArC),	  
121.3(1)	  (ArC),	  83.1	  (Ar2CH),	  83.0	  (Ar2CH),	  66.7	  (C-­‐2’),	  66.7	  (ArCH2),	  56.1	  (C-­‐2),	  55.3	  (C-­‐2),	  
46.5	   (C-­‐5),	   34.2	   (C-­‐1’),	   30.8	   (C-­‐3),	   23.3	   (C-­‐4);	  m/z	   (LC-­‐MS,	   ESI+)	   516	   (M(81Br)Na+),	   518	  




















To	   a	   0	   °C	   solution	   of	   Benzyl	   (2R)-­‐2-­‐{2’-­‐[(4’’-­‐
bromophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐135	   (256	   mg,	   0.52	  
mmol)	  in	  THF	  (6	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4M	  solution	  in	  THF,	  0.54	  mL,	  1.30	  mmol),	  
before	  being	  heated	  under	  reflux	  for	  16h.	  The	  reaction	  mixture	  was	  then	  cooled	  in	  an	  ice	  
bath	   and	   any	   reactive	   salts	   were	   quenched	   according	   to	   Fieser’s	   method	   (general	  
procedure	  B).	  	  The	  crude	  product	  was	  purified	  by	  reversed	  phase	  column	  chromatography	  
(5%	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  title	  compound	  (102	  mg,	  52%)	  
as	  a	  yellow	  oil.	  
	  
νmax	  (ATR)	  3028	  (w),	  2944	  (w),	  2869	  (w),	  2778	  (w),	  1697	  (w),	  1590	  (w),	  1485	  (m),	  1453	  (m),	  
1346	  (w),	  1184	  (w),	  1091	  (s),	  1071	  (s),	  1010	  (s)	  cm-­‐1;	  δH	  (600	  MHz,	  CDCl3)	  7.34	  -­‐	  7.29	  (8H,	  
m,	  ArH),	  7.27	  –	  7.23	  (2H,	  m,	  ArH),	  5.32	  (1H,	  m,	  Ar2CH),	  3.69	  –	  3.60	  (2H,	  m,	  2’-­‐HH’,	  5-­‐HH’),	  
3.53	  –	  3.46	  (1H,	  m,	  2’-­‐HH’),	  3.13	  -­‐	  2.93	  (1H,	  m,	  2-­‐H),	  2.68	  –	  2.62	  (4H,	  m,	  5-­‐HH’,	  NCH3),	  2.36	  
–	  2.24	  (1H,	  m,	  1’-­‐HH’),	  2.18	  –	  1.99	  (3H,	  m,	  1’-­‐HH’,	  3-­‐HH’,	  4-­‐HH’),	  1.96	  –	  1.76	  (2H,	  m,	  3-­‐HH’,	  
4-­‐HH’);	  δC	  (151	  MHz,	  CDCl3)	  142.1	  (C-­‐1Ph/1’Ph),	  142.0	  (C-­‐1Ph/1’Ph),	  128.6	  (C-­‐4Ph/4’Ph),	  127.8	  
(C-­‐3Ph/3’Ph),	  127.7	  (C-­‐3Ph/3’Ph),	  127.0(3)	  (C-­‐2Ph/2’Ph),	  127.9(5)	  (C-­‐2Ph/2’Ph),	  84.1	  (Ar2CH),	  66.3	  
(C-­‐2),	  65.9	  (C-­‐2’),	  56.4	  (C-­‐5),	  39.6	  (NCH3),	  31.4	  (C-­‐1’),	  30.1	  (C-­‐3),	  21.8	  (C-­‐4);	  m/z	  (LC-­‐MS,	  ESI+)	  




General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.6	   mL,	   24.8	   mmol)	   and	   4-­‐
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chromatography	  (0%	  →	  20%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (4.10g,	  98%)	  
as	  a	  white	  solid.	  
	  
M.p.	  59	  –	  60	  °C	  (lit.:254	  61	  -­‐	  62	  °C);	  νmax	  (ATR)	  3355	  (br,	  m),	  3065	  (w),	  3030	  (w),	  2981	  (w),	  
1601	  (w),	  1486	  (s),	  1453	  (m),	  1402	  (m),	  1345	  (w),	  1319	  (w),	  1288	  (w),	  1273	  (w),	  1247	  (w),	  
1192	  (m),	  1086	  (m),	  1034	  (m),	  1022	  (s),	  1011	  (s)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.36	  –	  7.26	  (9H,	  
m,	  ArH),	  5.81	  (1H,	  s,	  Ar2CH),	  2.25	  (1H,	  s,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  143.6	  (ArC),	  142.3	  (ArC),	  
133.4	  (ArC),	  128.8	  (ArC),	  128.7	  (ArC),	  128.0	  (ArC),	  128.0	  (ArC),	  126.7	  (ArC),	  75.6	  (Ar2C).	  m/z	  
(LC-­‐MS,	  ESI+)	  218	  (M(35Cl)H+),	  220	  (M(37Cl)H+).	  	  
	  
Benzyl	   (2R)-­‐2-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐168	  
	  
General	  Procedure	  C	  was	   followed	  using	  4-­‐chlorophenyl(phenyl)methanol	   113	   (311	  mg,	  
1.42	  mmol)	  and	  benzyl	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐133	  (353	  mg,	  
1.42	  mmol)	  with	  the	  modification	  of	  AuCl	  (33	  mg,	  0.14	  mmol)	  as	  the	  catalyst	  in	  the	  place	  
of	   PdCl2	  with	   a	   reaction	   time	   of	   20	   h.	   The	   crude	   product	  was	   purified	   by	   flash	   column	  
chromatography	  (0	  →	  20	  %	  EtOAc	  in	  hexanes)	  to	  afford	  title	  compound	  (514	  mg,	  80%).	  
	  
νmax	  (ATR)	  2960	  (w),	  2874	  (w),	  1695	  (s),	  1489	  (w),	  1452	  (w),	  1409	  (m),	  1356	  (m),	  1335	  (w),	  
1306	   (w),	   1260	   (w),	   1184	   (w),	   1090	   (s),	   1014	   (m)	   cm-­‐1.	   δH	   (700	  MHz,	   CDCl3,	  mixture	  of	  
diastereomers)	  7.38	  –	  7.18	  (14H,	  m,	  ArH),	  5.34	  –	  5.30	  (0.5H,	  m,	  Ar2CH),	  5.22	  -­‐	  5.18	  (0.5H,	  
m,	  Ar2CH),	  5.17	  -­‐	  5.07	  (2H,	  m,	  ArCH2),	  4.07	  –	  3.96	  (1H,	  m,	  2-­‐H),	  3.55	  -­‐	  3.35	  (4H,	  m,	  2’-­‐H2,	  5-­‐
H2),	  2.25	  –	  2.18	  (0.5H,	  m,	  1’-­‐HH’),	  2.16	  –	  2.08	  (0.5H,	  m,	  1’-­‐HH’),	  1.98	  -­‐	  1.91	  (1H,	  m,	  3-­‐HH’),	  
1.90	  –	  1.80	  (2H,	  m,	  4-­‐H2),	  1.79	  -­‐	  1.72	  (1H,	  m,	  3-­‐HH’),	  1.70	  -­‐	  1.55	  (1H,	  m,	  1’-­‐HH’);	  δC	  (176	  
MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  155.1	   (CO),	  155.0	   (CO),	  142.1	   (ArC),	  141.2	   (ArC),	  
137.2	  (ArC),	  137.1	  (ArC),	  133.1	  (ArC),	  128.6(1)	  (ArC),	  128.5(8)	  (ArC),	  128.5(6)	  (ArC),	  128.4(1)	  












(ArC),	  126.9	  (ArC),	  126.6(5)	  (ArC),	  83.0	  (Ar2CH),	  66.8	  (C-­‐2’),	  66.6	  (ArCH2),	  56.2	  (C-­‐2),	  55.2	  (C-­‐
2),	  46.7	  (C-­‐5),	  46.4	  (C-­‐5),	  34.8	  (C-­‐1’),	  34.1	  (C-­‐1’),	  31.0	  (C-­‐3),	  30.6	  (C-­‐3),	  24.0	  (C-­‐4),	  23.1	  (C-­‐4).	  
m/z	  (LC-­‐MS,	  ESI+)	  474	  (M(37Cl)Na+),	  472	  (M(35Cl)Na+);	  Accurate	  mass:	  Found	  MH+,	  450.1826:	  
C27H29NO335Cl	  requires	  M,	  450.1836.	  
	  
Benzyl	   (2S)-­‐2-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(S)-­‐168	  
	  
4-­‐Chlorophenyl(phenyl)methanol	   113	   and	   benzyl	   (2S)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐
carboxylate	  (S)-­‐133	  	  were	  reacted	  together	  under	  the	  same	  conditions	  as	  the	  synthesis	  of	  
benzyl	   (2R)-­‐2-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐
168.	  
	  
νmax	  (ATR)	  3031	  (w),	  2954	  (w),	  2874	  (w),	  1695	  (s),	  1489	  (m),	  1452	  (w),	  1409	  (s),	  1357	  (m),	  
1336	  (m),	  1185	  (w),	  1089	  (s),	  1029	  (w),	  1014	  (m).	  δH	  (700	  MHz,	  CDCl3)	  7.38	  –	  7.22	  (14H,	  m,	  
ArH),	  5.36	  –	  5.19	  (1H,	  m,	  Ar2CH),	  5.17	  –	  5.06	  (2H,	  m,	  ArCH2),	  4.07	  –	  3.96	  (1H,	  m,	  2-­‐H),	  3.54	  
–3.35	  (4H,	  m,	  5-­‐H2,	  	  2’-­‐H2),	  2.27	  –	  2.07	  (1H,	  m,	  1’-­‐HH’),	  2.00	  –	  1.90	  (1H,	  m,	  3-­‐HH’),	  1.90	  –	  
1.80	  (2H,	  m,	  4-­‐H2),	  1.80	  –	  1.72	  (1H,	  m,	  3-­‐HH’),	  1.71	  –	  1.57	  (1H,	  m,	  1’-­‐HH’);	  δC	  (176	  MHz,	  
CDCl3,	  mixture	  of	  diastereomers)	  155.1	   (CO),	  142.1(0)	   (ArC),	  141.9(9)	   (ArC),	  141.2	   (ArC),	  
141.1	  (ArC),	  137.2	  (ArC),	  133.2	  (ArC),	  133.1	  (ArC),	  128.6(1)	  (ArC),	  128.5(8)	  (ArC),	  128.5(7)	  
(ArC),	  128.3	  (ArC),	  128.0	  (ArC),	  127.9	  (ArC),	  127.7(3)	  (ArC),	  127.6(9)	  (ArC),	  127.0(2)	  (ArC),	  
126.9(7)	  (ArC),	  83.0(0)	  (Ar2CH),	  82.9(5)	  (Ar2CH),	  66.7	  (C-­‐2’),	  66.7	  (ArCH2),	  56.2	  (C-­‐2),	  55.2	  
(C-­‐2),	  46.5	  (C-­‐5),	  34.7	  (C-­‐1’),	  30.8	  (C-­‐3),	  23.2	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  474	  (M(37Cl)Na+),	  472	  


















To	  a	  0	  °C	  solution	  of	  benzyl	  (2R)-­‐2-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐
1-­‐carboxylate	  (R)-­‐168	  (305	  mg,	  0.68	  mmol)	  in	  THF	  (8	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4M	  
solution	  in	  THF,	  0.7	  mL,	  1.70	  mmol),	  before	  being	  heated	  to	  reflux	  for	  16h.	  The	  reaction	  
mixture	  was	  then	  cooled	  in	  an	  ice	  bath	  and	  any	  reactive	  salts	  were	  quenched	  according	  to	  
Fieser’s	  method	  (general	  procedure	  B).	  The	  crude	  product	  was	  purified	  by	  reversed	  phase	  
column	  chromatography	  (5%	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  title	  
compound	  (165	  mg,	  74%)	  as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  2955	  (w),	  1698	  (s),	  1599	  (w),	  1488	  (w),	  1453	  (w),	  1411	  (m),	  1357	  (w),	  1264	  (w),	  
1100	  (m),	  1045	  (w)	  cm-­‐1;	  δH	  (600	  MHz,	  CDCl3)	  7.35	  –	  7.23	  (9H,	  m,	  ArH),	  5.29	  (1H,	  s,	  Ar2CH),	  
3.55	  –	  3.49	  (1H,	  m,	  2’-­‐HH’),	  3.49	  –	  3.44	  (1H,	  m,	  2’-­‐HH’),	  3.18	  –	  3.08	  (1H,	  m,	  5-­‐HH’),	  2.34	  
(1.5H,	  s,	  NCH3),	  2.34	  (1.5H,	  s,	  NCH3),	  2.31	  –	  2.24	  (1H,	  m,	  2-­‐H),	  2.23	  –	  2.17	  (1H,	  m,	  5-­‐HH’),	  
2.14	  –	  2.07	  (1H,	  m,	  1’-­‐HH’),	  1.97	  –	  1.88	  (1H,	  m,	  3-­‐HH’),	  1.85	  –	  1.74	  (1H,	  m,	  4-­‐HH’),	  1.73	  –	  
1.65	  (1H,	  m,	  4-­‐HH’),	  1.65	  –	  1.57	  (1H,	  m,	  1’-­‐HH’),	  	  1.56	  –	  1.46	  (1H,	  m,	  3-­‐HH’);	  δC	  (151	  MHz,	  
CDCl3,	  mixture	  of	   diastereomers)	   142.1	   (ArC),	   142.0	   (ArC),	   141.1(9)	   (ArC),	   141.(6)	   (ArC),	  
133.2(4)	   (ArC),	  133.2(1)	   (ArC),	  128.6(4)	   (ArC),	  128.6(3)	   (ArC),	  128.6(0)	   (ArC),	  128.4	   (ArC),	  
128.3	  (ArC),	  127.8	  (ArC),	  127.7	  (ArC),	  127.0(2)	  (ArC),	  126.9(6)	  (ArC),	  83.2(4)	  (Ar2CH),	  83.2(2)	  
(Ar2CH),	  67.1(1)	  (C-­‐2’),	  67.0(7)	  (C-­‐2’),	  64.2	  (C-­‐2),	  57.2	  (C-­‐5),	  40.5	  (NCH3),	  33.8	  (C-­‐1’),	  30.9(4)	  
(C-­‐3),	   30.9(0)	   (C-­‐3),	   22.0(4)	   (C-­‐4),	   22.0(3)	   (C-­‐4).	  m/z	   (LC-­‐MS,	   ESI+)	   354	   (M(37Cl)Na+),	   352	  






















Benzyl	   (2S)-­‐2-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	   (S)-­‐
168	   	   was	   reduced	   under	   the	   same	   conditions	   as	   the	   synthesis	   of	   (2R)-­‐2-­‐{2-­‐[(4-­‐
chlorophenyl)(phenyl)methoxy]ethyl}-­‐1-­‐methylpyrrolidine	  (R)-­‐112.	  
	  
νmax	  (ATR)	  2921	  (w),	  1489	  (w),	  1088	  (w),	  1014	  (w).	  δH	  (700	  MHz,	  CDCl3)	  7.35	  –	  7.23	  (9H,	  m,	  
ArH),	  5.29	  (1H,	  s,	  Ar2CH),	  3.61	  –	  3.55	  (1H,	  m,	  2’-­‐HH’),	  3.51	  –	  3.44	  (1H,	  m,	  2’-­‐HH’),	  3.44	  –	  
3.35	  (1H,	  m,	  5-­‐HH’),	  2.75	  –	  2.60	  (1H,	  m,	  2-­‐H),	  2.57	  –	  2.49	  (3H,	  m,	  NCH3),	  2.48	  –	  2.39	  (1H,	  m,	  
5-­‐HH’),	  2.26	  –	  2.17	  (1H,	  m,	  1-­‐HH’),	  2.10	  –	  1.91	  (2H,	  m,	  3-­‐HH’,	  4-­‐HH’),	  1.90	  –	  1.76	  (2H,	  m,	  1’-­‐
HH’,	  4-­‐HH’),	  1.74	  –	  1.62	  (1H,	  m,	  3-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  141.8	  
(ArC),	  141.7	  (ArC),	  140.9	  (ArC),	  133.4(0)	  (ArC),	  133.3(6)	  (ArC),	  128.7(1)	  (ArC),	  128.6(9)	  (ArC),	  
128.6(7)	   (ArC),	  128.3(4)	   (ArC),	  128.2(8)	   (ArC),	  127.9(4)	   (ArC),	  127.8(9)	   (ArC),	  127.0	   (ArC),	  
126.9	  (ArC),	  83.4	  (Ar2CH),	  83.3	  (Ar2CH),	  66.5(3)	  (C-­‐2’),	  66.4(5)	  (C-­‐2’),	  65.3	  (C-­‐2),	  56.7	  (C-­‐5),	  
40.0	  (NCH3),	  32.4(7)	  (C-­‐1’),	  30.5(2)	  (C-­‐1’),	  30.4(3)	  (C-­‐3),	  21.9(2)	  (C-­‐4),	  21.8(9)	  (C-­‐4).	  m/z	  (LC-­‐
MS,	   ESI+)	   332	   (M(37Cl)H+),	   330	   (M(35Cl)H+);	   	   Accurate	   mass:	   Found	   MH+,	   330.1616:	  




General	   procedure	   A	   was	   used	   with	   bromobenzene	   (3.01	   mL,	   28.64	   mmol)	   and	   3-­‐
methoxybenzaldehyde	  (2.70	  mL,	  22.03	  mmol).	  The	  product	  was	  purified	  by	  flash	  column	  
chromatography	  (0%	  →	  30%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (2.99	  g,	  66%)	  


















νmax	  (ATR)	  3404	  (w),	  1597	  (m),	  1585	  (m),	  1487	  (m),	  1453	  (m),	  1435	  (m),	  1314	  (w),	  1255	  (s),	  
1186	  (w),	  1147	  (m),	  1021	  (s)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.40	  -­‐	  7.37	  (2H,	  m,	  ArH),	  7.36	  -­‐	  7.33	  
(2H,	  m,	  ArH),	  7.30	  –	  7.24	  (2H,	  m,	  ArH),	  6.98	  –	  6.95	  (2H,	  m,	  ArH),	  6.83	  –	  6.80	  (1H,	  m,	  ArH),	  
5.79	  (1H,	  s,	  Ar2CH),	  3.79	  (3H,	  s,	  CH3),	  2.45	  (1H,	  s,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  159.8	  (C-­‐3),	  145.6	  
(C-­‐1),	   143.8	   (C-­‐1’),	   129.6	   (ArC),	   128.6	   (ArC),	   127.7	   (ArC),	   126.6	   (ArC),	   119.0	   (ArC),	   113.1	  
(ArC),	  112.2	  (ArC),	  76.2	  (Ar2C),	  55.3	  (CH3).	  m/z	  (GC-­‐MS,	  EI)	  214	  (M+).	  	  
	  
Benzyl	   (2R)-­‐2-­‐{2-­‐[(3-­‐methoxyphenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐170	  
	  
General	  Procedure	  C	  was	  used	  with	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐
133	   (332	   mg,	   1.33	   mmol)	   and	   (3-­‐methoxyphenyl)(phenyl)methanol	   169	   (285	   mg,	   1.33	  
mmol)	  with	  the	  modification	  of	  AuCl	  (30	  mg,	  0.13	  mmol)	  as	  the	  catalyst	  in	  the	  place	  of	  PdCl2	  
with	   a	   reaction	   time	   of	   20	   h.	   The	   crude	   product	   was	   purified	   by	   flash	   column	  
chromatography	  (0%	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (171	  mg,	  29%)	  
as	  a	  yellow	  oil.	  
	  
νmax	  (ATR)	  2955	  (w),	  1697	  (w),	  1598	  (m),	  1492	  (m),	  1452	  (m),	  1259	  (m),	  1152	  (w),	  1075	  (w),	  
1040	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.40	  –	  7.28	  (9H,	  m,	  ArH),	  7.25	  -­‐	  7.20	  (2H,	  m,	  ArH),	  6.97	  
-­‐6.85	  (2H,	  s,	  ArH),	  6.80	  –	  6.76	  (1H,	  m,	  ArH),	  5.38	  -­‐	  5.28	  (0.5H,	  m,	  Ar2CH),	  5.27	  -­‐	  5.19	  (0.5H,	  
m,	  Ar2CH),	  5.18	  -­‐	  5.07	  (2H,	  m,	  ArCH2),	  4.09	  –	  3.98	  (1H,	  m,	  2-­‐H),	  3.77	  (3H,	  s,	  CH3),	  3.58	  –	  3.35	  
(4H,	  m,	  2’-­‐H2,	  5-­‐H2),	  2.28	  –	  2.19	  (0.5H,	  m,	  1’-­‐HH’),	  2.18	  –	  2.08	  (0.5H,	  m,	  1’-­‐HH’),	  1.99	  –	  1.92	  
(1H,	  m,	  4-­‐HH’),	  1.91	  –	  1.85	  (1H,	  m,	  3-­‐HH’),	  1.85	  -­‐	  1.76	  (2H,	  m,	  4-­‐HH’,	  3-­‐HH’),	  1.72-­‐1.56	  (1H,	  
m,	  1’-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  159.7(7)	  (C-­‐3Ph),	  159.7(6)	  (C-­‐3Ph),	  
155.0	  (CO),	  144.2(4)	  (C-­‐1Ph),	  144.1(5)	  (C-­‐1Ph),	  142.5	  (C-­‐1’Ph),	  142.4	  (C-­‐1’Ph),	  137.2	  (ArC),	  129.5	  
(ArC),	  129.4	  (ArC),	  128.5	  (ArC),	  128.4(4)	  (ArC),	  128.4(2)	  (ArC),	  127.9(1)	  (ArC),	  127.9(0)	  (ArC),	  
127.4(8)	   (ArC),	  127.4(5),	  126.9	   (ArC),	  119.5	   (ArC),	  112.8	   (ArC),	  112.7	   (ArC),	  83.6	   (Ar2CH),	  
















34.2	   (C-­‐1’),	   31.0	   (C-­‐3),	   30.7	   (C-­‐3),	   23.9	   (C-­‐4),	   23.1	   (C-­‐4).	  m/z	   (LC-­‐MS,	   ESI+)	   468	   (MNa+);	  
Accurate	  mass:	  Found	  MH+,	  446.2320:	  C28H32NO4	  requires	  M,	  446.2331.	  
(2R)-­‐2-­‐{2-­‐[(3-­‐methoxyphenyl)(phenyl)methoxy]ethyl}-­‐1-­‐methylpyrrolidine	  (R)-­‐144	  
	  
To	   a	   0	   °C	   solution	   of	   Benzyl	   (2R)-­‐2-­‐{2-­‐[(3-­‐
methoxyphenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐170	   (143	   mg,	   0.32	  
mmol)	  in	  THF	  (4	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4M	  solution	  in	  THF,	  0.33	  mL,	  0.80	  mmol),	  
before	  being	  heated	  to	  reflux	  for	  16h.	  The	  reaction	  mixture	  was	  then	  cooled	  in	  an	  ice	  bath	  
and	  any	  reactive	  salts	  were	  quenched	  according	  to	  Fieser’s	  method	  (general	  procedure	  B).	  
The	  crude	  product	  was	  purified	  by	   reversed	  phase	  column	  chromatography	   (5	  →	  100%	  
MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  title	  compound	  (104	  mg,	  40%)	  as	  a	  colourless	  
oil.	  	  
	  
νmax	  (ATR)	  2946	  (m),	  1599	  (m),	  1488	  (m),	  1454	  (m),	  1265	  (m),	  1154	  (w),	  1095	  (m),	  1049	  (m)	  
cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.35	  -­‐	  7.29	  (4H,	  m,	  ArH),	  7.25	  –	  7.21	  (2H,	  m,	  ArH),	  6.93	  –	  6.90	  
(2H,	  m,	  ArH),	  6.80	  –	  6.76	  (1H,	  m,	  ArH),	  5.29	  (1H,	  s,	  Ar2CH),	  3.78	  (3H,	  s,	  OCH3),	  3.57	  –	  3.51	  
(1H,	  m,	  2’-­‐HH’),	  3.51	  –	  3.45	  (1H,	  m,	  2’-­‐HH’),	  3.15	  –	  3.09	  (1H,	  m,	  5-­‐HH’),	  2.35	  (3H,	  s,	  NCH3),	  
2.32	  –	  2.24	  (1H,	  m,	  2-­‐H),	  2.22	  –	  2.16	  (1H,	  m,	  5-­‐HH’),	  2.15	  –	  2.09	  (1H,	  m,	  1’-­‐HH’),	  1.98	  –	  1.90	  
(1H,	  m,	  3-­‐HH’),	  1.84	  –	  1.75	  (1H,	  m,	  4-­‐HH’),	  1.73	  -­‐	  1.65	  (1H,	  m,	  4-­‐HH’),	  1.64	  –	  1.56	  (1H,	  m,	  
1’-­‐HH’),	  1.55	  –	  1.46	  (1H,	  m,	  3-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  159.8	  
(ArC),	  144.2(2)	  (ArC),	  144.2(0)	  (ArC),	  142.4(7)	  (ArC),	  142.4(3)	  (ArC),	  129.5	  (ArC),	  128.5	  (ArC),	  
127.6	   (ArC),	   127.5	   (ArC),	   127.0(3)	   (ArC),	   126.9(8)	   (ArC),	   119.5(2)	   (ArC),	   119.4(7)	   (ArC),	  
112.8(0)	  (ArC),	  112.7(6)	  (ArC),	  112.6(9)	  (ArC),	  112.6(5)	  (ArC),	  83.8	  (Ar2CH),	  67.1	  (C-­‐2’),	  64.2	  
(C-­‐2),	  57.2	  (C-­‐5),	  55.3	  (OCH3),	  40.5	  (NCH3),	  33.9	  (C-­‐1’),	  31.0	  (C-­‐3),	  22.0	  (C-­‐4).	  m/z	  (LC-­‐MS,	  


















General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.60	   mL,	   24.80	   mmol)	   and	   4-­‐
methoxybenzaldehyde	  (2.32	  mL,	  19.10	  mmol).	  The	  product	  was	  purified	  by	  flash	  column	  
chromatography	  (0%	  →	  80%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (1.73	  g,	  43%)	  
as	  a	  white	  solid.	  	  
	  
M.p.	  63	  –	  64	  °C	  (lit.:256	  63	  –	  64	  °C);	  νmax	  (ATR)	  3401	  (br,	  w),	  1610	  (m),	  1587	  (w),	  1510	  (s),	  
1494	  (s),	  1445	  (s),	  1304	  (w),	  1249	  (s),	  1239	  (s),	  1172	  (s),	  1110	  (w),	  1031	  (s),	  1018	  (s),	  1008	  
(s)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.40	  -­‐	  7.36	  (2H,	  m,	  ArH),	  7.36	  -­‐	  7.32	  (2H,	  m,	  ArH),	  7.32	  –	  7.26	  
(3H,	  m,	  ArH),	  6.89	  –	  6.86	  (2H,	  m,	  ArH),	  5.83	  –	  5.80	  (1H,	  m,	  Ar2CH),	  3.80	  –	  3.78	  (3H,	  m,	  CH3),	  
2.19	  –	  2.17	  (1H,	  m,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  159.2	  (ArC),	  144.2	  (ArC),	  136.3	  (ArC),	  128.6	  
(ArC),	  128.1	  (ArC),	  127.6	  (ArC),	  126.5	  (ArC),	  114.0	  (ArC),	  76.0	  (Ar2C),	  55.4	  (CH3).	  m/z	  (GC-­‐
MS,	  EI)	  214	  (M+).	  
	  
Benzyl	   (2R)-­‐2-­‐{2-­‐[(4-­‐methoxyphenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐172	  
	  
General	  Procedure	  C	  was	  used	  with	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐
133	  (332	  mg,	  1.33	  mmol)	  (257	  mg,	  1.03	  mmol)	  and	  (4-­‐methoxyphenyl)(phenyl)methanol	  
171	  (221	  mg,	  1.03	  mmol)	  with	  the	  modification	  of	  AuCl	  (30	  mg,	  0.13	  mmol)	  as	  the	  catalyst	  
in	  the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  The	  product	  was	  purified	  by	  flash	  column	  
chromatography	  (0	  →	  30%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (205	  mg,	  45%).	  
	  
νmax	  (ATR)	  2953	  (w),	  1698	  (s),	  1610	  (w),	  1510	  (s),	  1452	  (w),	  1412	  (s),	  1357	  (m),	  1303	  (w),	  



















7.27	  (10H,	  m,	  ArH),	  7.25	  -­‐	  7.21	  (1H,	  m,	  ArH),	  6.89	  -­‐	  6.85	  (1H,	  m,	  ArH),	  6.85	  –	  6.81	  (2H,	  m,	  
ArH),	  5.32	  –	  5.30	  (0.5H,	  m,	  Ar2CH),	  5.23	  –	  5.19	  (0.5H,	  m,	  Ar2CH),	  5.16	  -­‐	  5.07	  (2H,	  m,	  ArCH2),	  
4.07	  -­‐	  3.96	  (1H,	  m,	  2-­‐H),	  3.80–3.77	  (3H,	  m,	  CH3),	  3.54–3.32	  (4H,	  m,	  2’-­‐H2,	  5-­‐H2),	  2.25	  –	  2.18	  
(0.5H,	  m,	  1’-­‐HH’),	  2.15	  -­‐	  2.08	  (0.5H,	  m,	  1’-­‐HH’),	  1.97–	  1.90	  (1H,	  m,	  3-­‐HH’),	  1.90-­‐1.74	  (3H,	  m,	  
4-­‐H2,	  3-­‐HH’),	  1.70	  –	  1.64	  (1H,	  m,	  1’-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  
159.2	  (ArC),	  159.0	  (ArC),	  144.2	  (ArC),	  136.3	  (ArC),	  128.6	  (ArC),	  128.4(1)	  (ArC),	  128.3(6)	  (ArC),	  
128.0	  (ArC),	  127.9	  (ArC),	  127.6	  (ArC),	  127.3	  (ArC),	  126.9(4)	  (ArC),	  126.8(6)	  (ArC),	  126.5	  (ArC),	  
114.0	   (ArC),	   113.8(6)	   (ArC),	   113.8(5)	   (ArC),	   83.3	   (Ar2CH),	   83.2	   (Ar2CH),	   66.8	   (C-­‐2’),	   66.6	  
(CH2Ar),	  56.4	  (C-­‐2),	  55.4	  (CH3),	  46.7	  (C-­‐5),	  46.4	  (C-­‐5),	  34.8	  (C-­‐1’),	  34.1	  (C-­‐1’),	  31.0	  (C-­‐3),	  30.6	  
(C-­‐3),	  24.0	   (C-­‐4),	  23.2	   (C-­‐4).	  m/z	   (LC-­‐MS,	  ESI+)	  468	  (MNa+).	  Accurate	  mass:	  Found	  MNa+,	  




To	   a	   0	   °C	   solution	   of	   Benzyl	   (2R)-­‐2-­‐{2-­‐[(4-­‐
methoxyphenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	   (R)-­‐172	   (148	   mg,	   0.33	  
mmol)	  in	  THF	  (4	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4M	  solution	  in	  THF,	  0.35	  mL,	  0.83	  mmol),	  
before	  being	  heated	  to	  reflux	  for	  16h.	  The	  reaction	  mixture	  was	  then	  cooled	  in	  an	  ice	  bath	  
and	  any	  reactive	  salts	  were	  quenched	  according	  to	  Fieser’s	  method	  (general	  procedure	  B).	  
The	  crude	  product	  was	  purified	  by	   reversed	  phase	  column	  chromatography	   (5	  →	  100%	  
MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  title	  compound	  (47	  mg,	  44%)	  as	  a	  colourless	  
oil.	  
	  
νmax	  (ATR)	  2961	  (w),	  1611(w),	  1510	  (m),	  1453	  (w),	  1247	  (m),	  1172	  (w),	  1090	  (m),	  1031	  (m)	  
cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.32	  -­‐	  7.12	  (7H,	  m,	  ArH),	  6.83	  –	  6.77	  (2H,	  m,	  ArH),	  5.23	  (1H,	  s,	  
Ar2CH),	  3.72	  (3H,	  s,	  OCH3),	  3.55	  –	  3.49	  (1H,	  m,	  2’-­‐HH’),	  3.48	  –	  3.38	  (2H,	  m,	  2’-­‐HH’,	  5-­‐HH’),	  
2.77	  –	  2.69	  (1H,	  m,	  2-­‐H),	  2.50	  (3H,	  s,	  NCH3),	  2.47	  –	  2.40	  (1H,	  m,	  5-­‐HH’),	  2.21	  –	  2.12	  (1H,	  m,	  
1’-­‐HH’),	  2.05	  –	  1.96	  (1H,	  m,	  3-­‐HH’),	  1.95	  –	  1.85	  (1H,	  m,	  4-­‐HH’),	  1.82	  –	  1.71	  (2H,	  m,	  1’-­‐HH’,	  












(ArC),	  159.0(1)	  (ArC),	  142.5	  (ArC),	  142.4	  (ArC),	  134.3(4)	  (ArC),	  134.2(9)	  (ArC),	  128.4	  (ArC),	  
128.3	  (ArC),	  128.2	  (ArC),	  127.4(4)	  (ArC),	  127.3(9)	  (ArC),	  126.8	  (ArC),	  126.7	  (ArC),	  113.8	  (ArC),	  
83.5	  (Ar2C),	  83.4	  (Ar2C),	  66.1(0)	  (C-­‐2’),	  66.0(6)	  (C-­‐2’),	  65.0	  (C-­‐2),	  56.0	  (C-­‐5),	  55.3	  (OCH3),	  39.5	  
(NCH3),	  31.8(4)	  (C-­‐1’),	  31.8(1)	  (C-­‐1’),	  30.2(3)	  (C-­‐3),	  30.2(0)	  (C-­‐3),	  21.7	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  




General	   procedure	   A	   was	   used	   with	   bromobenzene	   (3.01	   mL,	   28.64	   mmol)	   and	   3-­‐
chlorobenzaldehyde	   (2.15	  mL,	   19.10	  mmol).	   The	   product	   was	   purified	   by	   flash	   column	  
chromatography	  (0%	  →	  30%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (700	  mg,	  17%)	  
as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  3335	  (br,	  m),	  3064	  (w),	  1596	  (m),	  1575	  (m),	  1495	  (m),	  1475	  (m),	  1454	  (m),	  1429	  
(m),	  1184	  (m),	  1021	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.41	  –	  7.22	  (9H,	  m,	  ArH),	  5.76	  (1H,	  s,	  
Ar2CH),	  2.48	  (1H,	  s,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  145.8	  (ArC),	  143.3	  (ArC),	  134.5	  (ArC),	  129.8	  
(ArC),	  128.8	  (ArC),	  128.0	  (ArC),	  127.7	  (ArC),	  126.7	  (ArC),	  124.7	  (ArC),	  75.8	  (Ar2C).	  m/z	  (LC-­‐
MS,	  ESI+)	  201	  (M(35Cl)–OH+),	  203	  (M(37Cl)–OH+).	  	  
	  
Benzyl	   (2R)-­‐2-­‐{2-­‐[(3-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐174	  
	  
General	  Procedure	  C	  was	  used	  with	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐
133	  (269	  mg,	  1.08	  mmol)	  and	  compound	  (3-­‐chlorophenyl)(phenyl)methanol	  	  173	  (237	  mg,	  
1.08	  mmol)	  with	  the	  modification	  of	  AuCl	  (25	  mg,	  0.11	  mmol)	  as	  the	  catalyst	  in	  the	  place	  
of	   PdCl2	  with	   a	   reaction	   time	  of	   20	   h.	   The	   crude	  product	  was	   purified	   by	   flash	   column	  
OH















chromatography	  (0	  →	  30%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  as	  a	  colourless	  
oil	  (172	  mg,	  38%).	  	  
	  
νmax	  (ATR)	  2950	  (w),	  2875	  (w),	  1695	  (s),	  1595	  (w),	  1574	  (w),	  1495	  (w),	  1454	  (w),	  1411	  (s),	  
1357	  (m),	  1335	  (w),	  1184	  (w),	  1100	  (s),	  1078	  (s),	  1029	  (w)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3,	  mixture	  
of	  diastereomers)	  7.42	   -­‐7.05	   (14H,	  m,	  ArH),	  5.31	   (0.5H,	   s,	  Ar2CH),	  5.21	  –	  5.17	   (0.5H,	  m,	  
Ar2CH),	  5.16	  –	  5.04	  (2H,	  m,	  OCH2),	  4.09	  –	  3.94	  (1H,	  m,	  2H),	  3.56	  –	  3.31	  (4H,	  m,	  2’-­‐H2,	  5-­‐H2),	  
2.21	  (0.5H,	  s,	  1’-­‐HH’),	  2.12	  (0.5H,	  s,	  1’-­‐HH’),	  1.99	  -­‐	  1.91	  (1H,	  m,	  3-­‐HH’),	  1.91	  –	  1.72	  (3H,	  m,	  
4-­‐H2,	  3-­‐HH’),	  1.71	   -­‐	  1.64	   (1H,	  m,	  1’-­‐HH’);	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  
155.1	  (CO),	  155.0	  (CO),	  144.8	  (ArC),	  141.9	  (ArC),	  137.3	  (ArC),	  137.1	  (ArC),	  134.4(0)	  (ArC),	  
134.3(7)	  (ArC),	  128.6(2)	  (ArC),	  128.6(0)	  (ArC),	  128.5(8)	  (ArC),	  128.0	  (ArC),	  127.9	  (ArC),	  127.8	  
(ArC),	   127.7	   (ArC),	   127.6	   (ArC),	   127.1	   (ArC),	   127.0	   (ArC),	   125.2	   (ArC),	   125.0	   (ArC),	   83.1	  
(Ar2CH),	  83.0	  (Ar2CH),	  	  67.1	  (C-­‐2’),	  66.9	  (ArCH2),	  66.7	  (ArCH2),	  66.6	  (C-­‐2’),	  56.3	  (C-­‐2),	  55.3	  
(C-­‐2),	  46.7	  (C-­‐5),	  46.4	  (C-­‐5),	  34.8	  (C-­‐1’),	  34.2	  (C-­‐1’),	  31.0	  (C-­‐3),	  30.7	  (C-­‐3),	  24.0	  (C-­‐4),	  23.2	  (C-­‐
4).	  m/z	  (LC-­‐MS,	  ESI+)	  450	  (M(35Cl)H+),	  452	  (M(37Cl)H+).	  Accurate	  mass:	  Found	  (M(35Cl)H+),	  




General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.60	   mL,	   24.80	   mmol)	   and	   4-­‐
fluorobenzaldehyde	   (2.05	  mL,	   19.10	  mmol).	   The	   product	   was	   purified	   by	   flash	   column	  
chromatography	  (0	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (3.82	  g,	  99%)	  as	  
a	  white	  solid.	  
	  
M.p.	  48–	  49	  °C	  (lit.:259	  48	  °C);	  νmax	  (ATR)	  3378	  (br,	  m),	  1602	  (m),	  1508	  (s),	  1494	  (s),	  1447	  (m),	  
1419	  (w),	  1335	  (w),	  1270	  (w),	  1227	  (s),	  1173	  (m),	  1159	  (m),	  1097	  (w),	  1014	  (s).	   	  δH	  (700	  
MHz,	  CDCl3)	  7.38	  –	  7.28	  (7H,	  m,	  ArH),	  7.04	  –	  7.00	  (2H,	  m,	  ArH),	  5.77	  (1H,	  s,	  Ar2CH),	  2.64	  
(1H,	  s,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  162.2	  (d,	  J	  =	  245.5	  Hz,	  C-­‐4),	  143.7	  (C-­‐1’),	  139.7	  (d,	  J	  =	  3.0	  
Hz,	  C-­‐1),	  128.7	  (ArC),	  128.3	  (d,	  J	  =	  8.0	  Hz,	  C-­‐2),	  127.8	  (ArC),	  126.6	  (ArC),	  115.4	  (d,	  J	  =	  21.5	  












Benzyl	   (2R)-­‐2-­‐{2-­‐[(4-­‐fluorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  
(R)-­‐176	  
	  
General	  Procedure	  C	  was	  used	  with	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐
133	  (250	  mg,	  1.00	  mmol)	  and	  (4-­‐fluorophenyl)(phenyl)methanol	  175	  (202	  mg,	  1.00	  mmol)	  
with	  the	  modification	  of	  AuCl	  (24	  mg,	  0.1	  mmol)	  as	  the	  catalyst	  in	  the	  place	  of	  PdCl2	  with	  a	  
reaction	  time	  of	  20	  h.	  	  	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  
→	  30%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (305	  mg,	  70%)	  as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  3032	  (w),	  2954	  (w),	  2875	  (w),	  1694	  (s),	  1604	  (w),	  1507	  (m),	  1409	  (s),	  1356	  (m),	  
1335	  (m),	  1220	  (m),	  1156	  (w),	  1089	  (s),	  1028	  (w),	  1014	  (w).	  	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  
diastereomers)	  7.38	  –	  7.20	  (7H,	  m,	  ArH),	  7.02	  –	  6.94	  (2H,	  m,	  3Ph-­‐H),	  5.36	  –	  5.31	  (0.5H,	  m,	  
Ar2CH),	  5.24	  –	  5.19	  (0.5H,	  m,	  Ar2CH),	  5.18	  –	  5.06	  (2H,	  m,	  OCH2Ar),	  4.08	  –	  3.96	  (1H,	  m,	  2-­‐H),	  
3.55	  –	  3.33	  (4H,	  m,	  2’-­‐H2,	  5-­‐H2),	  2.26	  –	  2.17	  (0.5H,	  m,	  1’-­‐HH’),	  2.16	  –	  2.08	  (0.5H,	  m,	  1’-­‐HH’),	  
2.00	  –	  1.90	  (1H,	  m,	  3-­‐HH’),	  1.90	  -­‐	  1.79	  (2H,	  m,	  4-­‐H2),	  1.79	  –	  1.72	  (1H,	  m,	  3-­‐HH’),	  1.71	  –	  1.56	  
(1H,	  m,	  1’	  -­‐	  HH’);	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  162.1(9)	  (C-­‐4Ph,	  d,	  J	  =	  242.5	  
Hz),	  162.1(7)	  (C-­‐4Ph,	  d,	  J	  =	  242.5	  Hz),	  155.1	  (CO),	  142.4	  (ArC),	  138.5	  (ArC),	  137.2	  (ArC),	  128.7	  
(C-­‐2Ph,	  d,	  J	  =	  8.3	  Hz),	  128.6	  (ArC),	  128.5(4)	  (ArC),	  128.5(3)	  (ArC),	  128.0	  (ArC),	  127.9	  (ArC),	  	  
127.6	  (ArC),	  127.0	  (ArC),	  126.9	  (ArC),	  115.2(8)	  (C-­‐3Ph,	  d,	  J	  =	  21.5	  Hz),	  115.2(5)	  (C-­‐3Ph,	  d,	  J	  =	  
21.5	  Hz),	  83.0	  (Ar2CH),	  66.8	  (C-­‐2’),	  66.6	  (ArCH2),	  56.3	  (C-­‐2),	  55.3	  (C-­‐2),	  46.7	  (C-­‐5),	  46.4	  (C-­‐5),	  
34.9	   (C-­‐1’),	  34.2	   (C-­‐1’),	  31.0	   (C-­‐3),	  30.6	   (C-­‐3),	  24.0	   (C-­‐4),	  23.1	   (C-­‐4).	  δF	   (376	  MHz,	  CDCl3,	  
mixture	  of	   rotamers)	   -­‐115.10-­‐	   -­‐115.62	   (m,	  4-­‐F).	  m/z	   (LC-­‐MS,	  ESI+)	  456	   (MNa+),	  Accurate	  























To	  a	  0	  °C	  solution	  of	  benzyl	  (2R)-­‐2-­‐{2-­‐[(3-­‐Fluorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐
1-­‐carboxylate	  (R)-­‐176	  (206	  mg,	  0.48	  mmol)	  in	  THF	  (7	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4M	  
solution	   in	   THF,	   0.50	  mL,	   1.19	  mmol),	   before	  being	  heated	  under	   reflux	  overnight.	   The	  
reaction	  mixture	  was	   then	   cooled	   in	   an	   ice	  bath	   and	  any	   reactive	   salts	  were	  quenched	  
according	   to	  Fieser’s	  method	   (general	  procedure	  B).	  The	  crude	  product	  was	  purified	  by	  
reversed	  phase	  column	  chromatography	  (5	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  
to	  afford	  title	  compound	  (74	  mg,	  49%)	  as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  2942,	  2870,	  2777,	  1604,	  1508,	  1454,	  1348,	  1294,	  1221,	  1184,	  1156,	  1090,	  1029,	  
1016.	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  7.35	  –	  7.23	  (7H,	  m,	  ArH),	  7.02	  –	  6.97	  
(2H,	  m,	  3Ph-­‐H2),	  5.31	  (1H,	  s,	  Ar2CH),	  3.55	  –	  3.49	  (1H,	  m,	  2’-­‐HH’),	  3.49	  –	  3.43	  (1H,	  m,	  2’-­‐HH’),	  
3.14	  –	  3.08	  (1H,	  m,	  5-­‐HH’),	  2.34	  (1.5H,	  s,	  NCH3),	  2.34	  (1.5H,	  s,	  NCH3),	  2.29	  –	  2.21	  (1H,	  m,	  2-­‐
H),	  2.21	  –	  2.15	  (1H,	  m,	  5-­‐HH’),	  2.14	  –	  2.06	  (1H,	  m,	  1’-­‐HH’),	  1.96	  –	  1.88	  (1H,	  m,	  3-­‐HH’),	  1.83	  
–	  1.73	  (1H,	  m,	  4-­‐HH’),	  1.72	  –	  1.64	  (1H,	  m,	  4-­‐HH’),	  1.63	  –	  1.55	  (1H,	  m,	  1’-­‐HH’),	  1.53	  –	  1.44	  
(1H,	  m,	  3-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  162.2(1)	  (C-­‐4Ph,	  d,	  J	  =	  245.3),	  
162.1(9)	   (C-­‐4Ph,	  d,	   J	  =	  245.3	  Hz),	  142.4	   (ArC),	  142.3	   (ArC),	  138.4(5)	   (C-­‐1Ph,	  d,	   J	  =	  3.0	  Hz),	  
138.4(2)	  (C-­‐1Ph,	  d,	  J	  =	  3.0	  Hz),	  	  128.7(0)	  (ArC),	  128.6(5)	  (ArC),	  128.5(9)	  (ArC),	  128.5(5)	  (ArC),	  
127.7	  (ArC),	  127.6	  (ArC),	  127.0	  (C-­‐2Ph,	  d,	  J	  =	  9.0	  Hz),	  115.3(0)	  (C-­‐3Ph,	  d,	  J	  =	  21.4	  Hz),	  115.2(9)	  
(C-­‐3Ph,	  d,	  J	  =	  21.4	  Hz),	  83.2	  (Ar2CH),	  66.1(0)	  (C-­‐2’),	  66.0(8)	  (C-­‐2’),	  64.1(2)	  (C-­‐2),	  64.1(1)	  (C-­‐2),	  
57.2	  (C-­‐5),	  40.5	  (CH3),	  33.9	  (C-­‐1’),	  31.0	  (C-­‐3),	  30.9	  (C-­‐3),	  22.1	  (C-­‐4).	  δF	  (376	  MHz,	  CDCl3)	  -­‐
115.3(2)	   (s,	   4-­‐F,	   isomer	   1),	   -­‐115.3(8)	   (s,	   4Ph-­‐F,	   isomer	   2).	  m/z	   (LC-­‐MS,	   ESI+)	   314	   (MH+).	  























General	   procedure	   A	   was	   used	   and	   the	   product	   was	   purified	   by	   flash	   column	  
chromatography	  (0%	  →	  40%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (2.99g,	  71%).	  
	  
M.p.	  46	  -­‐	  47	  °C	  (lit.:261	  47	  –	  49	  °C);	  νmax	  (ATR)	  3247	  (br,	  m),	  1603	  (m),	  1506	  (s),	  1416	  (w),	  
1326	  (w),	  1299	  (w),	  1218	  (s),	  1182	  (m),	  1155	  (m),	  1023	  (m),	  1011	  (m).	  δH	  (700	  MHz,	  CDCl3)	  
7.34	  –	  7.29	  (4H,	  m,	  2-­‐H),	  7.06	  –	  6.99	  (4H,	  m,	  3-­‐H),	  5.79	  (1H,	  s,	  Ar2CH).	  δC	  (176	  MHz,	  CDCl3)	  
162.4	  (C-­‐4,	  d,	  J	  =	  246.0	  Hz),	  139.5	  (C-­‐1,	  d,	  J	  =	  3.0	  Hz),	  128.3	  (C-­‐2,	  d,	  J	  =	  8.0	  Hz),	  115.5	  (C-­‐3,	  d,	  
J	  =	  21.5	  Hz),	  75.1	  (Ar2CH).	  δF	  (376	  MHz,	  CDCl3)	  -­‐114.70	  (4-­‐F).	  m/z	  (LC-­‐MS,	  ESI+)	  203	  (M–OH+).	  
Accurate	  mass:	  Found	  (M–OH+),	  203.0678:	  C13H9F2	  requires	  M,	  203.0672.	  
	  
Benzyl	  (2R)-­‐2-­‐{2-­‐[bis(4-­‐fluorophenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐178	  
	  
General	  Procedure	  C	  was	  used	  with	  (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐carboxylate	  (R)-­‐
133	  (150	  mg,	  0.60	  mmol)	  and	  bis(4-­‐fluorophenyl)methanol	  177	  (132	  mg,	  0.60	  mmol)	  with	  
the	  modification	  of	  AuCl	  (14	  mg,	  0.05	  mmol)	  as	  the	  catalyst	   in	  the	  place	  of	  PdCl2	  with	  a	  
reaction	  time	  of	  20	  h.	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  
→	  40%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (210	  mg,	  77%)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2956	  (w),	  2876	  (w),	  1694	  (s),	  1603	  (w),	  1506	  (s),	  1410	  (s),	  1357	  (m),	  1335	  (w),	  
1220	  (s),	  1182	  (w),	  1154	  (m),	  1088	  (s),	  1014	  (w).	  δH	  (700	  MHz,	  CDCl3)	  7.39	  -­‐	  7.28	  (5H,	  m,	  
ArH),	  7.27	  -­‐	  7.18	  (5H,	  m,	  ArH),	  7.06	  -­‐	  6.95	  (3H,	  m,	  ArH),	  5.34	  -­‐	  5.17	  (1H,	  m,	  Ar2CH),	  5.17	  -­‐	  
5.07	  (2H,	  m,	  ArCH2),	  4.04	  -­‐	  3.97	  (1H,	  m,	  2-­‐H),	  3.53	  -­‐	  3.41	  (3H,	  m,	  2’-­‐H2,	  5-­‐HH’),	  3.41-­‐3.35	  























m,	  3-­‐HH’),	  1.70	  -­‐	  1.54	  (1H,	  m,	  1’-­‐HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  rotamers)	  162.2(7)	  (C-­‐
4Ph,	  d,	  J	  =	  245.5	  Hz),	  162.2(5)	  (C-­‐4Ph,	  d,	  J	  =	  245.5	  Hz),	  155.1	  (CO),	  138.2	  (C-­‐1Ph),	  138.1	  (C-­‐1Ph),	  
137.2	  (ArC),	  128.7	  (ArC),	  128.7	  (C-­‐2Ph,	  d,	  J	  =	  9.0	  Hz),	  128.0	  (C-­‐2Ph,	  d,	  J	  =	  9.0	  Hz),	  128.5(8)	  
(ArC),	  128.0	   (ArC),	  127.9	   (ArC),	  115.5	   (C-­‐3Ph,	  d,	   J	   =	  21.5),	  115.3	   (C-­‐3Ph,	  d,	   J	  =	  21.5),	  82.3	  
(Ar2CH),	  66.7(5)	  (C-­‐2’),	  66.7(3)	  (ArCH2),	  46.5	  (C-­‐5),	  34.8	  (C-­‐1’),	  30.9	  (C-­‐3),	  23.5	  (C-­‐4).	  δF	  (376	  
MHz,	   CDCl3,	   mixture	   of	   rotamers)	   -­‐114.73-­‐	   -­‐115.41	   (m,	   4Ph-­‐F).	   	  m/z	   (LC-­‐MS,	   ESI+)	   474	  




To	   a	   0	   °C	   solution	   of	   Benzyl	   (2R)-­‐2-­‐{2-­‐[bis(4-­‐fluorophenyl)methoxy]ethyl}pyrrolidine-­‐1-­‐
carboxylate	   (R)-­‐178	   (210	  mg,	   0.47	  mmol)	   in	   THF	   (4	  mL)	  was	   slowly	   added	   LiAlH4	   (2.4M	  
solution	  in	  THF,	  0.49	  mL,	  1.18	  mmol),	  before	  being	  stirred	  at	  rt	  for	  4	  h.	  The	  reaction	  mixture	  
was	  then	  cooled	  in	  an	  ice	  bath	  and	  any	  reactive	  salts	  were	  quenched	  according	  to	  Fieser’s	  
method	   (general	   procedure	   B).116	   The	   crude	   product	   was	   purified	   by	   reversed	   phase	  
column	  chromatography	  (5	  →	  100%	  MeCN	  in	  H2O)	  to	  afford	  title	  compound	  (99	  mg,	  63%)	  
as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2946	  (w),	  2871	  (w),	  1603	  (w),	  1506	  (s),	  1220	  (s),	  1154	  (w),	  1086	  (w).	  δH	  (700	  MHz,	  
CDCl3)	  7.28	  -­‐	  7.24	  (4H,	  m,	  2Ph-­‐H),	  7.02	  -­‐	  6.98	  (4H,	  m,	  3Ph-­‐H),	  5.28	  (1H,	  s,	  Ar2CH),	  3.53	  -­‐	  3.49	  
(1H,	  m,	  2’-­‐HH’),	  3.46	  -­‐	  3.42	  (1H,	  m,	  2’-­‐HH’),	  3.21	  -­‐	  3.15	  (1H,	  m,	  5-­‐HH’),	  2.38	  (3H,	  s,	  CH3),	  2.37	  
-­‐	  2.32	  (1H,	  m,	  2-­‐H),	  2.29	  -­‐	  2.22	  (1H,	  m,	  5-­‐HH’),	  2.14	  -­‐	  2.09	  (1H,	  m,	  1-­‐HH’),	  1.97	  -­‐	  1.90	  (1H,	  
m,	  4-­‐HH’),	  1.87	  -­‐	  1.78	  (1H,	  m,	  3-­‐HH’),	  1.75	  -­‐	  1.62	  (2H,	  m,	  3-­‐HH’,	  1’-­‐HH’),	  1.58	  -­‐	  1.49	  (1H,	  m,	  
4-­‐HH’).	  δC	  (176	  MHz,	  CDCl3)	  162.2(6)	  (C-­‐4Ph,	  d,	  J	  =	  245.5	  Hz),	  162.2(4)	  (C-­‐4Ph,	  d,	  J	  =	  245.5	  Hz),	  
138.0(9)	  (C-­‐1Ph,	  d,	  J	  =	  3.0),	  138.0(6)	  (C-­‐1Ph,	  d,	  J	  =	  3.0),	  128.6(2)	  (C-­‐2Ph,	  d,	  J	  =	  8.0	  Hz),	  128.5(6)	  
(C-­‐2Ph,	  d,	  J	  =	  8.0	  Hz),	  115.4(1)	  (C-­‐3Ph,	  d,	  J	  =	  21.5),	  115.3(9)	  (C-­‐3Ph,	  d,	  J	  =	  21.5),	  82.5	  (Ar2CH),	  

















CDCl3)	   -­‐115.01-­‐	   -­‐115.11	   (m,	   4Ph-­‐F).	  m/z	   (LC-­‐MS,	   ESI+)	   332	   (MH+).	   Accurate	  mass:	   Found	  
(MH+),	  332.1828:	  C20H24F2NO	  requires	  M,	  332.1826.	  	  
	  
(2R)-­‐2-­‐(2-­‐chloroethyl)-­‐1-­‐methylpyrrolidine	  hydrochloride202	  (R)-­‐90	  
	  
To	  a	  solution	  of	  2-­‐[(2R)-­‐N-­‐methylpyrrolidin-­‐2’-­‐yl]ethan-­‐1’-­‐ol	  (R)-­‐108	  (77	  mg,	  0.59	  mmol)	  in	  
chloroform	  (1.2	  mL),	  a	  solution	  of	   thionyl	  chloride	   (0.12	  mL)	   in	  chloroform	  (0.4	  ml)	  was	  
added	  dropwise	  at	  0	  °C,	  and	  the	  resulting	  mixture	  was	  refluxed	  for	  2h	  and	  concentrated	  
under	  reduced	  pressure	  to	  afford	  the	  crude	  product	  as	  an	  brown	  oil.	  This	  was	  recrystalised	  
from	  ethanol-­‐diethylether	  to	  provide	  product	  (63	  mg,	  72%)	  as	  a	  brown	  solid.	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +47.0°	  (lit.:
233	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐49.8°).	  M.p.	  
126	  -­‐	  127	  °C	  (lit.202:	  119	  –	  121	  °C);	  νmax	  (ATR)	  3410	  (br,	  w),	  2959	  (w),	  2550	  (br,	  w),	  1495	  (w).	  
δH	  (700	  MHz,	  CDCl3)	  12.56	  –	  12.44	  (1H,	  s,	  N+H),	  3.92	  -­‐	  3.84	  (2H,	  m,	  5’-­‐HH’,	  1-­‐HH’),	  3.58	  -­‐	  
3.53	  (1H,	  m,	  1-­‐HH’),	  3.41	  -­‐	  3.34	  (1H,	  m,	  2’-­‐H),	  2.91	  -­‐	  2.85	  (1H,	  m,	  5’-­‐HH’),	  2.84	  (3H,	  d,	  J	  =	  5.0	  
Hz,	  CH3),	  2.57	  -­‐	  2.51	  (1H,	  m,	  2-­‐HH’),	  2.49	  -­‐	  2.42	  (1H,	  m,	  2-­‐HH’),	  2.38	  -­‐	  2.31	  (1H,	  m,	  3’-­‐HH’),	  
2.30	  -­‐	  2.23	  (1H,	  m,	  4’-­‐HH’),	  2.11	  -­‐	  2.03	  (1H,	  m,	  4’-­‐HH’),	  2.02	  -­‐	  1.95	  (1H,	  m,	  3’-­‐HH’).	  δC	  (176	  
MHz,	  CDCl3)	  66.6	  (C-­‐2’),	  56.4	  (C-­‐5’),	  41.7	  (C-­‐1),	  39.6	  (CH3),	  32.6	  (C-­‐2),	  29.4	  (C-­‐3’),	  21.7	  (C-­‐4’).	  




Et2Zn	  (2.4	  mL,	  3.6	  mmol)	  was	  added	  dropwise	  to	  a	  solution	  of	  phenylboronic	  acid	  (146	  mg,	  
1.2	  mmol)	  in	  toluene	  (3	  mL)	  under	  an	  argon	  atmosphere.	  After	  stirring	  for	  12	  h	  at	  60	  °C,	  
the	   mixture	   is	   cooled	   to	   0	   °C	   and	   a	   toluene	   solution	   of	   [(2R)-­‐1-­‐methylpyrrolidin-­‐2-­‐
yl]diphenylmethanol	  (27	  mg,	  0.1	  mmol)	  was	   introduced.	  The	  reaction	  was	  stirred	  for	  an	  
additional	   15	  min	   and	   the	   4-­‐chlorobenzaldehyde	   (70	  mg,	   0.5	  mmol)	   then	   added.	   After	  


















(3	   x	   5	  mL).	   The	   combined	   organic	   layers	   were	   dried	   over	  MgSO4,	   filtered,	   and	   solvent	  
evaporated.	  Purification	  by	  chromatography	  (10%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  desired	  
product	  (77	  mg,	  56%)	  as	  a	  white	  solid.	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐27.0	  °	  (lit.:	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐16	  °);	  95	  %	  ee	  
(determined	  by	  chiral	  HPLC	  analysis).	  νmax	  (ATR)	  3347	  (br,	  m),	  1489	  (s),	  1453	  (m),	  1089	  (s),	  
1012	  (s).	  δH	  (400	  MHz,	  CDCl3)	  7.41	  -­‐	  7.28	  (9H,	  m,	  ArH),	  5.81	  (1H,	  s,	  Ar2CH),	  2.42	  (1H,	  s,	  OH).	  
δC	  (101	  MHz,	  CDCl3)	  143.5	  (ArC),	  142.3	  (ArC),	  133.4	  (ArC),	  128.8	  (ArC),	  128.7	  (ArC),	  127.9(9)	  




Et2Zn	  (2.4	  mL,	  3.6	  mmol)	  was	  added	  dropwise	  to	  a	  solution	  of	  phenylboronic	  acid	  (146	  mg,	  
1.2	  mmol)	  in	  toluene	  (3	  mL)	  under	  an	  argon	  atmosphere.	  After	  stirring	  for	  12	  h	  at	  60	  °C,	  
the	   mixture	   is	   cooled	   to	   0	   °C	   and	   a	   toluene	   solution	   of	   [(2S)-­‐1-­‐methylpyrrolidin-­‐2-­‐
yl]diphenylmethanol	  (27	  mg,	  0.1	  mmol)	  was	   introduced.	  The	  reaction	  was	  stirred	  for	  an	  
additional	   15	  min	   and	   the	   4-­‐chlorobenzaldehyde	   (70	  mg,	   0.5	  mmol)	   then	   added.	   After	  
stirring	  for	  12	  h	  at	  0	  °C	  the	  reaction	  was	  quenched	  with	  H2O	  (2	  mL)	  and	  extracted	  with	  DCM	  
(3	   x	   5	  mL).	   The	   combined	   organic	   layers	   were	   dried	   over	  MgSO4,	   filtered,	   and	   solvent	  
evaporated.	  Purification	  by	  chromatography	  (10%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  desired	  
product	  (134	  mg,	  97%)	  as	  a	  white	  solid.	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +17.9	  °	  (lit.:
233	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +19°);	  96	  %	  ee	  
(determined	  by	  chiral	  HPLC	  analysis).	  νmax	  (ATR)	  3347	  (br,	  m),	  1489	  (s),	  1453	  (m),	  1089	  (s),	  














(2R)-­‐2-­‐(2-­‐[(S)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]ethyl)-­‐1-­‐methylpyrrolidine	  (R,	  S)-­‐112	  
	  
General	  procedure	  D	  was	  used	  in	  the	  reaction	  of	  (S)-­‐4-­‐chlorophenyl(phenyl)methanol	  (S)-­‐
113	   (105	  mg,	   0.38	  mmol)	   and	   (2R)-­‐2-­‐(2-­‐chloroethyl)-­‐1-­‐methylpyrrolidine	   (R)-­‐90	   (58	  mg,	  
0.39	  mmol).	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (0	  →	  100%	  EtOAc	  
in	  hexanes	  with	  1%	  NEt3)	  to	  afford	  the	  title	  compound	  as	  a	  colourless	  oil	  (27	  mg,	  22%).	  	  
	  
νmax	  (ATR)	  2943	  (w),	  2870	  (w),	  2776	  (w),	  1490	  (m),	  1453	  (w),	  1088	  (s),	  1015	  (m).	  δH	  (700	  
MHz,	  CDCl3)	  7.32	  –	  7.22	  (9H,	  m,	  ArH),	  5.28	  (1H,	  s,	  Ar2CH),	  3.51	  -­‐	  3.42	  (2H,	  m,	  2’-­‐H2),	  3.05	  -­‐	  
3.01	  (1H,	  m,	  5-­‐HH’),	  2.29	  (3H,	  s,	  CH3),	  2.17	  -­‐	  2.03	  (3H,	  m,	  1’-­‐HH’,	  2-­‐H,	  5-­‐HH’),	  1.91	  -­‐	  1.84	  
(1H,	  m,	  3-­‐HH’),	  1.77	  -­‐	  1.69	  (1H,	  m,	  4-­‐HH’),	  1.67	  -­‐	  1.60	  (1H,	  m,	  4-­‐HH’),	  1.56	  -­‐	  1.50	  (1H,	  m,	  1’-­‐
HH’),	  1.46	  -­‐	  1.40	  (1H,	  m,	  3-­‐HH’).	  δC	  (176	  MHz,	  CDCl3)	  142.1	  (ArC),	  141.3	  (ArC),	  133.2	  (ArC),	  
128.6(2)	  (ArC),	  128.5(9)	  (ArC),	  128.3	  (ArC),	  127.7	  (ArC),	  127.0	  (ArC),	  83.2	  (Ar2CH),	  67.3	  (C-­‐
2’),	  63.9	  (C-­‐2),	  57.3	  (C-­‐5),	  40.6	  (NCH3),	  34.2	  (C-­‐1’),	  31.1	  (C-­‐3),	  22.1	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  
330	   (M(35Cl)H+),	   332	   (M(37Cl)H+).	   Accurate	   mass:	   Found	   (MH+),	   330.1643:	   C20H25NO35Cl	  
requires	  M,	  330.1625.	  
	  
(2R)-­‐2-­‐{2-­‐[(R)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}-­‐1-­‐methylpyrrolidine	  (R,	  R)-­‐112	  
	  
General	  procedure	  D	  was	  followed	  in	  the	  reaction	  of	  (R)-­‐4-­‐chlorophenyl(phenyl)methanol	  
(R)-­‐113	  (120	  mg,	  0.43	  mmol)	  and	  (2R)-­‐2-­‐(2-­‐chloroethyl)-­‐1-­‐methylpyrrolidine	  (R)-­‐90	  (63mg,	  
0.43	  mmol).	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (0	  →	  100%	  EtOAc	  
in	  hexanes	  with	  1%	  NEt3)	  to	  afford	  title	  compound	  (R,	  R)-­‐112	  as	  a	  colourless	  oil	  (53	  mg,	  
































Rf	  =	  0.32	  (80%	  EtOAc	  in	  hexanes	  with	  1%	  NEt3).	  νmax	  (ATR)	  2943	  (w),	  2776	  (w),	  1489	  (w),	  
1453	  (w),	  1088	  (m),	  1015	  (m).	  δH	  (700	  MHz,	  CDCl3)	  7.32	  –	  7.29	  (4H,	  m,	  2Ph-­‐H,	  3Ph-­‐H),	  7.29	  –	  
7.22	  (5H,	  m,	  2’Ph-­‐H,	  3’Ph-­‐H,	  4’Ph-­‐H),	  5.28	  (1H,	  s,	  Ar2CH),	  3.53	  –	  3.48	  (1H,	  m,	  2’-­‐HH’),	  3.47	  -­‐	  
3.42	  (1H,	  m,	  2’-­‐HH’),	  3.08	  –	  3.01	  (1H,	  m,	  5-­‐HH’),	  2.30	  (3H,	  s,	  CH3),	  2.19	  –	  2.04	  (3H,	  m,	  1’-­‐
HH’,	  2-­‐H,	  5-­‐HH’),	  1.93	  –	  1.86	  (1H,	  m,	  3-­‐HH’),	  1.79	  –	  1.70	  (1H,	  m,	  4-­‐HH’),	  1.69	  -­‐	  	  1.61	  (1H,	  m,	  
4-­‐HH’),	  1.58	  –	  1.50	  (1H,	  m,	  1’-­‐HH’),	  1.49	  -­‐1.40	  (1H,	  m,	  3-­‐HH’).	  δC	  (151	  MHz,	  CDCl3)	  142.1	  
(ArC),	  141.2	  (ArC),	  133.2	  (ArC),	  128.6(0)	  (ArC),	  128.5(6)	  (ArC),	  128.4	  (ArC),	  127.7	  (ArC),	  127.0	  
(ArC),	  83.2	  (Ar2CH),	  67.3	  (C-­‐2’),	  63.9	  (C-­‐2),	  57.3	  (C-­‐5),	  40.6	  (CH3),	  34.1	  (C-­‐1’),	  31.0	  (C-­‐3),	  22.1	  
(C-­‐4).	  m/z	   (LC-­‐MS,	   ESI+)	   330	   (M(35Cl)H+),	   332	   (M(37Cl)H+).	   Accurate	  mass:	   Found	   (MH+),	  
330.1608:	  C20H25NO35Cl	  requires	  M,	  330.1625.	  
	  
(4S)-­‐4-­‐[(R)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]-­‐1-­‐methylazepane	  (S,	  R)-­‐179	  
	  
Rf	  =	  0.27	  (80%	  EtOAc	  in	  hexanes	  with	  1%	  NEt3).	  νmax	  (ATR)	  2936	  (w),	  1489	  (w).	  δH	  (700	  MHz,	  
CDCl3)	  7.32	  –	  7.22	  (9H,	  m,	  ArH),	  5.40	  (1H,	  s,	  Ar2CH),	  3.67	  –	  3.61	  (1H,	  m,	  1-­‐H),	  2.81	  -­‐	  2.72	  
(1H,	  m,	  3-­‐HH’),	  2.69	  –	  2.63	  (1H,	  m,	  4-­‐HH’),	  2.62	  –	  2.56	  (1H,	  m,	  4-­‐HH’),	  2.54	  –	  2.47	  (1H,	  m,	  
3-­‐HH’),	  2.36	  (3H,	  s,	  CH3),	  2.07	  –	  2.00	  (1H,	  m,	  2-­‐HH’),	  1.98	  –	  1.89	  (2H,	  m,	  2-­‐HH’,	  6-­‐HH’),	  1.85	  
–	  1.77	  (2H,	  m,	  6-­‐HH’,	  5-­‐HH’),	  1.60	  –	  1.52	  (1H,	  m,	  5-­‐HH’).	  δC	  (176	  MHz,	  CDCl3)	  142.5	  (ArC),	  
141.6	  (ArC),	  133.2	  (ArC),	  128.6(3)	  (ArC),	  128.5(8)	  (ArC),	  128.5	  (ArC),	  127.7	  (ArC),	  127.1	  (ArC),	  
79.9	  (Ar2CH),	  75.6	  (C-­‐1),	  58.9	  (C-­‐4),	  52.7	  (C-­‐3),	  47.0	  (CH3),	  33.1	  (C-­‐2),	  32.9	  (C-­‐6),	  23.0	  (C-­‐5).	  
m/z	  (LC-­‐MS,	  ESI+)	  330	  (M(35Cl)H+),	  332	  (M(37Cl)H+).	  Accurate	  mass:	  Found	  (MH+),	  330.1620:	  




2,1,3-­‐benzoxadiazole-­‐5-­‐carbaldehyde	  (296	  mg,	  2.00	  mmol)	  was	  dissolved	  in	  THF	  (2	  mL)	  and	  


























and	  the	  reaction	  mixture	  was	  warmed	  to	  rt	  and	  stirred	  for	  4	  h.	  The	  reaction	  was	  quenched	  
with	  NH4Cl	   (5	  mL)	  and	  the	  product	  was	  extracted	  with	  EtOAc	  (3	  x	  5	  mL)	  and	  dried	  over	  
MgSO4.	   The	   crude	   product	  was	   purified	   by	   column	   chromatography	   (0	  →	   40%	   Et2O	   in	  
hexanes)	  to	  afford	  the	  title	  compound	  (323	  mg,	  71%)	  as	  a	  red	  oil	  
	  
νmax	  (ATR)	  3408	  (br,	  m),	  3064	  (w),	  2878	  (w),	  1634	  (w),	  1539	  (w),	  1493	  (w),	  1453	  (m),	  1138	  
(m),	  1025	  (m)	  1040	  (m),	  1008	  (m).	  δH	  (700	  MHz,	  CDCl3)	  7.96	  –	  7.95	  (1H,	  m,	  2-­‐H),	  7.71	  (1H,	  
dd,	  J	  =	  9.5,	  1.5	  Hz,	  5-­‐H),	  7.40	  –	  7.37	  (4H,	  m,	  2’-­‐H,	  3’-­‐H),	  7.36	  –	  7.32	  (1H,	  m,	  4’-­‐H),	  7.29	  (1H,	  
dd,	  J	  =	  9.5,	  1.5	  Hz,	  6-­‐H),	  5.86	  (1H,	  s,	  Ar2CH),	  2.50	  (1H,	  s,	  OH).	  δC	  (176	  MHz,	  CDCl3)	  149.4	  (C-­‐
3),	  148.9	  (C-­‐4),	  147.3	  (C-­‐1),	  141.6	  (C-­‐1’),	  131.6	  (C-­‐6),	  129.2	  (C-­‐3’),	  128.8	  (C-­‐4’),	  127.1	  (C-­‐2’),	  
116.6	  (C-­‐5),	  112.1	  (C-­‐2),	  75.8	  (Ar2CH).	  m/z	  (LC-­‐MS,	  ESI+)	  227	  (MH+).	  Accurate	  mass:	  Found	  




4-­‐Formyl-­‐2,1,3-­‐benzoxadiazole	  (296	  mg,	  2.00	  mmol)	  was	  dissolved	  in	  THF	  (2	  mL)	  and	  put	  
on	  ice.	  Phenyl	  magnesium	  bromide	  (1.14	  mL,	  3.20	  mmol)	  was	  then	  added	  dropwise	  and	  
the	  reaction	  mixture	  was	  warmed	  to	  rt	  and	  stirred	  for	  4	  h.	  The	  reaction	  was	  quenched	  with	  
NH4Cl	  (5	  mL)	  and	  the	  product	  was	  extracted	  with	  EtOAc	  (3	  x	  5	  mL)	  and	  dried	  over	  MgSO4.	  
The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (0	  →	  40%	  Et2O	  in	  hexanes)	  to	  
afford	  the	  title	  compound	  as	  a	  red	  oil	  (244	  mg,	  54%).	  
	  
νmax	  (ATR)	  3399	  (br,	  m).	  δH	  (700	  MHz,	  CDCl3)	  7.71	  (1H,	  d,	  J	  =	  9.0	  Hz,	  6-­‐H),	  7.53	  –	  7.50	  (3H,	  
m,	  6’-­‐H,	  2’-­‐H),	  7.50–	  7.49	  (1H,	  m,	  4-­‐H),	  7.40	  (1H,	  dd,	  J	  =	  9.0,	  6.5	  Hz,	  5-­‐H),	  7.37	  –	  7.33	  (2H,	  
m,	  3’-­‐H,	  5’-­‐H),	  7.32	  –	  7.28	  (1H,	  m,	  4’-­‐H),	  6.31	  (1H,	  s,	  Ar2CH),	  2.90	  (1H,	  s,	  OH).	  δC	  (176	  MHz,	  
CDCl3)	  149.5	  (C-­‐3),	  147.7	  (C-­‐2),	  141.4	  (C-­‐1’),	  133.2	  (C-­‐1),	  131.7	  (C-­‐5),	  128.9	  (C-­‐3’,	  C-­‐5’),	  128.6	  
(C-­‐4’),	  127.0	  (C-­‐2’,	  C-­‐6’),	  126.7	  (C-­‐4),	  115.5	  (C-­‐6),	  73.1	  (Ar2CH).	  m/z	  (LC-­‐MS,	  ESI+)	  209	  (M–






















General	   procedure	   D	   was	   used	   in	   the	   reaction	   of	   (2,1,3-­‐benzoxadiazol-­‐5-­‐
yl)(phenyl)methanol	   161	   (90	   mg,	   0.40	   mmol)	   and	   (2R)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐
methylpyrrolidine	   (R)-­‐90	   (83	  mg,	   0.56	  mmol).	   The	   crude	   product	   was	   purified	   by	   flash	  
column	  chromatography	   (0	  →	  100%	  EtOAc	   in	  hexanes	  with	  1%	  NEt3)	   to	  afford	   the	   title	  
compound	  (R)-­‐159	  (23	  mg,	  16%)	  as	  a	  brown/orange	  oil	  and	  by-­‐product	  (S)-­‐164	  (12	  mg,	  9%)	  
as	  a	  brown	  oil.	  
	  
Rf	  =	  0.30	  (80%	  EtOAc	  in	  hexanes	  with	  1%	  NEt3).	  νmax	  (ATR)	  2947	  (w),	  1095	  (w).	  δH	  (600	  MHz,	  
CDCl3,	  mixture	  of	  diastereomers)	  7.88	  –	  7.85	  (1H,	  m,	  2Ph-­‐H),	  7.73	  -­‐	  7.69	  (1H,	  m,	  6Ph-­‐H),	  7.39	  
–	  7.34	  (4H,	  m,	  2’Ph-­‐H,	  3’Ph-­‐H),	  7.33	  –	  7.30	  (1H,	  m,	  4’Ph-­‐H),	  7.30	  –	  7.27	  (1H,	  m,	  5Ph-­‐H),	  5.35	  
(1H,	  s,	  Ar2CH),	  3.61	  –	  3.49	  (2H,	  m,	  2’-­‐H2),	  3.16	  –	  3.09	  (1H,	  m,	  5-­‐HH’),	  2.37	  (1.5H,	  s,	  CH3),	  
2.35	  (1.5H,	  s,	  CH3),	  2.32	  –	  2.24	  (1H,	  m,	  2-­‐H),	  2.23	  –	  2.17	  (1H,	  m,	  5-­‐HH’),	  2.16	  –	  2.08	  (1H,	  m,	  
1’-­‐HH’),	  2.01	  –	  1.87	  (1H,	  m,	  3-­‐HH’),	  1.84	  -­‐	  1.74	  (1H,	  m,	  4-­‐HH’),	  1.74	  –	  1.60	  (2H,	  m,	  4-­‐HH’,	  1’-­‐
HH’),	  1.58	  –	  1.45	  (1H,	  m,	  3-­‐HH’).	  δC	  (151	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  149.4	  (C-­‐
4Ph),	   149.0	   (C-­‐3Ph),	   146.4(2)	   (C-­‐1Ph),	   146.4(0)	   (C-­‐1Ph),	   139.9(3)	   (C-­‐1’Ph),	   139.8(8)	   (C-­‐1’Ph),	  
131.7(0)	  (C-­‐5Ph),	  131.6(7)	  (C-­‐5Ph),	  129.0	  (C-­‐2’Ph/C-­‐3’Ph),	  128.6	  (C-­‐4’Ph),	  128.5	  (C-­‐4’Ph),	  127.4	  
(C-­‐2’Ph/C-­‐3’Ph),	   127.3	   (C-­‐2’Ph/C-­‐3’Ph),	   116.5(8)	   (C-­‐6Ph),	   116.5(5)	   (C-­‐6Ph),	   112.6(3)	   (C-­‐2Ph),	  
112.5(5)	  (C-­‐2Ph),	  83.2	  (Ar2CH),	  83.1	  (Ar2CH),	  67.4	  (C-­‐2’),	  67.3	  (C-­‐2’),	  64.2	  (C-­‐2),	  64.1	  (C-­‐2),	  
57.2	  (C-­‐5),	  40.6	  (CH3),	  33.8(1)	  (C-­‐1’),	  33.7(5)	  (C-­‐1’),	  31.0(3)	  (C-­‐3),	  30.8(8)	  (C-­‐3),	  22.0(8)	  (C-­‐4),	  
22.0(5)	   (C-­‐4).	   m/z	   (LC-­‐MS,	   ESI+)	   338	   (MH+).	   Accurate	   mass:	   Found	   (MH+),	   338.1881:	  






























Rf	  =	  0.26	  (80%	  EtOAc	  in	  hexanes	  with	  1%	  NEt3).	  νmax	  (ATR)	  2935	  (w),	  1065	  (w).	  δH	  (600	  MHz,	  
CDCl3)	  7.85	  –	  7.82	  (1H,	  m,	  2Ph-­‐H),	  7.70	  (1H,	  dd,	  J	  =	  9.5,	  1.0	  Hz,	  6Ph-­‐H),	  7.37	  –	  7.34	  (4H,	  m,	  
2’Ph-­‐H,	  3’Ph-­‐H),	  7.33	  –	  7.28	  (2H,	  m,	  5Ph-­‐H),	  5.47	  -­‐	  5.46	  (1H,	  m,	  Ar2CH),	  3.76	  –	  3.69	  (1H,	  m,	  1-­‐
H),	  2.81	  –	  2.73	  (1H,	  m,	  3-­‐H/4-­‐H),	  2.71	  –	  2.57	  (2H,	  m,	  3-­‐H/4-­‐H),	  2.56	  –	  2.48	  (1H,	  m,	  3-­‐H/4-­‐
H),	  2.38	  (3H,	  s,	  CH3),	  2.15	  –	  1.78	  (2H,	  m,	  2-­‐H2,	  6-­‐H2,	  5-­‐HH’),	  1.63	  –	  1.53	  (1H,	  m,	  5-­‐HH’).	  δC	  
(151	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  149.3(9)	  (C-­‐4Ph),	  149.3(9)	  (C-­‐4Ph),	  149.0	  (C-­‐3Ph),	  
146.9(0)	   (C-­‐1Ph),	   146.8(6)	   (C-­‐1Ph),	   140.3(8)	   (C-­‐1’Ph),	   140.3(5)	   (C-­‐1’Ph),	   131.9(3)	   (C-­‐5Ph),	  
131.9(2)	  (C-­‐5Ph),	  128.9(4)	  (C-­‐3’Ph),	  128.9(2)	  (C-­‐3’Ph),	  128.5	  (C-­‐4’Ph),	  128.4	  (C-­‐4’Ph),	  127.4(0)	  
(C-­‐2’Ph),	  127.3(6)	  (C-­‐2’Ph),	  116.5(2)	  (C-­‐6Ph),	  116.4(9)	  (C-­‐6Ph),	  112.7(1)	  (C-­‐2Ph),	  112.6(5)	  (C-­‐2Ph),	  
80.0	  (Ar2CH),	  79.9	  (Ar2CH),	  76.1	  (C-­‐1),	  60.0	  (C-­‐3/C-­‐4),	  58.9	  (C-­‐3/C-­‐4),	  52.7	  (C-­‐3/C-­‐4),	  47.1	  
(CH3),	  33.0	  (C-­‐2/C-­‐6),	  32.5	  (C-­‐2/C-­‐6),	  23.0	  (C-­‐5).	  m/z	  (LC-­‐MS,	  ESI+)	  338	  (MH+).	  Accurate	  mass:	  




General	   Procedure	   C	   was	   followed	   with	   2-­‐bromoethanol	   (0.1	   mL,	   1.41	   mmol)	   and	   (4-­‐
chlorophenyl)(phenyl)methanol	  113	  (218	  mg,	  1.00	  mmol)	  with	  the	  modification	  of	  AuCl	  (24	  
mg,	  0.14	  mmol)	  as	  the	  catalyst	  in	  the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  The	  product	  
was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  20	  %	  EtOAc	  in	  hexanes)	  to	  afford	  the	  
title	  compound	  (282	  mg,	  87%)	  as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  2858	  (w),	  1490	  (m),	  1453	  (w),	  1276	  (w),	  1185	  (w),	  1089	  (m),	  1029	  (w),	  1015	  (m)	  



























Ar2CH),	  3.82	  –	  3.74	  (2H,	  m,	  2’-­‐H),	  3.53	  (2H,	  t,	  J	  =	  6.0	  Hz,	  1’-­‐H).	  δC	  (176	  MHz,	  CDCl3)	  141.3	  
(ArC),	  140.5	  (ArC),	  133.5	  (ArC),	  128.7(2)	  (ArC),	  128.7(1)	  (ArC),	  128.4(5)	  (ArC),	  128.0	  (ArC),	  
127.1	  (ArC),	  83.4	  (Ar2CH),	  69.1	  (C-­‐2’),	  30.7	  (C-­‐1’).	  m/z	  (LC-­‐MS,	  ESI+)	  347	  (M(35Cl)(79Br)	  Na+),	  




1-­‐[(2-­‐Bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	   180	   (117	   mg,	   0.36	   mmol)	   is	  
dissolved	   in	  MeCN	  (3	  mL)	  and	  pyrollidine	   (0.04	  mL,	  0.43	  mmol)	  and	  K2CO3	   (69	  mg,	  0.50	  
mmol)	  are	  added.	  The	  reaction	  is	  heated	  to	  60	  °C	  and	  left	  to	  stir	  overnight.	  The	  reaction	  
was	  extracted	  with	  EtOAc	  (3	  x	  5	  mL)	  and	  washed	  with	  H2O	  (5	  mL)	  and	  dried	  over	  Na2SO4.	  
The	  crude	  product	  was	  purified	  by	   reversed	  phase	  column	  chromatography	   (5	  →	  100%	  
MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  the	  title	  compound	  (61	  mg,	  54%)	  as	  a	  yellow	  
oil.	  	  
	  
νmax	  (ATR)	  2962	  (w),	  2787	  (w),	  1490	  (m),	  1453	  (w),	  1088	  (s),	  1015	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  
CDCl3)	  7.33	  –	  7.23	  (9H,	  m,	  ArH),	  5.35	  (1H,	  s,	  Ar2CH),	  3.62	  (2H,	  t,	  J	  =	  6.0	  Hz,	  2’-­‐H2),	  2.82	  (2H,	  
t,	  J	  =	  6.0	  Hz,	  1’-­‐H2),	  2.66	  –	  2.61	  (4H,	  m,	  2-­‐H2,	  5-­‐H2),	  1.82	  –	  1.76	  (4H,	  m,	  3-­‐H2,	  4-­‐H2).	  δC	  (176	  
MHz,	   CDCl3)	   141.8	   (ArC),	   141.0	   (ArC),	   133.3	   (ArC),	   128.6(2)	   (ArC),	   128.5(9)	   (ArC),	   128.4	  
(ArC),	  127.8	  (ArC),	  127.1	  (ArC),	  83.4	  (Ar2CH),	  68.2	  (C-­‐2’),	  55.7	  (C-­‐1’),	  54.8	  (C-­‐2,	  C-­‐5),	  23.6	  (C-­‐
3,	   C-­‐4).	   m/z	   (LC-­‐MS,	   ESI+)	   316	   (M(35Cl)H+),	   318	   (M(37Cl)H+).	   Accurate	   mass:	   Found	  



















Methyl	   (2S)-­‐1-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐2-­‐carboxylate	  
(S)-­‐150	  
	  
1-­‐[(2-­‐Bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	   180	   (170	   mg,	   0.52	   mmol)	   is	  
dissolved	  in	  MeCN	  (5	  mL)	  and	  L-­‐proline	  methyl	  ester	  hydrochloride	  (104	  mg,	  0.63	  mmol)	  
and	  K2CO3	  (144	  mg,	  1.04	  mmol)	  are	  added.	  The	  reaction	  is	  heated	  to	  60	  °C	  and	  left	  to	  stir	  
overnight.	  The	  reaction	  was	  extracted	  with	  EtOAc	  (3	  x	  5	  mL)	  and	  washed	  with	  H2O	  (5	  mL)	  
and	   dried	   over	   Na2SO4.	   The	   crude	   product	   was	   purified	   by	   reversed	   phase	   column	  
chromatography	   (5	   →	   100%	   MeCN	   in	   H2O	   with	   0.1%	   formic	   acid)	   to	   afford	   the	   title	  
compound	  (104	  mg,	  54%)	  as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  2950	  (w),	  1732	  (m),	  1489	  (m),	  1452	  (w),	  1435	  (w),	  1262	  (w),	  1170	  (m),	  1087	  (s),	  
1014	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.32	  –	  7.20	  (9H,	  m,	  ArH),	  5.31	  (0.5H,	  s,	  Ar2CH),	  5.30	  
(0.5H,	  s,	  Ar2CH),	  3.61	  –	  3.56	  (2H,	  m,	  2’-­‐H2),	  3.55	  (3H,	  s,	  OCH3),	  3.42	  –	  3.33	  (1H,	  m,	  2-­‐H),	  3.24	  
–	  3.15	  (1H,	  m,	  1’-­‐HH’),	  3.01	  –	  2.91	  (1H,	  m,	  5-­‐HH’),	  2.89	  –	  2.80	  (1H,	  m,	  5-­‐HH’),	  2.61	  –	  2.49	  
(1H,	  m,	  1’-­‐HH’),	  2.19	  –	  2.09	  (1H,	  m,	  3HH’),	  1.95	  –	  1.84	  (2H,	  m,	  4H2),	  1.84	  –	  1.75	  (1H,	  m,	  
3HH’).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  174.5(4)	  (CO),	  174.4(9)	  (CO),	  141.9	  
(ArC),	  141.0(2)	  (ArC),	  141.0(0)	  (ArC),	  133.3	  (ArC),	  133.2	  (ArC),	  128.6(1)	  (ArC),	  128.5(9)	  (ArC),	  
128.5(6)	  (ArC),	  128.5(5)	  (ArC),	  128.5	  (ArC),	  128.3	  (ArC),	  127.8	  (ArC),	  127.7	  (ArC),	  127.1	  (ArC),	  
126.9	  (ArC),	  83.4	  (Ar2CH),	  68.1	  (C-­‐2’),	  65.9	  (C-­‐2),	  54.5(1)	  (C-­‐5),	  54.4(9)	  (C-­‐5),	  54.0	  (C-­‐1’),	  53.9	  
(C-­‐1’),	  51.7(8)	  (OCH3),	  51.7(7)	  (OCH3),	  29.7	  (C-­‐3),	  29.6	  (C-­‐3),	  23.3	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  
396.105	  (M(35Cl)Na+),	  398.016	  (M(37Cl)Na+).	  Accurate	  mass:	  Found	  (M(35Cl)H+),	  374.1516:	  























Methyl	   (2R)-­‐1-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐2-­‐carboxylate	  
(R)-­‐150	  	  
	  
1-­‐[(2-­‐Bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  180	  (462	  mg,	  1.42	  mmol)	  is	  dissolved	  
in	  MeCN	  (7	  mL)	  and	  D-­‐proline	  methyl	  ester	  hydrochloride	  (282	  mg,	  1.70	  mmol)	  and	  K2CO3	  
(471	  mg,	  3.41	  mmol)	  are	  added.	  The	  reaction	  is	  heated	  to	  60	  °C	  and	  left	  to	  stir	  overnight.	  
The	  reaction	  was	  extracted	  with	  EtOAc	  (3	  x	  10	  mL)	  and	  washed	  with	  H2O	  (10	  mL)	  and	  dried	  
over	  Na2SO4.	  The	  crude	  product	  was	  purified	  by	  reversed	  phase	  column	  chromatography	  
(5	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid)	  to	  afford	  the	  title	  compound	  (161	  mg,	  30%)	  
as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  2950	  (w),	  2870	  (w),	  1733	  (m),	  1489	  (m),	  1455	  (w),	  1435	  (w),	  1196	  (m),	  1169	  (m),	  
1087	  (s),	  1072	  (m),	  1012	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.32	  –	  7.20	  (9H,	  m,	  ArH),	  5.31	  –	  5.29	  
(1H,	  m,	  Ar2CH),	  3.58	  –	  3.53	  (5H,	  m,	  2’-­‐H2,	  OCH3),	  3.35	  –	  3.30	  (1H,	  m,	  2-­‐H),	  3.21	  –	  3.16	  (1H,	  
m,	  1’-­‐HH’),	  2.97	  –	  2.91	  (1H,	  m,	  5-­‐H),	  2.84	  –	  2.78	  (1H,	  m,	  5-­‐H),	  2.53	  –	  2.46	  (1H,	  m,	  1’-­‐HH’),	  
2.15	  –	  2.06	  (1H,	  m,	  3-­‐HH’),	  1.93	  –	  1.83	  (2H,	  m,	  4-­‐H2),	  1.81	  –	  1.74	  (1H,	  m,	  3-­‐HH’).	  δC	  (176	  
MHz,	   CDCl3,	   mixture	   of	   diastereomers)	   174.6(8)	   (CO),	   174.6(5)	   (CO),	   141.8(8)	   (ArC),	  
141.8(5)	  (ArC),	  141.1	  (ArC),	  141.0	  (ArC),	  133.2	  (ArC),	  133.1	  (ArC),	  128.5(7)	  (ArC),	  128.5(5)	  
(ArC),	  128.5(2)	  (ArC),	  128.5(0)	  (ArC),	  128.4	  (ArC),	  128.3	  (ArC),	  127.7(3)	  (ArC),	  127.6(5)	  (ArC),	  
127.1	  (ArC),	  126.9	  (ArC),	  83.3	  (Ar2CH),	  68.2(1)	  (C-­‐2’),	  68.1(8)	  (C-­‐2’),	  65.9(4)	  (C-­‐2),	  65.9(2)	  (C-­‐
2),	  54.5	  (C-­‐5),	  54.0(3)	  (C-­‐1’),	  53.9(9)	  (C-­‐1’),	  51.7	  (OCH3),	  29.7	  (C-­‐3),	  29.6	  (C-­‐3),	  23.4(0)	  (C-­‐4),	  
23.3(9)	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  396.343	  (M(35Cl)Na+),	  398.256	  (M(37Cl)Na+).	  Accurate	  mass:	  

























To	  a	  0	  °C	  solution	  of	  methyl	  (2S)-­‐1-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐
2-­‐carboxylate	   (S)-­‐150	  (50	  mg,	  0.13	  mmol)	   in	  THF	  (2	  mL)	  was	  slowly	  added	  LiAlH4	  (2.4	  M	  
solution	  in	  THF,	  0.14	  mL,	  0.33	  mmol),	  before	  being	  warmed	  to	  rt	  and	  stirred	  for	  3h.	  The	  
reaction	  mixture	  was	   then	   cooled	   in	   an	   ice	  bath	   and	  any	   reactive	   salts	  were	  quenched	  
according	  to	  Fieser’s	  method	  (general	  procedure	  B).	  The	  product	  was	  purified	  by	  reversed	  
phase	  column	  chromatography	  (5	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid).	  	  To	  afford	  
the	  title	  compound	  (22.5	  mg,	  50%)	  as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  3408	  (br,	  w),	  2870	  (w),	  1490	  (m),	  1088	  (s)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.34	  -­‐	  7.23	  
(9H,	  m,	  ArH),	  5.33	  (1H,	  s,	  Ar2CH),	  3.65	  –	  3.60	  (1H,	  m,	  HOCHH’),	  3.58	  –	  3.52	  (2H,	  m,	  2’-­‐H2),	  
3.41	  –	  3.36	  (1H,	  m,	  HOCHH’),	  3.21	  –	  3.14	  (1H,	  m,	  5–HH’),	  3.10	  –	  3.02	  (1H,	  m,	  1’-­‐HH’),	  2.77	  
–	  2.69	  (1H,	  m,	  2-­‐H),	  2.66	  –	  2.59	  (1H,	  m,	  1-­‐HH’),	  2.42	  –	  2.34	  (1H,	  m,	  5-­‐HH’),	  1.90	  –	  1.82	  (1H,	  
m,	  4-­‐HH’),	  1.77	  –	  1.68	  (3H,	  m,	  4-­‐HH’,	  3-­‐H2).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  
141.8(3)	   (ArC),	   141.7(7)	   (ArC),	   141.0	   (ArC),	   140.9	   (ArC),	   133.3(3)	   (ArC),	   133.3(1)	   (ArC),	  
128.7(0)	   (ArC),	   128.6(7)	   (ArC),	   128.3(2)	   (ArC),	   128.3(0)	   (ArC),	   127.9	   (ArC),	   127.8	   (ArC),	  
127.0(0)	  (ArC),	  126.9(5)	  (ArC),	  83.5(2)	  (Ar2CH),	  83.4(9)	  (Ar2CH),	  68.2(4)	  (C-­‐2’),	  68.1(9)	  (C-­‐2’),	  
65.2	  (C-­‐2),	  62.6	  (CH2OH),	  62.5	  (CH2OH),	  55.2	  (C-­‐5),	  55.1	  (C-­‐5),	  54.3(6)	  (C-­‐1’),	  54.3(5)	  (C-­‐1’),	  
27.6	  (C-­‐3),	  24.1	  (C-­‐4).	  m/z	  (LC-­‐MS,	  ESI+)	  368	  (M(35Cl)Na+),	  370	  (M(37Cl)Na+).	  Accurate	  mass:	  




To	  a	  0	  °C	  solution	  of	  methyl	  (2R)-­‐1-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}pyrrolidine-­‐





























solution	  in	  THF,	  0.31	  mL,	  0.75	  mmol),	  before	  being	  warmed	  to	  rt	  and	  stirred	  for	  3h.	  The	  
reaction	  mixture	  was	   then	   cooled	   in	   an	   ice	  bath	   and	  any	   reactive	   salts	  were	  quenched	  
according	  to	  Fieser’s	  method	  (general	  procedure	  B).	  The	  product	  was	  purified	  by	  reversed	  
phase	  column	  chromatography	  (5	  →	  100%	  MeCN	  in	  H2O	  with	  0.1%	  formic	  acid).	  	  To	  afford	  
the	  title	  compound	  (64	  mg,	  62%)	  as	  a	  yellow	  oil.	  	  
	  
νmax	  (ATR)	  3392	  (br,	  w),	  2946	  (w),	  2870	  (w),	  1489	  (m),	  1453	  (w),	  1403	  (w),	  1295	  (w),	  1185	  
(w),	  1086	  (s),	  1028	  (m),	  1014	  (s)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.35	  -­‐	  7.23	  (9H,	  m,	  ArH),	  5.35	  
(1H,	  s,	  Ar2CH),	  3.68	  –	  3.63	  (1H,	  m,	  HOCHH’),	  3.63	  –	  3.56	  (2H,	  m,	  2’-­‐H2),	  3.45	  –	  3.40	  (1H,	  m,	  
HOCHH’),	  3.27	  –	  3.18	  (1H,	  m,	  5–HH’),	  3.14	  –	  3.06	  (1H,	  m,	  1’-­‐HH’),	  2.85	  –	  2.75	  (1H,	  m,	  2-­‐H),	  
2.71	  –	  2.65	  (1H,	  m,	  1-­‐HH’),	  2.48	  –	  2.38	  (1H,	  m,	  5-­‐HH’),	  1.93	  –	  1.85	  (1H,	  m,	  4-­‐HH’),	  1.81	  –	  
1.70	  (3H,	  m,	  4-­‐HH’,	  3-­‐H2).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  141.7	  (ArC),	  141.6	  
(ArC),	   140.9	   (ArC),	   140.8	   (ArC),	   133.4	   (ArC),	   133.3	   (ArC),	   128.6(9)	   (ArC),	   128.6(8)	   (ArC),	  
128.6(6)	  (ArC),	  128.3(2)	  (ArC),	  128.2(8)	  (ArC),	  127.9	  (ArC),	  127.8	  (ArC),	  127.0	  (ArC),	  126.9	  
(ArC),	   83.5(3)	   (Ar2CH),	   83.5(1)	   (Ar2CH),	   67.9(5)	   (C-­‐2’),	   67.8(9)	   (C-­‐2’),	   65.7	   (C-­‐2),	   62.4(1)	  
(CH2OH),	  62.3(8)	  (CH2OH),	  55.1(8)	  (C-­‐5),	  55.1(6)	  (C-­‐5),	  54.5	  (C-­‐1’),	  27.5	  (C-­‐3),	  24.1	  (C-­‐4).	  m/z	  
(LC-­‐MS,	   ESI+)	   368	   (M(35Cl)Na+),	   370	   (M(37Cl)Na+).	   Accurate	   mass:	   Found	   (M(35Cl)H+),	  





1-­‐[(2-­‐bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	   180	   (160	   mg,	   0.49	   mmol)	   in	   DMF	  
(0.8	  mL)	  was	  added	  dropwise	  to	  a	  suspension	  of	  the	  (R)-­‐methoxymethylpyrrolidine	  (0.06	  
mL,	  0.49	  mmol),	  KI	  (8.3	  mg,	  0.08	  mmol)	  and	  K2CO3	  (135	  mg,	  0.98	  mmol)	  in	  DMF	  (0.5	  mL).	  
The	  reaction	  mixture	  was	  stirred	  at	  rt	   for	  4	  h.	  Following	  the	  addition	  of	  H2O	  (5	  mL)	  and	  
extraction	  with	  EtOAc	  (3	  x	  5mL),	  the	  combined	  organic	  layers	  were	  dried	  over	  Na2SO4	  and	  
concentrated	  in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (10%	  


















νmax	  (ATR)	  2871	  (w),	  2810	  (w),	  1489	  (m),	  1453	  (w),	  1185	  (w),	  1088	  (s),	  1015	  (m).	  δH	  (700	  
MHz,	  CDCl3)	  7.33	  –	  7.23	  (9H,	  m,	  ArH),	  5.37	  (1H,	  s,	  Ar2CH),	  3.74	  –	  3.57	  (2H,	  m,	  2’-­‐H2),	  3.56	  -­‐	  
3.41	  (1H,	  m,	  1-­‐HH’),	  3.37	  –	  3.29	  (4H,	  m,	  CH3,	  1-­‐HH’),	  3.29	  –	  3.11	  (2H,	  m,	  1’-­‐HH’,	  5-­‐HH’),	  2.95	  
–	  2.60	  (2H,	  m,	  1’-­‐HH’,	  2-­‐H),	  2.58	  –	  2.32	  (1H,	  m,	  5-­‐HH’),	  1.97	  –	  1.86	  (1H,	  m,	  3-­‐HH’),	  1.86	  –	  
1.70	   (2H,	   m,	   4-­‐H2),	   1.70	   –	   1.57	   (1H,	   m,	   3-­‐HH’).	   δC	   (176	   MHz,	   CDCl3,	   mixture	   of	  
diastereomers)	  141.8	  (ArC),	  141.7	  (ArC),	  141.0	  (ArC),	  140.9	  (ArC),	  133.3	  (ArC),	  133.2	  (ArC),	  
128.6(3)	  (ArC),	  128.6(1)	  (ArC),	  128.5(9)	  (ArC),	  128.4(4)	  (ArC),	  128.3(8)	  (ArC),	  127.8(2)	  (ArC),	  
127.7(7)	  (ArC),	  127.1	  (ArC),	  127.0	  (ArC),	  83.4	  (Ar2CH),	  75.4	  (C-­‐1),	  67.8	  (C-­‐2’),	  64.3	  (C-­‐2),	  59.2	  
(CH3),	   55.6	   (C-­‐5),	   55.5	   (C-­‐5),	   54.9	   (C-­‐1’),	   28.0	   (C-­‐3),	   23.2	   (C-­‐4).	  m/z	   (LC-­‐MS,	   ESI+)	   382	  
(M(35Cl)Na+),	   384	   (M(37Cl)Na+).	   Accurate	   mass:	   Found	   (MH+),	   360.1734:	   C21H27NO235Cl	  
requires	  M,	  360.1730.	  
	  
(2S)-­‐1-­‐{2-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}-­‐2-­‐(methoxymethyl)pyrrolidine	  	  	  	  	  	  
(S)-­‐153	  
	  
1-­‐[(2-­‐bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	   180	   (160	   mg,	   0.49	   mmol)	   in	   DMF	  
(0.8	  mL)	  was	  added	  dropwise	  to	  a	  suspension	  of	  the	  (S)-­‐methoxymethylpyrrolidine	  (0.06	  
mL,	  0.49	  mmol),	  KI	  (8.3	  mg,	  0.08	  mmol)	  and	  K2CO3	  (135	  mg,	  0.98	  mmol)	  in	  DMF	  (0.5	  mL).	  
The	  reaction	  mixture	  was	  stirred	  at	  rt	   for	  4	  h.	  Following	  the	  addition	  of	  H2O	  (5	  mL)	  and	  
extraction	  with	  EtOAc	  (3	  x	  5mL),	  the	  combined	  organic	  layers	  were	  dried	  and	  concentrated	  
in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (10%	  MeOH	  in	  
CHCl3)	  to	  afford	  the	  title	  compound	  (68	  mg,	  39	  %)	  as	  a	  brown	  oil.	  
	  
νmax	  (ATR)	  2871	  (w),	  2811	  (w),	  1489	  (m),	  1452	  (w),	  1185	  (m),	  1087	  (s),	  1014	  (m).	  δH	  (700	  
MHz,	  CDCl3)	  7.33	  -­‐	  7.30	  (4H,	  m,	  ArH),	  7.30	  –	  7.26	  (4H,	  m,	  ArH),	  7.26	  -­‐7.23	  (1H,	  m,	  ArH),	  5.36	  
(1H,	  s,	  Ar2CH),	  3.67	  -­‐	  3.55	  (2H,	  m,	  2’-­‐H2),	  3.53	  -­‐	  3.38	  (1H,	  m,	  1-­‐HH’),	  3.33	  –	  3.27	  (4H,	  m,	  CH3,	  
1-­‐HH’),	  3.25	  –	  3.14	  (2H,	  m,	  1’-­‐HH’,	  5-­‐HH’),	  2.80	  -­‐	  2.63	  (2H,	  m,	  1’-­‐HH’,	  2-­‐H),	  2.45	  –	  2.30	  (1H,	  

















δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  141.9	  (ArC),	  141.8	  (ArC),	  141.1	  (ArC),	  141.0	  
(ArC),	  133.2(2)	  (ArC),	  133.1(9)	  (ArC),	  128.5(9)	  (ArC),	  128.5(8)	  (ArC),	  128.5(7)	  (ArC),	  128.5(6),	  
128.4(2)	   (ArC),	   128.3(8)	   (ArC),	   127.8	   (ArC),	   127.7	   (ArC),	   127.1	   (ArC),	   127.0	   (ArC),	   83.3	  
(Ar2CH),	  75.8	  (C-­‐1),	  68.2	  (C-­‐2’),	  64.2	  (C-­‐2),	  59.2	  (CH3),	  55.5(1)	  (C-­‐5),	  55.4(5)	  (C-­‐5),	  54.9	  (C-­‐
1’),	  28.1	  (C-­‐3),	  23.2	  (C-­‐4).	  m/z	   (LC-­‐MS,	  ESI+)	  382	  (M(35Cl)Na+),	  384	  (M(37Cl)Na+).	  Accurate	  




1-­‐[(2-­‐bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  180	  (326	  mg,	  1.03	  mmol)	  in	  DMF	  (1	  
mL)	  was	   added	  dropwise	   to	   a	   suspension	  of	   the	   (R)-­‐2-­‐methyl-­‐pyrrolidine	   hydrochloride	  
(125	  mg,	  1.03	  mmol),	  KI	  (17	  mg,	  0.10	  mmol)	  and	  K2CO3	  (285	  mg,	  2.06	  mmol)	  in	  DMF	  (1.5	  
mL).	  The	  reaction	  mixture	  was	  stirred	  at	  rt	  for	  24	  h.	  Following	  the	  addition	  of	  H2O	  (5	  mL)	  
and	   extraction	   with	   EtOAc	   (3	   x	   5	   mL),	   the	   combined	   organic	   layers	   were	   dried	   and	  
concentrated	  in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (10%	  
MeOH	  in	  CHCl3)	  to	  afford	  the	  title	  compound	  (217	  mg,	  65	  %)	  as	  a	  brown	  oil.	  
	  
νmax	  (ATR)	  2962	  (w),	  2869	  (w),	  2786	  (w),	  1490	  (m),	  1453	  (w),	  1375	  (w),	  1185	  (w),	  1088	  (s)	  
1015	  (m).	  δH	  (700	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  7.33	  –	  7.23	  (9H,	  m,	  ArH),	  5.36	  (1H,	  
s,	  Ar2H),	  3.62	  –	  3.55	  (2H,	  m,	  2’-­‐H2),	  3.16	  –	  3.11	  (1H,	  m,	  5-­‐HH’),	  3.09	  –	  3.03	  (1H,	  m,	  1’-­‐HH’),	  
2.44	  -­‐	  2.38	  (1H,	  m,	  5-­‐HH’),	  2.38	  –	  2.31	  (1H,	  m,	  2-­‐H),	  2.24	  –	  2.16	  (1H,	  m,	  1’	  –HH’),	  1.93	  –	  1.85	  
(1H,	  m,	  3-­‐HH’),	  1.80	  –	  1.62	  (2H,	  m,	  4-­‐H2),	  1.43	  –	  1.34	  (1H,	  m,	  3-­‐HH’),	  1.09	  (1.5H,	  d,	  J	  =	  6.0	  
Hz,	  CH3),	   1.08	   (1.5H,	  d,	   J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  
142.0(2)	   (ArC),	   141.9(6)	   (ArC),	   141.2	   (ArC),	   141.1	   (ArC),	   133.2(2)	   (ArC),	   133.1(9)	   (ArC),	  
128.6(2)	  (ArC),	  128.5(7)	  (ArC),	  128.5	  (ArC),	  128.4	  (ArC),	  127.8	  (ArC),	  127.7	  (ArC),	  127.1(0)	  
(ArC),	  127.0(6)	  (ArC),	  83.4	  (Ar2CH),	  68.6(0)	  (C-­‐2’),	  68.5(6)	  (C-­‐2’),	  60.4(3)	  (C-­‐2),	  60.4(0)	  (C-­‐2),	  
55.0	  (C-­‐5),	  54.9	  (C-­‐5),	  53.5	  (C-­‐1’),	  53.4	  (C-­‐1’),	  32.6	  (C-­‐3),	  22.0	  (C-­‐4),	  19.2	  (CH3).	  m/z	  (LC-­‐MS,	  
ESI+)	   330	   (M(35Cl)Na+),	   332	   (M(37Cl)Na+).	   Accurate	   mass:	   Found	   (M(35Cl)H+),	   330.1630:	  


















1-­‐[(2-­‐bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  180	  (310	  mg,	  0.95	  mmol)	  in	  DMF	  (1	  
mL)	  was	   added	   dropwise	   to	   a	   suspension	   of	   the	   (S)-­‐2-­‐methyl-­‐pyrrolidine	   hydrochloride	  
(115	  mg,	  0.95	  mmol),	  KI	  (17	  mg,	  0.10	  mmol)	  and	  K2CO3	  (263	  mg,	  1.90	  mmol)	  in	  DMF	  (1.5	  
mL).	  The	  reaction	  mixture	  was	  stirred	  at	  rt	  for	  24	  h.	  Following	  the	  addition	  of	  H2O	  (5	  mL)	  
and	   extraction	   with	   EtOAc	   (3	   x	   5	   mL),	   the	   combined	   organic	   layers	   were	   dried	   and	  
concentrated	  in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (10%	  
MeOH	  in	  CHCl3)	  to	  afford	  the	  title	  compound	  (195	  mg,	  62	  %)	  as	  a	  brown	  oil.	  
	  
νmax	  (ATR)	  2962	  (w),	  2869	  (w),	  2785	  (w),	  1489	  (m),	  1453	  (w),	  1375	  (w),	  1293	  (w),	  1184	  (w),	  
1087	  (s),	  1014	  (m).	  δH	  (700	  MHz,	  CDCl3)	  7.32	  -­‐	  7.22	  (9H,	  m,	  ArH),	  5.36	  (1H,	  s,	  Ar2CH),	  3.65	  –	  
3.55	  (2H,	  m,	  2’-­‐H2),	  3.20	  –	  3.13	  (1H,	  m,	  5-­‐HH’),	  3.10	  –	  3.04	  (1H,	  m,	  1’-­‐HH’),	  2.47	  –	  2.35	  (2H,	  
m,	  5-­‐HH’,	  2-­‐H),	  2.28	  –	  2.20	  (1H,	  m,	  1’	  –HH’),	  1.94	  –	  1.85	  (1H,	  m,	  3-­‐HH’),	  1.81	  -­‐	  1.72	  (1H,	  m,	  
4-­‐HH’),	  1.71	  –	  1.63	  (1H,	  m,	  4-­‐HH’),	  1.46	  –	  1.36	  (1H,	  m,	  3-­‐HH’),	  1.10	  (3H,	  d,	  J	  =	  6.0,	  CH3).	  δC	  
(176	  MHz,	   CDCl3,	  mixture	   of	   diastereomers)	   141.9(3)	   (ArC),	   141.8(6)	   (ArC),	   141.1	   (ArC),	  
141.0	  (ArC),	  133.2(2)	   (ArC),	  133.1(9)	   (ArC),	  128.6(0)	   (ArC),	  128.5(8)	   (ArC),	  128.5(5)	   (ArC),	  
128.4(2)	   (ArC),	   128.3(8)	   (ArC),	   127.8	   (ArC),	   127.7	   (ArC),	   127.1	   (ArC),	   127.0	   (ArC),	   83.4	  
(Ar2CH),	  68.3(2)	  (C-­‐2’),	  68.2(9)	  (C-­‐2’),	  60.5(9)	  (C-­‐2),	  60.5(6)	  (C-­‐2),	  54.9	  (C-­‐5),	  54.8	  (C-­‐5),	  53.4	  
(C-­‐1’),	  53.3	  (C-­‐1’),	  32.5	  (C-­‐3),	  32.4	  (C-­‐3),	  22.0(0)	  (C-­‐4),	  21.9(9)	  (C-­‐4),	  18.9(3)	  (CH3),	  18.9(1)	  
(CH3).	   m/z	   (LC-­‐MS,	   ESI+)	   330	   (M(35Cl)Na+),	   332	   (M(37Cl)Na+).	   Accurate	   mass:	   Found	  

























General	   Procedure	   C	   was	   followed	   with	   2-­‐bromoethanol	   (0.1	   mL,	   1.41	   mmol)	   and	   (4-­‐
fluorophenyl)(phenyl)methanol	  175	  (300	  mg,	  1.48	  mmol)	  with	  the	  modification	  of	  AuCl	  (35	  
mg,	  0.15	  mmol)	  as	  the	  catalyst	  in	  the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  3	  h.	  The	  product	  
was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  20	  %	  EtOAc	  in	  hexanes)	  to	  afford	  the	  
title	   compound	   contaminated	   with	   20%	   fluorodiphenylmethane	   and	   16%	   4-­‐
fluorobenzophenone	  (272	  mg,	  62%)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  3030	  (w),	  2858	  (w),	  1660	  (w),	  1603	  (m),	  1507	  (s),	  1452	  (m),	  1276	  (w),	  1221	  (s),	  
1184	   (w),	   1156	   (m),	   1096	   (m),	   1014	   (m).	   δH	   (400	   MHz,	   CDCl3,	   shows	   20%	  
fluorodiphenylmethane,	  16%	  4-­‐fluorobenzophenone)	  7.38	  –	  7.27	  (7H,	  m,	  ArH),	  7.06	  –	  7.01	  
(2H,	  m,	  3-­‐H),	  5.43	  (1H,	  s,	  Ar2CH),	  3.79	  (2H,	  td,	  J	  =	  6.0,	  2.5	  Hz,	  2’-­‐H2),	  3.53	  (2H,	  t,	  J	  =	  6.0	  Hz,	  
1’-­‐H2)	   δC	   (176	   MHz,	   CDCl3,	   shows	   20%	   fluorodiphenylmethane,	   16%	   4-­‐
fluorobenzophenone)	  162.4	  (d,	  J	  =	  246.0	  Hz,	  C-­‐4),	  141.5	  (ArC),	  137.7	  (d,	  J	  =	  3.0	  Hz,	  C-­‐1),	  
128.8	  (d,	  J	  =	  8.0	  Hz,	  C-­‐2),	  128.7	  (ArC),	  128.0	  (ArC),	  127.1	  (ArC),	  115.4	  (d,	  J	  =	  21.5	  Hz,	  C-­‐3),	  
83.4	  (Ar2C),	  69.0	  (C-­‐2’),	  30.7	  (C-­‐1’).	  δF	  (376	  MHz,	  CDCl3,	  shows	  20%	  fluorodiphenylmethane,	  





1-­‐[(2-­‐Bromoethoxy)(phenyl)methyl]-­‐4-­‐fluorobenzene	  181	  (151	  mg,	  0.49	  mmol)	  in	  DMF	  (0.8	  
mL)	  was	  added	  dropwise	  to	  a	  suspension	  of	  the	  (R)-­‐2-­‐methyl-­‐pyrrolidine	  hydrochloride	  (60	  
mg,	  0.49	  mmol),	  KI	  (8.3	  mg,	  0.08	  mmol)	  and	  K2CO3	  (135	  mg,	  0.98	  mmol)	  in	  DMF	  (0.5	  mL).	  





























extraction	  with	  EtOAc	  (3	  x	  5	  mL),	  the	  combined	  organic	  layers	  were	  dried	  and	  concentrated	  
in	  vacuo.	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (10%	  MeOH	  in	  
CHCl3)	  to	  afford	  the	  title	  compound	  as	  a	  brown	  oil	  (56	  mg,	  35	  %).	  
	  
νmax	  (ATR)	  2962	  (m),	  2870	  (w),	  2786	  (w),	  1604	  (m),	  1508	  (s),	  1454	  (m),	  1376	  (w),	  1295	  (w),	  
1222	  (s),	  1156	  (m),	  1089	  (s),	  1015	  (w).	  δH	  (700	  MHz,	  CDCl3)	  7.34	  –	  7.29	  (6H,	  m,	  ArH),	  7.27	  –	  
7.23	  (1H,	  m,	  ArH),	  7.02	  –	  6.97	  (2H,	  m,	  3Ph-­‐H),	  5.38	  (1H,	  s,	  Ar2CH),	  3.67	  –	  3.57	  (2H,	  m,	  2’-­‐HH),	  
3.22	  –	  3.16	  (1H,	  m,	  5-­‐HH’),	  3.13	  –	  3.06	  (1H,	  m,	  1’-­‐HH’),	  2.51	  –	  2.40	  (2H,	  m,	  5-­‐HH’,	  2-­‐H),	  2.33	  
–	  2.24	  (1H,	  m,	  1’-­‐HH’),	  1.96	  –	  1.86	  (1H,	  m,	  3-­‐HH’),	  1.83	  –	  1.75	  (1H,	  m,	  4-­‐HH’),	  1.73	  –	  1.66	  
(1H,	  m,	  4-­‐HH’),	  1.48	  –	  1.38	  (1H,	  m,	  3-­‐HH’),	  1.13	  (3H,	  d,	  J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3,	  
mixture	  of	  diastereomers)	  162.2(3)	  (C-­‐4Ph,	  d,	  J	  =	  245.5	  Hz),	  162.2(0)	  (C-­‐4Ph,	  d,	  J	  =	  245.5	  Hz),	  
142.2	  (ArC),	  142.1	  (ArC),	  138.2(6)	  (C-­‐1Ph,	  d,	  J	  =	  3.0	  Hz),	  138.2(4)	  (C-­‐1Ph,	  d,	  J	  =	  3.0	  Hz),	  128.7(3)	  
(C-­‐2Ph,	  d,	  J	  =	  16.5	  Hz),	  128.7(3)	  (ArC),	  128.6	  (ArC),	  128.5	  (ArC),	  127.7	  (ArC),	  127.6	  (ArC),	  127.1	  
(ArC),	   127.0	   (ArC),	   115.3(0)	   (C-­‐3Ph,	   d,	   J	   =	   21.5	  Hz),	   115.2(7)	   (C-­‐3Ph,	   d,	   J	   =	   21.5	  Hz),	   83.4	  
(Ar2CH),	   68.1	   (C-­‐2’),	   60.7	   (C-­‐2),	   54.8(2)	   (C-­‐5),	   54.7(8)	   (C-­‐5),	   53.3(4)	   (C-­‐1’),	   53.3(2)	   (C-­‐1’),	  
32.4(2)	  (C-­‐3),	  32.4(1)	  (C-­‐3),	  22.0	  (C-­‐4),	  18.8	  (CH3).	  δF	  (376	  MHz,	  CDCl3)	  -­‐115.30	  (s,	  4-­‐F,	  isomer	  
1),	  -­‐115.36	  (s,	  4-­‐F,	   isomer	  2).	  m/z	  (LC-­‐MS,	  ESI+)	  314	  (MH+).	  Accurate	  mass:	  Found	  (MH+),	  




2-­‐Bromoethanol	  (0.23	  mL,	  3.20	  mmol)	  in	  dry	  MeCN	  (2	  mL)	  was	  added	  dropwise	  to	  a	  mixture	  
of	   (R)-­‐2-­‐methylpyrrolidine	   (415mg,	   3.32	  mmol)	   and	   K2CO3	   (918	  mg,	   6.64	  mmol)	   in	   dry	  
MeCN	  (2	  mL)	  heated	  under	  reflux.	  After	  15	  h	  the	  mixture	  was	  cooled	  to	  rt,	   filtered	  and	  
concentrated.	  Et2O	  (5	  mL)	  was	  then	  added	  and	  the	  product	  extracted	  with	  1M	  HCl	  (2	  x	  5	  
mL).	  The	  aqueous	  phase	  was	  made	  basic	  with	  solid	  NaOH,	  then	  extracted	  with	  DCM	  (3	  x	  5	  
mL).	  The	  organic	  layers	  were	  combined,	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated	  to	  
















	  [α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐58.8°.	  νmax	  (ATR)	  3385	  (br,	  m),	  2963	  (m),	  2875	  (m),	  2806	  
(m),	  1677	  (m),	  1416	  (m),	  1509	  (m).	  δH	  (400	  MHz,	  CDCl3)	  4.03	  –	  3.86	  (3H,	  m,	  2-­‐H2,	  5’-­‐HH’),	  
3.42	  –	  3.35	  (1H,	  m,	  1-­‐HH’),	  3.33	  –	  3.23	  (1H,	  m,	  2’-­‐H),	  3.01	  –	  2.91	  (2H,	  m,	  1-­‐HH’,	  5’-­‐HH’),	  2.29	  
–	  2.18	  (2H,	  m,	  3’-­‐HH’,	  4-­‐HH’),	  2.08	  –	  1.98	  (1H,	  m,	  4-­‐HH’),	  1.97	  -­‐	  1.87	  (2H,	  m,	  3’-­‐HH’),	  1.54	  
(3H,	  d,	  J	  =	  6.5	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  64.6	  (C-­‐2’),	  57.6	  (C-­‐2),	  57.2	  (C-­‐5’),	  54.6	  (C-­‐1),	  
31.4	   (C-­‐3’),	   21.7	   (C-­‐4’),	   15.9	   (CH3).	  m/z	   (LC-­‐MS,	   ESI+)	   130	   (MH+).	   Accurate	  mass:	   Found	  




2-­‐Bromoethanol	  (0.14	  mL,	  1.93	  mmol)	  in	  dry	  MeCN	  (1	  mL)	  was	  added	  to	  a	  refluxing	  mixture	  
of	  (S)-­‐2-­‐methylpyrrolidine	  (257	  mg,	  2.00	  mmol),	  K2CO3	  (535	  mg,	  3.87	  mmol)	  in	  dry	  MeCN	  
(2	  mL).	  After	  15	  h	  the	  mixture	  was	  cooled	  to	  rt,	  filtered	  and	  concentrated.	  Et2O	  (5	  mL)	  was	  
then	  added	  and	  the	  product	  extracted	  with	  1M	  HCl	   (2	  x	  5	  mL).	  The	  aqueous	  phase	  was	  
made	  basic	  with	  solid	  NaOH,	  then	  extracted	  with	  DCM	  (3	  x	  5	  mL).	  The	  organic	  layers	  were	  
dried	  over	  Na2SO4,	   filtered	  and	   concentrated	   to	   afford	   the	  product	   (200	  mg,	   48%)	   as	   a	  
colourless	  oil.	  Carried	  through	  without	  further	  purification.	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +60.0°.	  νmax	  (ATR)	  3337	  (br,	  m),	  2948	  (m),	  2657	  (m),	  1451	  
(m),	  1053	  (m).	  NMR	  and	  mass	  spectra	  were	  consistent	  with	  the	  R	  enantiomer.	  
	  
(2R)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐methylpyrrolidine	  hydrochloride	  (R)-­‐154	  
	  
A	   solution	   of	   thionyl	   chloride	   (0.57	   mL,	   7.87	   mmol)	   in	   chloroform	   (3	   mL)	   was	   added	  
dropwise	  to	  a	  solution	  of	  2-­‐((2R)-­‐2-­‐methylpyrrolidin-­‐1-­‐yl)ethan-­‐1-­‐ol	  (R)-­‐155	  (377	  mg,	  2.92	  























and	  then	  concentrated	  under	  reduced	  pressure.	  Precipitation	  from	  a	  mixture	  of	  EtOH	  and	  
Et2O	   afforded	   the	   title	   compound	   contaminated	  with	   19%	  2-­‐((2R)-­‐2-­‐methylpyrrolidin-­‐1-­‐
yl)ethan-­‐1-­‐ol	  hydrochloride	  (353	  mg,	  35%)	  as	  a	  brown	  semi-­‐solid.	  	  	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  -­‐23.7°.	  νmax	  (ATR)	  3392	  (br,	  m),	  2974	  (m),	  2554	  (m),	  2453	  
(m),	  1452	  (m),	  1422	  (m),	  1393	  (m).	  δH	  (700	  MHz,	  CDCl3,	  19%	  2-­‐((2R)-­‐2-­‐methylpyrrolidin-­‐1-­‐
yl)ethan-­‐1-­‐ol	  hydrochloride)	  12.56	  (1H,	  s,	  NH+),	  4.15	  –	  4.10	  (1H,	  m,	  4’-­‐HH’),	  4.05	  –	  3.99	  (1H,	  
m,	  4-­‐HH’),	  3.97	  –	  3.90	  (1H,	  m,	  5’-­‐HH’),	  3.72	  –	  3.66	  (1H,	  m,	  3’-­‐HH’),	  3.31	  –	  3.24	  (1H,	  m,	  2’-­‐
H),	  3.12	  –	  3.05	  (1H,	  m,	  3’-­‐HH’),	  3.04	  –	  2.97	  (1H,	  m,	  5’-­‐HH’),	  2.30	  –	  2.17	  (2H,	  m,	  2-­‐H2),	  2.08	  
–	   1.95	   (2H,	  m,	   1-­‐H2),	   1.64	   (3H,	   d,	   J	   =	   6.5	   Hz,	   CH3).	   δC	   (176	  MHz,	   CDCl3,	   19%	   2-­‐((2R)-­‐2-­‐
methylpyrrolidin-­‐1-­‐yl)ethan-­‐1-­‐ol	  hydrochloride)	  65.3	  (C-­‐2’),	  54.0	  (C-­‐3’),	  53.8	  (C-­‐5’),	  37.6	  (C-­‐
4’),	  31.1	  (C-­‐2),	  21.6	  (C-­‐1),	  15.7	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  148	  (M(35Cl)H+),	  150	  (M(37Cl)H+).	  	  
	  
(2S)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐methylpyrrolidine	  hydrochloride	  (S)-­‐154	  
	  
A	  solution	  of	  thionyl	  chloride	  (0.87	  mL,	  12	  mmol)	  in	  chloroform	  (5	  mL)	  was	  added	  dropwise	  
to	  a	  solution	  of	  2-­‐((2S)-­‐2-­‐methylpyrrolidin-­‐1-­‐yl)ethan-­‐1-­‐ol	  (S)-­‐155	  (575	  mg,	  4.45	  mmol)	  in	  
chloroform	  (5	  mL)	  at	  0	  °C.	  The	  resulting	  mixture	  was	  heated	  under	  reflux	  for	  2	  h	  and	  then	  
concentrated	   under	   reduced	   pressure.	   Precipitation	   from	   a	   mixture	   of	   EtOH	   and	   Et2O	  
afforded	   the	   title	   compound	   contaminated	   with	   19%	   2-­‐((2S)-­‐2-­‐methylpyrrolidin-­‐1-­‐
yl)ethan-­‐1-­‐ol	  hydrochloride	  (302	  mg,	  37%)	  as	  a	  brown	  semi-­‐solid.	  	  	  
	  
[α]D	  (c	  =	  1.00	  g/100	  mL,	  CHCl3)	  +20.4°.	  	  νmax	  (ATR)	  3389	  (br,	  m),	  2974	  (m),	  2557	  (m),	  2461	  



















(2S)-­‐1-­‐{2-­‐[(S)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}-­‐2-­‐methylpyrrolidine	  (S,	  S)-­‐147	  
	  
General	  procedure	  D	  was	  used	  in	  the	  reaction	  of	  (S)-­‐4-­‐chlorophenyl(phenyl)methanol	  (S)-­‐
113	   (119	  mg,	  0.43	  mmol)	  and	  (2S)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐methylpyrrolidine	   (S)-­‐154	   (63	  mg,	  
0.43	  mmol).	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  100%	  
EtOAc	  in	  hexanes	  with	  1%	  NEt3)	  to	  afford	  the	  title	  compound	  (78mg,	  55%)	  as	  a	  colourless	  
oil.	  
	  
νmax	  (ATR)	  2962	  (w),	  2869	  (w),	  2787	  (w),	  1489	  (m),	  1453	  (w),	  1375	  (w),	  1086	  (s),	  1014	  (m).	  
δH	  (700	  MHz,	  CDCl3)	  7.31	  -­‐	  7.22	  (9H,	  m,	  ArH),	  5.34	  (1H,	  s,	  Ar2CH),	  3.57	  (2H,	  t,	  J	  =	  6.5	  Hz,	  2’-­‐
H2),	  3.15	  –	  3.09	  (1H,	  m,	  5-­‐HH’),	  3.04	  (1H,	  dt,	  J	  =	  12.5,	  6.5	  Hz,	  1’-­‐HH’),	  2.39	  (1H,	  dt,	  J	  =	  12.5,	  
6.5	  Hz,	  1’-­‐HH’),	  2.36	  –	  2.30	  (1H,	  m,	  2-­‐H),	  2.22	  –	  2.16	  (1H,	  m,	  5-­‐HH’),	  1.91	  –	  1.84	  (1H,	  m,	  3-­‐
HH’),	  1.78	  –	  1.69	  (1H,	  m,	  4-­‐HH’),	  1.69	  -­‐	  1.61	  (1H,	  m,	  4-­‐HH’),	  1.41	  -­‐	  1.33	  (1H,	  m,	  3-­‐HH’),	  1.07	  
(3H,	  d,	  J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  142.0	  (ArC),	  141.2	  (ArC),	  133.2	  (ArC),	  128.6(1)	  
(ArC),	  128.6(0)	  (ArC),	  128.4	  (ArC),	  127.8	  (ArC),	  127.1	  (ArC),	  83.4	  (Ar2CH),	  68.6	  (C-­‐2’),	  60.5	  
(C-­‐2),	   54.9	   (C-­‐5),	   53.4	   (C-­‐1’),	   32.6	   (C-­‐3),	   22.0	   (C-­‐4),	   19.1	   (CH3).	  m/z	   (LC-­‐MS,	   ESI+)	   330	  
(M(35Cl)H+),	  332	  (M(37Cl)H+).	  Accurate	  mass:	  Found	  (MH+),	  330.1624:	  C20H25NO35Cl	  requires	  
M,	  330.1625.	  
	  
(2R)-­‐1-­‐{2-­‐[(S)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}-­‐2-­‐methylpyrrolidine	  (R,	  S)-­‐147	  
	  
General	  procedure	  D	  was	  used	  in	  the	  reaction	  of	  (S)-­‐4-­‐chlorophenyl(phenyl)methanol	  (S)-­‐
113	   (67	  mg,	   0.24	  mmol)	   and	   (2R)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐methylpyrrolidine	   (R)-­‐154	   (12	  mg,	  
0.08	  mmol).	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  100%	  



























νmax	  (ATR)	  2963	  (w),	  2870	  (w),	  2789	  (w),	  1490	  (w),	  1453	  (w),	  1375	  (w),	  1089	  (m),	  1015	  (w).	  
δH	  (700	  MHz,	  CDCl3)	  7.33	  –	  7.29	  (4H,	  m,	  ArH),	  7.29	  -­‐	  7.27	  (4H,	  m,	  ArH),	  7.26	  –	  7.23	  (1H,	  m,	  
ArH),	  5.36	  (1H,	  s,	  Ar2CH),	  3.69	  –	  3.54	  (2H,	  m,	  2’-­‐H2),	  3.22	  -­‐	  3.14	  (1H,	  m,	  5-­‐HH’),	  3.12	  –	  3.05	  
(1H,	  m,	  1’-­‐HH’),	  2.54	  –	  2.36	  (2H,	  m,	  1-­‐HH’,	  2-­‐H),	  2.34	  –	  2.22	  (1H,	  m,	  5-­‐HH’),	  1.98	  –	  1.86	  (1H,	  
m,	  3-­‐HH’),	  1.84	  –	  1.74	  (1H,	  m,	  4-­‐HH’),	  1.73	  –	  1.64	  (1H,	  m,	  4-­‐HH’),	  1.49	  –	  1.36	  (1H,	  m,	  3-­‐HH’),	  
1.12	  (3H,	  d,	  J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  141.9	  (ArC),	  141.0	  (ArC),	  133.3	  (ArC),	  128.7	  
(ArC),	  128.6	  (ArC),	  128.5	  (ArC),	  127.8	  (ArC),	  127.1	  (ArC),	  83.5	  (Ar2CH),	  68.2	  (C-­‐2’),	  60.7	  (C-­‐
2),	  54.8	  (C-­‐5),	  53.4	  (C-­‐1’),	  32.4	  (C-­‐3),	  22.0	  (C-­‐4),	  18.9	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  330	  (M(35Cl)H+),	  
332	   (M(37Cl)H+).	   Accurate	   mass:	   Found	   (MH+),	   330.1634:	   C20H25NO35Cl	   requires	   M,	  
330.1625.	  
	  
(2R)-­‐1-­‐{2-­‐[(R)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]ethyl}-­‐2-­‐methylpyrrolidine	  (R,	  R)-­‐147	  
	  
General	  procedure	  D	  was	  used	  in	  the	  reaction	  of	  (R)-­‐4-­‐chlorophenyl(phenyl)methanol	  (R)-­‐
113	  (100	  mg,	  0.36	  mmol)	  and	  (2R)-­‐1-­‐(2-­‐chloroethyl)-­‐2-­‐methylpyrrolidine	  (R)-­‐154	  (53	  mg,	  
0.36	  mmol).	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  100%	  
EtOAc	  in	  hexanes	  with	  1%	  NEt3)	  to	  afford	  the	  title	  compound	  as	  a	  colourless	  oil	  (72	  mg,	  
61%).	  	  
	  
νmax	  (ATR)	  2962	  (w),	  2869	  (w),	  2788	  (w),	  1490	  (w),	  1088	  (m),	  1015	  (w).	  	  δH	  (700	  MHz,	  CDCl3)	  
7.32	  -­‐	  7.20	  (9H,	  m,	  ArH),	  5.35	  (1H,	  s,	  Ar2CH),	  3.61	  –	  3.55	  (2H,	  m,	  2’-­‐H2),	  3.16	  –	  3.12	  (1H,	  m,	  
5-­‐HH’),	  3.06	  (1H,	  dt,	  J	  =	  12.5,	  6.5	  Hz,	  1’-­‐HH’),	  2.41	  (1H,	  dt,	  J	  =	  12.5,	  6.5	  Hz,	  1’-­‐HH’),	  2.38	  –	  
2.32	  (1H,	  m,	  2-­‐H),	  2.24	  –	  2.18	  (1H,	  m,	  5-­‐HH’),	  1.91	  –	  1.85	  (1H,	  m,	  3-­‐HH’),	  1.80	  –	  1.71	  (1H,	  
m,	  4-­‐HH’),	  1.70	  -­‐	  1.63	  (1H,	  m,	  4-­‐HH’),	  1.42-­‐1.35	  (1H,	  m,	  3-­‐HH’),	  1.09	  (3H,	  d,	  J	  =	  6.0	  Hz,	  CH3).	  
δC	  (176	  MHz,	  CDCl3)	  141.9	   (ArC),	  141.1	   (ArC),	  133.2	   (ArC),	  128.5(8)	   (ArC),	  128.5(7)	   (ArC),	  
128.4	  (ArC),	  127.7	  (ArC),	  127.1	  (ArC),	  83.4	  (Ar2CH),	  68.5	  (C-­‐2’),	  60.5	  (C-­‐2),	  54.9	  (C-­‐5),	  53.4	  
(C-­‐1’),	  32.5	  (C-­‐3),	  22.0	  (C-­‐4),	  19.1	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  330	  (M(35Cl)H+),	  332	  (M(37Cl)H+).	  

















1-­‐[(2-­‐Bromoethoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  180	  (170	  mg,	  0.50	  mmol)	  in	  DMF	  (1	  
mL)	  was	  added	  dropwise	   to	  a	   suspension	  of	  dimethylamine	  hydrochloride	   (41	  mg,	  0.50	  
mmol),	  KI	  (8	  mg,	  0.05	  mmol)	  and	  K2CO3	  (138	  mg,	  1.00	  mmol)	  in	  DMF	  (1	  mL).	  The	  reaction	  
mixture	  was	  stirred	  at	  rt	  for	  4	  h	  and	  then	  further	  portions	  of	  dimethylamine	  hydrochloride	  
(82	  mg,	  1.00	  mmol)	  and	  K2CO3	  (207	  mg,	  1.5	  mmol)	  were	  added	  and	  the	  mixture	  was	  stirred	  
at	  rt	  for	  a	  further	  24	  h.	  Following	  the	  addition	  of	  H2O	  (5	  mL)	  and	  extraction	  with	  EtOAc	  (3	  x	  
5	  mL),	   the	   combined	   organic	   layers	   were	   dried	   and	   concentrated	   in	   vacuo.	   The	   crude	  
product	  was	  purified	  by	  column	  chromatography	   (0	  →	  100%	  EtOAc	   in	  hexanes	  with	  1%	  
NEt3)	  to	  afford	  the	  title	  compound	  (41	  mg,	  28	  %)	  as	  a	  brown	  oil.	  
	  
νmax	  (ATR)	  2942	  (w),	  2862	  (w),	  2819	  (w),	  1490	  (w),	  1454	  (w),	  1089	  (w),	  1015	  (w).	  δH	  (600	  
MHz,	  CDCl3)	  7.33	  -­‐7.23	  (9H,	  m,	  ArH),	  5.34	  (1H,	  s,	  Ar2CH),	  3.58	  –	  3.52	  (2H,	  m,	  2’-­‐H2),	  2.59	  
(2H,	  t,	  J	  =	  6.0	  Hz,	  1’-­‐H2),	  2.27	  (6H,	  s,	  2	  x	  CH3).	  δC	  (151	  MHz,	  CDCl3)	  141.9	  (ArC),	  141.1	  (ArC),	  
133.2	   (ArC),	   128.6(2)	   (ArC),	   128.6(0)	   (ArC),	   128.5	   (ArC),	   127.8	   (ArC),	   127.1	   (ArC),	   83.5	  
(Ar2CH),	   67.8	   (C-­‐2’),	   59.1	   (C-­‐1’),	   46.2	   (CH3).	   m/z	   (LC-­‐MS,	   ESI+)	   290	   (M(35Cl)H+),	   292	  





To	  a	  solution	  of	  4-­‐chlorophenyl(phenyl)methanol	  113	  (500	  mg,	  2.29	  mmol)	  and	  AuCl	  (33	  
mg,	  0.23	  mmol)	  in	  DCE	  was	  added	  3-­‐bromopropanol	  (318	  mg,	  2.29	  mmol).	  This	  reaction	  




















purified	  by	  flash	  column	  chromatography	  (0	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  product	  
as	  a	  colourless	  oil	  (244	  mg,	  54%).	  	  
	  
νmax	  (ATR)	  3029	  (w),	  2866	  (w),	  1489	  (m),	  1088	  (s),	  1014	  (m).	  δH	  (700	  MHz,	  CDCl3)	  7.37	  –	  7.27	  
(9H,	  m,	  ArH),	  5.5	  (1H,	  s,	  Ar2CH),	  3.61	  –	  3.56	  (4H,	  m,	  3’-­‐H2,	  1’-­‐H2),	  2.18	  (2H,	  p,	  J	  =	  6.0	  Hz,	  2’-­‐
H2).	  δC	  (176	  MHz,	  CDCl3)	  141.8	  (ArC),	  140.9	  (ArC),	  133.3	  (ArC),	  128.7	  (ArC),	  128.6	  (ArC),	  128.4	  
(ArC),	  127.9	  (ArC),	  127.0	  (ArC),	  83.3	  (Ar2CH),	  66.6	  (C-­‐3’),	  33.1	  (C-­‐2’),	  30.8	  (C-­‐1’).	  m/z	  (LC-­‐MS,	  
ESI+)	  201	  (M(35Cl)-­‐OC3H6Br+),	  203	  (M(37Cl)-­‐	  OC3H6Br+).	  Accurate	  mass:	  Found	  (M-­‐OC3H6Br+),	  




1-­‐[(3-­‐bromopropoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  183	  (320	  mg,	  0.94	  mmol)	  in	  DMF	  (5	  
mL)	  was	  added	  dropwise	  to	  a	  suspension	  of	  (2S)-­‐2-­‐methylpyrrolidine	  hydrochloride	  (115	  
mg,	  0.94	  mmol),	  KI	  (17g,	  0.1	  mmol)	  and	  K2CO3	  (210mg,	  1.88	  mmol)	  in	  DMF	  (10	  mL).	  	  The	  
reaction	  was	  then	  stirred	  at	  rt	  for	  24	  h.	  Following	  the	  addition	  of	  EtOAc	  (10	  mL),	  the	  organic	  
layer	  was	  washed	  with	  H2O	  (5	  x	  10	  mL),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated	   in	  
vacuo.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (10%	  MeOH	  in	  CHCl3)	  
to	  afford	  the	  title	  compound	  (217	  mg,	  65	  %)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2960	  (w),	  2869	  (w),	  2789	  (w),	  1489	  (m),	  1087	  (s),	  1014	  (m).	  δH	  (600	  MHz,	  CDCl3,	  
mixture	  of	  diastereomers)	  7.32	  –	  7.29	  (4H,	  m,	  ArH),	  7.28	  –	  7.26	  (4H,	  m,	  ArH),	  7.26	  –	  7.22	  
(1H,	  m,	  ArH),	  5.30	  (1H,	  s,	  Ar2CH),	  3.51	  –	  3.47	  (2H,	  m,	  3’-­‐H2),	  3.17	  –	  3.09	  (1H,	  m,	  5-­‐HH’),	  2.95	  
–	  2.86	  (1H,	  m,	  1’-­‐HH’),	  2.31	  –	  2.22	  (1H,	  m,	  2-­‐H),	  2.16	  –	  2.10	  (1H,	  m,	  1’-­‐HH’),	  2.10	  –	  2.04	  (1H,	  
m,	  5-­‐HH’),	  1.93	  –	  1.81	  (3H,	  m,	  2’-­‐H2,	  3-­‐HH’),	  1.80	  –	  1.71	  (1H,	  m,	  4-­‐HH’),	  1.70	  –	  1.62	  (1H,	  m,	  
4-­‐HH’),	  1.46	  –	  1.36	  (1H,	  m,	  3-­‐HH’),	  1.08	  (1.5H,	  d,	  J	  =	  6.0,	  CH3),	  1.08	  (1.5H,	  d,	  J	  =	  6.0,	  CH3).	  δC	  
(151	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  142.2	  (C-­‐1’Ph),	  141.2(8)	  (C-­‐1Ph),	  141.2(8)	  (C-­‐1Ph),	  
























(ArC),	  128.4	  (ArC),	  127.6(6)	  (C-­‐4’Ph),	  127.6(5)	  (C-­‐4’Ph),	  127.0	  (ArC),	  83.0	  (Ar2CH),	  67.8(3)	  (C-­‐
3’),	  67.8(0)	  (C-­‐3’),	  60.3	  (C-­‐2),	  54.0(7)	  (C-­‐5),	  54.0(6)	  (C-­‐5),	  51.3	  (C-­‐1’),	  51.2	  (C-­‐1’),	  32.8	  (C-­‐3),	  
29.2	   (C-­‐2’).	   21.7	   (C-­‐4),	   19.1	   (CH3).	   m/z	   (LC-­‐MS,	   ESI+)	   344	   (M(35Cl)H+),	   346	   (M(37Cl)H+).	  




3-­‐Bromopropanol	   (0.72	   mL,	   7.9	   mmol)	   in	   dry	   MeCN	   (5	   mL)	   was	   added	   dropwise	   to	   a	  
mixture	  of	   (S)-­‐2-­‐methylpyrrolidine	   (1	  g,	  8.2	  mmol)	   and	  K2CO3	   (2.27g,	  16.4	  mmol)	   in	  dry	  
MeCN	  (5	  mL)	  heated	  under	  reflux.	  After	  15	  h	  the	  mixture	  was	  cooled	  to	  rt,	   filtered	  and	  
concentrated.	  Et2O	  (10	  mL)	  was	  then	  added	  and	  the	  product	  extracted	  with	  1M	  HCl	  (2	  x	  10	  
mL).	  The	  aqueous	  phase	  was	  made	  more	  basic	  with	  solid	  NaOH,	  then	  extracted	  with	  DCM	  
(3	   x	   10	   mL).	   The	   organic	   layers	   were	   combined,	   dried	   over	   Na2SO4,	   filtered	   and	  
concentrated	  to	  afford	  product	  (620	  mg,	  55%)	  as	  a	  colourless	  oil.	  Carried	  through	  without	  
further	  purification.	  
	  
νmax	  (ATR)	  3372	  (br),	  2961	  (m),	  2872	  (w),	  1114	  (w).	  δH	  (400	  MHz,	  CDCl3)	  3.81	  –	  3.72	  (2H,	  m,	  
3-­‐H2),	  3.35	  –	  3.26	  (1H,	  m,	  1-­‐HH’),	  3.02	  –	  2.91	  (1H,	  m,	  5’-­‐HH’),	  2.43	  –	  2.34	  (1H,	  m,	  5’-­‐HH’),	  
2.33	  –	  2.23	  (1H,	  m,	  2’-­‐HH’),	  2.13	  -­‐	  2.02	  (1H,	  m,	  1-­‐HH’),	  2.01	  -­‐	  	  1.81	  (2H,	  m,	  2-­‐HH’,	  3’-­‐HH’),	  
1.79	  –	  1.60	  (2H,	  m,	  4’-­‐H2),	  1.58	  -­‐	  1.46	  (1H,	  m,	  2-­‐HH’),	  1.43	  -­‐	  1.29	  (1H,	  m,	  3’-­‐HH’),	  1.11	  (3H,	  
d,	  J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  69.3	  (C-­‐2’),	  61.9	  (C-­‐5’),	  54.0	  (C-­‐1),	  50.9	  (C-­‐3),	  32.2	  (C-­‐
3’),	  27.3	  (C-­‐2),	  21.6	  (C-­‐4’),	  18.1	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  144	  (MH+).	  Accurate	  mass:	  Found	  




















	  (2S)-­‐1-­‐(3-­‐chloropropyl)-­‐2-­‐methylpyrrolidine	  hydrochloride	  (S)-­‐185	  
.	  HCl	  
	  
A	   solution	   of	   thionyl	   chloride	   (0.74	  mL,	   10.24	  mmol)	   in	   chloroform	   (2	  mL)	   was	   added	  
dropwise	  to	  a	  solution	  of	  3-­‐[(2S)-­‐2-­‐methylpyrrolidin-­‐1-­‐yl]propan-­‐1-­‐ol	  (S)-­‐184	  (491	  mg,	  3.43	  
mmol)	   in	   chloroform	   (6	   mL)	   at	   0	   °C.	   The	   mixture	   was	   heated	   to	   reflux	   for	   2	   h	   and	  
concentrated	   under	   reduced	   pressure.	   The	   product	  was	   precipitated	   from	   ethanol	   and	  
diethylether	  to	  afford	  the	  title	  compound	  (172	  mg,	  25%)	  contaminated	  with	  19%	  3-­‐[(2S)-­‐2-­‐
methylpyrrolidin-­‐1-­‐yl]propan-­‐1-­‐ol	  hydrochloride.	  	  	  
	  
νmax	  (ATR)	  3404	  (br),	  2964	  (m),	  2600	  (w),	  2511	  (w),	  1633	  (w),	  1453	  (w),	  1063	  (w).	  M.p.	  125	  
–	  127	  °C	  	  (lit.266:	  150.5	  –	  152.0	  °C).	  δH	  (700	  MHz,	  CDCl3,	  19%	  3-­‐[(2S)-­‐2-­‐methylpyrrolidin-­‐1-­‐
yl]propan-­‐1-­‐ol	  hydrochloride)	  12.15	  (1H,	  s,	  N+H),	  3.93	  -­‐	  3.83	  (1H,	  m,	  5’-­‐HH’),	  3.74	  –	  3.62	  
(2H,	  m,	  3-­‐H2),	  3.44	  -­‐	  3.37	  (1H,	  m,	  1-­‐HH’),	  3.24	  –	  3.12	  (1H,	  m,	  2’-­‐H),	  3.00	  –	  2.92	  (1H,	  m,	  1-­‐
HH’),	  2.89	  –	  2.79	  (1H,	  m,	  5’-­‐HH’),	  2.72	  –	  2.61	  (1H,	  m,	  2-­‐HH’),	  2.29	  -­‐	  2.16	  (3H,	  m,	  3’-­‐HH’,	  4’-­‐	  
HH’,	  2-­‐HH’),	  2.11	  –	  1.96	  (2H,	  m,	  3’-­‐HH’,	  4’-­‐	  HH’),	  1.64	  (3H,	  d,	  J	  =	  6.5	  Hz,	  CH3).	  δC	  (176	  MHz,	  
CDCl3,	  19%	  3-­‐[(2S)-­‐2-­‐methylpyrrolidin-­‐1-­‐yl]propan-­‐1-­‐ol	  hydrochloride)	  65.3	  (C-­‐2’),	  53.5	  (C-­‐
5’),	  51.4	  (C-­‐1),	  42.1	  (C-­‐3),	  31.5	  (C-­‐3’),	  28.2	  (C-­‐2),	  21.5	  (C-­‐4’),	  15.7	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  
162	   (M(35Cl)H+),	   164	   (M(37Cl)H+).	   Accurate	   mass:	   Found	   (MH+),	   162.1041:	   C8H17N35Cl	  
requires	  M,	  162.1050.	  
	  
	  (2S)-­‐1-­‐{3-­‐[(R)-­‐(4-­‐chlorophenyl)(phenyl)methoxy]propyl}-­‐2-­‐methylpyrrolidine	  (S,	  R)-­‐157	  
	  
General	  procedure	  D	  was	  used	  for	  the	  reaction	  of	  (R)-­‐4-­‐chlorophenyl(phenyl)methanol	  113	  

































mmol).	  The	  crude	  product	  was	  purified	  by	  flash	  column	  chromatography	  (0	  →	  100%	  EtOAc	  
in	  hexanes	  with	  1%	  NEt3)	  to	  afford	  the	  title	  compound	  (78	  mg,	  55%)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2960	  (w),	  1489	  (w),	  1089	  (w).	  δH	  (700	  MHz,	  CDCl3)	  7.32	  –	  7.29	  (4H,	  m,	  ArH),	  7.27	  
–	  7.22	  (5H,	  m,	  ArH),	  5.30	  (1H,	  s,	  Ar2CH),	  3.49	  (2H,	  td,	  J	  =	  6.0,	  1.5	  Hz,	  3’-­‐H2),	  3.21	  –	  3.15	  (1H,	  
m,	  5-­‐HH’),	  2.98	  –	  2.90	  (1H,	  m,	  1’-­‐HH’),	  2.39	  –	  2.31	  (1H,	  m,	  2-­‐H),	  2.22	  –	  2.10	  (2H,	  m,	  1’-­‐HH’,	  
5-­‐HH’),	  1.96	  –	  1.85	  (3H,	  m,	  2’-­‐H2,	  3-­‐HH’),	  1.83	  –	  1.75	  (1H,	  m,	  4-­‐HH’),	  1.73	  –	  1.65	  (1H,	  m,	  4-­‐
HH’),	  1.50	  –	  1.42	  (1H,	  m,	  3-­‐HH’),	  1.12	  (3H,	  d,	  J	  =	  6.0	  Hz,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  142.1	  (C-­‐
1’Ph),	  141.2	  (C-­‐1Ph),	  133.2	  (C-­‐4Ph),	  128.5(7)	  (ArC),	  128.5(6)	  (ArC),	  128.4	  (ArC),	  127.7	  (C-­‐4’Ph),	  
127.0	  (ArC),	  83.0	  (Ar2CH),	  67.6	  (C-­‐3’),	  60.7	  (C-­‐2),	  53.9	  (C-­‐5),	  51.2	  (C-­‐1’),	  32.7	  (C-­‐3),	  28.9	  (C-­‐
2’),	  21.7	  (C-­‐4),	  18.7	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  344	  (M(35Cl)H+),	  346	  (M(37Cl)H+).	  Accurate	  mass:	  




General	   procedure	   C	   was	   used	   for	   4-­‐chlorophenyl(phenyl)methanol	   113	   (531	  mg,	   2.43	  
mmol)	  and	  4-­‐bromobutanol	  (372	  mg,	  2.43	  mmol)	  with	  the	  modification	  of	  AuCl	  (56	  mg,	  
0.24	  mmol)	  as	  the	  catalyst	   in	  the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  The	  crude	  
product	  was	  purified	  by	  column	  chromatography	  (0	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  
title	  compound	  (350	  mg,	  41%)	  as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  3029	  (w),	  2941	  (w),	  2863	  (w),	  1489	  (m),	  1086	  (s),	  1014	  (m).	  δH	  (600	  MHz,	  CDCl3)	  
7.36	  –	  7.24	  (9H,	  m,	  ArH),	  5.30	  (1H,	  s,	  Ar2CH),	  3.47	  (2H,	  t,	  J	  =	  6.5	  Hz,	  4’-­‐H2),	  3.43	  (2H,	  t,	  J	  =	  
6.5	  Hz,	  1’-­‐H2),	  2.00	  (2H,	  p,	  J	  =	  6.5	  Hz,	  2’-­‐H),	  1.79	  (2H,	  p,	  J	  =	  6.5	  Hz,	  3’-­‐H).	  δC	  (176	  MHz,	  CDCl3)	  
142.0	  (C-­‐1Ph),	  141.1	  (C-­‐1’Ph),	  133.2	  (C-­‐4Ph),	  128.6(4)	  (C-­‐3’Ph),	  128.6(1)	  (C-­‐3Ph),	  128.3	  (C-­‐2Ph),	  
127.8	  (C-­‐4’Ph),	  127.0	  (C-­‐2’Ph),	  83.1	  (Ar2CH),	  68.1	  (C-­‐4’),	  33.8	  (C-­‐1’),	  29.9	  (C-­‐2’),	  28.5	  (C-­‐3’).	  
m/z	  (LC-­‐MS,	  ESI+)	  201	  (M(35Cl)-­‐OC4H8Br]+),	  203	  (M(37Cl)-­‐OC4H8Br]+).	  Accurate	  mass:	  Found	  




















	  (2S)-­‐1-­‐{4-­‐[(4-­‐chlorophenyl)(phenyl)methoxy]butyl}-­‐2-­‐methylpyrrolidine	  (S)-­‐158	  
	  
1-­‐[(4-­‐bromobutoxy)(phenyl)methyl]-­‐4-­‐chlorobenzene	  186	  (106	  mg,	  0.3	  mmol)	  in	  DMF	  (0.5	  
mL)	  was	  added	  dropwise	  to	  a	  suspension	  of	  (2R)-­‐2-­‐methylpyrrolidine	  hydrochloride	  (46	  mg,	  
0.38	  mmol),	  KI	   (7	  mg,	  0.04	  mmol)	  and	  K2CO3	  (105	  mg,	  0.76	  mmol)	   in	  DMF	   (1	  mL).	   	  The	  
reaction	  was	  stirred	  at	  rt	   for	  24	  h.	  Following	  the	  addition	  of	  EtOAc	  (10	  mL),	  the	  organic	  
layer	  was	  washed	  with	  H2O	  (5	  x	  10	  mL),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated	   in	  
vacuo.	  The	  crude	  product	  was	  purified	  by	  column	  chromatography	  (0	  →	  100%	  EtOAc	   in	  
hexanes	  with	  1%	  NEt3)	  to	  afford	  the	  title	  compound	  as	  a	  colourless	  oil	  (49	  mg,	  46	  %).	  
	  
	  νmax	  (ATR)	  2954	  (w),	  2867	  (w),	  2789	  (w),	  1490	  (m),	  1453	  (w),	  1089	  (s),	  1015	  (m).	  δH	  (600	  
MHz,	  CDCl3)	  7.31	  –	  7.28	  (4H,	  m,	  ArH),	  7.27	  -­‐	  	  7.21	  (5H,	  m,	  ArH),	  5.28	  (1H,	  s,	  Ar2CH),	  3.47	  –	  
3.41	  (2H,	  m,	  3’-­‐H2),	  3.18	  –	  3.12	  (1H,	  m,	  5-­‐HH’),	  2.81	  –	  2.74	  (1H,	  m,	  1’-­‐HH’),	  2.29	  –	  2.19	  (1H,	  
m,	  2-­‐H),	  2.09	  –1.96	  (2H,	  m,	  5-­‐HH’,	  1’-­‐HH’),	  1.93	  –	  1.85	  (1H,	  m,	  3-­‐HH’),	  1.81	  –	  1.72	  (1H,	  m,	  
4-­‐HH’),	  1.72	  –	  1.55	  (5H,	  m,	  4-­‐HH’,	  3’-­‐H2,	  2’-­‐H2),	  1.45	  –	  1.38	  (1H,	  m,	  3-­‐HH’),	  1.07	  (3H,	  d,	  J	  =	  
6.0,	  CH3).	  δC	  (176	  MHz,	  CDCl3,	  mixture	  of	  diastereomers)	  142.2(1)	  (C-­‐1’Ph),	  142.2(0)	  (C-­‐1’Ph),	  
141.3	  (C-­‐1Ph),	  133.2	  (C-­‐4Ph),	  128.6(0)	   (ArC),	  128.5(9)	   (ArC),	  128.5(7)	   (ArC),	  128.5(6)	   (ArC),	  
128.3(9)	  (ArC),	  128.3(8)	  (ArC),	  127.7	  (C-­‐4’Ph),	  127.0(3)	  (ArC),	  127.0(1)	  (ArC),	  83.1	  (Ar2CH),	  
69.1(6)	  (C-­‐4’),	  69.1(5)	  (C-­‐4’),	  60.5	  (C-­‐2),	  54.3	  (C-­‐1’),	  54.2	  (C-­‐1’),	  54.1	  (C-­‐5),	  32.8	  (C-­‐3),	  28.2(4)	  
(C-­‐2’),	  28.2(3)	  (C-­‐2’),	  25.7	  (C-­‐3’),	  21.7	  (C-­‐4),	  19.0	  (CH3).	  m/z	  (LC-­‐MS,	  ESI+)	  358	  (M(35Cl)H+),	  



































General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.60	   mL,	   24.80	   mmol)	   and	  
benzaldehyde	  (1.95	  mL,	  19.10	  mmol).	  The	  product	  was	  purified	  by	  column	  chromatography	  
(0	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (1.35	  g,	  38	  %)	  as	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  3371	  (br,	  m),	  1596	  (w),	  1494	  (m),	  1455	  (m),	  1494	  (m),	  1351	  (w),	  1269	  (m),	  1182	  
(m),	  1171	  (m),	  1031	  (m),	  1017	  (s).	  	  M.p.	  60–	  61	  °C	  (lit.:268	  63	  -­‐	  64	  °C);	  δH	  (600	  MHz,	  CDCl3)	  
7.40	  –	  7.37	  (4H,	  m,	  2-­‐H),	  7.36	  –	  7.32	  (4H,	  m,	  3-­‐H),	  7.29	  –	  7.26	  (2H,	  m,	  4-­‐H),	  5.86	  (1H,	  s,	  
Ar2CH).	  δC	  (151	  MHz,	  CDCl3)	  143.9	  (C-­‐1),	  128.7	  (C-­‐3),	  127.7	  (C-­‐4),	  126.7	  (C-­‐2),	  76.4	  (Ar2CH).	  








Diarylamine	  (248	  mg,	  1.00	  mmol)	  was	  dissolved	  in	  dioxane	  (3	  mL)	  and	  phenacetylchloride	  
(0.26	  mL,	  2.00	  mmol)	  was	  added	  dropwise	  at	  rt.	  Then,	  the	  mixture	  was	  refluxed	  for	  1h.	  
After	  cooling,	  the	  mixture	  was	  poured	  in	  ice-­‐water	  (10	  mL)	  and	  extracted	  with	  EtOAc	  (3	  x	  5	  
mL).	  The	  combined	  organics	  were	  washed	  with	  brine	  (10	  mL)	  and	  dried	  over	  Na2SO4.	  Crude	  
product	  was	   purified	   by	   flash	   column	   chromatography	   (0	  →	  30%	   EtOAc	   in	   hexanes)	   to	  
afford	  the	  title	  compound	  (221	  mg,	  60%)	  as	  a	  white	  solid.	  	  
	  
M.p.	  73	  –	  75	  °C;	  νmax	  (ATR)	  3030	  (w),	  1668	  (s),	  1593	  (w),	  1486	  (s),	  1453	  (w),	  1349	  (m),	  1263	  
(m),	  1206	  (w),	  1139	  (w),	  1100	  (w),	  1069	  (m),	  1030	  (w),	  1011	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  
7.49	  –	  7.32	  (4H,	  m,	  ArH),	  7.29	  –	  7.21	  (4H,	  m,	  ArH),	  7.19	  –	  7.15	  (2H,	  m,	  ArH),	  7.14	  –	  7.05	  (4H,	  















(ArC),	   132.8	   (ArC),	   132.1	   (ArC),	   129.9	   (ArC),	   129.1	   (ArC),	   128.6	   (ArC),	   127.9	   (ArC),	   127.0	  
(ArC),	   126.6	   (ArC),	   119.4	   (ArC),	   42.3	   (ArCH2).	   m/z	   (LC-­‐MS,	   ESI+)	   367	   (M(81Br)H+),	   369	  





To	  a	  5	  °C	  	  solution	  of	  N-­‐(4-­‐bromophenyl)-­‐N,2-­‐diphenylacetamide	  188	  (1.55	  g,	  4.22	  mmol)	  
in	  THF	  (17	  mL)	  was	  added	  borane	  dimethyl	  sulfide	  complex	  (2.10	  mmol,	  22	  mmol)	  gradually	  
and	  the	  reaction	  mixture	  was	  stirred	  at	  rt	  for	  4	  h.	  Then,	  10	  %	  acetic	  acid	  in	  MeOH	  (26	  mL)	  
was	  added	  and	  the	  resulting	  solution	  was	  stirred	  for	  20	  h.	  The	  solvent	  was	  removed	  by	  
evaporation	   and	   product	   was	   extracted	   with	   EtOAc	   (3	   x	   10mL)	   in	   H2O	   (10	   mL).	   The	  
combined	  organics	  were	  dried	  over	  Na2SO4	  and	  the	  crude	  product	  was	  purified	  by	  column	  
chromatography	  (0	  →	  30%	  EtOAc	  in	  hexanes)	  to	  afford	  title	  compound	  (280	  mg,	  19%)	  as	  a	  
colourless	  oil.	  
	  
νmax	  (ATR)	  3026	  (w),	  2930	  (w),	  1581	  (m),	  1486	  (s),	  1355	  (m),	  1244	  (m),	  1178	  (m),	  1072	  (m),	  
1024	  (w),	  1008	  (w)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.35	  –	  7.29	  (6H,	  m,	  ArH),	  7.26	  –	  7.23	  (1H,	  m,	  
ArH),	  7.21	  -­‐	  7.18	  (2H,	  m,	  ArH),	  7.06	  -­‐	  7.00	  (3H,	  m,	  ArH),	  6.82	  -­‐	  6.77	  (2H,	  m,	  ArH),	  3.95	  -­‐3.90	  
(2H,	  m,	  1-­‐H2),	  2.98	  –	  2.93	  (2H,	  m,	  2-­‐H2).	  δC	  (176	  MHz,	  CDCl3)	  147.4	  (ArC),	  147.1	  (ArC),	  139.3	  
(ArC),	   132.2	   (ArC),	   129.7	   (ArC),	   128.9	   (ArC),	   128.7	   (ArC),	   126.5	   (ArC),	   122.7	   (ArC),	   122.5	  
(ArC),	  121.3	  (ArC),	  112.8	  (ArC),	  54.2	  (C-­‐1),	  33.7	  (C-­‐2).	  m/z	  (LC-­‐MS,	  ESI+)	  354	  (M(81Br)H+),	  352	  
















General	  procedure	  C	  was	  used	  with	  phenyl	  propanol	  (136	  mg,	  1.00	  mmol)	  and	  1-­‐phenyl	  
ethanol	   (122	  mg,	  1.00	  mmol)	  with	   the	  modification	  of	  AuCl	   (23	  mg,	  0.10	  mmol)	   as	   the	  
catalyst	  in	  the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  The	  crude	  product	  was	  purified	  
by	  flash	  column	  chromatography	  (0%	  →	  20%	  EtOAc	  in	  hexanes)	  to	  afford	  title	  compound	  
(116	  mg,	  48%)	  as	  a	  colourless	  oil.	  
	  
νmax	  (ATR)	  2927	  (w),	  1494	  (w),	  1453	  (w),	  1104	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.38	  –	  7.15	  
(10H,	  m,	  ArH),	  4.40	  (1H,	  q,	  J	  =	  6.5	  Hz,	  ArCHCH3),	  3.37	  –	  3.31	  (2H,	  m,	  1-­‐H2),	  2.78	  –	  2.59	  (2H,	  
m,	  3-­‐H2),	  1.93	  –	  1.84	  (2H,	  m,	  2-­‐H2),	  1.47	  (3H,	  d,	  J	  =	  6.5	  Hz).	  δC	  (151	  MHz,	  CDCl3)	  144.3	  (ArC),	  
142.2	  (ArC),	  128.6	  (ArC),	  128.5	  (ArC),	  128.4	  (ArC),	  127.5	  (ArC),	  126.3	  (ArC),	  125.8	  (ArC),	  78.1	  




General	   procedure	   A	   was	   used	   with	   bromobenzene	   (2.40	   mL,	   22.67	   mmol)	   and	   4-­‐
bromoacetophenone	   (3.00	   g,	   15.10	   mmol).	   The	   product	   was	   purified	   by	   flash	   column	  
chromatography	  (0%	  →	  20%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (1.20	  g,	  29%)	  
as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  3434	  (br,	  w),	  2977	  (w),	  1590	  (w),	  1485	  (m),	  1446	  (m),	  1394	  (m),	  1372	  (m),	  1328	  
(m),	  1224	  (w),	  1120	  (w),	  1173	  (w),	  1120	  (w),	  1027	  (w),	  1070	  (m),	  1008	  (s)	  cm-­‐1.	  δH	  (700	  MHz,	  












7.38	  (3H,	  m,	  ArH),	  1.92	  (3H,	  s,	  CH3).	  δC	  (176	  MHz,	  CDCl3)	  147.5	  (ArC),	  147.2	  (ArC),	  131.3	  
(ArC),	   128.4	   (ArC),	   127.8	   (ArC),	   127.4	   (ArC),	   125.9	   (ArC),	   121.0	   (ArC),	   76.1	   (Ar2CH),	   30.8	  




General	   Procedure	   C	   was	   used	   with	   benzyl	   (2R)-­‐2-­‐(2’-­‐hydroxyethyl)pyrrolidine-­‐1-­‐
carboxylate	  (R)-­‐133	  (216	  mg,	  0.87	  mmol)	  and	  1-­‐(4-­‐bromophenyl)-­‐1-­‐phenylethan-­‐1-­‐ol	  191	  
	  (241	  mg,	  0.87	  mmol)	  with	  the	  modification	  of	  AuCl	  (20	  mg,	  0.09	  mmol)	  as	  the	  catalyst	  in	  
the	  place	  of	  PdCl2	  with	  a	  reaction	  time	  of	  20	  h.	  The	  crude	  product	  was	  purified	  by	  flash	  
column	  chromatography	  (0%	  →	  10%	  ether	  in	  hexanes)	  to	  afford	  the	  title	  compound	  (163	  
mg,	  72%)	  as	  a	  colourless	  oil.	  	  
	  
νmax	  (ATR)	  1660	  (w),	  1587	  (w),	  1485	  (w),	  1447	  (w),	  1394	  (w),	  1316	  (w),	  1281	  (w),	  1270	  (w),	  
1071	  (w),	  1010	  (m)	  cm-­‐1.	  δH	  (700	  MHz,	  CDCl3)	  7.49	  -­‐	  7.46	  (2H,	  m,	  ArH),	  7.38	  -­‐	  7.31	  (5H,	  m,	  
ArH),	  7.25	  –	  7.21	  (2H,	  m,	  ArH),	  5.49	  (1H,	  s,	  CHH’),	  5.47	  (1H,	  s,	  CHH’).	  δC	  (176	  MHz,	  CDCl3)	  
149.2	   (Ar2C),	  141.1	   (ArC),	  140.6	   (ArC),	  131.5	   (ArC),	  130.0	   (ArC),	  128.4	   (ArC),	  128.3	   (ArC),	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8.	  Biological	  experimental	  	  
	  
8.1.	  General	  experimental	  details	  
	  
MATERIALS:	  Biological	   grade	  materials,	   solvents,	   reagents	  and	  media	   components	  were	  
purchased	  from	  commercial	  suppliers	  and	  used	  as	  provided.	  NBD-­‐C6-­‐ceramide	  80	  was	  from	  
Invitrogen	  and	  AG	  4-­‐X4	  ion	  exchange	  resin	  was	  from	  Bio-­‐Rad.	  Reactions	  and	  media	  were	  
prepared	  using	  ultrapure	  water	  from	  Milli-­‐Q®	  water	  purification	  system.	  FBS	  refers	  to	  heat-­‐
inactivated	   foetal	   bovine	   serum.	   Solutions	  of	   test	   compounds	  were	  made	  up	   in	  DMSO,	  
unless	  otherwise	  stated.	  	  
	  
INSTRUMENTS	  AND	  EQUIPMENT:	  1.5	  mL	  Eppendorfs	  were	  used	  during	  the	  preparation	  of	  
serial	  dilutions.	  Media	  were	  filter-­‐sterilised	  using	  a	  vacuum	  filter	  with	  a	  0.22	  μm	  pore	  CA	  
membrane.	   Centrifugation	   steps	   were	   carried	   out	   using	   Sorvall®	   Legend	   RT	   centrifuge,	  
Sorvall®	  Legend	  Micro	  17R	  centrifuge,	  Beckman	  Coulter®	  centrifuges	  and	  ultracentrifuges.	  
Eppendorf	  tubes	  were	  centrifuged	  using	  Sigma	  1-­‐14	  microfuge.	  Disruption	  of	  yeast	  cells	  
was	  performed	  using	  an	   IKA®	  Vortex	  Genius	  3.	  Protein	  content	  and	  optical	  density	   (OD)	  
were	  determined	  using	  a	  Boeco	  S-­‐32	  spectrophotometer.	  Eppendorf	  contents	  were	  dried	  
using	   an	   Eppendorf	   Vacuum	   Concentrator	   5301.	   Cells	   were	   counted	   using	   a	   Neubauer	  
haemocytometer.	  96-­‐well	  plates	  used	  were	  Nest	  Biotechnology	  Co.,	  Ltd	  cell	  culture	  plates	  
(clear);	  Corning®	  Costar®	  cell	  culture	  plates	  (clear);	  Corning®	  V-­‐bottom	  (clear);	  MultiScreen®	  
Solvinert	  filter	  plates	  (Merck	  Millipore)	  and	  PerkinElmer	  OptiPlate-­‐96	  (black).	  24-­‐well	  plates	  
were	   supplied	   by	   Nest	   Biotechnology	   Co.,	   Ltd	   and	   cover	   slips	   from	   Thomas	   Scientific®.	  
Fluorescence	   quantification	   was	   carried	   out	   using	   SpectraMax®	  microplate	   reader	   with	  
SoftMax®	   Pro	   6.4	   data	   analysis	   software	   from	  Molecular	   Devices	   and	   Synergy	   H4	   and	  
FLx800	  microplate	  readers	  with	  Gen5®	  1.08	  data	  analysis	  software	  from	  Biotek.	  HPTLC	  silica	  
plates	  were	  from	  Merck	  Millipore	  and	  imaged	  using	  a	  Fuji	  FLA-­‐3000	  plate	  reader	  with	  AIDA	  











8.2.	  Solutions,	  buffers	  and	  media	  compositions	  
	  	  
Buffer/Solutions	   Vol./Mass	   Stock	  	  








Tris-­‐HCl	  (1	  M,	  pH	  7.4)	  
Sucrose	  (1	  M)	  
EDTA	  (0.5	  M,	  pH	  8)	  
Complete®	   Protease	  
Inhibitor	  Cocktail	  
H2O	  










Glycerol	  (80%	  w/v)	  
MgCl2	  (1	  M)	  
Complete®	   Protease	  
Inhibitor	  Cocktail	  
H2O	  
Phosphate	  Buffer	  	  







Resazurin	  Solution	   5	  mg	  
40	  mL	  
Resazurin	  sodium	  salt	  
PBS	  
	  













Yeast	   Nitrogen	   Base	   –	   Amino	   acids	   –	  
(NH4)2SO4	  LoFlo	  
Amino	  acids	  Drop-­‐Out	  Supplement	  -­‐W-­‐L	  
H2O	  




Schneider’s	  Insect	  Medium,	  
Merck®	  (stock)	  








Schneider’s	  Insect	  Medium	  
NaHCO3	  
CaCl2	  
HCl	  (for	  pH	  adjustment)	  
NaOH	  (for	  pH	  adjustment)	  
H2O	  
Schneider’s	  Insect	  Medium	  




Schneider’s	  Insect	  Medium	  (stock)	  
FBS	  
Penicillin	  	  Steptomycin	  (Pen	  Strep|)	  
Medium	  199,	  Cultilab®	  








Penicillin	  	  Steptomycin	  (Pen	  Strep|)	  
RPMI	   1640	   Medium,	  





HCl	  (for	  pH	  adjustment)	  




All	  of	  the	  following	  biological	  procedures	  were	  carried	  out	  under	  sterile	  conditions	  unless	  
otherwise	  stated.	  
	  
8.3.1.	  Leishmania	  culture	  
	  
Leishmania	   amazonensis	   (MHOM/Br/75/JOSEFA),	   Leishmania	   donovani	   (LV9)	   and	  
Leishmania	   infantum	   (NCL)	   promastigotes	   were	   maintained	   at	   26	   °C	   in	   Medium	   199,	  
supplemented	   with	   15%	   FBS.	   Leishmania	   amazonensis	   (MHOM/Br/75/JOSEFA),	  
Leishmania	   major	   (FV1)	   WT	   and	   Δ	   LCB2	   promastigotes	   were	   maintained	   at	   26	   °C	   in	  
Schneider’s	  insect	  medium	  at	  pH	  7,	  supplemented	  with	  15%	  FBS.	  Leishmania	  major	  (FV1)	  
PX	   promastigotes	   were	   maintained	   at	   26	   °C	   in	   Schneider’s	   insect	   medium	   at	   pH	   7,	  
supplemented	  with	  15%	  FBS	  and	  40	  µg	  mL-­‐1	  G418	  (Gibco	  BRL).	  Leishmania	  amazonensis-­‐




GFP	  were	  selected	  for	  bright	  green	  fluorescence	  by	  48	  h-­‐incubation	  in	  the	  presence	  of	  1000	  
µg	  mL-­‐1	  G418	  (Gibco	  BRL).	  
	  
8.3.2.	  Animals	  and	  ethics	  statement	  
	  
All	  mice	  used	  in	  the	  experiments	  were	  maintained	  under	  controlled	  temperature,	  filtered	  
air	  and	  water,	  autoclave	  bedding,	  and	  commercial	  food	  at	  the	  animal	  facilities	  at	  Federal	  
University	  of	  Rio	  de	  Janeiro.	  
	  
The	   animal	   protocols	   for	   this	   study	  were	   approved	   by	   the	   Federal	  University	   of	   Rio	   de	  
Janeiro	   Institutional	   Animal	   Care	   and	   Use	   Committee	   under	   the	   number	   030/17.	   The	  
research	  was	  conducted	  in	  compliance	  with	  the	  principles	  stated	  in	  the	  Guide	  for	  the	  Care	  
and	  Use	  of	  Laboratory	  Animals	  (NIH).272	  
	  
8.3.3.	  Isolation	  of	  Bone	  Marrow	  Derived	  Macrophages	  (BMDM)	  
	  
BMDM	  were	  differentiated	  from	  bone	  marrow	  of	  BALB/C,	  C57BL/6	  and	  knock	  out	  C57BL/6	  
mice	   using	   L929-­‐cell	   conditioned	   medium	   (LCCM)	   as	   a	   source	   of	   macrophage	   colony-­‐
stimulating	   factor	   (M-­‐CSF)	   as	   described	   by	   Zamboni	   et	   al.273	  Briefly,	   bone	  marrow	  was	  
extracted	   from	   the	   femurs	   and	   tibias	   and	   re-­‐suspended	   in	   bone	  marrow	  differentiated	  
media	  (which	  is	  RPMI	  1640	  medium	  supplemented	  with	  20%	  LCCM)	  in	  Petri	  dishes	  for	  7	  
days	   at	   37	   °C	   with	   5%	   CO2.	   After,	   the	   plates	   were	   washed	   with	   warm	   PBS	   to	   remove	  
detached	  cells,	  the	  adherent	  BMDM	  were	  gently	  scraped	  off	  the	  surface	  and	  re-­‐suspended	  
in	  RPMI	   (without	  LCCM).	  These	  cells	  are	  ready	  to	  use	   in	   the	  assays	  described	   in	  section	  




Clemastine	   fumarate,	   miltefosine,	   pentostam,	   amphotericin	   B	   and	   cycloheximide	   were	  
purchased	  from	  Sigma-­‐Aldrich.	  Glucantime	  solution	  (meglumine	  antimoniate,	  300	  mg	  mL-­‐1)	  
was	   a	   gift	   from	   Sanofi	   Aventis.	   Clemastine	   derivatives	   were	   synthesised	   using	   the	  
procedure	  outline	  in	  the	  previous	  section.	  Stock	  solutions	  of	  clemastine	  and	  its	  derivatives	  
(10	  mM)	  were	  prepared	   in	  dimethyl	  sulfoxide	   (DMSO)	  and	  kept	  at	  0	   -­‐	  4°	  C.	  Subsequent	  
dilutions	  were	  done	  in	  culture	  media.	  For	  in	  vitro	  assays,	  all	  drugs	  were	  serially	  diluted	  in	  




100%	  DMSO,	  and	  then	  diluted	  1:100	  in	  culture	  medium,	  so	  that	  all	  final	  drug	  concentrations	  
contained	  1%	  DMSO.	  
In	  vivo	  assay	  1:	  clemastine	  fumarate	  (oral)	  and	  miltefosine	  (oral)	  were	  dissolved	  in	  vehicle	  
composed	  of	  sodium	  carboxymethylcellulose	  0.5%	  w/v,	  benzyl	  alcohol	  0.5%	  v/v,	  Tween-­‐80	  
0.4%	   v/v	   diluted	   in	   0.9%	   aqueous	   NaCl	   solution.	   The	   vehicle	   for	   clemastine	   (IL)	   and	  
pentostam	  was	  PBS.	  	  
In	  vivo	  assay	  2:	  clemastine	  fumarate	  (oral)	  was	  dissolved	  in	  ORA-­‐PLUS	  (Perrigo).	  ORA-­‐PLUS	  
is	  composed	  of	  purified	  water,	  microcrystalline	  cellulose,	  carboxymethylcellulose	  sodium,	  
xanthan	  gum,	  carrageenan,	  calcium	  sulfate,	  trisodium	  phosphate,	  citric	  acid	  and	  sodium	  
phosphate	  as	  buffers,	  dimethicone	  antifoam	  emulsion.	  Preserved	  with	  methylparaben	  and	  
potassium	  sorbate.	  
	  
8.3.5.	  Fluorescence	  quantification	  
	  
The	  fluorescence	  spectra	  of	  analogue	  (R)-­‐159	  were	  quantified	  using	  the	  above	  SpectraMax®	  
microplate	   reader.	   Images	   were	   taken	   using	   Nikon®	   microscope	   and	   B-­‐2A	   filter	   cube	  
(Ex470/Em515).	  
	  
8.3.6.	  Preparation	  of	  LmjIPCS	  microsomal	  material	  
	  
Auxotrophic	  AUR1	  mutant	  S.	   cerevisiae	  was	   complemented	  by	   the	   expression	   of	   the	   L.	  
major	  IPCS	  to	  create	  YPH499-­‐HIS-­‐GAL-­‐AUR1	  pRS246	  LmjIPCS.184	  These	  steps	  were	  carried	  
out	  under	  non-­‐sterile	  conditions.	  
	  
Step	  1:	  Preparation	  of	  cell	  extract	  
Crude	  membranes	  from	  this	  mutant	  S.	  cerevisiae	  were	  prepared	  as	  described	  by	  Fischl	  et	  
al.274	  The	  complemented	  yeast	  cells	  were	  propagated	   in	  SGR-­‐W-­‐L	  media	  until	  OD	  ≥	  0.8.	  
Cells	  were	  harvested	  by	  centrifugation	  (4,000	  x	  g,	  4	  °C,	  10	  min)	  and	  washed	  with	  cold	  PBS	  
(3	  x	  20	  mL).	  The	  cell	  pellet	  was	  weighed	  and	  re-­‐suspended	  in	  STE	  buffer	  (1.5	  mL	  per	  1g	  wet	  
cell	  mass	  (WCM)).	  The	  yeast	  cells	  were	  disrupted	  using	  pre-­‐chilled,	  acid	  washed	  glass	  beads	  
(425-­‐600	  µm,	  1.5	  mL	  per	  1g	  WCM),	  using	  a	  vortex	  mixer.	  Disruption	  step	  involved	  30	  cycles	  
of	  1	  min	  vortex	  mixing	  followed	  by	  a	  1	  min	  rest	  on	  ice.	  Glass	  beads,	  unbroken	  cells	  and	  cell-­‐
wall	  debris	  were	  pelleted	  by	  centrifugation	  (3,800	  x	  g,	  4	  °C,	  15	  min)	  to	  obtain	  cell	  extract	  
(supernatant)	  which	  was	  removed	  and	  stored	  on	  ice.	  The	  pellet	  was	  re-­‐suspended	  in	  STE	  




buffer	   (0.5	   mL	   per	   1g	   WCM)	   and	   subjected	   to	   20	   further	   disruption	   cycles.	   Following	  
centrifugation	   (3,800	  x	  g,	  4	   °C,	  15	  min),	   the	  supernatant	  was	   removed	  and	  cell	  extracts	  
combined.	  
	  
Step	  2:	  Preparation	  of	  crude	  microsomal	  membrane	  fraction	  
The	  microsomal	  membrane	  faction,	  enriched	  in	  IPCS,	  was	  isolated	  from	  the	  cell	  extract	  by	  
differential	  centrifugation.	  An	  initial	  centrifugation	  of	  the	  cell	  extract	  (23,000	  x	  g,	  4	  °C,	  15	  
min)	   pelleted	   large	   organelles	   and	   cell	   debris.	   The	   supernatant	   was	   removed	   and	   re-­‐
centrifuged	   (150,000	   x	   g,	   4	   °C,	   90	   min)	   to	   obtain	   a	   pellet	   enriched	   with	   microsomal	  
membranes.	  The	  pellet	  was	  re-­‐suspended	  in	  storage	  buffer	  (approximately	  100	  µL)	  and	  the	  
protein	   content	  was	  determined	  according	   to	  Bradford’s	  protocol.275	   The	   concentration	  
was	  adjusted	  to	  20	  mg	  ml-­‐1	  and	  100	  µL	  aliquots	  	  were	  stored	  in	  LoBind	  Eppendorf	  tubes	  at	  
-­‐80	  °C.	  
	  
Step	  3:	  Preparation	  of	  washed	  microsomal	  membranes	  
The	  crude	  microsomal	  membranes	  were	  adjusted	  to	  a	  concentration	  of	  10	  mg	  mL-­‐1	  using	  
STE	  buffer.	  Equal	  volume	  of	  the	  microsomal	  membranes	  and	  2.5%	  CHAPS	  solution	  were	  
mixed	   together	   and	   kept	   on	   ice	   for	   1	   h	  without	   shaking.	   The	  mixture	  was	   centrifuged	  
(150,000	   x	   g,	   4	   °C,	   90	  min)	   and	   the	   pellet	   re-­‐suspended	   in	   storage	   buffer.	   The	   protein	  
content	   was	   quantified	   according	   to	   Bradford’s	   protocol275	   and	   the	   membranes	   were	  
stored	  in	  LoBind	  Eppendorf	  tubes	  at	  -­‐80	  °C.	  
	  
Step	  4:	  Determination	  of	  the	  Protein	  Content	  in	  Enzyme	  Units	  
To	   standardise	   the	   assay	   and	   remove	   variability	   from	   sample	   preparation,	   microsome	  
samples	  were	  normalised	  with	  respect	  to	  active	  enzyme	  content.	  The	  data	  is	  presented	  in	  
enzyme	  units	  (U),	  where	  one	  unit	  (U)	  of	  enzyme	  converts	  1	  pmol	  of	  substrate	  per	  minute	  
under	  the	  conditions	  described	  (1U	  =	  1	  pmol(product)	  min-­‐1).	  
	  
A	  stock	  solution	  of	  NBD-­‐C6-­‐ceramide	  80	  at	  a	  concentration	  of	  10	  pmol	  µL-­‐1	  was	  used	  to	  
produce	  a	  standard	  curve	  ranging	  from	  0.2	  pmol	  to	  80	  pmol.	  The	  volumes	  were	  adjusted	  
to	   200	   µL	   with	   1M	   potassium	   formate	   in	   MeOH	   and	   the	   fluorescence	   was	   read	  
(Ex460/Em540).	  	  
	  




Samples	  of	  the	  washed	  microsomal	  membranes	  were	  incubated	  with	  NBD-­‐C6-­‐ceramide	  80	  
and	   PI	   under	   assay	   conditions	   8.4.7.	   and	   the	   product	   fluorescence	   measured	  
(Ex460/Em540).	  Correlation	  with	  the	  standard	  curve	  allowed	  the	  activity	  of	  the	  microsome	  
preparation	  to	  be	  determined	  in	  U	  µL-­‐1.	  The	  membranes	  were	  adjusted	  to	  1.5	  U	  µL-­‐1	  with	  




8.4.1.	  Anti-­‐promastigote	  assays	  
	  
L.	  major	  promastigotes	  in	  Schneider’s	  insect	  medium	  (100	  μL	  at	  1	  ×	  106	  mL−1)	  were	  
incubated	  in	  96-­‐well	  plates	  with	  compounds	  in	  triplicate	  (amphotericin	  B	  and	  
cycloheximide	  were	  used	  as	  positive	  controls,	  and	  untreated	  parasites	  with	  1%	  DMSO	  as	  a	  
negative	  control)	  at	  26	  °C	  for	  48	  h.	  Resazurin	  Solution	  (10	  μL)	  was	  then	  added	  and	  the	  
plate	  incubated	  at	  26	  °C	  for	  4	  h	  prior	  to	  measurement	  using	  a	  fluorescence	  plate	  reader	  
(555	  -­‐	  585	  nm).	  EC50	  values	  were	  calculated	  using	  sigmoidal	  regression	  analysis	  (GraphPad	  
Prism).	  
	  
Protocol	  1:	  L.	  amazonensis	  promastigotes	   in	  Medium	  199	  (100	  μL	  at	  5	  ×	  105	  mL−1)	  were	  
incubated	   in	  96-­‐well	  plates	  with	  compounds	   in	  triplicate	   (amphotericin	  B	  was	  used	  as	  a	  
positive	  control,	  and	  untreated	  parasites	  with	  DMSO	  as	  a	  negative	  control)	  at	  26	  °C	  for	  72	  
h.	  Resazurin	  Solution	  (10	  μL)	  was	  then	  added	  and	  the	  plate	  incubated	  at	  26	  °C	  for	  4	  h	  prior	  
to	   measurement	   using	   a	   fluorescence	   plate	   reader	   (555	   -­‐	   585	   nm).	   EC50	   values	   were	  
calculated	  using	  sigmoidal	  regression	  analysis	  (GraphPad	  Prism).	  	  
Protocol	  2:	  Same	  procedure	  as	  above	  with	  the	  modification	  of	  a	  48	  h	  incubation	  time	  as	  
opposed	  to	  72	  h	  and	  Leishmania	  amazonensis	  (MHOM/Br/75/JOSEFA)	  in	  Schneider’s	  insect	  
medium	  in	  the	  place	  of	  Leishmania	  amazonensis	  (MHOM/Br/75/JOSEFA)	  in	  Medium	  199.	  
	  
L.	  donovani	  promastigotes	  in	  Medium	  199	  (100	  μL	  at	  2	  ×	  106	  mL−1)	  were	  incubated	  in	  96-­‐
well	  plates	  with	  compounds	  in	  triplicate	  (amphotericin	  B	  was	  used	  as	  a	  positive	  control,	  
and	  untreated	  parasites	  with	  DMSO	  as	   a	  negative	   control)	   at	   26	   °C	   for	   72	  h.	   Resazurin	  
Solution	   (10	   μL)	   was	   then	   added	   and	   the	   plate	   incubated	   at	   26	   °C	   for	   4	   h	   prior	   to	  
measurement	  using	  a	  fluorescence	  plate	  reader	  (555	  -­‐	  585	  nm).	  EC50	  values	  were	  calculated	  
using	  sigmoidal	  regression	  analysis	  (GraphPad	  Prism).	  	  





L.	  infantum	  promastigotes	  in	  Medium	  199	  (100	  μL	  at	  2	  ×	  106	  mL−1)	  were	  incubated	  in	  96-­‐
well	  plates	  with	  compounds	  in	  triplicate	  (amphotericin	  B	  was	  used	  as	  a	  positive	  control,	  
and	  untreated	  parasites	  with	  DMSO	  as	   a	  negative	   control)	   at	   26	   °C	   for	   72	  h.	   Resazurin	  
Solution	   (10	   μL)	   was	   then	   added	   and	   the	   plate	   incubated	   at	   26	   °C	   for	   4	   h	   prior	   to	  
measurement	  using	  a	  fluorescence	  plate	  reader	  (555	  -­‐	  585	  nm).	  EC50	  values	  were	  calculated	  
using	  sigmoidal	  regression	  analysis	  (GraphPad	  Prism).	  
	  
8.4.2.	  Anti-­‐amastigote	  intramacrophage	  assay	  	  
	  
Bone	   marrow	   derived	   macrophages	   obtained	   as	   in	   8.3.3.	   were	   diluted	   in	   RPMI	   1640	  
medium	  to	  a	  concentration	  of	  2	  x	  105	  well-­‐1	  in	  a	  24-­‐well	  plate	  with	  round	  cover	  slips	  and	  
incubated	   for	   24	   h	   at	   37	   °C	   and	   5%	   CO2.	   They	   were	   infected	   with	   L.	   amazonensis	  
promastigotes	  (10:1)	  at	  37	  °C	  for	  4	  h.	  Then	  washed	  with	  PBS	  twice	  to	  remove	  extracellular	  
promastigotes	  and	  fresh	  RPMI	  medium	  supplemented	  with	  5%	  FBS	  was	  added.	  After	  24	  h	  
serial	  dilutions	  of	  the	  test	  compounds	  in	  RPMI	  medium	  (350	  μL)	  were	  added	  and	  the	  cells	  
were	   incubated	   at	   37	   °C	   for	   48	   h.	   The	   adherent	   infected	   cells	   were	   then	   stained	  with	  
Giemsa	   modified	   solution	   and	   amastigotes	   were	   counted	   using	   an	   optical	   Nikon®	  
microscope.	  
	  
8.4.3.	  Macrophage	  cytotoxicity	  assay	  
	  	  
Bone	  marrow	  derived	  macrophages	  in	  RPMI	  1640	  medium	  were	  seeded	  (1	  ×	  106	  mL−1,	  100	  
μL	  well-­‐1)	  in	  96-­‐well	  plates	  and	  incubated	  for	  24	  h	  at	  37	  °C	  and	  5%	  CO2.	  Following	  removal	  
of	  media,	  serial	  dilutions	  of	  the	  test	  compounds	  in	  fresh	  RPMI	  medium	  (100	  μL)	  were	  added	  
and	  the	  cells	  were	  incubated	  for	  48	  h	  at	  37	  °C	  and	  5%	  CO2.	  Aliquots	  of	  resazurin	  solution	  
(10	  μL)	  were	  then	  added	  and	  the	  cells	  were	  incubated	  at	  37	  °C	  and	  5%	  CO2	  for	  4	  h.	  Cell-­‐
viability	  measurement	  was	  carried	  out	  using	  a	  fluorescence	  plate	  reader.	  Triton	  was	  used	  
as	  a	  reference	  compound.	  EC50	  values	  were	  calculated	  using	  sigmoidal	  regression	  analysis.	  	  
	  
8.4.4.	  NO	  assay	  
	  
The	  generation	  of	  nitrite	  in	  bone	  marrow	  derived	  macrophages	  was	  assessed	  by	  the	  Griess	  
Reagent	  System	  (1%	  sulfanilamide	  /	  0.1%	  N-­‐(1-­‐naphthyl)-­‐ethylenediaminedihydrochloride/	  
2.5%	  H3PO4).	  Uninfected	  macrophages	  (1	  ×	  106	  mL−1,	  100	  μL	  well-­‐1)	  in	  96-­‐well	  plates	  were	  




incubated	  for	  24	  h	  at	  37	  °C	  and	  5%	  CO2.	  Following	  removal	  of	  media,	  serial	  dilutions	  of	  the	  
test	  compounds	  in	  fresh	  RPMI	  medium	  (100	  μL)	  were	  added	  and	  the	  plate	  was	  incubated	  
for	  48	  h	   at	   37	   °C	  and	  5%	  CO2.	   The	  plates	  were	   centrifuged	  at	   500	  g/5	  min	  and	   culture	  
supernatants	   were	   then	   incubated	   with	   the	   Griess	   Reagent	   for	   30	   min	   at	   37	   °C.	   The	  
absorbance	  was	  measured	  at	  570	  nm,	  and	  the	  nitrite	  concentration	  was	  determined	  using	  
a	  standard	  curve	  of	   sodium	  nitrite	   (0	   to	  50	  µM).	  The	  positive	  control	  was	  macrophages	  
incubated	  with	  1	  µg	  mL-­‐1	  of	  LPS	  (Sigma-­‐Aldrich,	  Brazil)	  and	  10%	  conditioned	  medium	  of	  
lymphocytes	   as	   a	   source	   of	   IFN.	   Negative	   controls	   were	   cells	   treated	   with	   DMSO	   and	  
untreated	  cells.	  
	  
8.4.5.	  In	  vivo	  assay	  
	  
Assay	  1:	  	  
	  
3	  month	  old	  BALB/c	  female	  mice,	  weighing	  20–25	  g	  and	  of	  approximately	  the	  same	  age	  
were	   used	   for	   the	   study.	   For	   infection	   of	   mice,	   stationary	   phase	   GFP	   L.	   amazonensis	  
promastigotes	  were	  collected,	  washed	  and	  suspended	  in	  sterile	  PBS.	  A	  volume	  of	  10	  μl	  of	  
sterile	  PBS	  containing	  2	  x	  106	  parasites	  was	   injected	   into	  the	  right	  ear.	  On	  day	  seven	  of	  
infection,	  animals	  were	  randomly	  distributed	  into	  5	  groups;	  oral	  clemastine	  fumarate	  (3	  
animals),	   miltefosine	   (4	   animals),	   IL	   clemastine	   fumarate	   (5	   animals),	   pentostam	   (5	  
animals)	  and	  untreated	  (4	  animals).	  Mice	  were	  treated	  with	  clemastine	  fumarate	  at	  a	  dose	  
of	  30	  mg	  kg-­‐1	  and	  miltefosine	  at	  a	  dose	  of	  2.5	  mg	  kg-­‐1	  by	  oral	  gavage	  five	  times	  a	  week	  for	  
29	  days.	  Mice	  were	  treated	  with	  clemastine	  fumarate	  and	  pentostam	  at	  a	  dose	  of	  0.22	  mg	  
kg-­‐1	   by	   intralesional	   injection	   twice	   a	   week	   for	   28	   days.	   Infected	   ear	   thicknesses	   were	  
measured	  once	  or	  twice	  a	  week	  with	  a	  caliper	  gauge,	  and	  the	  lesion	  sizes	  were	  expressed	  
as	   the	   difference	   between	   the	   thickness	   of	   infected	   and	   non-­‐infected	   ear.	   On	   day	   45	  
animals	  were	  sacrificed	  and	  the	  fluorescence	  measured	  (485	  -­‐	  528	  nm)	  and	  parasite	  load	  
quantified	  using	  a	  limiting	  dilution	  assay	  (LDA).	  





Assay	  2:*	  	  
	  
Two	  month	  old	  BALB/c	  female	  mice,	  weighing	  20	  -­‐	  25	  g	  and	  of	  approximately	  the	  same	  age	  
were	   used	   for	   the	   study.	   For	   infection	   of	   mice,	   stationary	   phase	   GFP	   L.	   amazonensis	  
promastigotes	  were	  collected,	  washed	  and	  suspended	  in	  sterile	  PBS.	  A	  volume	  of	  10	  μl	  of	  
sterile	  PBS	  containing	  2	  x	  106	  parasites	  was	   injected	   into	  the	  right	  ear.	  On	  day	  seven	  of	  
infection,	  animals	  were	  randomly	  distributed	  into	  5	  groups;	  oral	  clemastine	  fumarate	  (5	  
animals),	   IP	   clemastine	   fumarate	   (5	   animals),	   IL	   clemastine	   fumarate	   (5	   animals),	   IP	  
glucantime	   solution	   (5	   animals)	   and	   untreated	   (6	   animals).	   Mice	   were	   treated	   with	  
clemastine	  fumarate	  at	  a	  dose	  of	  134	  mg	  kg-­‐1	  by	  oral	  gavage	  five	  times	  a	  week	  for	  28	  days.	  
Mice	  were	  treated	  with	  clemastine	  fumarate	  and	  glucantime	  solution	  at	  a	  dose	  of	  11.65	  
mg	  kg-­‐1	  and	  1.30	  g	  kg-­‐1	  respectively,	  by	  intraperitoneal	  injection	  twice	  a	  week	  for	  28	  days.	  
Mice	  were	   treated	  with	   clemastine	   fumarate	   at	   a	   dose	  of	   1.17	  mg	   kg-­‐1	   by	   intralesional	  
injection	  twice	  a	  week	  for	  28	  days.	  Infected	  ear	  thicknesses	  were	  measured	  once	  or	  twice	  
a	  week	  with	  a	  caliper	  gauge,	  and	  the	  lesion	  sizes	  were	  expressed	  as	  the	  difference	  between	  
the	  thickness	  of	  infected	  and	  non-­‐infected	  ear.	  On	  day	  41	  animals	  were	  sacrificed	  and	  the	  
fluorescence	  measured	  (485	  -­‐	  528	  nm)	  and	  parasite	  load	  quantified	  using	  a	  limiting	  dilution	  
assay	  (LDA).	  
	  
Data	  on	  lesion	  progression	  were	  analysed	  for	  statistical	  significance	  by	  using	  the	  Dunnett	  
test	  as	  part	  of	  the	  one-­‐way	  ANOVA	  (GraphPad	  Prism	  8	  software).	  A	  result	  was	  considered	  







*Collaboration	  with	  Douglas	  Escrivani	  at	  UFRJ	  




8.4.6.	  High	  performance	  thin	  layer	  chromatography	  (HPTLC)	  based	  LmjIPCS	  assay	  
	  
The	  following	  protocol	  was	  adapted	  from	  a	  literature	  procedure	  and	  carried	  out	  under	  non-­‐
sterile	  conditions.146	  
	  
Stock	  1:	  Dry	  PI	  (1	  mM,	  30	  µL)	  in	  a	  LoBind	  Eppendorf	  tube	  using	  a	  vacuum	  concentrator.	  To	  
the	  dried	  PI,	  phosphate	  buffer	  (71.4	  mM	  ,	  pH	  7.0,	  105	  µL),	  CHAPS	  (3	  mM,	  30	  	  µL)	  and	  NBD-­‐
C6-­‐ceramide	  80	  (200	  µM,	  1.7	  µL)	  was	  added.	  The	  solution	  was	  mixed	  by	  vortex	  and	  stored	  
on	  ice.	  
	  
Stock	  2:	  	  Phosphate	  buffer	  (71.4	  mM	  ,	  pH	  7.0,	  105	  µL),	  CHAPS	  (3	  mM,	  30	  	  µL),	  storage	  buffer	  
(6	  µL)	  and	  microsomal	  membranes	  (1.5	  µL)	  were	  combined	  in	  a	  LoBind	  Eppendorf	  tube.	  
	  
Stock	  2	  (23.75	  µL)	  was	  added	  to	  n	  LoBind	  Eppendorf	  tubes	  (where	  n	  is	  the	  number	  of	  test	  
compounds	  +	  controls),	  followed	  by	  the	  addition	  test	  compounds	  in	  DMSO	  (5	  mM,	  1	  µL).	  
After	  pre-­‐incubation	  at	  30	  °C	  for	  20	  min,	  the	  reaction	  was	  started	  by	  the	  addition	  of	  stock	  
1	  (23.75	  µL)	  to	  each	  tube	  and	  incubation	  at	  30	  °C	  	  for	  30	  min.	  The	  reaction	  mixtures	  were	  
quenched	  with	  CHCl3:MeOH:H20	  (10:10:3,	  150	  µL).	  
	  
The	  mixtures	  were	   centrifuged	   to	   separate	  phases,	   the	  organic	   layer	  was	   removed	  and	  
dried	   using	   a	   vacuum	   concentrator.	   The	   residue	  was	   re-­‐suspended	   in	   CHCl3:MeOH:H20	  
(10:10:3,	  20	  µL)	  and	  loaded	  (3	  x	  3	  µL	  )	  onto	  HPTLC	  plates	  (silica	  gel	  60	  F254).	  This	  was	  run	  
using	   the	   solvent	   system	  CHCl3:MeOH:0.25%	  KCl(aq)	   (55:45:10)	   and	   the	  Rf	   values	   for	   the	  
excess	   NBD-­‐C6-­‐ceramide	   80	   and	   the	   product	   NBD-­‐	   C6-­‐IPC	   81	   were	   0.96	   and	   0.57	  
respectively.	   Product	   quantification	   was	   carried	   out	   using	   a	   fluorescence	   plate	   reader	  
(Ex473/Em520).	  
	  
8.4.7.	  96-­‐well	  plate–based	  LmjIPCS	  assay	  
	  
The	  following	  protocol	  was	  adapted	  from	  a	  literature	  procedure	  and	  carried	  out	  under	  non-­‐
sterile	  conditions.146	  
	  




Stock	  1:	  Dry	  PI	  (1	  mM,	  48	  µL)	  in	  a	  glass	  vial	  using	  a	  vacuum	  concentrator.	  To	  the	  dried	  PI,	  
phosphate	  buffer	  (71.4	  mM	  ,	  pH	  7.0,	  1680	  µL),	  CHAPS	  (3	  mM,	  480	  µL)	  and	  NBD-­‐C6-­‐ceramide	  
80	  (200	  µM,	  120	  µL)	  was	  added.	  The	  solution	  was	  mixed	  by	  vortex	  and	  stored	  on	  ice.	  
Stock	  2:	  Phosphate	  buffer	  (71.4	  mM	  ,	  pH	  7.0,	  1680	  µL),	  CHAPS	  (3	  mM,	  480	  µL),	  storage	  
buffer	  (72	  µL)	  and	  CHAPS-­‐washed	  microsomal	  membranes	  (0.6	  U)	  were	  combined	  in	  a	  glass	  
vial.	  The	  solution	  was	  mixed	  by	  vortex	  and	  stored	  on	  ice.	  
	  
In	  a	  V-­‐bottom	  96-­‐well	  plate,	  stock	  1	  (19	  µL	  well-­‐1)	  and	  test	  compounds	  (0.8	  µL)	  were	  added.	  
The	  reaction	  was	  initiated	  by	  the	  addition	  of	  stock	  2	  (20	  µL	  well-­‐1)	  and	  was	  incubated	  at	  30	  
°C	  	  for	  25	  min	  before	  quenching	  with	  MeOH	  (200	  µL	  well-­‐1).	  
	  
Separation	  of	  the	  reaction	  product,	  NBD-­‐C6-­‐ceramide	  80,	  from	  the	  starting	  material,	  IPC-­‐
C6-­‐caramide	  81,	  was	   achieved	  using	   anion	  exchange	   chromatography.	   20%	  w/v	  AG4-­‐X4	  
resin	  in	  EtOH	  (200	  µL	  well-­‐1)	  was	  added	  to	  a	  96-­‐well	  filter	  plate	  and	  centrifuged	  (2,450	  x	  g,	  
rt,	  27	  seconds).	  The	  resin	  was	  incubated	  with	  formic	  acid	  (50	  µL	  well-­‐1)	  for	  5	  minutes	  before	  
being	  centrifuged	  (2,450	  x	  g,	  rt,	  27	  seconds).	  The	  resin	  was	  then	  washed	  with	  water	  and	  
dried	  by	  centrifugation	  (2,450	  x	  g,	  rt,	  27	  seconds).	  
	  	  
The	  reaction	  mixture	  (200	  µL)	  was	  loaded	  onto	  the	  resin	  and	  the	  starting	  material,	  NBD-­‐C6-­‐
ceramide	  	  80,	  removed	  by	  centrifugation	  (2,450	  x	  g,	  rt,	  1	  min).	  The	  resin	  was	  washed	  with	  
MeOH	  (5	  x	  200	  µL)	  and	  subsequent	  centrifugation	  (2,450	  x	  g,	  rt,	  1	  min).	  The	  product,	  NBD-­‐
C6-­‐IPC	  81,	  was	  eluted	  into	  black	  plates	  with	  potassium	  formate	  in	  MeOH	  (1M,	  4	  x	  50	  µL)	  
followed	  by	  centrifugation	   (2,450	  x	  g,	   rt,	  1	  min).	  Product	  quantification	  was	  carried	  out	  
using	   a	   fluorescence	  plate	   reader	   (Ex460/Em540)	   and	   IC50	   values	  were	   calculated	  using	  
sigmoidal	  regression	  analysis	  (GraphPad	  Prism).	  	  
	  
8.4.8.	  Error	  calculations	  
	  
Each	  dose	  response	  curve	  is	  representative	  of	  one	  experiment	  and	  error	  bars	  represent	  
the	  dose	  in	  triplicate.	  Errors	  for	  EC50	  and	  CC50	  values	  against	  promastigotes	  (Appendix	  B),	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9	   L.	  major	  	   Promastigotes	   0.11	   	  
-­‐	  
Y	   61	  
L.	  donovani	  	   Promastigotes	   0.14	   N	  
Axenic	  amastigotes	   0.07	  
10	   L.	  major	  	   Promastigotes	   0.12	   0.08	   N	   62	  
Axenic	  amastigotes	   2.37	  
11	   L.	  donovani	  	   Intracellular	  
amastigotes	  
1.08	   7.04	   Y	   66	  
L.	  mexicana	   Intracellular	  
amastigotes	  
2.63	   2.89	   N	  
12	   L.	  donovani	  	   Intracellular	  
amastigotes	  
3.73	   1.88	   Y	  
L.	  amazonensis	   Intracellular	  
amastigotes	  
6.87	   1.02	   N	  
L.	  mexicana	   Intracellular	  
amastigotes	  
4.72	   1.48	   N	  
L.	  major	   Intracellular	  
amastigotes	  
3.77	   1.86	   N	  
13	   L.	  donovani	  	   Intracellular	  
amastigotes	  
2.49	   2.41	   Y	  
14	   L.	  amazonensis	   -­‐	   -­‐	   -­‐	   Y	   67	  
15	   L.	  donovani	   Axenic	  amastigotes	   0.47	   10	   N	   68	  








18	   L.	  infantum	   Promastigotes	   7.73	   2.69	   N	   74	  
Axenic	  amastigotes	   1.88	  







L.	  donovani	   -­‐	   -­‐	   -­‐	   Y	   75	  










19	   L.	  donovani	   Intracellular	  
amastigotes	  
1.27	   -­‐	   Y	   78	  
NCs-­‐19	   L.	  donovani	   Intracellular	  
amastigotes	  
0.72	   -­‐	  
20	   L.	  amazonensis	   Promastigotes	   13.51	   	  
-­‐	  





21	   L.	  amazonensis	   Promastigotes	   30.2	   	  
1.77	  




22	   L.	  major	   Intracellular	  
amastigotes	  
>105	   -­‐	   Y	   276	  	  
23	   L.	  major	   -­‐	   -­‐	   -­‐	   Y	   277	  	  




25	   L.	  amazonensis	  
	  








26	   L.	  amazonensis	   Promastigotes	   34.10	   3.28	   N	   90	  
Intracellular	  
amastigotes	  
29.81	   	  
L.	  braziliensis	   Promastigotes	   81.25	   2.27	   N	  
Intracellular	  
amastigotes	  
38.43	   	  








29	   L.	  infantum	   Promastigotes	   8.97	   -­‐	   N	  
30	   L.	  infantum	   Promastigotes	   2.81	  
31	   L.	  major	   Intracellular	  
amastigotes	  
0.015	   >407	   	  
N	  
95	  
32	   0.061	   >100	  
33	   0.091	   14.2	  









L.	  donovani	   -­‐	   -­‐	   -­‐	   Y	   97	  
L.	  amazonensis	   Promastigote	   7.2	   115	   N	   98	  
36	   L.	  donovani	   Promastigotes	   5.6	   	  
>17.9	  
Y	   100	  
	  
	  
Axenic	  amastigotes	   2.8	  
Intracellular	  
amastigotes	  
Inactive	   -   	   	  








38	   L.	  amazonensis	   Promastigotes	   8.4	   7.66	   Y	   108	  















41	   L.	  amazonensis	   -­‐	   -­‐	   -­‐	   Y	   111	  
42	   L.	  amazonensis	   -­‐	   -­‐	   -­‐	   Y	   111	  
43	   L.	  mexicana	   -­‐	   -­‐	   -­‐	   Y	   115	  
L.	  donovani	   -­‐	   -­‐	   -­‐	   Y	  
44	   L.	  major	   Intracellular	  
amastigotes	  
16	   -­‐	   Y	   118,	  119	  












45	   L.	  amazonensis	   Intracellular	  
amastigotes	  
4.86	   -­‐	   Y	   122	  
L.	  donovani	   Intracellular	  
amastigotes	  
2.96	   -­‐	   Y	  
L.	  major	   Intracellular	  
amastigotes	  
1.06	   -­‐	   Y	  
46	   L.	  amazonensis	   -­‐	   -­‐	   -­‐	   Y	   280	  












48	   L.	  donovani	   Promastigotes	   0.020	   >3125	   Y	   127	  
Axenic	  amastigotes	   0.005	   >10000	  
Intracellular	  
amastigotes	  
0.087	   >575	  
49	   L.	  donovani	   Intracellular	  
amastigotes	  
Inactive	   -­‐	   Y	   135	  
50	   L.	  donovani	   Promastigotes	   Inactive	   -­‐	   N	   136	  
Axenic	  amastigotes	   Inactive	   -­‐	  
Intracellular	  
amastigotes	  
Active	   -­‐	  
L.	  major	   Intracellular	  
amastigotes	  
21-­‐42	   -­‐	   Y	   281	  








L.	  major	   Promastigotes	   0.17	   -­‐	   N	  
Intracellular	  
amastigotes	  
3.06	   >6.5	  
L.	  donovani	   Promastigotes	   0.023	   -­‐	   Y	  
L.	  infantum	   Promastigotes	   0.69	   -­‐	   N	  
52	   L.	  donovani	  	   Intracellular	  
amastigotes	  
4.90	   -­‐	   Y	   282	  
53	   L.	  donovani	  	   Intracellular	  
amastigotes	  
8.60	   0.55	   N	   153	  
54	   L.	  infantum	   Promastigotes	   14.5	   -­‐	   Y	   156	  
Intracellular	  
amastigotes	  
12.6	   -­‐	  
55	   L.	  donovani	   Promastigotes	   22.38	   >5.50	   Y	   157,	  283	  











56	   	   Intracellular	  
amastigotes	  
13.32	   	   	   	  




57	   L.	  donovani	   Promastigotes	   17.30	   3.02	   N	   63	  




58	   L.	  donovani	  	  
	  
Promastigotes	   37	  
	  




59	   L.	  donovani	  	  
	  
















62	   L.	  mexicana	   Promastigotes	   0.9	   -­‐	   Y	   166	  















L.	  amazonensis	   Promastigotes	   4.71	   -­‐	  
L.	  major	   Promastigotes	   7.33	   -­‐	  
L.	  braziliensis	   Promastigotes	   3.54	   -­‐	  





























































































































Column	   A	   B	  
	  
C	  	   D	   E	  
	  

























0.020	  ±	  0.003	  






0.020	  ±	  0.003	  
	  
0.69	  ±	  0.01	  
	  
20	  ±	  2	  
	  
	  
0.08	  ±	  0.03	  
0.29	  ±	  0.04*	  
	  
0.38	  ±	  0.01*	   0.06	  ±	  0.02	  
	  
2.75	  ±	  1	  
	  
62	  ±	  20	  
	  
	  
0.80	  ±	  0.1*	   0.79	  ±	  0.1*	   	   	   	  
	  
0.53	  ±	  0.2	  
1.40	  ±	  0.2*	  
1.33	  ±	  0.1*	   	   	   	  
	  
0.026	  ±	  0.003	  
0.13	  ±	  0.01*	  
0.13	  ±	  0.01*	   	   	   75	  ±	  16	  
	  







































0.94	  ±	  0.2	  
1.17	  ±	  0.3*	  
	  
	  




28.66	  ±	  5	   80	  ±	  10	  
	  
	  
0.35	  ±	  0.1	  
0.63	  ±	  0.6*	  
	  
8.44	  ±	  0.3*	   0.82	  ±	  0.3	  
	  
19.15	  ±	  3	  
	  
85	  ±	  10	  
	  
	  
0.50	  ±	  0.3	  
0.50	  ±	  0.3*	  
	  
6.83	  ±	  0.4*	  	   1.02	  ±	  0.15	  
	  
17.29	  ±	  3	  
	  
70	  ±	  20	  
	  
	  
1.62	  ±	  0.2*	   2.25	  ±	  0.1*	   	   	   	  
	  
2.74	  ±	  0.4*	   2.87	  ±	  0.4*	   	   	   	  
	  
0.56	  ±	  0.03	  
1.30	  ±	  0.3*	  
2.80	  ±	  0.02*	   	   	   	  
	  
6.0	  ±	  0.5*	   17.33	  ±	  1*	   	   	   	  
	   	  
21.73	  ±	  1	  
	  

















































19.18	  ±	  3	  
	  
-­‐	   -­‐	   -­‐	   -­‐	  
	  
3.27	  ±	  0.7	  
	  
	  
-­‐	   2.30	  ±	  1	  
	  





10.16	  ±	  2	  
9.75	  ±	  2*	  
49.2	  ±	  2*	   -­‐	   -­‐	   -­‐	  
	  
17.39	  ±	  0.7	   23.83	  ±	  10*	   	   	   	  
	  
3.20	  ±	  0.7*	   5.88	  ±	  2*	   	   	   	  
	  
1.47	  ±	  0.6	  
3.37	  ±	  1*	  
2.76	  ±	  0.6*	   1.71	  ±	  0.8	  
	  
28.25	  ±	  20	  
	  
60	  ±	  20	  
	  	  	  
	  
	  
12.35	  ±	  3*	   14.41	  ±	  4*	   	   	   	  
	  
6.33	  ±	  2*	   4.68	  ±	  2*	   	   	   	  
	  
1.35	  ±	  0.8	  
3.40	  ±	  0.9*	  




























































4.10	  ±	  1*	   2.65	  ±	  1*	   	   	   	  
	  
-­‐	   7.05	  ±	  0.5*	   	   	   	  
	  
-­‐	   11.5	  ±	  0.9*	   	   	   	  
	  
-­‐	   1.7	  ±	  0.3*	   	   	   	  
	  
0.038	  ±	  0.02	   0.09	  ±	  0.02*	   	   	   81	  ±	  12	  
	  
0.02	  ±	  0.01	   0.058	  ±	  
0.007*	  
	  
	   	   73	  ±	  14	  
	  
0.52	  ±	  0.1	   1.21	  ±	  0.5*	   	   	   46	  ±	  14	  
	  
23.17	  ±	  4*	   26.80	  ±	  6*	   	   	   	  
	  
51	  ±	  1*	   70	  ±	  20*	   	   	   	  
	  
	  









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	   	  
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
